MENINGITIS A M EDICAL D ICTIONARY , B IBLIOGRAPHY , AND A NNOTATED R ESEARCH G UIDE TO I NTERNET R E FERENCES
J AMES N. P ARKER , M.D. AND P HILIP M. P ARKER , P H .D., E DITORS
ii
ICON Health Publications ICON Group International, Inc. 4370 La Jolla Village Drive, 4th Floor San Diego, CA 92122 USA Copyright 2003 by ICON Group International, Inc. Copyright 2003 by ICON Group International, Inc. All rights reserved. This book is protected by copyright. No part of it may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without written permission from the publisher. Printed in the United States of America. Last digit indicates print number: 10 9 8 7 6 4 5 3 2 1
Publisher, Health Care: Philip Parker, Ph.D. Editor(s): James Parker, M.D., Philip Parker, Ph.D. Publisher's note: The ideas, procedures, and suggestions contained in this book are not intended for the diagnosis or treatment of a health problem. As new medical or scientific information becomes available from academic and clinical research, recommended treatments and drug therapies may undergo changes. The authors, editors, and publisher have attempted to make the information in this book up to date and accurate in accord with accepted standards at the time of publication. The authors, editors, and publisher are not responsible for errors or omissions or for consequences from application of the book, and make no warranty, expressed or implied, in regard to the contents of this book. Any practice described in this book should be applied by the reader in accordance with professional standards of care used in regard to the unique circumstances that may apply in each situation. The reader is advised to always check product information (package inserts) for changes and new information regarding dosage and contraindications before prescribing any drug or pharmacological product. Caution is especially urged when using new or infrequently ordered drugs, herbal remedies, vitamins and supplements, alternative therapies, complementary therapies and medicines, and integrative medical treatments. Cataloging-in-Publication Data Parker, James N., 1961Parker, Philip M., 1960Meningitis: A Medical Dictionary, Bibliography, and Annotated Research Guide to Internet References / James N. Parker and Philip M. Parker, editors p. cm. Includes bibliographical references, glossary, and index. ISBN: 0-597-83628-0 1. Meningitis-Popular works. I. Title.
iii
Disclaimer This publication is not intended to be used for the diagnosis or treatment of a health problem. It is sold with the understanding that the publisher, editors, and authors are not engaging in the rendering of medical, psychological, financial, legal, or other professional services. References to any entity, product, service, or source of information that may be contained in this publication should not be considered an endorsement, either direct or implied, by the publisher, editors, or authors. ICON Group International, Inc., the editors, and the authors are not responsible for the content of any Web pages or publications referenced in this publication.
Copyright Notice If a physician wishes to copy limited passages from this book for patient use, this right is automatically granted without written permission from ICON Group International, Inc. (ICON Group). However, all of ICON Group publications have copyrights. With exception to the above, copying our publications in whole or in part, for whatever reason, is a violation of copyright laws and can lead to penalties and fines. Should you want to copy tables, graphs, or other materials, please contact us to request permission (E-mail:
[email protected]). ICON Group often grants permission for very limited reproduction of our publications for internal use, press releases, and academic research. Such reproduction requires confirmed permission from ICON Group International Inc. The disclaimer above must accompany all reproductions, in whole or in part, of this book.
iv
Acknowledgements The collective knowledge generated from academic and applied research summarized in various references has been critical in the creation of this book which is best viewed as a comprehensive compilation and collection of information prepared by various official agencies which produce publications on meningitis. Books in this series draw from various agencies and institutions associated with the United States Department of Health and Human Services, and in particular, the Office of the Secretary of Health and Human Services (OS), the Administration for Children and Families (ACF), the Administration on Aging (AOA), the Agency for Healthcare Research and Quality (AHRQ), the Agency for Toxic Substances and Disease Registry (ATSDR), the Centers for Disease Control and Prevention (CDC), the Food and Drug Administration (FDA), the Healthcare Financing Administration (HCFA), the Health Resources and Services Administration (HRSA), the Indian Health Service (IHS), the institutions of the National Institutes of Health (NIH), the Program Support Center (PSC), and the Substance Abuse and Mental Health Services Administration (SAMHSA). In addition to these sources, information gathered from the National Library of Medicine, the United States Patent Office, the European Union, and their related organizations has been invaluable in the creation of this book. Some of the work represented was financially supported by the Research and Development Committee at INSEAD. This support is gratefully acknowledged. Finally, special thanks are owed to Tiffany Freeman for her excellent editorial support.
v
About the Editors James N. Parker, M.D. Dr. James N. Parker received his Bachelor of Science degree in Psychobiology from the University of California, Riverside and his M.D. from the University of California, San Diego. In addition to authoring numerous research publications, he has lectured at various academic institutions. Dr. Parker is the medical editor for health books by ICON Health Publications. Philip M. Parker, Ph.D. Philip M. Parker is the Eli Lilly Chair Professor of Innovation, Business and Society at INSEAD (Fontainebleau, France and Singapore). Dr. Parker has also been Professor at the University of California, San Diego and has taught courses at Harvard University, the Hong Kong University of Science and Technology, the Massachusetts Institute of Technology, Stanford University, and UCLA. Dr. Parker is the associate editor for ICON Health Publications.
vi
About ICON Health Publications To discover more about ICON Health Publications, simply check with your preferred online booksellers, including Barnes & Noble.com and Amazon.com which currently carry all of our titles. Or, feel free to contact us directly for bulk purchases or institutional discounts: ICON Group International, Inc. 4370 La Jolla Village Drive, Fourth Floor San Diego, CA 92122 USA Fax: 858-546-4341 Web site: www.icongrouponline.com/health
vii
Table of Contents FORWARD .......................................................................................................................................... 1 CHAPTER 1. STUDIES ON MENINGITIS .............................................................................................. 3 Overview........................................................................................................................................ 3 The Combined Health Information Database................................................................................. 3 Federally Funded Research on Meningitis..................................................................................... 5 E-Journals: PubMed Central ....................................................................................................... 71 The National Library of Medicine: PubMed ................................................................................ 86 CHAPTER 2. NUTRITION AND MENINGITIS .................................................................................. 219 Overview.................................................................................................................................... 219 Finding Nutrition Studies on Meningitis ................................................................................. 219 Federal Resources on Nutrition ................................................................................................. 226 Additional Web Resources ......................................................................................................... 226 CHAPTER 3. ALTERNATIVE MEDICINE AND MENINGITIS ............................................................ 229 Overview.................................................................................................................................... 229 National Center for Complementary and Alternative Medicine................................................ 229 Additional Web Resources ......................................................................................................... 237 General References ..................................................................................................................... 238 CHAPTER 4. DISSERTATIONS ON MENINGITIS .............................................................................. 239 Overview.................................................................................................................................... 239 Dissertations on Meningitis ...................................................................................................... 239 Keeping Current ........................................................................................................................ 240 CHAPTER 5. CLINICAL TRIALS AND MENINGITIS ......................................................................... 241 Overview.................................................................................................................................... 241 Recent Trials on Meningitis ...................................................................................................... 241 Keeping Current on Clinical Trials ........................................................................................... 249 CHAPTER 6. PATENTS ON MENINGITIS ......................................................................................... 251 Overview.................................................................................................................................... 251 Patents on Meningitis................................................................................................................ 251 Patent Applications on Meningitis............................................................................................ 257 Keeping Current ........................................................................................................................ 258 CHAPTER 7. BOOKS ON MENINGITIS............................................................................................. 259 Overview.................................................................................................................................... 259 Book Summaries: Federal Agencies............................................................................................ 259 Book Summaries: Online Booksellers......................................................................................... 261 The National Library of Medicine Book Index ........................................................................... 263 Chapters on Meningitis ............................................................................................................. 264 CHAPTER 8. MULTIMEDIA ON MENINGITIS .................................................................................. 273 Overview.................................................................................................................................... 273 Video Recordings ....................................................................................................................... 273 Audio Recordings....................................................................................................................... 274 Bibliography: Multimedia on Meningitis .................................................................................. 275 CHAPTER 9. PERIODICALS AND NEWS ON MENINGITIS ............................................................... 277 Overview.................................................................................................................................... 277 News Services and Press Releases.............................................................................................. 277 Newsletter Articles .................................................................................................................... 283 Academic Periodicals covering Meningitis................................................................................ 285 CHAPTER 10. RESEARCHING MEDICATIONS................................................................................. 287 Overview.................................................................................................................................... 287 U.S. Pharmacopeia..................................................................................................................... 287 Commercial Databases ............................................................................................................... 288 Researching Orphan Drugs ....................................................................................................... 289
viii Contents
APPENDIX A. PHYSICIAN RESOURCES .......................................................................................... 293 Overview.................................................................................................................................... 293 NIH Guidelines.......................................................................................................................... 293 NIH Databases........................................................................................................................... 295 Other Commercial Databases..................................................................................................... 298 APPENDIX B. PATIENT RESOURCES ............................................................................................... 299 Overview.................................................................................................................................... 299 Patient Guideline Sources.......................................................................................................... 299 Associations and Meningitis...................................................................................................... 305 Finding Associations.................................................................................................................. 307 APPENDIX C. FINDING MEDICAL LIBRARIES ................................................................................ 309 Overview.................................................................................................................................... 309 Preparation................................................................................................................................. 309 Finding a Local Medical Library................................................................................................ 309 Medical Libraries in the U.S. and Canada ................................................................................. 309 ONLINE GLOSSARIES................................................................................................................ 315 Online Dictionary Directories ................................................................................................... 319 MENINGITIS DICTIONARY ..................................................................................................... 321 INDEX .............................................................................................................................................. 419
1
FORWARD In March 2001, the National Institutes of Health issued the following warning: "The number of Web sites offering health-related resources grows every day. Many sites provide valuable information, while others may have information that is unreliable or misleading."1 Furthermore, because of the rapid increase in Internet-based information, many hours can be wasted searching, selecting, and printing. Since only the smallest fraction of information dealing with meningitis is indexed in search engines, such as www.google.com or others, a non-systematic approach to Internet research can be not only time consuming, but also incomplete. This book was created for medical professionals, students, and members of the general public who want to know as much as possible about meningitis, using the most advanced research tools available and spending the least amount of time doing so. In addition to offering a structured and comprehensive bibliography, the pages that follow will tell you where and how to find reliable information covering virtually all topics related to meningitis, from the essentials to the most advanced areas of research. Public, academic, government, and peer-reviewed research studies are emphasized. Various abstracts are reproduced to give you some of the latest official information available to date on meningitis. Abundant guidance is given on how to obtain free-of-charge primary research results via the Internet. While this book focuses on the field of medicine, when some sources provide access to non-medical information relating to meningitis, these are noted in the text. E-book and electronic versions of this book are fully interactive with each of the Internet sites mentioned (clicking on a hyperlink automatically opens your browser to the site indicated). If you are using the hard copy version of this book, you can access a cited Web site by typing the provided Web address directly into your Internet browser. You may find it useful to refer to synonyms or related terms when accessing these Internet databases. NOTE: At the time of publication, the Web addresses were functional. However, some links may fail due to URL address changes, which is a common occurrence on the Internet. For readers unfamiliar with the Internet, detailed instructions are offered on how to access electronic resources. For readers unfamiliar with medical terminology, a comprehensive glossary is provided. For readers without access to Internet resources, a directory of medical libraries, that have or can locate references cited here, is given. We hope these resources will prove useful to the widest possible audience seeking information on meningitis. The Editors
1
From the NIH, National Cancer Institute (NCI): http://www.cancer.gov/cancerinfo/ten-things-to-know.
3
CHAPTER 1. STUDIES ON MENINGITIS Overview In this chapter, we will show you how to locate peer-reviewed references and studies on meningitis.
The Combined Health Information Database The Combined Health Information Database summarizes studies across numerous federal agencies. To limit your investigation to research studies and meningitis, you will need to use the advanced search options. First, go to http://chid.nih.gov/index.html. From there, select the “Detailed Search” option (or go directly to that page with the following hyperlink: http://chid.nih.gov/detail/detail.html). The trick in extracting studies is found in the drop boxes at the bottom of the search page where “You may refine your search by.” Select the dates and language you prefer, and the format option “Journal Article.” At the top of the search form, select the number of records you would like to see (we recommend 100) and check the box to display “whole records.” We recommend that you type “meningitis” (or synonyms) into the “For these words:” box. Consider using the option “anywhere in record” to make your search as broad as possible. If you want to limit the search to only a particular field, such as the title of the journal, then select this option in the “Search in these fields” drop box. The following is what you can expect from this type of search: •
Performance After Cochlear Implantation: A Comparison of Children Deafened by Meningitis and Congenitally Deaf Children Source: Journal of Laryngology and Otology. 114(1): 33-37. January 2000. Contact: Available from Royal Society of Medicine Press Limited. Publications Subscription Department, P.O. Box 9002, London W1A 0ZA, United Kingdom. E-mail:
[email protected]. Summary: This article reports on a study in which the speech perception and speech production performance following cochlear implantation of congenitally deaf children and children deafened by meningitis were analyzed. Three groups consisting of 70 congenitally deaf children, 22 children deafened by meningitis before two years of age, and 14 children deafened by meningitis after two years of age were compared. The
4
Meningitis
group deafened by meningitis after two years of age demonstrated significantly better speech perception than the other two groups. Their speech production appeared better, but did not achieve statistical significance compared with the other two groups. There were no significant differences in speech perception or production between the congenitally deaf group and the group deafened by meningitis before two years of age. Further research is required to determine whether this is a consequence of meningitis, whether they have failed to derive benefit from their previous auditory experience, or whether any benefit they may have derived has been lost during their period of deafness. 2 figures. 9 tables. 15 references. •
Risk Factors for Hearing Loss from Meningitis in Children Source: Archives of Otolaryngology-Head and Neck Surgery. 125(5): 509-514. May 1999. Contact: Available from American Medical Association. Subscriber Services, P.O. Box 10946, Chicago, IL 60610-0946. (800) 262-3250 or (312) 670-7827. Fax (312) 464-5831. Email:
[email protected]. Website: www.ama-assn.org/oto. Summary: This article reports on a study undertaken to identify statistically significant risk factors for hearing loss in children with meningitis, determine the overall incidence of hearing loss in a large group of children with confirmed meningitis, and quantify the percentage of children with progressive or fluctuating hearing loss after meningitis. The study included 432 children admitted to the Children's Hospital, Birmingham, Alabama, from 1985 to 1995. Of 432 children with meningitis, 59 (13.7 percent) developed hearing loss. Of these 59 children, 46 (78.0 percent) had stable sensorineural hearing loss and 13 (22. 0 percent) had either progressive or fluctuating hearing loss. Of the variables examined, only 5 appeared to be significantly associated with the development of hearing loss: CT scan evidence of increased intracranial pressure, male sex, the common logarithm of glucose levels in the cerebrospinal fluid, Streptococcus pneumoniae as the causative organism, and the presence of neck rigidity. In the children with progressive hearing loss, the time for progression varied from 3 months to 4 years before hearing stabilized. 1 figure. 4 tables. 12 references. (AA-M).
•
Prevention of Hearing Loss From Meningitis Source: Lancet. 350(9072): 158-159. July 19, 1997. Summary: This brief commentary presents information on the prevention of hearing loss due to meningitis. Before the introduction of the Haemophilus influenzae type b conjugate vaccines, bacterial meningitis accounted for close to 10 percent of acquired deafness in children in the United States. In hearing loss due to bacterial meningitis, suppurative labyrinthitis precedes the destruction of cochlear structures. Bacteria may reach the cochlea by various routes. Exactly how suppurative labyrinthitis leads to deafness is not totally clear. Hearing loss caused by bacterial meningitis occurs quite early in the course of the infection. Differences in the ability of various microorganisms to reach the cochlea and cause damage and in host response to infection are possible reasons why some children develop hearing loss after bacterial meningitis and some do not. In order to prevent or diminish the likelihood of hearing loss due to bacterial meningitis, the author recommends optimum antimicrobial therapy, surveillance and careful monitoring of recommended treatment regimens, dexamethasone as an adjunctive measure, and other, newer adjunctive drug therapies that may reduce the incidence of hearing loss. The author concludes that in developed countries, deafness due to H. influenzae type b meningitis has been all but eliminated by protein conjugate vaccines that prevent invasive infections effectively. The hope is that protein conjugate
Studies
5
vaccines under development will eventually prevent pneumococcal and meningococcal infections, including meningitis. 1 figure. 7 references. •
Vestibular Dysfunction Due to Cryptococcal Meningitis Source: Otolaryngology-Head and Neck Surgery. 116(4): 536-540. April 1997. Contact: Available from Mosby-Year Book, Inc. Subscription Services, 11830 Westline Industrial Drive, St. Louis, MO 63146-3318. (800) 453-4351 or (314) 453-4351. Fax (314) 432-1158. E-mail:
[email protected]. Summary: Cryptococcus neoformans is an encapsulated, opportunistic, fungal organism found primarily in soil and pigeon feces. Human beings presumably are infected through inhalation of the organism, which causes pulmonary (lung) cryptococcus that can then spread hematogenously (through the blood) to the central nervous system, bone, and kidneys. This article presents the case of a nonimmunosuppressed and previously healthy woman with subacute onset of severe ataxia (impaired ability to coordinate movement) in whom cryptococcal meningitis was subsequently diagnosed. This case is unique in that the patient had bilateral vestibular hypofunction and only a moderate unilateral sensorineural hearing loss (SNHL). The other unique aspect was the reversal of the vestibular symptoms after appropriate treatment, which included decompression of obstructive hydrocephalus (fluid on the brain) and long term antifungal therapy. This is the first case reported in the recent otolaryngologic literature in which a reversal rather than merely a stabilization of vestibular symptoms occurred in cryptococcal meningitis. The authors remind readers that the diagnosis of cryptococcal meningitis can be difficult because of the subacute nature of the infection and the initially mild symptoms. Audiovestibular damage is the result of direct invasion of the neural tissue and sensory end organs by the organism. 3 figures. 13 references.
•
Hearing Impairment After Bacterial Meningitis: A Review Source: Archives of Disease in Childhood. 67(9): 1128-1133. 1992. Summary: This journal article, intended for health professionals, reviews the recent literature on the incidence of hearing impairment following bacterial meningitis. The article discusses the rate of hearing impairment following bacterial meningitis, possible predictive factors, the permanence of hearing loss following bacterial meningitis, and possible means of reducing the risks of postmeningitic sensorineural hearing loss. It recommends that all children recovering from bacterial meningitis be referred for audiological assessment before discharge from the hospital. Bibliographic references are included.
Federally Funded Research on Meningitis The U.S. Government supports a variety of research studies relating to meningitis. These studies are tracked by the Office of Extramural Research at the National Institutes of Health.2 CRISP (Computerized Retrieval of Information on Scientific Projects) is a searchable database of federally funded biomedical research projects conducted at universities, hospitals, and other institutions. 2
Healthcare projects are funded by the National Institutes of Health (NIH), Substance Abuse and Mental Health Services (SAMHSA), Health Resources and Services Administration (HRSA), Food and Drug Administration (FDA), Centers for Disease Control and Prevention (CDCP), Agency for Healthcare Research and Quality (AHRQ), and Office of Assistant Secretary of Health (OASH).
6
Meningitis
Search the CRISP Web site at http://crisp.cit.nih.gov/crisp/crisp_query.generate_screen. You will have the option to perform targeted searches by various criteria, including geography, date, and topics related to meningitis. For most of the studies, the agencies reporting into CRISP provide summaries or abstracts. As opposed to clinical trial research using patients, many federally funded studies use animals or simulated models to explore meningitis. The following is typical of the type of information found when searching the CRISP database for meningitis: •
Project Title: 26TH INTL HERPESVIRUS WORKSHOP, REGENSBURG, GERMANY Principal Investigator & Institution: Nelson, Jay A. Director & Professor; Molecular Microbiol and Immun; Oregon Health & Science University Portland, OR 972393098 Timing: Fiscal Year 2001; Project Start 01-JUL-2001; Project End 01-AUG-2002 Summary: (provided by applicant) This proposal requests funds to enable young investigators to attend the 26th International Herpesvirus Workshop at the University of Regensburg in Germany, July 28-August 3, 2001. The International Herpesvirus Workshop is the premier scientific meeting for herpesvirus researchers, and the only meeting with an interdisciplinary focus on all the major subfamilies of herpesviruses and all aspects of research from molecular biology to clinical studies. The strength of the Workshop rests on the cross-fertilization that results from comparison of different herpesviruses, different approaches to key questions and on the support and participation of leading researchers in the field, most significantly including promising young investigators and students in training. Moreover, the forum is truly international, with broad-based world-wide attendance. The medical importance of this meeting is clearly indicated from the wide variety of diseases caused by the now recognized eight human herpesviruses. These include skin and eye ulcerations (HSV-1), genital lesions (HSV-2), meningitis and encephalitis (HSV-1 and HSV-2), infectious mononucleosis (EBV) chicken pox and shingles (VZV). CMV is a major cause of birth defects including mental retardation, blindness and deafness due to congenital transmission but also a significant opportunistic pathogen in AIDS patients and organ transplant recipients. More recently, CMV and HSV have been implicated as pathogenic contributors in the development of atherosclerosis. Cancer has also been associated with herpesvirus infections. EBV is associated with Burkitt's lymphoma, other B cell neoplasias and nasopharyngeal carcinoma. The most recent human herpesvirus discovered (HHV-8 or KSHV) is associated with Kaposi's sarcoma in AIDS patients and other immunosupressed persons and in other groups. All of the herpesviruses persist for life and therefore pose significant problems in the treatment of immunologically compromised persons. Disease due to reactivation of most human herpesviruses are a significant cause of morbidity and mortality in various immune patient populations. Shingles and post-herpetic neuralgia are problems in the elderly. Animal herpes significant economic importance to the poultry (Marek's and others), swine (pseudorabies virus), cattle (several bovine herpesviruses) and horses (several equine herpesviruses). In addition, these animal herpes serve as important model systems for studying herpesvirus pathogenesis. Finally, recombinant DNA technology permits the design of novel vaccines for controlling the spread of animal herpesvirus infection and the design of herpesvirus vectors for gene therapy. Workshop sessions will take an interdisciplinary approach to the following topics: virus structure, mechanism of virus entry and cell-cell spread, membrane proteins, pathogenesis and latency, DNA replication, vaccination and the immune response, transcriptional control, regulation of gene expression, chemotherapeutic targets, and virus gene therapy,
Studies
7
Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: A MENINGOCOCCAL LOS VACCINE Principal Investigator & Institution: Griffiss, John M. Associate Professor; Northern California Institute Res & Educ San Francisco, CA 941211545 Timing: Fiscal Year 2003; Project Start 15-JUN-2003; Project End 30-NOV-2005 Summary: (provided by applicant): Meningococcal disease primarily affects infants and very young children. The group B capsule is not immunogenic, and outer membrane protein vaccines provide only short-lived protection, in older children, that is restricted to serotypes in the vaccine. Protection is mediated by bactericidal antibodies that are induced by asymptomatic colonization by organisms that share lipooligosaccharides (LOS). By adolescence most children have LOS IgG that are bactericidal for most meningococcal strains. These antibodies prevent meningococcal disease, regardless of protein serotype. LOS are immunogenic at birth, and LOS antibodies can be induced by vaccination. During disease, infants make bactericidal antibodies against their infecting strains. These antibodies bind to a conserved LOS structure that is expressed well by 126E (L1,8), other L1 strains, and by L3,7 and L4,6 strains. This structure has not been definitively identified. LOS antibodies induced during infancy can prevent the monoclonal antibody (mAb), D6A, from binding to 126E LOS, and we have used this mAb, which binds to meningococci of all groups and types, as a surrogate for the LOS structure. MAb D6A binds the deeply truncated LOS of deltagalE mutants that have only a conserved basal structure, but it is not clear that this truncated LOS is the optimal immunogen. We now propose to affinity purify human IgG that binds the conserved LOS structure by 1) passage of IVIG over deltagalE LOS, and 2) by sequential passage of IVIG over L1, L1,8, L3,7 and L4,6 LOS, each coupled to Sepharose. We will assess how well each IgG kills 34 consecutive and unique endemic meningococcal case strains, and whether they can opsonize these meningococci for PMN killing. We will compare the binding of this pauciclonal IgG (pclgG) to that of mAb D6A and use Mass Spectrometry combined with chemical and enzymatic degradations to confirm the LOS structure recognized by mAb D6A and pclgG. We will immunize transgenic mice that have human immmunoglobulin loci (XenoMouse) with a deltagalE mutant to insure that this LOS structure is immunogenic for the human immune system, and characterize the functional activity of the induced IgG, as for the IVIG IgG. We will use enrichment of a coliphage display library with mAb D6A to identify a peptide mimic of the mAb D6A LOS antigen, use this peptide to immunize XenoMouse mice and functionally charaterize the induced IgG. We also will try to identify a peptide mimic that binds the human pclgG. The resulting data should confirm the suitability of a conserved LOS structure as a vaccine for the prevention of endemic group B disease in infants and young children. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: AMBISOME VS APHOTERICIN B IN AIDS PATIENTS WITH CRYPTOCOCCAL MENINGITIS Principal Investigator & Institution: Javaly, Kedernath; New York University School of Medicine 550 1St Ave New York, NY 10016 Timing: Fiscal Year 2001 Summary: This abstract is not available. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
8
Meningitis
•
Project Title: ANALYSIS OF M. CATARRHALIS LOS: ROLE IN IMMUNITY Principal Investigator & Institution: Campagnari, Anthony A. Professor; State University of New York at Buffalo 402 Crofts Hall Buffalo, NY 14260 Timing: Fiscal Year 2001; Project Start 01-MAR-2001; Project End 28-FEB-2006 Summary: Moraxella catarrhalis, a human mucosal pathogen, is a prominent cause of otitis media in young children and lower respiratory tract infections in adults with COPD. The significant financial burden on the health care system in this country, has stimulated research studies aimed at identifying possible vaccine components expressed on the bacterial surface. Recent studies have focused on components of the bacterial outer membrane, as these structures would most likely be available for interaction with the host immune response. However, it is clear that little is known about the virulence factors and the host immune response to M. catarrhalis. One prominent bacterial surface component, implicated as a potential virulence factor, is the lipooligosaccharide (LOS). Structural studies have shown that this major glycolipid is relatively conserved among clinical isolates obtained from adults. There have been three LOS serotypes reported using polyclonal rabbit sera for detection. In addition, a comparison of M. catarrhalis LOS has shown that this structure has oligosaccharide epitopes which share homology with the LOS of 9other important Gram-negative human pathogens, including Neisseria meningitis, Neisseria gonorrhea and Haemophilus influenzae. The LOPS epitopes shared by M. catarrhalis and these other important pathogens have been implicated as potential virulence factors involved in various mechanisms of pathogenesis including adherence and invasion of mucosal cells, serum resistance and resistance to opsonophagocytosis. In addition, recent studies have shown that antibodies to M. catarrhalis LOS elicit bactericidal activity, suggesting that this molecule may be an important component of a multifactorial vaccine. Despite these data, there is very little known about the role of M. catarrhalis LOS in colonization of infection, and there are no studies reported which characterize the genes and gene products of this important bacterial component. In this proposal, we will clone and sequence genes involved in the biosynthesis and assembly of LOS and we will construct specific isogenic mutants in these genes. These LOS mutants will be evaluated in various biologic assays to begin to understand the role of this molecule in pathogenesis. Also, we will perform a detailed analysis of the human antibody response to LOS in both children and adults which will provide insight into the host-pathogen relationship. The data obtained from these studies will provide critical information to our understanding of the steps involved in the pathogenesis of M. catarrhalis infections which will lead to new insight into strategies designed to prevent disease. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: ANTIGEN SPECIFIC T CELL ACCUMULATION IN THE CNS Principal Investigator & Institution: Fabry, Zsuzsanna; Professor; Pathology and Lab Medicine; University of Wisconsin Madison 750 University Ave Madison, WI 53706 Timing: Fiscal Year 2001; Project Start 01-FEB-2000; Project End 31-JAN-2004 Summary: The influx of T lymphocytes into the Central Nervous System (CNS) is an important part of the pathology of various autoimmune and infectious diseases, which are associated with inflammation in the brain, including viral encephalitis, chronic meningitis and Multiple Sclerosis (MS). Typically, inflammatory reactions involve the following phases: 1.) the initial entry phase of activated T cells; 2.) the preferential accumulation and site-specific survival of a small number of activated, antigen specific T cells; 3.) recruitment phase, in which, inflammatory mediators produced by these
Studies
9
antigen specific T cells contribute to the influx of non-antigen specific leukocytes resulting in an amplification of the inflammatory response. The primary goal of this application is to achieve progress toward understanding the mechanism of entry and accumulation of antigen specific T cells in the early initiation phase of CNS inflammatory reactions. The first part of our work (Specific Aims 1 and 2) will focus on understanding how antigen specific T cell responses are initiated by systemic or CNS introduction of antigens. We will compare different routes of antigenic stimulation and determine which one results in the most exacerbated T cell response in the brain parenchyma and Cerebral Spinal Fluid (CSF). Because of the difficulties in monitoring the very small numbers of antigen specific T cells found in a normal animal, we will use a novel technology already available in our laboratory, involving T cell receptor transgenic animals and their respective antigens. In this way we will be able to follow the accumulation of a monospecific T cell population in the CNS. The goal of Specific Aim 3 will be to interfere with the initial entry (phase 1) of antigen specific and nonspecific T cells into the CNS. Molecules governing this initial entry phase of T cells will be defined. Characterization of this process will be crucial to understanding the pathogenesis of disease, and developing effective immunotherapies. We believe that the successful completion of this research project will lead to an improved understanding of the role of T cells in CNS inflammatory diseases and will provide the foundation for new therapeutic methodologies for controlling CNS inflammatory diseases, such as MS. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: BACTERIAL PHOSPHORYLCHOLINE AND PATHOGENESIS Principal Investigator & Institution: Weiser, Jeffrey N. Associate Professor; Microbiology; University of Pennsylvania 3451 Walnut Street Philadelphia, PA 19104 Timing: Fiscal Year 2001; Project Start 01-AUG-1999; Project End 31-JUL-2004 Summary: Description (Adapted from Applicant's Abstract): The bacterial cell surface is generally considered to be highly divergent from species to species. An exception to this rule is the expression of phosphorylcholine (ChoP). This unusual prokaryotic structure is now known to be exposed on the surface of the most common pathogens infecting the human respiratory tract; Haemophilus influenzae, mycoplasma, and Streptococcus pneumoniae. In addition, based on cross-reactivity to a MAb recognizing this structure, ChoP may be present on diverse phase-variable structures on N. meningitidis, N. gonorrhoeae, P. aeruginosa, and A. actinomycetemcomitans. We have defined the genetic basis of ChoP expression and the molecular mechanism controlling its phase variation in H. influenzae. This has allowed direct genetic analysis of clinical samples to show that the ChoP+ phase variants predominate on the mucosal surface of humans. The structure, however, is the target of innate immunity mediated by binding of C-reactive protein (CRP), which is bactericidal in the presence of complement. The focus of this proposal is to define the biological role of variants both with and without ChoP using H. influenzae as a prototype human respiratory tract pathogen. In Aim 1, we will determine whether switching to the ChoP- phenotype is required in natural H. influenzae infection (otitis media, pneumonia, bacteremia, and meningitis) to evade clearance by CRP and bactericidal anti-ChoP IgG. The ChoP phenotype in vivo will be determined by direct genetic analysis and compared to the local concentration of CRP and anti-ChoP antibody during infection. The local expression and concentration of CRP in the upper respiratory tract will be investigated. In Aim 2, we will determine how ChoP contributes to persistence on the mucosal surface. Genetically defined H. influenzae mutants with constitutive ChoP-on and ChoP-off phenotypes will be used to determine whether this host membrane-like
10 Meningitis
structure contributes to (a) resistance to respiratory tract antibacterial peptides including LL-37 and tracheal antimicrobial peptide (TAP), and (b) colonization by functioning as a bacterial adhesin to host epithelial cells via putative ChoP ligands including GalNAcb 14Gal on the asialo-GM1 glycolipid and the platelet activating factor receptor. The blocking of complement mediated killing by naturally acquired secretory IgA recognizing ChoP will be explored as an explanation for the selection of the ChoP+ phenotype on the mucosal surface, despite the increased susceptibility of this phenotype to CRP and complement. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: BACTERIAL VACCINE ANTIGEN DISCOVERY Principal Investigator & Institution: Paoletti, Lawrence C.; Brigham and Women's Hospital 75 Francis Street Boston, MA 02115 Timing: Fiscal Year 2003; Project Start 30-SEP-2003; Project End 31-AUG-2004 Summary: (provided by applicant): New directions in bacterial vaccine discovery may arise from studies of host-microbe interactions, particularly through the use of a newly described technology: the dynamic in vitro attachment and invasion system (DIVAS). DIVAS was developed to study bacterial attachment and invasion with cells held at specific and controlled conditions of growth, metabolism, and nutrient levels. Results from experiments performed with DIVAS and group B Streptococcus (GBS) type III strains substantiated earlier findings that capsular polysaccharide is not critical for invasion of respiratory epithelial cells. Moreover, GBS invaded these cells only when held at a fast as opposed to a relatively slower rate of growth and they expressed several proteins solely under growth conditions conducive for invasion. In this proposal, we seek to test the hypothesis that GBS proteins involved with invasion of eukaryotic cells are new and important targets of protective immunity. GBS is a major cause of neonatal sepsis and meningitis, and is increasingly prevalent among nonpregnant adults and the elderly with underlying illnesses. Preclinical and clinical trials have been successfully performed with protein conjugate vaccines prepared with polysaccharides from most of the nine currently known GBS serotypes. GBS protein antigens with virulence properties have been described and some with vaccine potential have been tested preclinically. In this proposal, we seek to use DIVAS to identify physiological conditions conducive for bacterial attachment/invasion of eukaryotic cells using GBS as a model pathogen. We plan to isolate and identify GBS membrane proteins expressed solely under invasive conditions (Specific Aim 1). Several of these newly expressed proteins will be purified directly from GBS, or cloned and recombinantly expressed, and tested as vaccine candidates in mice (Specific Aim 2). Findings from these studies utilizing this unique approach to vaccine antigen discovery could be directly applied to other bacterial pathogens including those on the category A bioterrorism list. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: MENINGITIS
BIOACTIVITIES
OF
PNEUMOCOCCAL
CELL
WALL
IN
Principal Investigator & Institution: Tuomanen, Elaine I. Chair, Professor; St. Jude Children's Research Hospital Memphis, TN 381052794 Timing: Fiscal Year 2001; Project Start 01-JUN-1989; Project End 31-JAN-2005 Summary: The pneumococcus remains the cause of meningitis with the greatest morbidity and mortality in children and older adults. This pattern persists despite the use of antibiotics of exceptionally rapid bactericidal activity. Over the past 10 years of
Studies 11
this proposal we have sought to understand the biochemical basis of the inflammatory response to pneumococci in the subarachnoid space. We established that the pneumococcal cell wall is a library of inflammatory components which incites the cytokine, coagulation and arachidonate cascades and directly injures endothelial cells of the blood brain barrier. Further, we established that the release of cell wall during antibiotic-induced death engenders a dramatic host response that is responsible for serious injury to host tissues. This provided a rationale for use of agents like dexamethasone that can act as partner drugs with antibiotics to selectively control the injurious components of the host defense response. The current proposal seeks to determine the molecular details of the mechanism of pneumococcal invasion into brain and how neuronal cells are killed during meningitis. Blocking information decreases some sequelae of infection but does not appear to be sufficient in controlling neuronal loss, particularly for pneumococcal disease. Over half of the current survivors of this injection still have major permanent sequelae. Understanding this process will allow design of agents to specifically attenuate these ongoing losses. We propose to apply our expertise in the identification and characterization of pneumococcal surface components, to map the process of transcytosis across the blood brain barrier. We will identify the pneumococcal components involved, specifically focusing on CbpA. This protein is required for pneumococcal invasion. Secondly, we will characterize the process of pneumococcal translocation in terms of the intracellular vesicle and the signaling process. Involvement of the PAF receptor that binds pneumococci and sIgA that ligates CbpA in actual translocation will be determined. Finally, we will investigate preliminary evidence that upon inhibition of apoptosis suggest this is an important contributor to sequelae. The detailed mechanism appears to be novel and will potentially instruct cell biology as well as pathogenesis. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: BIOLOGY OF H INFLUENZAE HIA AND HSF ADHESINS Principal Investigator & Institution: St Geme, Joseph W. Associate Professor; Pediatrics; Washington University Lindell and Skinker Blvd St. Louis, MO 63130 Timing: Fiscal Year 2001; Project Start 15-DEC-1998; Project End 30-NOV-2003 Summary: Haemophilus influenzae is common cause of localized respiratory tract disease, including otitis media, sinusitis, bronchitis, and pneumonia. Less commonly, this organism causes serious systemic disease, such as meningitis, endocarditis, and septicemia. The initial step in the pathogenesis of H. influenzae disease involves colonization of the upper respiratory mucosa. We have identified a high-molecularweight protein called Hia, which is present in nontypable (nonencapsulated) H. influenzae and promotes attachment to human epithelium. In addition, we have identified a homolog of Hia called Hsf, which is univerally present among encapsulated H. influenzae and also mediates in vitro adherence. Interestingly, Hia has a predicted molecular mass of approximately 114 kDa and is not detectable by coventional transmission electron microscopy, while Hsf has a predicted molecular mass of approximately 245 kDa and is associated with the presence of short, thin surface fibrils visible by negative staining electron microscopy. Based on our in vitro results, we speculate that Hia and Hsf are important colonization factors. In the present proposal, we plan to characterize the pathway by which Hia and Hsf are localized on the surface of the organism. In particular, we will define the structural features of these proteins that direct them to the periplasm and facilitate their translocation across the outer membrane. We will dissect the influence of an unusual N-terminal extremity, a Cterminal domain predicted to form a beta-barrel, and a putative ATP-binding motif. In
12 Meningitis
additional studies, we will examine the architecture of Hia and will investigate the relationship between structure and adhesive activity, focusing in particular on the role of a predicted coiled coil motif. We will also determine whether Hia and Hsf function interchangeably in an encapsulated strain. From a practical perspective, the results of these experiments may facilitate efforts to develop a vaccine protective against non-type b H. influenzae and suggest targets for novel antimicrobials with activity against a broad range of gram-negative bacteria. More generally, they may provide fundamental insights into the biogenesis of non-pilus adhesins and the nature of the host-microbial relationship. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: BIOMARKER OF NEUROPROTECTANT EFFICACY IN ALS Principal Investigator & Institution: Gabbita, Somasundar P.; Phase 2 Discovery, Inc. 3130 Highland Ave, 3Rd Fl Cincinnati, OH 45219 Timing: Fiscal Year 2003; Project Start 15-APR-2003; Project End 31-MAR-2004 Summary: (provided by applicant): The objective of this Phase I feasibility study is to develop a reliable biomarker of neuronal damage in a validated mouse model of amyotrophic lateral sclerosis (ALS). Currently, there is no widely accepted biomarker to quantify ALS-induced motor neuron injury. Previously, we have shown that neuronal degeneration in rodents and humans results in cleavage of the cytoskeletal protein MAP-tau. Our laboratory has developed a sensitive ELISA that specifically measures cleaved MAP-tau (C-tau) in rodent models of traumatic brain injury and bacterial meningitis. Using this C-tau ELISA assay, our preliminary studies demonstrate that spinal cord C-tau levels are tenfold higher in late stage symptomatic ALS (G93A-SOD1 mutation) mice as compared to control mice. Using a rotorod motor performance assay, Hensley et al. have recently demonstrated that administration of Nor-dihydroguaiaretic acid (NDGA) to ALS mice delays onset of neurologic deficits. We hypothesize that 1) Ctau is a reliable biomarker of motor neuron injury in ALS mice and 2) C-tau can serve as a screening tool to identify neuroprotectant drags for treating ALS. We will test these hypotheses by determining the relationship between C-tau levels and progression of neurologic deficits in ALS mice. Furthermore, we will test whether the demonstrated neuroprotectant effect of NDGA that delays onset of neurologic deficits in ALS mice also exerts expected effects on C-tau levels. Our Specific Aims are: Specific Aim 1: Compare spinal cord C-tau levels in ALS mice and control mice at 120 days. Specific Aim 2: Determine the relationship between C-tau levels and neurologic deficits in ALS mice as compared to controls. Neurologic deficits and spinal cord C-tau levels will be determined in ALS and age-matched control mice and statistically compared from the presymptomatic stages to late symptomatic stages of disease progression. Specific Aim 3: Determine if C-tau levels reliably quantify the effect of a demonstrated neuroprotectant drag intervention in ALS mice. C-tau levels and rotorod performance will be determined and compared as a function of NDGA treatment. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: BIOMARKER OF NEUROTOXICITY IN MENINGITIS Principal Investigator & Institution: Mulchahey, James J. Assistant Professor; Phase 2 Discovery, Inc. 3130 Highland Ave, 3Rd Fl Cincinnati, OH 45219 Timing: Fiscal Year 2002; Project Start 01-AUG-2002; Project End 31-JUL-2003 Summary: (provided by applicant): The objective of this Phase I application is to develop a sensitive biomarker for quantifying neurotoxicity and neuroprotectant
Studies 13
efficacy in meningitis. Previous research documents that brain injury caused by meningitis affects multiple brain areas with a heterogeneous distribution. We have previously shown that the cytoskeletal protein MAP-tau is cleavedin brain during axonal degeneration. We developed a sensitive ELISA that specifically quantifies this biomarker of neuronal degeneration, cleaved-tau (C-tau). Our preliminary studies demonstrate that levels of C-tau are increased over 300-fold in an animal model of group B streptococcus meningitis (GBM). We will use the well-documented neurotoxicity of GBM to validate the C-tau as a biomarker of neurotoxicity and a measure of neuroprotectant efficacy. Our Specific Aims are: Specific Aim 1: Determine whether GBM results in a time-dependent elevation in brain, plasma and CSF concentrations of C-tau. Specific Aim 2: Determine it C-tau levels in brain, CSF and plasma correlate with traditional measures of neuronal damage in GBM. Specific Aim 3: Determine whether perihperal tissues such as liver, kidney or spleen are potential sources of C-tau measured in GBM. Specific Aim 4: Determine whether a neuroprotectant intervention known to be effective in GBM has predictable effects on Ctau levels. PROPOSED COMMERCIAL APPLICATIONS: The C-tau ELISA may be used to quantify the severity of brain injury in meningitis and to quantify the effects of neuroprotectant interventions in basic science, preclinical and clinical research settings. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: CLINICAL TRIALS WITH SOLID INTRACRANIAL TUMORS & NEOPLASTIC MENINGITIS Principal Investigator & Institution: Bigner, Darell D. Jones Cancer Research Professor; Duke University Durham, NC 27706 Timing: Fiscal Year 2002 Summary: Given the toxicity and poor survival results after current treatment modalities, regional therapy using monoclonal antibody-based strategies and alkylators may have clinical potential. The PI proposes to define the MTD and therapeutic benefits of 9 different approaches, 6 for solid intracranial tumors and 3 for neoplastic meningitis. For solid tumors, 4 approaches involved intratumoral or intracystic infusions: (1) 131-I81C6, (2) 211-Att-ch81C6, (3) ch81C6-streptavidin followed by 211-At-biotin or 131-Ibiotin, (4) 211-At or I-131 conjugated alpha-EGFRvIII/ fragments; and 2 approaches only intratumoral infusions: (1) MRI (a-EGFRvIII-scFv-pseudomonas toxin), and (2) TP38 (TGFa-pseudomonas toxin). For neoplastic meningitis, two treatment studies were chemotherapy based: melphalan and camptothecin analogues and the rest utilized 131-IMel-14, 131-I-81C6, and other anti-medullobastoma antibodies and genetic variants. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: ANTIGENICITY
COMPUTATIONAL
ANALYSIS
OF
CARBOHYDRATE
Principal Investigator & Institution: Woods, Robert J. None; University of Georgia 617 Boyd, Gsrc Athens, GA 306027411 Timing: Fiscal Year 2003; Project Start 01-MAR-1997; Project End 30-APR-2007 Summary: (provided by applicant): Group Beta Streptococcus and Neisseria meningitidis are leading causes of neonatal sepsis and meningitis. The increasing use of carbohydrate-based conjugate vaccines is founded on the observation that antibodies against the type-specific bacterial capsular polysaccharides (CPS) are often protective, and-is driven by the increasing prevalence of antibiotic resistant strains. However, the relationships between the carbohydrate sequence in the CPS and antigenicity are poorly
14 Meningitis
understood. Similarly, the immune response to the CPS is structure-sensitive; some are poor immunogens and others good. The goal of this proposal is to provide an understanding of the structural features of antigenic oligosaccharides that are responsible for mediating the affinity and specificity of their interactions with antibodies. Ultimately, this information would form a basis for the rational development of more effective antibacterial vaccines. We have selected three systems (Aims 1-3) for study that display complementary levels of complexity. In Aims 1 and 2, we will use computational and experimental methods to determine the conformational properties of the bacterial CPSs from iV. meningitides and Group B Streptococcus, both free and bound to monoclonal antibody fragments. This information will provide a structural basis for interpreting the antigenicities and antibody specificities for these systems, as well as assist in the determination of the conformation of the immunodominant regions. To aid in the development and validation of the computational methods, in Aim 3, we will examine the properties of the related anionic sugars in glycosaminoglycans (GAGs), for which considerable experimental data exist. Computational methods, such as molecular dynamics (MD) simulations, are useful aids in the conformationat analysis of oligosaccharides and oligosaccharide-protein complexes; yet at present they have been developed only for neutral carbohydrates. The CPSs from N. meningitides and Group B Streptococcus, and from many other pathogenic bacteria, contain anionic carbohydrate residues. Accurate modeling of these molecules will require the extension and validation of our existing carbohydrate force field parameters (GLYCAM). To assist in this development, we will examine a number of anionic GAGs, such as hyaluronan, chondroitin and heparin sulfate as well as heparin, free and complexed to antithrombin III, whose conformational properties have been well characterized experimentally. Validation of the MD simulations will be based on comparisons with NMR and X-ray data and binding affinity measurements. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: CONGENIC NEOFORMANS
STRAINS
OF
SEROTYPE
A
CRYPTOCOCCUS
Principal Investigator & Institution: Wickes, Brian L. Assistant Professor; Microbiology and Immunology; University of Texas Hlth Sci Ctr San Ant 7703 Floyd Curl Dr San Antonio, TX 78229 Timing: Fiscal Year 2003; Project Start 01-FEB-2003; Project End 31-JAN-2006 Summary: (provided by applicant): Cryptococcus neoformans is an important human fungal pathogen that can cause life-threatening infections. Infections are opportunistic in nature and typically occur in immunocompromised patients, with AIDS patients being at greatest risk. Cryptococcosis is usually manifested as meningitis, which is often treated as incurable in AIDS patients and can require life-long antifungal therapy. Infections are worldwide with approximately 90- 95% of all infections being caused by serotype A strains. The importance of this fungus as a pathogen resulted in the solicitation and funding of a genome-sequencing project. The strain that was chosen, however, was a serotype D strain, which causes less than 10% of all infections. This strain was chosen because sexually compatible strains (designated MATalpha and MATa) exist, whereas compatible serotype A strains are not available due to the absence of a fertile MATa strain. An added significance of mating in C. neoformans is that virtually all infections are caused by one mating type (MATalpha). We have recently identified a serotype A MATa strain that is fertile and crosses efficiently with serotype A MATalpha strains, including strain H99, the standard laboratory strain for this serotype. The existence of this strain provides a powerful tool for studying C. neoformans because
Studies 15
it will enable traditional genetic studies to be performed in serotype A strains. This proposal consists of three aims. The first aim will prepare two congenic pairs of strains that differ only in mating type. Genetic markers will be inserted into these strains to make them useful tools for future genetic and molecular studies. The second aim will test the role of mating type in virulence. By using congenic strains in these experiments, the role of information at the mating type locus in virulence can be tested independent of non mating-type information. In the last aim, the serotype A MATa mating type locus will be cloned and mapped to determine its size. Presently three out of the four mating type loci of C. neoformans var. neoformans (comprised of serotype A and D) are in various stages of characterization. Isolation of the serotype A MATa locus will complete this study, which is significant because of the role that mating type plays in virulence. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: CORE--PHASE I / II CLINICAL TRIALS CORE Principal Investigator & Institution: Reardon, David; Duke University Durham, NC 27706 Timing: Fiscal Year 2002; Project Start 30-SEP-2002; Project End 31-AUG-2004 Summary: (provided by applicant): Core 3 will design, implement and review all clinical trials sponsored by the SPORE application. There are four major areas of therapeutic intervention to be evaluated by clinical trials overseen by the core. First, therapeutics to overcome chemoresistance will be evaluated. UG-BG, a potent inhibitor of 06alkylguanine- DNA alkyltransferase (AGT), the major mediator of chemoresistance among malignant gliomas, is ineffective and associated with significant toxicity when administered systemically. Therefore we will evaluate the compartmental administration of Ub-BG, as well as other agents identified in Project 4, via intrathecal injection for patients with neoplastic meningitis (NM) and intratumorally via intracerebral microinfusion (ICM) for patients with malignant brain tumors. Second, we will continue to evaluate therapeutics targeting tumor- specific markers (Project l), including armed and unarmed monoclonal antibodies (MAbs) and recombinant immunotoxins, delivered compartmentally via injection into the resection cavity or into the intrathecal space, or via direct intratumoral microinfusion. Therapeutic targets for these agents include EGFR, EGFRvIII, tenascin C, GP 240, MDRP3, GPNMB as well as others identified in Project 2. Our recent Phase I1 study showed that I-labeled antitenascin MAb 81C6 significantly improved survival for patients with newly diagnosed malignant glioma compared to conventional external beam radiotherapy and chemotherapy. Therefore, we are advancing our extensive preclinical and clinical studies with "'1-81 C6 and investigating the role of human and mouse chimeric MAbs, MAb fragments such as F(ab'), and alternative radioisotopes such as astatine- 211. The third major area of focus is the evaluation of administering therapeutics by intracerebral microinfusion as a method of achieving maximum intratumoral concentration while minimizing systemic exposure. and thereby significantly improving drug therapeutic index. Fourth, we are continuing to evaluate cytotoxic chemotherapeutics that have shown promising, preclinical efficacy in the extensive Duke panel of brain tumor cell lines and xenograft models. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: CORE--X RAY CRYSTALLOGRAPHY Principal Investigator & Institution: Sundaramoorthy, Munirathinam; University of Kansas Medical Center Msn 1039 Kansas City, KS 66160
16 Meningitis
Timing: Fiscal Year 2001; Project Start 30-SEP-2001; Project End 31-AUG-2006 Summary: The success of several sequence genomics projects heralds a new era in the study of the gene products and many of them are attractive targets for drug design. The new proteomics research uses multidisciplinary approach to study the "cellular protein universe" using several high-throughput methods. X-ray crystallography plays a pivotal role in both proteomics and structure based drug design. The University of Kansas Medical Center has envisioned a plan to establish "Kansas City Proteomics Initiative" and will set up an X-ray crystallography lab as a part of this plan in the Department of Biochemistry. This will serve as the Core facility for COBRE investigators who apply crystallography to their research. Funds are requested from COBRE for its maintenance. The Principal Investigator will direct the Core and his Research Project is summarized below. Gram-negative bacteria Neisseria meningitidis and Escherichia coli K1 are associated with sepsis and meningitis. There is no promising vaccine against N. Meningitidis group B and E. coli K1. Their capsular polysaccharides are sialylated, which are structurally similar to those found in mammalian glycolipids. This host mimicry plays and important role in the pathogenecity by allowing the bacteria to evade the host's immune system. Thus, sialic acid (N-acetylneuraminic acid, NeuNAc) is a virulence factor in these pathogenic bacteria. The biosynthesis of polysialic acid involves the formation and activation of NeuNAc. In bacteria, these two steps are catalyzed by NeuNAc synthase and CMP-NeuNAc synthetase, respectively. Our long-term goal is to study the structure-function relations of these enzymes using molecular biology, protein chemistry, and crystallography methods and use the structural knowledge of rational drug design. The specific aims of this application are: Aim 1: NeuNAc synthases from N. meningitidis and E. coli K1. In bacteria, sialic acid is synthesized by the condensation of N-acetylmannosamine with polyenolpyruvate by NeuNAc synthase. The human enzyme uses the phosphorylated substrates. The differences in the substrate specificity between human and bacterial enzymes may be due to different active site structures. Selective inhibition of bacterial enzyme is a viable strategy to prevent the synthesis of sialic acid in the pathogen. We will overexpress, purify, and crystallize NeuNAc synthases from N. meningitidis and E. coli K1 for structural-functions studies. Aim 2: CMP-NeuNAc synthetase from E. coli K1. The E coli K1 CMP-NeuNAc synthetase is twice as large as the other bacterial enzymes and about the same size as the mouse enzyme, the only mammalian CMP-NeuAc synthetase is sequenced. The N-terminal half of the E. coli K1 sequence is highly homologous to other bacterial sequences, but the full-length sequence share a limited homology with the mouse sequence. We will crystallize the E. coli K1 CMP-NeuAc synthetase for structure determination. The structural differences of these functional homologues will be used to design drugs to target the bacterial enzymes specifically. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: COXSACKIE MYOCARDITIS AND VIRAL PERSISTENCE IN THE HEART Principal Investigator & Institution: Whitton, J Lindsay. Professor; Scripps Research Institute 10550 N Torrey Pines Rd La Jolla, CA 920371000 Timing: Fiscal Year 2003; Project Start 01-JAN-1998; Project End 31-DEC-2007 Summary: (provided by applicant): Coxsackieviruses (CVB) are important human pathogens, causing myocarditis, meningitis, and other diseases, which may be lethal, especially in neonates. This proposal has five specific aims focused on CVB pathogenesis (Aims 1-3) and immunity (Aims 4, 5). Aim 1. Does CVB preferentially infect proliferating cells in vivo? We have shown, in tissue culture, that the cell cycle exerts a
Studies 17
dramatic effect on CVB gene expression & virus production. Is this also true in vivo, in the heart, central nervous system, or immune system? We shall identify proliferating cells in these tissues, and will determine if they are more susceptible to infection. If the heart is injured in vivo, does this alter its susceptibility to subsequent CVB infection? Aim 2. What component of the virus responds to the host cell cycle? Next, we shall study the viral side of the equation. We hypothesize that the internal ribosome entry site may be the viral "response element"; this will be evaluated in tissue culture, and in vivo. Aim 3. What role do the proposed CVB receptors play in tropism & pathogenesis in the heart & CNS? We shall evaluate the expression levels of the receptors. Do they change with age? Following infection / tissue damage, are the receptors upregulated in neighboring cells? Aim 4. How do CD8+ T cells contribute to the control of CVB infection? We have shown that, during CVB infection, CD8+ T cells can reduce viral titers, and that this effect does not require perforin. What effector functions are involved in the antiviral effect? Do these effector functions contribute to tissue damage?Aim 5. How does CVB so effectively avoid inducing strong CD8+ T cell responses? Most virus infections induce high levels of antiviral CD8+ T cells. How does CVB avoid this? Can we rectify the situation? Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: DEAFNESS AND OSSIFICATION IN LABYRINTHITIS OSSIFICANS Principal Investigator & Institution: Brodie, Hilary A. Otolaryngology; University of California Davis Sponsored Programs, 118 Everson Hall Davis, CA 95616 Timing: Fiscal Year 2001; Project Start 01-JAN-2000; Project End 31-DEC-2004 Summary: (Adapted from the Investigator's Abstract) Labyrinthitis ossificans (LO) is the growth of pathologic new bone within the lumen of the cochlea. It is multifactorial in origin and may result in deafness. Profound hearing loss and LO in children are most commonly associated with meningogenic labyrinthitis. The relationship of LO to meningogenic cochlear pathology and its mechanism of induction have not been clearly defined. Cochlear implants are a significant treatment option for improving hearing and quality of life in these patients. However, LO can reduce the efficacy of cochlear implantation. The long-term objective of this research program is to understand the mechanisms which lead to the development, progression, and destructive aspects of LO. Such an understanding may lead to new strategies to prevent the devastating effects of hearing loss associated with this disease. The specific aims of this application are: (1) to correlate hearing loss with the temporal and spatial progression of bacterial meningitis from the subarachnoid space to the cochlea; (2) to correlate hearing loss with the temporal and spatial sequence for both labyrinthine fibrosis and ossification and the histopathology of cochlear tissues: spiral ganglion, organ of Corti, Reissner's membrane, stria vascularis, and spiral ligament; (3) to determine the relationship of bone lining cells to osteoblast formation and recruitment during labyrinthine neo-ossification; and (4) to determine the effects of decomplementation, non-steroidal anti-inflammatory compounds, and bacteriostatic vs. bactericidal antibiotics on neo-ossification and hearing loss. There are four hypotheses/specific aims outlined and they are as follows: Bacterial invasion of the cochlear labyrinth from the subarachnoid space correlates with hearing loss and occurs principally via the cochlear aqueduct and not the internal auditory canal; The destruction of cochlear tissue occurs subsequent to the arrival of inflammatory cells and not with the appearance of bacteria within the cochlea. Hearing loss may occur prior to observable pathology and reflect central auditory damage related to meningitis; Bone lining cells of the endosteum are activated and become mature osteoblasts and are the principal source of neo-ossification in labyrinthitis
18 Meningitis
ossificans; and The inflammatory response to suppurative labyrinthitis includes fibrosis and neo-ossification formation and causes cochlear tissue destruction. Inhibition of this process will result in a reduction in both hearing loss and bone deposition. Methods used: The investigators propose to use an experimental gerbilline model of LO, histomorphometry, fluorescent bone histomorphometry, transmission and scanning electron microscopy, autoradiography, and auditory brainstem evoked response. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: DETERMINANTS OF INNATE IMMUNITY TO GROUP B STREPTOCOCCI Principal Investigator & Institution: Levy, Ofer; Brigham and Women's Hospital 75 Francis Street Boston, MA 02115 Timing: Fiscal Year 2002; Project Start 01-MAR-2002; Project End 28-FEB-2006 Summary: (provided by applicant): The central goal of this project is to understand the role of innate immunity in infections caused by Group B streptococci (S. agalactiae or GBS). GBS are the major cause of neonatal sepsis and meningitis and thus a leading cause of neonatal morbidity and mortality. GBS-induced inflammatory mediators include tumor necrosis factor (TNF) that, when excessive, can contribute to host morbidity and mortality. Recent evidence suggests that a variety of Gram-positive bacterial surface molecules activate the innate immune system via phagocyte innate immune receptors including cellular differentiation antigen-14 (CD14), complement receptors-3 and -4 (CR3/4), and Toll-like receptor 2 (TLR2). The candidate will further characterize bacterial and host determinants of innate immunity to GBS and test the following hypotheses: Specific molecular interactions between GBS surface components and phagocyte innate immune receptors mediate the host inflammatory response to GBS infection, that such responses are down-regulated by neutrophil-derived antimicrobial peptides that bind and neutralize inflammatory GBS surface molecules, and that these pro- and anti-inflammatory innate immune responses differ between newborns and adults. In Aim 1, GBS surface components that activate host phagocytes (i.e., neutrophils and monocytes) will be identified and characterized. In Aim 2, newborn and adult phagocytes will be compared with respect to expression and function of CR3/4, CD14, and TLR2. In Aim 3, putative neutrophil-derived peptides with anti-inflammatory activity against GBS will be isolated and characterized. The candidate seeks an intensive, formal, mentored training as preparation for becoming an independent scientist. As a specialist in pediatric infectious diseases, his long-term goal is to identify molecular pathways of innate immunity that might someday be modulated to improve outcomes of GBS and other bacterial infections in neonates. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: MENINGITIS
DISCONTINUATION
ANTIFUNGAL
FOR
CRYPTOCOCCAL
Principal Investigator & Institution: Aberg, Judith; University of California San Francisco 500 Parnassus Ave San Francisco, CA 94122 Timing: Fiscal Year 2001 Summary: This abstract is not available. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
Studies 19
•
Project Title: E COLI TRANSLOCATION ACROSS INTESTINAL EPITHELIUM Principal Investigator & Institution: Pietzak, Michelle M.; Children's Hospital Los Angeles 4650 Sunset Blvd Los Angeles, CA 90027 Timing: Fiscal Year 2001; Project Start 01-JUL-1999; Project End 30-JUN-2004 Summary: This application for a Mentored Clinician Scientist Development Award (K08) seeks support for Michelle Pietzak, M.D., who has recently completed her fellowship in Pediatric Gastroenterology and Nutrition and joined the faculty as an Instructor of Pediatrics at Childrens Hospital Los Angeles (Assistant Professor pending). Under the mentorship of Kwang Sik Kim M.D., Dr. Pietzak will continue to pursue her basic investigations into the mechanisms by which Escherichia coli (E. coli) is able to translocate across intestinal epithelium and cause sepsis. E. coli is a leading cause of severe bacterial infections in premature infants, neonates, immunocompromised hosts, and children with central lines and primary intestinal diseases. Dr. Kim is a prominent researcher in the field of the pathogenesis of E. coli meningitis, having (a) established the virulence roles for the K1 capsular polysaccharide, outer membrane protein A, and S fimbriae using in vitro and in vivo models of the blood brain barrier developed in his lab and (b) identified several novel genes thought to be responsible for invasion of E. coli strain RS218 across the blood brain barrier, using these same models. E. coli strain RS218 is a clinical isolate from the cerebrospinal fluid of a human neonate with E. coli meningitis. Dr. Pietzak's project is focused on investigating the mechanisms by which E. coli strain RS218 is able to penetrate the intestinal epithelial barrier, both in vitro and in vivo. In earlier studies, Dr. Pietzak has used strain E44, a spontaneous rifampin resistant mutant of E. coli strain RS218, to demonstrate that this bacterium is able to invade two intestinal epithelial cell lines, Caco-2 and C2BBe-1. The specific aims of this proposal are to further characterize the invasive phenotype of E-44 in vitro, using both gentamicin invasion assays and a trans-well system. An in vivo model, using neonatal rats, will also be used to test the invasive phenotype of E-44. Environmental factors, which mimic the intraluminal gastrointestinal milieu, will be employed to examine their effects on E. coli invasion and translocation in vitro. The virulence of TnphoA transposon mutants, created in our lab and already shown to be noninvasive to the blood brain barrier in vitro and in vivo, will be determined for the intestinal epithelial barrier both in vitro and in vivo. The precise contribution of these genes to the intestinal translocation of E. coli strain RS218 will then be examined using additional molecular techniques. Under Dr. Kim's mentorship, and with Institutional support, Dr. Pietzak will be able to perfect her techniques in cell tissue culture and animal models of bacterial infection, as well as acquire new knowledge and skills in the sciences of bacterial genetics and molecular pathogenesis. Nurturing these ambitions in a collaborative environment will help Dr. Pietzak achieve her goal of becoming an independent investigator, who hopefully will be able to bring the results of her investigations from the benches of the lab to the bedsides of chronically ill children with gastrointestinal and other diseases. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: E. COLI BINDING TO BRAIN ENDOTHELIAL CELLS Principal Investigator & Institution: Kim, Kwang S. Professor and Director; Pediatrics; Johns Hopkins University 3400 N Charles St Baltimore, MD 21218 Timing: Fiscal Year 2001; Project Start 01-APR-2000; Project End 31-MAR-2004 Summary: (Adapted from the Applicant's Abstract): The principal investigator has established an infant rat model of experimental hematogenous meningitis, which mimics human E. coli meningitis (i.e., hematogenous infection of the meninges without
20 Meningitis
the need for adjuvant or direct inoculation of bacteria into cerebrospinal fluid). They have established an in vitro model of blood-brain barrier using brain microvascular endothelial cells (BMEC). Using both in vitro and in vivo systems and the BMEC model, they have shown that successful traversal of E. coli across the blood-brain barrier may be a complex process involving separate steps of E. coli-BMEC interactions, i.e., binding to BMEC and invasion of BMEC. They have shown that S fimbriae are the major E. coli structures contributing to binding to BMEC. They therefore hypothesize that the role of S fimbriae is to have a more intimate contact for circulating E. coli to BMEC to withstand blood flow, which may be required for subsequent crossing of the blood-brain barrier, but there is no information to support this hypothesis. The overall aim of the proposal is to study the role of binding via S fimbriae in the pathogenesis of E. coli meningitis, both in vitro (using BMEC in culture) and in vivo (using an experimental animal model of hematogenous E. coli meningitis that closely mimics the pathogenesis of human E. coli meningitis). The specific aims are: (1)to continue to construct isogenic S fimbriae operon deletion (delta sfaII) mutant of invasive E. coli K1 strain RS218 by chromosomal gene replacement (allelic exchange); (2)to examine the ability of S fimbriae negative (delta sfaII) mutant to bind and invade brain microvascular endothelial cells (BMEC) in vitro and in vivo; (3)to determine whether it is possible to restore the ability of S fimbriae negative (delta sfaII) mutant to bind and invade BMEC by complementation with the cloned sfaII gene cluster; (4)to assess which specific subunits of S fimbriae are responsible for binding to BMEC by constructing single gene deletion mutants (delta sfaIIS, delta sfaIIA, delta sfaIIG, delta sfaIIH); (5)and to identify and characterize BMEC glycoprotein(s) interactive with S fimbriae. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: EARLY LYME--CNS INVASION Principal Investigator & Institution: Coyle, Patricia K. Associate Professor; State University New York Stony Brook Stony Brook, NY 11794 Timing: Fiscal Year 2001 Summary: Lyme disease is an important emerging infection caused by a tick borne spirochete B. burgdorfi (Bb). Originally characterized as an arthritis, it appears that neurologic involvement is also a significant early manifestation of the disease in North America. Neurologic complications of the disease can involve meningitis, facial nerve palsy (or other cranial neuropathy) and radiculoneuritis in early disseminated infection. It is also unclear at what point the infection changes from a localized skin erythema migrans (EM) to an early disseminated syndrome. The objective of this study is to characterize the frequency, clinical correlates and outcome of central nervous system infection in early Lyme disease. The study parameters will include clinical features, immune response, cerebrospinal fluid changes, neurocognitive disturbances, and psychosocial aspects of the disease. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: EHRLICHIA CHAFFEENSIS SURFACE PROTEINS Principal Investigator & Institution: Walker, David H. Professor; Pathology; University of Texas Medical Br Galveston 301 University Blvd Galveston, TX 77555 Timing: Fiscal Year 2001; Project Start 30-SEP-1991; Project End 31-MAR-2005 Summary: (provided by the applicant): The long-term goal of this research is the elucidation of the mechanisms of protective immunity against Ehrlichia chaffeensis, the causative agent of human monocytotropic ehrlichiosis (HME). Achievement of this goal
Studies 21
requires knowledge of which humoral and cellular immune mechanisms stimulated by ehrlichiae are effective in the clearance of ehrlichiae. HME is a life-threatening tickborne infection associated with adult respiratory distress syndrome, meningitis, and shock in immunocompetent patients, overwhelming infection in immunocompromised patients, and a fatality rate of 2.7 percent. More than 2,200 cases have been diagnosed with laboratory confirmation, and the incidence is 1,000 cases per 1,000,000 population in tick-exposed rural populations. The specific aims test the hypothesis that the immunodominant, surface-exposed p28 antigens stimulate protective immunity by antibodies and cellular mechanisms and determine the importance and mechanisms) of antibodies and cellular mechanisms of protective immunity in mouse models of HME. The research design includes sequencing of the loci of the p28 multigene families of major immunodominant surface proteins of Ehrlichia muris and a related ehrlichia (IOE) DNA and recombinant protein vaccines in the E. muris mouse model and the highly pathogenic IOE-C57BL/6 mouse model. Humoral immunity will be passive polyclonal and monoclonal antibodies to the conserved and variable regions of p28 families in IOE-infected mice including Fc-receptor knockout mice. Opsonization will be investigated in murine macrophages in vitro with E. muris and specific polyclonal and monoclonal antibodies. Cellular immune mechanisms will be elucidated using gene knockout mice (MHC Class I, MHC Class II, delta T-cell receptor, IFN-gamma, perforin, iNOS, and TNF-alpha receptor) and TNF-alpha depleted mice, immunohistochemical and flow cytometric analyses of the cell subsets and their cytokine profiles, adoptive transfer of T-lymphocyte subsets including T-cell clones in the outstanding new mouse model of HME. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: EMERGING INFECTIOUS DISEASES AND URBANIZATION Principal Investigator & Institution: Ko, Albert I. Medicine; Weill Medical College of Cornell Univ New York, NY 10021 Timing: Fiscal Year 2003; Project Start 20-SEP-1997; Project End 31-MAR-2008 Summary: (provided by applicant): The Division of International Medicine and Infectious Disease, Weill Medical College of Cornell University (Cornell) has had a joint training and research program on endemic tropical diseases with Brazilian institutions in the city of Salvador since the 1964. More recently, the investigations of Cornell and its Brazilian collaborators have brought to attention infectious diseases, such as epidemic leptospirosis, which have emerged in the urban setting due to rapid urbanization and increasing social inequality. Through the Fogarty-sponsored International Training in Emerging Infectious Diseases (ITREID) Program, we have been established at the Oswaldo Cruz Foundation (Fiocruz), Brazilian Ministry of Health in Salvador: 1) a multidisciplinary team of epidemiologists, clinicians, microbiologists and basic researchers, 2) on-going population-based surveillance for leptospirosis and bacterial meningitis; 2) a diagnostic laboratory that is now the national reference center for leptospirosis surveillance; 3) a molecular strain typing center, and 4) field sites to perform community-based longitudinal studies designed to identify determinants of transmission for leptospirosis and the etiologic pathogens for bacterial meningitis. Moreover, ITREID projects have convinced the Brazilian government to prioritize emerging infectious diseases such as leptospirosis, and in turn have led to national projects to sequence the Leptospira genome and develop a vaccine against leptospirosis. The infrastructure created at Fiocruz since 1996 provides a vehicle to pursue multidisciplinary training approaches for emerging infectious diseases. In this proposal, we will use leptospirosis and bacterial meningitis as disease models to address the
22 Meningitis
following specific objectives: 1) Expand training opportunities that will provide Brazilian trainees at Fiocruz the capacity to develop treatment, control and prevention strategies for emerging infectious diseases; and 2) Work jointly with the Brazilian Ministry of Health to disseminate expertise already established at Fiocruz in laboratorybased surveillance, outbreak investigations and molecular epidemiology to other regions of Brazil. The proposal emphasizes the use of in-country expertise and resources to provide training. For the first aim, we propose long-term training to 6 predoctoral and 2 postdoctoral fellows each year to address specific needs in expertise within the areas of clinical and field epidemiology, molecular epidemiology, pathogenesis and biotechnology application to develop public health interventions. In-country training provided by outstanding Brazilian mentors will be augmented with short training experiences in the institutions of long-standing US collaborators. For the second aim, Fiocruz will work with the National Center of Epidemiology, Brazilian Ministry of Health in providing short-term training opportunities and a yearly course, the National Course in Molecular Epidemiology in Emerging Infectious Diseases, which are designed to enhance the capacity of local public health epidemiologists and reference laboratory staff to perform laboratory-based surveillance and apply molecular strain typing tools to epidemiological investigations. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: ENTEROVIRUS 71 LEADER: TARGET FOR PEPTIDE INHIBITORS Principal Investigator & Institution: Thompson, Sunnie R. Microbiology and Immunology; Stanford University Stanford, CA 94305 Timing: Fiscal Year 2001; Project Start 01-MAR-2001 Summary: Every year hundreds of thousands of children are infected with enterovirus 71 (EV71). Infection with EV71 can lead to serious complications such as polio-like paralysis, encephalitis, meningitis or even death. Currently, there is no treatment or vaccine against EV71. EV71 belongs to the picornavirus family, whose members contain positive-stranded RNA genomes that are translated by an unusual mechanism of internal ribosome entry. The differences between the model of translational initiation of most cellular and viral mRNAs will be exploited to identify small peptides that can selectively inhibit the translation of the EV71 mRNA. Specifically, retroviruses expressing conformationally constrained peptide libraries will be used to infect cells expressing the EV71 5' non-coding region linked to an enhanced green fluorescent protein (EGFP) reporter gene and a cellular c-myc 5' non- coding region linked to an enhanced yellow fluorescence protein (EYFP). Infected cells which fail to express EGFP but still express EYFP will be isolated by cell sorting, and the gene encoding the putative inhibitor will be isolated. Studying the targets of the inhibitory peptides and characterizing the molecular interactions that they are disrupting will reveal more about how viruses function to recruit host cell molecules for their translation. Selection and characterization of intracellularly stable peptides that can inhibit the amplification of a viral RNA genome should level to novel ways in the search for antiviral therapeutics. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: ENTEROVIRUS RNA TRANSLATION AND REPLICATION Principal Investigator & Institution: Barton, David J. Assistant Professor; Microbiology; University of Colorado Hlth Sciences Ctr P.O. Box 6508, Grants and Contracts Aurora, CO 800450508 Timing: Fiscal Year 2003; Project Start 15-SEP-2003; Project End 31-AUG-2004
Studies 23
Summary: (provided by applicant): Enteroviruses cause a diverse spectrum of human diseases including conjunctivitis, myocarditits, aseptic meningitis, acute flaccid paralysis, and fatal systemic infections in neonates. Poliovirus, the prototypic enterovirus, is well characterized at the molecular level and still serves as the most appropriate virus for studies of RNA translation and replication. In this proposal, poliovirus mRNA translation and RNA replication will be studied in cell-free reactions capable of supporting the sequential translation and replication of poliovirus RNA. These reactions are advantageous because they support authentic translation and replication of poliovirus RNA while providing numerous technical advantages including the ability to synchronize viral mRNA translation and viral RNA replication. The interaction of cis-active RNA structures at the termini of poliovirus RNA will be examined. Temporally dynamic ribonucleoproteins form on poliovirus cis-active RNA structures to mediate and regulate the sequential steps of replication. Experiments will be performed to: 1) determine how the 5' cloverleaf RNA structure of poliovirus potentiates viral mRNA translation, 2) determine how translating ribosomes regulate, in part, the switch from viral mRNA translation to RNA replication, 3) determine how apparently distal cis-active RNA structures interact to regulate sequential steps of viral RNA translation and replication, and 4) determine the mechanisms behind the asymmetric replication of poliovirus RNA. These experiments will help elucidate the fundamental sequence of molecular interactions required for enterovirus RNA translation and replication. This information will provide for a better understanding of the mechanisms by which enteroviruses replicate. In particular, these studies will contribute substantial new information to support the popular new paradigm of 5'-3' RNA interactions in messenger ribonucleoprotein complexes and RNA replication complexes. The experiments directly test a hypothesis concerning the mechanism by which RNA replication machinery avoids ribosome-replicase collisions. Finally, the experiments test a new model that clearly explains the mechanisms controlling asymmetric RNA replication. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: ESCHERICHIA COLI INVASION OF BRAIN ENDOTHELIAL CELLS Principal Investigator & Institution: Huang, Sheng-He; Children's Hospital Los Angeles 4650 Sunset Blvd Los Angeles, CA 90027 Timing: Fiscal Year 2001; Project Start 01-JUL-1997; Project End 30-JUN-2002 Summary: (Adapted from the applicant's abstract): Bacterial meningitis continues to be associated with high morbidity and mortality despite advances in chemotherapy and supportive care. E. coli is the most common gram-negative organism that causes neonatal meningitis. Most cases develop as a result of hematogenous spread, but it is not clear how circulating E. coli traverse the brain microvascular endothelium, which constitutes the blood brain barrier. The PI has demonstrated that the invasion of brain microvascular endothelial cells (BMEC) by E. coli K1 is mediated by multiple factors. Two separate genetic loci, identified by the PI as pathogenicity islands (paiA and paiB) apparently contribute to E. coli meningitis. PaiA contains the 20 kb E. coli locus identified as the major invasion gene cluster in K1 E. coli strain RS218. A TnphoA insertion mutant of E. coli RS218 was unable to invade BMEC in tissue culture and to cause hematogenous meningitis in a newborn rat model. Encoded on paiA is ibe10, which encodes an 8.2 kDa protein displaying the characteristics of an integral membrane protein with four transmembrane domains. A recombinant Ibe10 protein was able to block invasion of BMEC by E. coli K1. Ibe10 was detected in 30% of clinical isolates of K1 E. coli causing meningitis. Six clones for Ibe10 have been isolated from a lambda Gem-
24 Meningitis
12 library. A recombinant plasmid carrying a 15 kb E. coli fragment was able to complement the non-invasive TnphoA mutant 10A-23. And, in an appendix, the PI reports that he has succeeded in conferring invasiveness on a strain of E. coli K12 using an 18 kb fragment of paiA. The long term goal of this work is to develop novel strategies for the prevention and treatment of E. coli meningitis (such as vaccines) based on a full understanding of the molecular mechanisms responsible for E. coli invasion of the blood-brain barrier. The PI hypothesizes that the phenotype of E. coli invasion of the blood-brain barrier is encoded by the pathogenic E. coli K1-specific genetic determinants, the pai's. The proposal comprises two aims: Aim 1: To further characterize the role of the invasion gene cluster paiA and/or paiB in the pathogenesis of E. coli meningitis by using in vitro (BMEC invasion) and in vivo (infant rat) models and molecular and genetic approaches. Aim 2: To determine the function and functional domains of invasion protein ibe10 by identification of the BMEC receptor for ibe10, in vitro mutagenesis and epitope mapping. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: FORMATION OF CORTICAL PLAQUES BY NEISSERIA Principal Investigator & Institution: So, Magdalene Y. Chair; Molecular Microbiol and Immun; Oregon Health & Science University Portland, OR 972393098 Timing: Fiscal Year 2001; Project Start 01-AUG-2001; Project End 31-MAY-2006 Summary: (provided by the applicant): The Neisseria type IV pilus modulates bacterial infectivity by mediating adhesion and inducing cell signaling pathways. Upon binding its receptor, CD46, the pilus causes a transient increase in cytosolic free Ca2+ levels, triggering endosome and lysosome exocytosis. Piliated bacteria next trigger elongation of microvilli and formation of cortical plaques at the plasma membrane beneath the site of contact. Cortical plaques contain clusters of Opa receptors, transmembrane signaling proteins, actin microfilaments and ezrin, a protein that tethers the membrane to the actin cytoskeleton. These plaques serve multiple signaling functions that promote bacterial infection. Unlike the Ca2+ response, which can be induced with purified pill, cortical plaque formation requires live diplococci and PilT, a protein that functions in pilus assembly and DNA transformation. PilT also controls pilus retraction, a process that drives twitching motility and the ability of diplococci to aggregate into microcolonies. Retraction generates substantial force on the substrate to which the pilus is attached. External forces placed on the membranes of eucaryotic cells result in the induction of kinase cascades, cytoskeleton reorganization and alterations in translation. The tension generated on the plasma membrane by retraction of pili during infection may therefore act as a signal to promote the formation of cortical plaques and subsequent bacterial invasion. Based on these and other observations, we propose a model for early events in pilus-induced cortical plaque formation. In this proposal, we describe experiments to test key predictions of this model. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: FREQUENCY DOMAIN CEREBRAL OXIMETER FOR PEDIATRICS Principal Investigator & Institution: Kurth, Dean C. Attending Anesthesiologist; Near Infrared Monitoring, Inc. (Nim) 3401 Market St, Ste 140F Philadelphia, PA 19104 Timing: Fiscal Year 2001; Project Start 01-APR-2000; Project End 29-SEP-2002 Summary: Brain damage from hypoxia-ischemia represents a major health problem in pediatrics. At present, no method exists in clinical care to diagnose cerebral hypoxiaischemia in real-time at the bedside, thereby limiting prevention and treatment of the
Studies 25
brain damage. Near infrared spectroscopy (cerebral oximetry) is an emerging optical technology with the potential to fulfill this role. In previous work, we built a prototype frequency domain near infrared cerebral oximeter and found it measures cerebral O2 saturation accurately. However, before clinicians will use cerebral O2 saturation to diagnose cerebral hypoxia-ischemia, the measure needs to be related to other known measures of hypoxia-ischemia, and the instrument needs to be engineered to the clinical environment. This fast-track proposal will develop a frequency domain near infrared cerebral oximeter to diagnose cerebral hypoxia-ischemia in real-time at the bedside for pediatrics (<8 years). Instrument development includes construction of "user-friendly" hardware and software, evaluation of its performance in a simulated clinical environment, and identification of critical cerebral 02 saturation-in piglets to diagnose hypoxia-ischemia. The instrument will be operable by the nurse caring for the child at the bedside and will display cerebral O2 saturation and messages to facilitate its operation. PROPOSED COMMERCIAL APPLICATION: The cerebral oximeter will be used in children at risk of hypoxic-ischemic brain damage. The population at risk, encompassing about 5% of pediatrics, includes sick premature infant and lull term infants, as well as children with congenital heart disease, sickle cell anemia, seizure disorders, or meningitis. The market is enormous as it consists of all hospitals and freestanding clinics treating this population. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: FUNCTIONAL SIMILARITIES IN RENAL AND COCHLEAR EPITHELIA Principal Investigator & Institution: Steyger, Peter S. Otolaryngology Head & Neck Surgery; Oregon Health & Science University Portland, OR 972393098 Timing: Fiscal Year 2003; Project Start 15-MAR-2003; Project End 28-FEB-2005 Summary: (provided by applicant): Aminoglycosides are clinically essential for treating life-threatening Gram-negative bacterial infections, e.g., meningitis, and in preventing infection in burns and premature babies. However, there is a high incidence of ototoxicity and sensory hair cell death. Sensitive hair cell function is dependent on a structurally and physiologically intact ear. Thus, studies to determine mechanisms of ototoxicity have used intact animals, or inner ear explants excised from animals. There are a number of functional, toxicological, and pharmacological similarities between inner ear cells and cells of the kidney tubules. To exploit these similarities, we have developed cloned sub-lines of currently-available kidney cell lines to determine their validity as in vitro models to study the mechanisms of aminoglycoside transport and toxicity in the inner ear. Using the aminoglycoside gentamicin, we propose to use cloned kidney cells to study two distinct aspects of aminoglycoside ototoxicity: 1) Like hair cells, proximal tubule epithelial cells of the kidney are among the few cell types that are toxicologically sensitive to clinical doses of aminoglycosides. These cell types also share pharmacological sensitivities to several other drugs. We will use a clone of OK cells, a proximal kidney tubule line, to determine the feasibility of using proximal tubule cells as valid in vitro models of aminoglycoside uptake and toxicity by hair cells. 2) Little work has been done to determine the mechanism of drug entry into the endolymph. Research suggests that hair cell uptake of aminoglycosides is across the apical membrane that is exposed only to the highly-regulated endolymph. Thus, pathways of drug entry into the endolymph will be highly-potent sites of intervention to prevent ototoxicity during treatment. The various epithelia surrounding the endolymph are cumbersome to acquire as explants in the quantity and proper configurations to facilitate direct examination of aminoglycoside transit across these epithelia. Therefore,
26 Meningitis
we have developed a kidney distal tubule cell line to use as a model for aminoglycoside transport across the various epithelia enclosing the endolymph compartment. Distal tubule cells share several characteristics with inner ear epithelia such as the marginal cells of the stria vascularis. We will use a clone of MDCK cells, a distal tubule line, to determine the feasibility of using distal tubule cells as valid in vitro models for aminoglycoside transport across the epithelia enclosing the scala media. Results obtained from both studies will periodically be compared with animal models for confirmation. Preliminary data obtained with use of our cloned kidney cell lines have already dramatically changed our understanding of aminoglycoside entry into, distribution within, and transit across epithelia. Both of these in vitro models should provide powerful tools for finding co-therapeutics to reduce or eliminate ototoxicity during aminoglycoside treatment, blocking both toxic events in the hair cells and drug access to the endolymph and, thus, the hair cells. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: DISCOVERY
GBS:
EPIDEMIOLOGIC
CHARACTERIZATION
FOR
GENE
Principal Investigator & Institution: Foxman, Betsy; Professor; Epidemiology; University of Michigan at Ann Arbor 3003 South State, Room 1040 Ann Arbor, MI 481091274 Timing: Fiscal Year 2003; Project Start 01-JAN-2003; Project End 31-DEC-2007 Summary: (provided by applicant): Group B Streptococcus (GBS) is a major cause of neonatal sepsis and meningitis. First emerging as a pathogen in newborn nurseries in the 1970s, it is now a pathogen of concern in nursing homes, intensive care units and outpatient settings. Little is known about GBS virulence factors. The overall goals of this application are 1) to use genetic fingerprinting techniques to better describe the molecular epidemiology of GBS of several epidemiologically defined collections; and 2) to identify new genes associated with GBS disease. By combining epidemiologic information with molecular genetics, we can maximize our ability to detect GBS virulence-related genes associated with invasive disease, extra-intestinal colonization, transmission and antibiotic resistance. This strategy also gives us insight as to the relative importance of the identified genes and their potential mechanism. A better understanding of the molecular epidemiology and the identification of new GBS virulence genes will facilitate the discovery of new therapies and prevention strategies for GBS disease. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: GENE DISCOVERY FOR PNEUMOCOCCAL OTITIS MEDIA Principal Investigator & Institution: Pettigrew, Melinda M. Epidemiology and Public Health; Yale University 47 College Street, Suite 203 New Haven, CT 065208047 Timing: Fiscal Year 2003; Project Start 01-JUL-2003; Project End 30-JUN-2006 Summary: (provided by applicant): Otitis media (OM) is the most common bacterial infection in the United States among young children for which medical care is sought, and Streptococcus pneumoniae strains are the leading cause of bacterial OM. These gram-positive diplococci colonize the respiratory tract in up to 50% of healthy children and only cause disease under special circumstances. Recent genomic sequencing projects and advancements in molecular biology have resulted in the identification of numerous putative virulence factors. These factors have mainly been studied in the context of invasive pneumococcal diseases such as pneumonia, or have been studied in one or a few laboratory strains. While more virulence factors remain to be discovered,
Studies 27
the new challenge is to identify which of these many factors warrant further study, to link these factors specifically to OM pathogenesis, and to estimate the relative importance of these virulence factors among the S. pneumoniae strains in circulation. This project is built on the observation that S. pneumoniae strains differ in their ability to cause disease, and that these differences are likely due to genetic differences between strains that extend beyond the polysaccharide capsule. The goal of this project is to identify genes associated with pneumococcal OM and to evaluate the relative frequency of pneumococcal virulence genes among a collection of isolates obtained from healthy children and children with clinical disease. A four step interdisciplinary approach utilizing techniques of molecular biology and epidemiology will include: 1. Selection of S. pneumoniae strains for genomic subtraction with the highest potential to identify genes associated with OM. 2. Identification of DNA sequences (sPCR fragments) unique to strains causing OM (tester strains) and absent in strains from healthy carriers (driver strains) using genomic subtraction. 3. Epidemiologic screening of a large collection of isolates from healthy children and children with OM, meningitis, pneumonia, or bacteremia using sPCR fragments. 4. Identification of genes associated with sPCR fragments important for OM pathogenesis and description of their biological and clinical characteristics. Discovery of additional factors involved in streptococcal OM will facilitate the development of new strategies for the control and prevention of this important disease. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: GENETIC IMMUNIZATION AGAINST PNEUMOCOCCAL DISEASE Principal Investigator & Institution: Zeng, Mingtao; Microbiology and Immunology; University of Rochester Orpa - Rc Box 270140 Rochester, NY 14627 Timing: Fiscal Year 2002; Project Start 20-SEP-2002; Project End 31-AUG-2005 Summary: (provided by applicant): Streptococcus pneumoniae is the most common bacterial cause of otitis media and acute respiratory infection and is estimated to result in over three million deaths in children every year worldwide from invasive diseases such as pneumonia, bacteremia, meningitis, and septicemia. The low efficacy of currently licensed pneumococcal polysaccharide vaccine has necessitated research into more efficient vaccines against pneumococcal disease. The long-term goal of this research is to develop a multi-component vaccine against pneumococcal disease, using genetically and antigenically conserved outer membrane proteins PspA, PsaA, and detoxified pneumolysin (PdB) from S. pneumoniae. Our hypothesis is that an effective pneumococcal vaccine should be composed of multiple conserved relevant antigens delivered preferably by a mucosal route in order to provide the best non-serotypedependent protection against S. pneumoniae infection. Intranasal and transcutaneous immunization with replication-incompetent adenoviral vectors have proved to be efficient and simple for immunization. This non-invasive vaccine delivery will undoubtedly enhance the compliance of a vaccination program. In this project, adenovirus and plasmid expression vectors encoding PspA, PsaA and PdB will be constructed. In order to obtain an optimal vaccination protocol, immunization regimens with different combinations of adenoviral vectors through the intranasal and transcutaneous delivery modes will be compared with the intramuscular injection of plasmid expression vectors. The specific aims of this project are: Specific Aim#1: To develop a replication-incompetent adenovirus-vectored vaccine against Streptococcus pneurnoniae. Specific Aim #2: To compare the mucosal and systemic immunity elicited by adenovirus-vectored vaccine through intranasal and transcutaneous administrations with that elicited by plasmid expression vectors through intramuscular injection.
28 Meningitis
Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: GENETIC MUTATIONS THAT PREDOPOSE TO INFECTIOUS DISEASE Principal Investigator & Institution: Butler, Bruce; Scripps Research Institute 10550 N Torrey Pines Rd La Jolla, CA 920371000 Timing: Fiscal Year 2002; Project Start 30-SEP-2002; Project End 31-JUL-2007 Summary: The innate immune response is dependent upon a discrete collection of proteins that mediate the detection of microbial invaders and their elimination. Only a handful of these proteins are known at present, and among them, the Toll-like receptors and associated signaling proteins play a prominent role as sensors. The program of which this Bridging proposal is a part will permit the identification of many critical genes involved in the innate immune response. We propose to examine each of these genes in turn, starting with the Toll-like receptors and moving to new genes as they are discovered. Our ultimate goal is to determine whether mutations at these loci contribute to susceptibility to sepsis in humans, or influence the outcome of sepsis once it is established. The approach taken is one in which modem techniques for mutation detection will be used to assay genetic load within the coding region at each locus, in disease populations and in ethnically matched control populations. In particular, we will emphasize the use of advanced methods for mutation detection, coupled with highthroughput sequencing to achieve this end. In accordance with the emerging principle that most complex human diseases may be ascribed to low-frequency codominant mutations affecting multiple loci, it is expected that mutations will be over-represented in specific loci within a disease population, given that those loci encode genes that are important in fighting infection. Preliminary work has supported this principle as it applies to the TLR4 locus in meningococcal disease: there is a significant excess ofmissense mutations at this locus in the disease population, compared with controls. We intend to generalize the principle, seeking to establish the importance of rare mutations at multiple loci in the pathogenesis of diverse infections. This proposal will entail extensive interactions between the Forward Genetics Core, the Genomics Core, and the Sequencing Core. Mutational data bearing on the involvement of specific genes in sepsis will quickly be disseminated to the scientific community at large through a webbased information system. Ultimately, these studies may foretell susceptibility to infection, and explain the strong heritability of infectious diseases in molecular terms. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: GENETIC SCREEN FOR VIRULENCE GENES IN C NEOFORMANS Principal Investigator & Institution: Lodge, Jennifer K. Assistant Professor; Biochem and Molecular Biology; St. Louis University St. Louis, MO 63110 Timing: Fiscal Year 2001; Project Start 01-MAR-1999; Project End 29-FEB-2004 Summary: The Biochemistry and Molecular Biology Department at St. Louis University School of Medicine is an ideal environment for the candidate to focus on a novel and potentially prolific research project identifying genes required for pathogenesis in the opportunistic fungal pathogen, Cryptococcus neoformans. The University offers a dynamic research environment including interactions with other mycologists, molecular geneticists and biochemists, and a generous allotment of space and equipment for the candidate to conduct a productive research program. The candidate has been committed to a carer in biological research and now has the opportunity to make a significant contribution to biomedical research and public health. The proposed research will
Studies 29
identify new genes which are essential for pathogensis of the C. neoformans. C. neoformans causes cryptococcal meningitis in 6-10 percent of patients with AIDS. As a geneticlly manipulable haploid organism with several key molecular genetic tools already available, C. neoformans is an excellent model for other opportunistic fungal pathogens. To identify fungal genes that are essential for pathogenesis, "signaturetagged" mutagenesis, a novel screen which has been highly successul in Salmonella, will be adapted for use in C. neoformans. Mutants strains of C. neoformans will be generated by insertion of a unique "signature-tag" randomly throughout the genome. The mutant strains will be pooled and injected into a mouse. A strain that fails to proliferate in the animal host will be identified by the absence of its signature-tag in the genomic DNA of the recovered pooled organisms. Strains which are confirmed to be less virulent, will be analyzed thoroughly and the genes which have been disrupted by the signature tag will be cloned and characterized. Some of the genes identified in this screen could increase our understanding of which factors contribute to the ability of an organism to be an opportunistic pathogen. Other genes may prove to be promising new leads for novel antifungal targets. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: GENETICS OF PICORNAVIRUS RNA REPLICATION Principal Investigator & Institution: Flanegan, James B. Professor; Molecular Genetics & Microbiol; University of Florida Gainesville, FL 32611 Timing: Fiscal Year 2001; Project Start 01-JAN-1992; Project End 30-APR-2002 Summary: The Picornaviridae, a family of small positive-strand RNA viruses includes a large number of important human pathogens that cause a wide variety of diseases, including respiratory infections, meningitis, encephalitis, poliomyelitis, myocarditis and hepatitis. Viral RNAs with deletions in the capsid coding region of the viral genome act as replicons and are efficiently translated and replicated in the host cell. Replicons with most of the polyprotein coding sequence deleted can replicate in in vitro reactions containing viral proteins synthesized in trans from a non-replicating helper RNA. In this proposal, molecular genetic techniques are being used to investigate poliovirus RNA replication. A mutagenic analysis of structure-function relationships for viral proteins and RNA sequences, genetic complementation assays in vivo and in vitro, genetic recombination assays and the isolation and characterization of revertant viruses are being used to define the genetic elements that are required for the replication of the viral genome. Complementation assays have been developed that can be used in transfected cells and in RNA replication assays in vitro. Both conditional and nonviable mutations can be characterized in these assays. The recent demonstration that all of the viral proteins required for RNA replication can be synthesized in trans provides a powerful new approach for genetic analysis of RNA replication. The following specific aims are proposed to continue these studies : (1) Further characterize the cis and trans genetic elements in the viral genome using a mutagenic approach and complementation assays in vivo and in vitro, (2) develop RNA recombination assays for use in the in vitro replication assays, (3) identify cis-active sequences in the viral genome that are required for RNA replication, and (4) characterize RNA sequences and structures in the 3'NTR which are required for viral RNA replication, and test the proposed model for generating revertants in the 3'NTR. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
30 Meningitis
•
Project Title: GENETICS STREPTOCOCCUS
OF
VIRULENCE
OF
TYPE
III
GROUP
B
Principal Investigator & Institution: Rubens, Craig E. Professor; Children's Hospital and Reg Medical Ctr Box 5371, 4800 Sand Point Way Ne, Ms 6D-1 Seattle, WA 98105 Timing: Fiscal Year 2001; Project Start 01-JUL-1985; Project End 30-JUN-2004 Summary: Group B streptococci (GBS) remain the most significant bacterial pathogen causing neonatal sepsis, pneumonia, and meningitis in the USA despite chemoprophylaxis strategies for preventing this infection recommended by the CDC. Although serotype III GBS account for the majority of infections, newer serotypes are emerging, eg. type V. We have demonstrated the importance of the capsular polysaccharide (CPS) to GBS virulence. Using transposon mutagenesis we identified a 20Kb region of the type III chromosome responsible for the biosynthesis of the type III capsular polysaccharide. 16 genes have now been identified by sequencing analysis which are organized according to function, putatively involved in regulation, chain length determination, export, pentasaccharide repeating unit synthesis, and sialic acid synthesis. The genetic organization is similar to that observed for the genes encoding complex polysaccharide synthesis in other gram (+) and gram (-) bacteria. Several cps genes share homology with cps genes in other organisms, although we have identified unique genes as well, which require further characterization. We have identified the first sialic acid (SA) synthesis genes in a gram (+) bacteria which share functional homology with the neu genes responsible for sialic acid and CPS synthesis in E. coli K1. This proposal seeks to extend our investigation of the type III cps gene loci. The type III cps genes are transcribed as a large polycistronic message and therefore to investigate their function we will need to develop non-polar mutations in each of the 16 genes. These mutants will be critical for investigating gene function within GBS and will be derived in aim 1, using contemporary genetic methods we developed for this organism. Each wild type gene will be cloned during the mutagenesis process, which will be important for subsequent complementation studies. Aim 2 will investigate the unique SA synthesis genes, exploiting our recent observations that they complement homologue mutations in E.coli K1. During this investigation we will perform complementation analysis of the non-polar mutants with the SA synthesis genes from E.coli, will confirm the biochemical function of each gene, and identify the sialyltransferase gene responsible for linking sialic acid to CPS. Aims 3 and 4 will begin to characterize mutants in the putative glycosyltransferases, chain length, and export loci using complementation with homologue genes from S. pneumoniae type 14 and biochemical analysis, to identify, their functional role in cps synthesis. These studies should enhance our understanding of the genetic basis of CPS expression in GBS and other encapsulated gram (+) pathogenic bacteria. They may also provide clues to the evolution of new GBS serotypes which are now causing human infections. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: GENOME ANALYSIS OF STREPTOCOCCUS AGALACTIAE Principal Investigator & Institution: Tettelin, Herves' S. Associate Investigator; Institute for Genomic Research Rockville, MD 20850 Timing: Fiscal Year 2001; Project Start 30-SEP-2001; Project End 29-SEP-2003 Summary: (provided by applicant): Group B streptococci (GBS) or Streptococcus agalactiae are weakly beta-hemolytic, facultatively anaerobic Gram-positive cocci, which have emerged over the past 50 years as the most significant bacterial cause of neonatal sepsis, pneumonia, and meningitis. GBS account for 30-50 percent of neonatal bacterial
Studies 31
infections and increases in adult GBS infections have also been noted. This demonstrates that GBS infections remain an important public health problem. We propose to sequence the 2.1 Mb genome of S. agalactiae serotype Ia strain A909 using a genome-wide random shotgun approach. We will then use the final assembled sequence and its complete annotation to perform detailed comparative genomics analyses between serotype Ia and other organisms causing pneumonia and meningitis. These analyses will allow to identify virulence determinants shared by all organisms or specific to individual ones. These determinants will be related to Drs. Jones and Rubens? experiments on signature tagged mutagenesis and TnphoZ translational fusion (identification of secreted proteins) mutant libraries constructed through transposon insertions in strain A909. Regions where transposons inserted will be aligned to the genome sequence to identify the genes affected. A subset of the mutants conserved across serotypes will be analyzed in the rat sepsis model to evaluate their virulence. This collaborative effort will provide extensive preliminary data for future proposals relevant to understanding the pathogenesis of S. agalactiae infections. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: GLOBAL PATHOGENESIS
REGULATORY
INTERACTIONS
IN
BACTERIAL
Principal Investigator & Institution: Akerley, Brian J. Microbiology and Immunology; Microbiology and Immunology; University of Michigan at Ann Arbor 3003 South State, Room 1040 Ann Arbor, MI 481091274 Timing: Fiscal Year 2002; Project Start 01-JUN-2002; Project End 31-MAY-2007 Summary: (provided by applicant): Haemophilus influenzae efficiently and chronically colonizes the human nasopharyngeal mucosa, and is capable of causing invasive disease including otitis media, pneumonia, and, more rarely, meningitis. A number of factors involved in H. influenzae virulence have been identified in the pre-genomic era. Taking advantage of the genome sequence and the advent of new technologies, such as global expression profiling, we intend to advance understanding of critical virulence characteristics of this organism. Lipopolysaccharide (LPS) structural modifications are essential virulence determinants for H. influenzae. Using expression profiling with DNA microarrays, complemented by classical approaches, we have recently uncovered a previously unappreciated link between redox regulation and LPS modifications in H. influenzae. In addition, we have isolated a mariner transposon insertion mutation in H. influenzae that disrupts redox control over one such modification (addition of a phosphorylcholine epitope, termed ChoP, to the LPS) and also results in a pronounced colonization defect in an animal model of H. influenzae infection. These observations are of potential significance for in vivo modulation of the LPS structure by environmental signals. We propose to use such signaling and regulatory mutants generated in our laboratory to examine the role of redox signaling in controlling virulence genes in H. influenzae. Global genomic approaches we have developed for studies of H. influenzae will facilitate our analysis of how LPS modifications are modulated in response to environmental conditions. We will also determine whether other genes that play a role in pathogenesis are coregulated, inversely regulated, or constitutively transcribed under the varied redox conditions that affect LPS modification. We believe that these studies will provide important insights into the relationship between physiological adaptations to the host environment and the coordinated production of bacterial cell-surface structures critical for interactions with host cells or for evading the immune response. Specifically, we will: 1. Characterize the redox control mechanisms involved in the regulation of the ChoP cell surface LPS
32 Meningitis
modification. 2. Investigate the role of signaling pathways in H. influenzae in the context of epithelial cell interactions and in a model of respiratory tract infection. 3. Examine coordinate regulation of virulence factors by redox signaling systems. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: GROUP B STREP TYPE II CONJUGATE VACCINES WITH ALUM Principal Investigator & Institution: Molrine, Deborah C. Director of Clinical Affairs; Children's Hospital (Boston) Boston, MA 021155737 Timing: Fiscal Year 2001 Summary: Phase I, multi-center, randomized, double-blind study. Group B Streptococcus type III - tetanus toxoid conjugate vaccine will be administered to healthy, non-pregnant adult volunteers. A single dose of one of three vaccine concentrations with or without alum will be given intramuscularly. Subjects will be randomized to one of four groups. Backround: Group B Streptococcus (GBS, Streptococcus agalactiae) has been recognized as a major cause of neonatal sepsis and meningitis in the United States for more than 25 years. It is also a significant cause of pregnancy-related morbidity (i.e. bacteremia, chorioamnionitis, urinary tract infection) affecting at least 50,000 women annually in the United States. There has been increased recognition during the past decade that GBS infections are a major public health problem in nonpregnant adults. It has been estimated that in the U.S. about 8,000 cases of GBS disease occur annually among persons 15 years of age and older. Risk factors that hae been identified for GBS disease in nonpregnant adults include age <60 years, chronic illnesses such as diabetes mellitus, cirrhosis, renal failure, neurologic disease, and immunosuppression from cancer or human immunodeficiency virus infection. The spectrum of clinical disease from GBS in adults includes primary bacteremia, skin and soft tissue infections, osteomyelitis, urosepsis, pneumonia, meningitis and endocarditis. Approximately 20% of cases of adult GBS disease are fatal. A strategy to prevent GBS disease through active immunization would potentially be of benefit not only for pregnant women and their newborns, but also for nonpregnant adults with defined risk factors. Purpose: 1) To asses the safety of a single injection of monovalent type III GBS polysaccharide-tetanus toxoid conjugate vaccines at different dosages with or without alum in healthy nonpregnant adults. 2) To determine the effect of an adjuvant, alum, on the immunogenicity of monovalent GBS type III polysaccharide-tetanus toxoid conjugate vaccines. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: GROUP B. STREPTOCOCCI AND TOLL-LIKE RECEPTORS Principal Investigator & Institution: Golenbock, Douglas T. Professor, Chief; Medicine; Univ of Massachusetts Med Sch Worcester Office of Research Funding Worcester, MA 01655 Timing: Fiscal Year 2002; Project Start 15-AUG-2002; Project End 31-JUL-2007 Summary: (provided by applicant): Group B streptococci (GBS) are the leading cause of neonatal sepsis, the third most frequent cause of bacterial meningitis and an increasingly important cause of bacteremia and sepsis in adults in the United States today. Preliminary studies have identified a novel proinflammatory component of GBS, which we have designated GBS-factor (GBS-F). Based on experiments in mice with targeted genetic deletions in Toll-like receptor (TLR) expression and on experiments with engineered cell lines, we have determined that responses to GBS-F require expression of CD14, TLRs 2 and 6, and the Toll-adapter protein, MyD88. Activation of
Studies 33
this receptor complex by GBS-F initiates important signaling events such as the activation of NF-kB, the phosphorylation of MAP kinases, the formation of proinflammatory cytokines, and the intracellular production of the toxic oxidant peroxynitrate. In contrast, although other components of GBS appear to engage TLRs, the exact identity of contributing TLRs is entirely unknown. The overall goal of this proposal is to identify and define components of GBS, focusing first on GBS-F, and their cognate Toll-like receptors (TLRs). We propose to characterize the structure of GBS-F and assess its function in vitro and in vivo. Furthermore, we will determine if TLR2, and related downstream signal transduction molecules, mediate a variety of important innate immune responses to GBS, including leukocyte chemotaxis and the intracellular killing of bacteria. Finally, we intend to determine what other TLRs, and associated signal transduction molecules, are involved in GBS recognition and response. The data learned from these studies should help in the development of rational therapeutic strategies to interfere with the deleterious hyperinflammation triggered by GBS and similar microbial organisms. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: HEALTH BURDEN OF CO INFECTING DEER ASSOCIATED ZOONOTIC CNS DISEASE Principal Investigator & Institution: Krause, Peter; University of Connecticut Sch of Med/Dnt Bb20, Mc 2806 Farmington, CT 060302806 Timing: Fiscal Year 2001 Summary: This abstract is not available. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: HEMOGLOBIN MENINGOCOCCI
UTILIZATION
AND
VIRULENCE
OF
Principal Investigator & Institution: Stojiljkovic, Igor; Microbiology and Immunology; Emory University 1784 North Decatur Road Atlanta, GA 30322 Timing: Fiscal Year 2001; Project Start 01-DEC-1998; Project End 30-NOV-2002 Summary: Description (Adapted from the applicant's abstract): Hemoglobin is the most abundant reservoir of iron in the body. Pathogenic microorganisms have developed surface-exposed, Hb-binding receptors that enable the assimilation of Hb-iron. The PI and others have shown that the possession of Hb-binding receptors represents a virulence trait for bacteria. These receptors have, however, only recently become the object of investigation, and our understanding of Hb-iron is therefore very limited at present. In this respect, N. meningitidis, the most common causative agent of meningitis in children in the US, expresses different Hb-iron acquisition systems. The PI has recently identified and partially characterized the Hb-binding outer membrane receptor (HmbR) of Neisseria meningitidis HmbR was expressed in all tested N. meningitidis strains. HmbR is likely a virulence factor because an hmbR mutant was impaired in virulence in an infant rat model. The mechanism and protein domains by which HmbR (or any other Hb bacterial receptor) binds and uses Hb as a source of iron are unknown. To fully understand the role of Hb-iron acquisition in virulence, the PI proposes to identify and characterize all meningococcal systems involved in Hb utilization. The PI and others have identified a second and third Hb- acquisition system of meningococci. The PI will genetically characterize the third system and use welldefined mutants in all three systems to assess the role of Hb-iron acquisition in virulence of meningococci. The study of Hb-iron acquisition systems will not only contribute to
34 Meningitis
our understanding of meningococcal virulence, but could also identify new vaccine targets against N. meningitidis. Finally, understanding Hb-iron acquisition systems may assist scientists in design of a new family of Hb-based blood substitutes that do not increase the risk of infection by Hb-utilizing bacteria. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: HIPPOCAMPAL DENTATE GYRUS INJURY IN NEONATAL BACTERIAL Principal Investigator & Institution: Pleasure, Samuel J.; University of California San Francisco 500 Parnassus Ave San Francisco, CA 94122 Timing: Fiscal Year 2002; Project Start 25-SEP-2002; Project End 31-AUG-2007 Summary: Bacterial meningitis in newborns leads to brain damage and subsequent neurologic sequelae including learning and memory deficits. In an infant rat model of neonatal bacterial meningitis, damage to the dentate gyrus of the hippocampal formation occurred regularly and showed two fundamentally distinct forms: (1) Scattered apoptotic injury confined to cells in the subgranular zone and (2) injury of the lower blade of the dentate gyrus with clusters of pyknotic appearing cells. Since the hippocampus is critical for learning and memory function, damage to it may be the basis for the learning deficits in survivors of bacterial meningitis. Indeed, damage to the dentate gyrus was associated with learning deficits in experimental meningitis. The dentate gyrus of the hippocampus is unique in two respects. First, the morphogenesis occurs very late in development in both rodents and humans, perhaps making it more vulnerable to pathologic insult at later developmental stages than other brain regions. Second, the dentate gyrus is a continuously developing system throughout life, containing progenitor cells able to multiply and give rise to new neurons. This has been implicated in the ability to form new memories and learn new tasks later in life. In meningitis, the progenitor cells appear to be selectively damaged. We will test the hypothesis that bacterial meningitis in young animals leads to selective damage within the dentate gyrus, including the progenitors or their immediate progeny, giving rise to neuroanatomical and functional abnormalities that underlie some of the permanent neurologic deficits affecting survivors of bacterial meningitis. Specifically, we will determine the nature of cell death in the dentate gyrus (apoptosis or necrosis); we will identify the cells damaged by the meningitic process )progenitor cells, immature or mature granule cell neurons, interneurons, glia); we will identify pathophysiologic factors leading to cell death (e.g., ischemia, excitatory amino acids, oxygen radicals, cytokines); and we will define in adult animals the neuroanatomical and functional consequences of damage to the immature dentate gyrus. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: HUMAN ANTIBODIES TO CRYPTOCOCCUS NEOFORMANS Principal Investigator & Institution: Pirofski, Liise-Anne A. Professor; Medicine; Yeshiva University 500 W 185Th St New York, NY 10033 Timing: Fiscal Year 2001; Project Start 01-DEC-1993; Project End 30-NOV-2003 Summary: (Adapted from the Applicant's Abstract): Cryptococcal meningitis remains a cause of morbidity and mortality in HIV-infected (HIV+) individuals and new modalities are needed for therapy. Profound CD4+ T cell deficiency is found in HIV+ individuals with cryptococcosis, though only a subset of patients develop infection. Therefore, additional immunologic defects probably predispose some patients to cryptococcal infection. In the previous grant period, this group demonstrated
Studies 35
differences in the specificity and titer of antibodies to GXM in HIV- and HIV+ individuals. These groups are relatively resistant and susceptible to infection, respectively. The authors showed that human antibodies to GXM are derived from VH3 genes. Together with others' reports of decreased VH3 positive B cells in HIV+ individuals, their findings support the idea that combined with underlying cellmediated immunity, qualitative and quantitative differences in antibodies to GXM may play a role in the protection of HIV-, and susceptibility of HIV+ individuals to cryptococcosis. This hypothesis will be investigated in this proposal with 3 interrelated aims. First, the authors will use purified antibody subsets from HIV- and HIV+ individuals to determine if idiotype and isotype-specific subsets of antibodies to GXM alter the course of experimental cryptococcosis in normal and immunodeficient mouse strains. In this aim they will also construct and compare VH3 gene libraries from B cells of HIV- and HIV+ individuals with and without cryptococcosis to determine if the frequency of specific VH3 gene segment expression of somatic mutation is correlated with resistance or susceptibility to C. neoformans. Second, they will generate human mAbs to GXM in human immunoglobulin transgenic mice by splenic fusion and determine their VH3 usage, specificity, and functional efficacy in vitro and in experimental cryptococcosis. Third, they will isolate peptide epitopes of the mAbs from phage libraries and use them to compare the specificity of antibodies to GXM from HIVand HIV+ individuals with and without cryptococcosis. The authors believe that these studies will reveal if antibody repertoire differences contribute to cryptococcal pathogenesis and provide novel human mAbs and peptide mimotopes for passive and active vaccination approaches for therapy of human cryptococcosis. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: HUMAN CELLULAR IMMUNE RESPONSES TO LEPTOSPIRA Principal Investigator & Institution: Klimpel, Gary R. Microbiology and Immunology; University of Texas Medical Br Galveston 301 University Blvd Galveston, TX 77555 Timing: Fiscal Year 2003; Project Start 30-SEP-2003; Project End 31-JAN-2008 Summary: (provided by applicant): Leptospirosis, a zoonotic disease caused by spirochetes of the genus Leptospira, is transmitted to humans via urine of infected mammals. Found worldwide in temperate and tropical climates, it is a public health threat in the U.S. and abroad. Human infections by Leptospira have a broad spectrum of clinical manifestations, ranging from asymptomatic seroconversion to undifferentiated febrile syndrome, with or without aseptic meningitis, to fulminant jaundice, renal failure and hemorrhage with a fatality rate up to approximately 25%. There is no vaccine to prevent human leptospirosis and veterinary vaccines may not be used in humans because of toxicity. Little is known about how this organism interacts with human lymphocytes and/or the mechanisms of leptospiral pathogenesis or immunity. We propose to examine molecular and cellular interactions of Leptospira with human peripheral blood mononuclear cells (PBMC) with a focus on different T cell populations. We have found that leptospires activate T cells in PBMC from Leptospira-naive humans, leading to proliferation and production of high IFN gamma levels. Our hypothesis is that Leptospira activation of T cells expressing the alpha/beta or gamma/delta form of the T cell receptor for antigen plays an important regulatory role in protective immunity and immunopathogenesis associated with human infections due to Leptospira spp. Our aims are to: 1) Determine the cell:cell interactions and cytokine profiles of PBMC cultures exposed to Leptospira, and characterize the phenotype, function, and specificity of T cells activated in such cultures; 2) Identify and purify Leptospira components that activate T cells; and 3) Determine the relationship between peripheral blood T cell
36 Meningitis
phenotype and function and disease severity of human leptospirosis patients in an endemic region in the Peruvian Amazon. Learning how Leptospira interact with the human immune system will lead us to understand the pathogenesis of leptospirosis and how to develop vaccines and strategies to control the associated pathology. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: IDENTIFYING AND REDUCING ERRORS WITH SURGICAL SIMULATION Principal Investigator & Institution: Fried, Marvin P.; Montefiore Medical Center (Bronx, Ny) Bronx, NY 104672490 Timing: Fiscal Year 2001; Project Start 27-SEP-2001; Project End 31-AUG-2004 Summary: The training of a surgeon requires the acquisition of a number of characteristics. These include a knowledge base (cognitive), problem formulation, decision processing, psychosocial relationships and others that can be evaluated and graded by objective testing such as National Board or Specialty Certifying examinations. Critical to the surgeon are the technical skills that are at the core of the profession. This proposal responds to the need to create a battery of sophisticated devices and objective measurements to teach and evaluate the inherent technical ability of trainees. We hypothesize that by innovative, state- of-the-art simulation, devices that train both surgical tasks and skills through repetitive proctored challenges, without risk to patients, will allow for detection and analysis of surgical errors and "near misses". In an analogy to flight simulation, "near miss" detection is where potential errors are found and complications prevented Using a number of otolaryngology residencies, a controlled training curriculum will be developed based on complimentary simulation tools [the endoscopic sinus surgery simulator (ES3), minimally invasive surgical trainer virtual reality (MIST VR), perceptual and 3- dimensional testing] with objective metrics used for assessment of trainees. Technical errors will be identified, quantified and used to train and monitor surgical performance and for outcomes analysis to improve patient safety. Some current validated metrics include: time- to-completion, errors, economy of motion and psychomotor tracking. Correlation with psychometric parameters (perception, psychomotor, visio-spatial, cognitive mapping, etc.) will be used to identify technical errors and to validate both the simulator and the curriculum. The collaborating investigators and institutions have expertise in the areas of metrics, curriculum, database development, simulator creation and modification, and outcomes analysis. Endoscopic sinus surgery is the operation substrate since it is frequently performed (greater than 300,000 procedures annually) and carries a significant risk of injury to the contiguous structures ofthe eye (loss of vision and /or eye motion) and brain (CSF leakage, meningitis, death). The ES3 is also the most advanced surgical simulation device existing and based largely on jet pilot flight simulation (Lockheed Martin). Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: IMMUNOSENESCENCE AND CHLAMYDIA PNEUMONIAE Principal Investigator & Institution: Fresa, Kerin L. Pathology, Microbio/Immunology; Philadelphia College of Osteopathic Med 4170 City Ave Philadelphia, PA 19131 Timing: Fiscal Year 2001; Project Start 01-MAY-2001; Project End 30-APR-2004 Summary: (the Applicant's Abstract): With increasing age, there is increased incidence and severity of infectious diseases, including pneumonia, meningitis and sepsis, as well as many non-infectious diseases including cancers, heart disease, Alzheimer' s disease and other dementias. The obligate intracellular bacterial parasite Chlamydia
Studies 37
pneumoniae is an established pathogen for respiratory infection. Recent evidence from a number of laboratories suggests that C. pneumoniae may be a factor in the pathogenesis of a number of non-respiratory diseases including Alzheimer's disease and atherosclerosis. It has been repeatedly hypothesized that increased incidence of infectious and other diseases with age may be the result of age alterations in the immune system, particularly in cell mediated immune reactions. It is well established that T cell function, as measured in vivo by delayed type hypersensitivity reactions and in vitro as proliferative responses to antigenic or mitogenic stimulation, both decline with age. While infection with C. pneumoniae as well as other Chlamydial species induces production of antibodies, recent evidence suggests that cell mediated immune mechanisms play a key role in recovery from infection as well as immunopathology associated with Chlamydial infection. It has not been established whether old animals are able to clear infection by C. pneumoniae or remain chronically infected. It also remains unknown whether the immune response, particularly the cell-mediated immune response, to acute chlamydial infection is altered with age. Finally, the extent to which the cell-mediated immune response to Chlamydia, or lack thereof, contributes to the pathogenesis of diseases such as atherosclerosis or Alzheimer's disease is entirely speculative. We propose here to begin to address these issues in a mouse model. The working hypothesis is that the cellular immune response against C. pneumoniae declines with age. The Specific Aims of this project are: 1) To assess whether aging is associated with alterations in the clinical course of experimental intranasal infection of mice by C. pneumoniae; and 2) To assess whether there are age-associated changes in the immune response to C. pneumoniae. Specifically, we will examine proliferative responses, generation of cytotoxic T cells, and production of Th1 associated cytokines (IL-2 and IFN-g). Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: INHIBITORS OF KD08-PHOSPHATE SYNTHASE AS ANTIBIOTICS Principal Investigator & Institution: Green, David W.; Cubist Pharmaceuticals, Inc. 65 Hayden Ave Lexington, MA 02421 Timing: Fiscal Year 2001; Project Start 30-SEP-2001; Project End 29-SEP-2002 Summary: (provided by applicant): The increasing occurrence of pathogenic bacteria that are resistant to historically successful antibiotics has driven the need to develop new classes of drugs that have a unique mechanism of action. Gram-negative pathogens pose a serious health threat as they can be the causative agents of life-threatening conditions such as septicemia (Escherichia coli), meningitis (Haemophilus influenzae) or pyrogenic infections in burn patients and diabetics (Pseudomonas aeruginosa). 3deoxy-D-manno-octulosonic-8-phosphate synthase (KDO8PS; EC 4.1.2.16) has been demonstrated to be an essential enzyme for gram-negative pathogen viability as it carries out a key step in the biosynthesis of the outer membrane lipopolysaccharide component, namely the condenstaion of phosphoenolpyruvate and arabinose-5phosphate to form 3-deoxy-D-mann-octulosonic-8-phosphate. We propose to identify inhibitors of KDO8PS that can be further developed into antibiotics for use in treating infections by gram-negative pathogens. The specific aims are to clone and express the gene for KDO8PS from E. coli and P. aeruginosa, purify the enzyme to homogeneity, and develop assays for high throughput screening and compound characterization that can be used to identify and develop inhibitors of KDO8PS as potential antibiotics. PROPOSED COMMERCIAL APPLICATION: NOT AVAILABLE Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
38 Meningitis
•
Project Title: INOS AND COX2 CEREBRAL BLOOD VESSELS Principal Investigator & Institution: Faraci, Frank M. Professor; University of Iowa Iowa City, IA 52242 Timing: Fiscal Year 2001 Summary: Endothelial and neuronal isoforms of nitric oxide synthase (NOS) appear to play a major role in regulation of cerebral circulation. The overall objectives of this project is to examine the influence of inducible NOS II and inducible cyclooxygenase (COX-2) on cerebral blood vessels. Both NOS II and COX-2 may be expressed in blood vessels in response to proinflammatory stimuli and under some pathophysiologi-cal conditions. The investigators propose to examine the influence of NOS II and COX-2 on vascular tone and permeability of the blood-brain barrier, and to examine mechanisms which regulate expression of these genes. To define the role of NOS iI in cerebral vessels, studies will now be performed using two state-of-the-art molecular approaches - NOS II knockoutmice and local overexpression using adenoviral- mediated gene transfer of NOS II. The functional importance of nuclear factor-Kappa Beta in mediating these responses will be examined. There may be interactions between the NOS and COX systems. Studies in NOS II knockout mice will allow examination of the functional importance of COX-2 in the presence and absence of NOS II. Interleukin-10 (IL-10) is an anti-inflammatory cytokine which protects against endotoxin shock. The role of IL- 10 in blood vessels is not known. Using IL-10 knockout mice, we plan to examine the hypothesis that interleukin 10 is a major endogenous regulator of expression of NOS II and COX-2 in cerebral vessels. Preliminary data support this hypothesis. Thus, state-ofthe-art approaches will be used to study the role of NOS II, COX-2, and IL-10 in cerebral blood vessels. The studies should provide new insight into regulation of the cerebral circulation. Expression of these genes may be important in brain under several pathophysiological conditions including meningitis, ischemia, and in response to inflammatory stimuli. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: IPC1 ROLE IN REGULATION OF PHAGOCYTOSIS OF C NEOFORMANS Principal Investigator & Institution: Del Poeta, Maurizio; Medical University of South Carolina 171 Ashley Ave Charleston, SC 29425 Timing: Fiscal Year 2002; Project Start 26-SEP-2002; Project End 31-AUG-2007 Summary: (provided by applicant): The long-term objective of this project is to elucidate the roles, mechanisms, and functions of inositol-phosphoryl ceramide synthase 1 (Ipc1) in cell regulation and fungal pathogenesis, focusing on Cryptococcus neoformans. Cryptococcus neoformans is an opportunistic pathogen that primarily infects immunocompromised patients. Infection initiates in the lung following inhalation, spreads hematogenously to the brain, and results in meningoencephalitis. It is the most common cause of fungal meningitis worldwide (8, 56). Since the lung is the port of entry for C. neoformans, phagocytosis by alveolar macrophages represents the first host immune response against the fungal organism. If phagocytosis succeeds by killing the organism there will be no disseminated disease. On the other hand, C. neoformans possesses the ability to produce virulence factors, which protect the fungal cells from the phagocytosis and/or the killing by the host alveolar macrophages. Therefore, the determination of how this opportunistic pathogen interacts with alveolar macrophages will lead to the understanding of the molecular mechanism(s) by which C. neoformans disseminates and, thus, produces disease. Ipc1 is a fungus-specific enzyme encoded by
Studies 39
the essential IPC1 gene (also called AUR1). It regulates the formation of complex sphingolipids (essential components of the membranes), the levels of phytoceramide and sphingoid bases (implicated in stress responses), and diacylglycerol (a wellestablished mitogen and activator of protein kinase C). Therefore, the regulation of Ipc1 might represent an important factor in the maintenance of crucial cellular functions. In the case of a fungal opportunistic pathogen (such as C. neoformans), the impairment of Ipcl activity could exert a significant impact on host-fungus interactions, either by modification of the production of virulence factors (fungal-factors) or/and by modification of the immune responses (host-factors). In our previous studies, we regulated the expression of the essential IPC1 gene by using the GAL7 promoter. We found that C. neoformans is no longer pathogenic in an animal model of cryptococcal meningitis when Ipc1 is down-regulated (54). In our ongoing studies to understand how Ipc1 regulates Ohyto Ipc1 pathogenicity of C. neoformans, we find that downregulation of Ipc1 increases phagocytosis whereas up-regulation of lpc1 decreases phagocy:tosis by the host alveolar macrophages. In preliminary epistasis analysis, we identified, through differential display RT-PCR, a novel protein, inhibitory protein 1 (IPI), which exerts antiphagocytic property, and whose level of expression is regulated by lpc1. Based on these observations, we HYPOTHESIZE that Ipc1 regulates the pathogenicity of C. neoformans in part by affecting its phagocytosis through the expression of lPI. Therefore we will: Specific Aim 1. To determine the mechanisms by which Ipc1 regulates IPI. Since Ipcl regulates in opposing directions the levels of two bioactive molecules, phytoceramide and DAG, and activates the transcription of IPI, we hypothesize that IPI expression is modulated by a transcription factor, which could be regulated by the level of phytoceramide or DAG. Therefore, in this specific aim we will: A) evaluate the transcriptional activation of IPI by Ipc1; and B) determine the effect of phytoceramide and DAG on this mechanism of regulation. Our hypothesis predicts that Ipcl regulates IPI at the transcriptional level and these studies will allow us to establish whether the lipids modulated by Ipc1 regulate this molecular mechanism through a transcription factor. Specific Aim 2. To establish the role of IPI in the regulation of pathogenicity of C. neoformans. Since IPI exerts an anti-phagocytic effect, we hypothesize that the increase of IPI by Ipc1 protects fungal cells from alveolar macrophages. Therefore in this specific aim we will: A) establish the effect of modulation of IPI on phagocytosis by alveolar macrophages; and B) determine the role of IPI on virulence of C. neoformans in the animal models. Our hypothesis predicts that IPI represents a virulence factor, protecting the fungal cells against phagocytosis by alveolar macrophages. Using our animal models, these studies will allow us to determine the impact of IPI on the initiation and the consequent dissemination of the infection from the lung to other organs and tissues. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: IRON ACQUISITION AND PNEUMOCOCCAL INFECTION Principal Investigator & Institution: Tai, Stanley S.; Howard University 2400 6Th St Nw Washington, DC 20059 Timing: Fiscal Year 2001 Summary: Children under two years of age, the elderly, and individuals with underlying disease are to great risk of developing pneumococcal otitis media, septicemia, meningitis, and pneumonia. Antibiotic prophylaxis and vaccination are the two major methods to treat and prevent invasive pneumococcal infections. However, the success of antibiotic treatments has been limited by the recent isolation of penicillinor multi-drug resistant pneumococci. The current pneumococcal vaccine, a mixture of
40 Meningitis
capsular polysaccharide of 23 most prevalent of possible 84 stereotypes, only elicits type-specific antibodies and can not provide protection against infection of other Streptococcus pneumoniae serotypes not used in the vaccine preparation. To control pneumococcal disease would require a new knowledge about the biology of S. pneumoniae. The long range goal of this investigation is to study how S. pneumoniae survives in infected animals where most of iron molecules are sequestered by ironbinding proteins, such as hemoglobin, transferrin, and lactoferrin. Iron limitation restricted the growth of S. pneumoniae and the limited growth could be restored by the addition of hemin or hemoglobin. Pneumococcal cells have a great ability to bind hemin. Several hemin binding proteins have been identified in the cell lysate of S. pneumoniae with the major species migrated as a molecular mass of 43 kDa. The specific aims of this proposal are employing genetic and immunological methods to seek answers to the following question: 1). What is the genetic determinant of 43-kDa hemin binding protein? 2). What roles does 43-kDa HBP play in the hemin acquisition of S. pneumoniae? 3) What roles does 43-kDa HBP play in S. pneumoniae infection in experimental animals? Results generated from the proposed studies not only will provide us with basic information about the iron acquisition of S. pneumoniae, but will allow us to gain insight into the pathogenic mechanism of S. pneumoniae disease. The knowledge obtained in this study will have practical applications as well in designing effective therapeutic strategy and agents for the control of pneumococcal disease. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: ISCHEMIC BRAIN INJURY IN NEONATAL MENINGITIS Principal Investigator & Institution: Tauber, Martin G.; University of California San Francisco 500 Parnassus Ave San Francisco, CA 94122 Timing: Fiscal Year 2001 Summary: Approximately 15,000 cases of bacterial meningitis occur each year in the United States. Meningitis in newborns has a particularly poor prognosis with mortality rates up to 35% for cases caused by group B streptococci (GBS), a major pathogen of neonatal meningitis. Only 50% of survivors of GBS meningitis are neurologically intact, while 21% have severe neurologic sequelae, including global mental retardation, cerebral palsy, and uncontrolled seizure disorder's. The goal of our research is to identify the mechanisms that lead to brain injury in neonatal meningitis in order to develop new therapies that protect the brain. The hypotheses to be tested in the present grant are (1) meningitis leads to global and focal Cerebral blood flow changes; (2) cerebral blood flow is modulated by the interplay of vasodilative and vasoconstrictive mediators; (3) ischemia resulting from cerebral hypoperfusion is a major factor leading to brain damage; and (4) hallmarks of parenchymal brain damage include the release of excitatory amino acids and activation of glial cells (as evidenced by the expression, of cytokines). These hypotheses will be tested in an infant rat model of neonatal meningitis that closely mimics the human disease and in primary cultures of neurons, astrocytes, and microglia. The project has five specific aims: 1. To analyze cerebral blood flow in a rat model of GBS neonatal meningitis and to correlated blood flow changes with the occurrence of tissue hypoxia and the development of neuronal injury. 2. To identify molecular mediators involved in the modulation of cerebral blood flow in the rat model of GBS neonatal meningitis. Using specific inhibitors/agonists, we will focus on the role of nitric oxide as potentially beneficial vasodilator and on endothelin as potentially harmful vasoconstrictor. 3. To examine the contribution of excitatory amino acids (EAA)to neuronal injury in the infant rat model of GBS meningitis by determining whether animals treated with different EAA antagonists have reduced brain injury
Studies 41
compared to control animals. 4. To characterize glial cell activation and the expression of selected cytokines (IL-1beta, TNF-alpha, IL-6, TGF-beta) in the GBS meningitis rat model. We will also examine the contribution of cytokines to the development of brain injury in the model: 5. To analyze in primary cultures in vitro which of the factors that play a role in the pathophysiology of meningitis lead to cytokine expression in glial cells, either by direct stimulation of glia or through thee effect on neurons. We will also examine whether the cytokines induced in glial cells have a beneficial or harmful effect on neuronal injury caused by EAA and ischemic conditions. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: ISOLATION AND CHARACTERIZATION OF GBS VIRULENCE GENES Principal Investigator & Institution: Clancy, Kathryn A.; Children's Hospital and Reg Medical Ctr Box 5371, 4800 Sand Point Way Ne, Ms 6D-1 Seattle, WA 98105 Timing: Fiscal Year 2001; Project Start 01-AUG-2001 Summary: Group B streptococci (GBS) are the leading cause of human neonatal pneumonia, sepsis and meningitis in the United States. The high incidence of infant mortality associated with GBS infection has led to a significant research effort focused on GS pathogenesis and the identification of virulence-related factors. However, the characteristics of GBS that are critical to the virulence of this pathogen and disease progression largely remain unknown. The long-term goals of this proposal are to gain a better understanding of the molecular basis for BS virulence in the human host and to identify important protein targets for the development of preventative and therapeutic measures such as vaccines and novel antimicrobials. Specifically, the aims of this proposal are to isolate putative virulence proteins from GBS and investigate the role of these proteins in the disease process. Gene fusion technology using alkaline phosphatase as a reporter enzyme will be employed to isolate secreted proteins from GBS, which are thought to be enriched for factors that participate in bacterial-host cell interactions, and have been shown to contribute to bacterial virulence in other microbial systems. Bacterial strains deficient for the putative protein effectors will be constructed and examined in vivo animal sepsis and infection models, which, in concert with in vitro cell-culture adherence and invasion assays, will help to characterize the function of the identified proteins and their importance in disease. The isolation of putative protein effectors from GBS is hoped to help identify future targets for therapeutic studies and development to provide treatment and protection against GBS infection. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: LEUKOCYTE TRANSMIGRATION IN NEONATAL CANDIDA MENINGITIS Principal Investigator & Institution: Lossinsky, Albert S.; Huntington Medical Research Institutes 734 Fairmount Ave Pasadena, CA 91105 Timing: Fiscal Year 2003; Project Start 01-JUL-2003; Project End 30-JUN-2005 Summary: (provided by applicant): Neonatal meningitis produced by opportunistic pathogenic microorganisms such as the yeast Candida albicans is an inflammatory condition that can occur during the first month after birth and is a leading cause of neurodegenerative states and morbidity in premature and immunocompromised infants. Meningitis in neonates is attributable to the incomplete development of the CNS, the blood-brain barrier (BBB) and the immune system. The precise nature of adhesion and transmigration of pathogenic organisms and leukocytes across the BBB
42 Meningitis
during inflammatory conditions remains unclear and is an issue of great interest in modern medicine. This research program will focus at the mechanisms of adhesion and transmigration of C. albicans and inflammatory leukocytes that appear in response to the microorganisms during the process of meningitis. Our study will be conducted in an in vivo model of experimentally induced meningitis in neonatal rats. Our hypothesis states that the pathogenic yeast C. albicans initially induce the inflammatory state in the meningeal blood vessels. Subsequently, leukocytes adhere to and traverse the endothelial cell (EC) barrier stimulated by the local release of chemoattractant substances in response to the yeast cells. The entire process of adhesion and transmigration across the BBB is facilitated by adhesion molecules including ICAM-1, PECAM-1 and VCAM-1 either across the ECs by a transcellular pathway, through EC junctional complexes by a paracellular pathway, or by both mechanisms. Our specific aim of the project will be to define and compare the light microscopic, immunohistochemical, ultrastructural and immunoultrastructural nature of adhesion and transmigration of a virulent strain of C. albicans, and the different major subsets of inflammatory leukocytes including neutrophils, mononuclear cells and lymphocytes that appear in response to the yeast-induced meningoencephalitis in neonatal rats. This will lay the groundwork for us to investigate how adhesion molecules regulate the attachment and transmigration of pathogenic yeast cells and leukocytes across the BBB via specialized anatomical "gateways to the brain" through either modified EC conduitlike structures, open EC junctional complexes or by both pathways. Such studies will hopefully establish a framework that may lead to the development of therapeutic intervention for the treatment of neonatal meningitis and several other inflammatory conditions of the CNS. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: LISTERIA AND SHIGELLA USE HOST CELL ACTIN Principal Investigator & Institution: Southwick, Frederick S. Professor; Medicine; University of Florida Gainesville, FL 32611 Timing: Fiscal Year 2002; Project Start 01-JUL-1993; Project End 31-MAY-2007 Summary: (provided by applicant): The gram-positive bacillus Listeria monocytogenes predominantly infects immunocompromised patients, causing bacteremia and meningitis while the gram-negative bacillus Shigella flexneri infects normal hosts causing severe diarrhea and dehydration. The pathogenesis of Listeriosis and Shigellosis absolutely requires these intracellular bacteria to usurp the host cell's contractile system. Listeria and Shigella induce host cell actin to assemble into rocket tails that rapidly propel the bacteria through the cytoplasm, allowing their cell-to-cell spread and avoidance of the humoral immune system. Actin assembly occurs in a discrete polymerization zone directly behind the motile bacteria. This region blocks the host cell actin-regulatory proteins, gelsolin, CapZ and CapG, that normally cap the fast growing ends of actin filaments. This blocking activity allows actin filaments to rapidly assemble in this discrete zone. Two of these proteins, gelsolin and CapG, require micromolar calcium to function. We will: Aim I - Elucidate how Listeria blocks barbed end-capping proteins in the polymerization zone. Pyrenyl actin and right angle light scattering will be used to examine how profilin combined PIP2 and VASP or N-WASP effects actin filament capping by CapG, CapZ and gelsolin. Capping inhibition by Listeria will be investigated in brain cell free extracts before and after depletion of profilin and VASP. Localization of PIP2 (well known to block capping activity) in Listeria and Shigella infected cells will be studied using a GFP labeled probe. The effects of blocking PIP2 production using the PI kinase inhibitors Wortmannin and quercetin, infecting cells
Studies 43
with Listeria ActA mutants lacking PIP2 binding sites, and ActA mutants lacking VASP binding sites will be examined. Aim II - Study the Calcium-Dependence of Listeria and Shigella actin-based motility. Calcium is a critical signal for turning on and off actin regulatory proteins, and we have found that the chelator BAPTAM blocks Shigella actinbased motility and slows the disassembly of Listeria rocket tails. The Ca2+-sensitivity of N-WASP and vinculin, cell proteins unique to Shigella-induced actin assembly, as well as gelsolin will be studied. These investigations should clarify key regulatory pathways required for Listeria- and Shigella-induced actin assembly and may identify new therapeutic targets for treating Listeriosis and Shigellosis. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: LISTERIA PROTEINS EFFECTS ON CELL FUNCTION Principal Investigator & Institution: Potter, Terry A. Associate Professor; National Jewish Medical & Res Ctr and Research Center Denver, CO 80206 Timing: Fiscal Year 2001; Project Start 01-JUL-1997; Project End 30-JUN-2003 Summary: (Adapted from applicant's abstract): The bacterium Listeria monocytogenes (LM) is a widespread, food borne pathogen that is responsible for periodic outbreaks of disease, causing gastrointestinal disease, sepsis, and in some cases, fatal meningitis. Listeriosis is often associated with an immunocompromised state, and in AIDS patients, it occurs at an incidence approximately 300 times greater than that found in the nonAIDS population. LM is taken up by different cells including macrophages. Upon internalization by macrophages, the bacterium can have two possible fates: (1) It can escape into the cytoplasm where it can replicate and subsequently invade other cells; (2) It remains within a phagocytic vesicle and is killed. They have obtained preliminary evidence which suggests that the pathway leading to either of these two possible outcomes is dictated by the mode of entry of the bacterium into the macrophage. If LM is taken up via the receptor for the third complement component (CR3), it does not escape into the cytoplasm and is killed. If LM enters a macrophage by binding of the bacterial internalin A (InlA) molecule to an as-yet unidentified surface molecule on the macrophage, the bacterium escapes into the cytoplasm and replicates. By analogy to the uptake of other bacteria, it is likely that the signal transduction events associated with the cell surface receptor molecules are initiated upon binding of LM to the macrophage. In this proposal they will conduct experiments to test the hypothesis that LM that enter a macrophage via interaction between InlA and its receptor will not be killed by the macrophage. First, they will define the role of In1A in binding, phagocytosis, and killing of LM by listericidal versus nonlistericidal macrophages. Second, they will delineate the molecular events within macrophages resulting from interaction between LM In1A and its putative macrophage receptor. They will define the signal transduction events which occur following binding of LM to the putative In1A receptor, and compare them to events initiated upon binding of LM to CR3. Third, they will attempt to identify, characterize and isolate the In1A receptor. These experiments should provide valuable information on the interaction of LM with phagocytic cells and may provide insights into the phagocytosis and killing of other intracellular bacteria. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: M DESIGN/EVALUATION
TUBERCULOSIS
CTL
EPITOPES:
VACCINE
Principal Investigator & Institution: Clayberger, Carol A. Associate Professor; Cardiovascular Surgery; Stanford University Stanford, CA 94305
44 Meningitis
Timing: Fiscal Year 2003; Project Start 15-FEB-2003; Project End 31-JAN-2008 Summary: (provided by applicant): Tuberculosis (TB) is the leading cause of death from a single infectious agent (Mycobacterium tuberculosis (Mtb)), causing approximately 3,000,000 deaths each year. Although TB can be effectively treated with a combination of antibiotics, drug resistant Mtb strains have recently emerged which are classified as Category C biological agents. Thus, it is widely felt that the long term control of TB will require the development of a more effective vaccine. Mycobacterium bovis Bacille Calmette-Guerin (BCG), the current anti-TB vaccine, is quite variable in its ability to protect against TB but is effective against tuberculosis meningitis, suggesting that for the foreseeable future, new TB vaccines will be given as an adjuvant or boost to BCG. Thus, understanding the immune response to both Mtb and BCG is critical for the development of an improved vaccine for TB. An increasing body of evidence indicates that both CD4+ and CD8+ T lymphocytes are critical to a protective immune response against Mtb. However, little is known about the antigens targeted by protective immune responses against Mtb in humans. Such information is required for the rational development and clinical evaluation of new, more effective TB vaccines. We propose here to characterize the human CD4+ and CD8+ T cell response to a panel of Mtb antigens in order to identify correlates with protective immunity. Antigens to be tested include proteins as well as peptide epitopes restricted by HLA-A2, an allele expressed by approximately 50% of the population. Some of these proteins and epitopes were selected from a subset of Mtb genes that are highly expressed under specified conditions and whose products are predicted to localize to the extracellular milieu, while the remainder represent previously identified HLA-A2 restricted epitopes. The T cell response to these antigens will be evaluated in peripheral blood leukocytes from three different groups of BCG immune and/or Mtb infected individuals: i. Neonates immunized a birth with one of 4 strains of BCG; ii. Individuals infected with Mtb but who do not progress to disease (latent TB infected individuals); and iii. PPD+ TB patients and PPD- "anergic" TB patients. Some of these peptide epitopes will be used to develop epitope oligomers which will be used to analyze anti-Mtb responses In vitro and in vivo. Lastly, the localization and function of Mtb peptide specific memory T cells will be studied in vivo. Correlates of protective immunity can be used to identify or prioritize protective antigens and vaccine candidates, to optimize vaccine dosing, schedules, adjuvants, etc., and to provide early evidence of efficacy. For TB, which takes years to decades to develop after infection with Mtb, immune correlates with protection are an attractive, and perhaps essential, supplement to efficacy trials. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MASS SPECTROMETRY OF BACTERIAL GLYCOCONJUGATES: HAEMOPHILUS DUCREYI & AIDS Principal Investigator & Institution: Gibson, Bradford; Professor; University of California San Francisco 500 Parnassus Ave San Francisco, CA 94122 Timing: Fiscal Year 2001; Project Start 01-MAR-2000; Project End 28-FEB-2002 Summary: The major emphasis of this project is to apply and advance mass spectrometric methods for the analysis of bacterial glycoconjugates. Our major scientific goal is to obtain an understanding of the structures and functions of the surface glycolipids or lipooligosaccharides (LOS) from pathogenic Neisseria and Haemophilusspecies. These studies include Haemophilus influenzae, Haemophilus ducreyi, Neisseria meningitidis and Neisseria gonorrhoeae. Hemophilus influenzae is responsible for a variety of serious adult and infant diseases e.g., meningitis, pheumonia. Haemophilus ducreyi causes the sexually transmitted disease, chancroid,
Studies 45
which has also been identified as a significant independent risk factor in the transmission of AIDS. LOS components from these organisms contain some of the major epitopes or antigenic determinants, and we have shown that many of them are similar to glycolipid structures present in human tissue. One of our current hypothesis is that the similarity to human glycoconjugates is a form of host mimicry, perhaps providing a means for the bacteria to evade the host defenses, or to adhere and/or invade various human cell types. In H. ducreyi, we have shown the most strains contain LOS that are sialylated, and differences in sialylation have been correlated to its cytotoxicity and ability to adhere to human skin cells. An understanding of the structures and immunochemistry of LOS from these pathogenic bacteria could provide the means to develop a carbohydrate-based vaccine and/or drugs that could interfere with key evasion or adhesion processes. In addition, we will plan to investigate the structure of an important adhesion molecule, presumably belonging to the glycosylaminoglycan glyconjugate structure class, in pathogenic Chlamydia trachomatis. Therefore, we propose to develop more sensitive mass spectrometric-based strategies for the structural characterization of these bacterial glycoconjugates. Our ultimate aim is to develop massspectrometric techniques that will have the sensitivity to analyze samples directly from clinical samples (picomole to femtomole amounts) without in vitro growth, which is known to alter the distribution and abundances of the outermembrane lipooligosaccharides. We propose to use both electrospray and matrix-assisted laser desorption ionization methods to achieve this latter goal. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MATRIX METALLOPROTEINASES AND THE BLOOD-BRAIN BARRIER Principal Investigator & Institution: Rosenberg, Gary A. Chairman & Professor; Neurology; University of New Mexico Albuquerque Controller's Office Albuquerque, NM 87131 Timing: Fiscal Year 2003; Project Start 15-AUG-2003; Project End 31-MAY-2007 Summary: (provided by applicant): Matrix metalloproteinases (MMPs) disrupt the blood-brain barrier (BBB) in many neuroinflammatory diseases. They are secreted as latent enzymes, which are activated by proteases and free radicals and inhibited by tissue inhibitors of metalloproteinases (TIMPs). Gelatinase A (MMP-2) and B (MMP-9) attack extracellular matrix around blood vessels. Cell cultures of astrocytes produce latent MMP-9 when stimulated by lipopolysaccharide (LPS), and microglia form active MMP-9. Microglia secrete stromelysin- 1 (MMP-3), which may be the activator of MMP9. Intracerebral injection of LPS induces cytokines, free radicals, and proteases that simulate the neuroinflammatory response by producing active forms of the MMPs and opening the BBB. We hypothesize that the balance between the MMPs and the TIMPs controls the permeability of the BBB, and that MMP-3 contributes to the BBB damage by activation of proMMP-9, while TIMP-3 protects the BBB by inhibiting the MMPs. To test the hypothesis, we propose to use mice lacking the MMP-3 or TIMP-3 genes. Specific Aim 1: To determine the relationship of the expression of the cytokines, MMPs, and TIMPs to the BBB damage after an intracerebral injection of LPS in mice. 3H-sucrose (m.w. 342) and 14C-dextran (m.w. 50-90 kDa) will be used for BBB permeability measurements. Expression of mRNA for TNF-alpha, IL-1beta, MMP-2, -3, and -9, and TIMP-1 and -3 will be measured by realtime rtPCR. Zymography and immunohistochemistry of the MMPs and TIMPs will be used to determine proteins and cellular localization. Specific Aims 2 and 3: To study the role of MMP-3 (aim 2) and TIMP-3 (aim 3) in BBB proteolysis by the use of MMP-3 and TIMP-3 null mice. BBB
46 Meningitis
permeability will be measured with radiolabeled tracers, and the effect of gene knock out on the production and activation of the MMPs will be measured by zymography and rt-PCR. Specific Aim 4: To identify the molecular mechanisms involved in the protection of the BBB by corticosteroids, tetracycline derivatives, and synthetic MMP inhibitors. BBB disruption is a major factor in multiple sclerosis, Guillain-Barre Syndrome, meningitis, and cerebral bleeding after thrombolysis. Understanding the molecular events in the BBB disruption by MMPs will provide a rational basis for drug design, and will lead to novel treatments in many important neurological diseases. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MECHANISM OF ANTIBODY PROTECTION AGAINST C. NEOFORMANS Principal Investigator & Institution: Morrison, Sherie L. Professor and Chair; Microbiol & Molecular Genetics; University of California Los Angeles 10920 Wilshire Blvd., Suite 1200 Los Angeles, CA 90024 Timing: Fiscal Year 2003; Project Start 01-DEC-2002; Project End 30-NOV-2007 Summary: (provided by applicant): Cryptococcus neoformans causes a lethal meningoencephalitis in 8 percent of AIDS patients in the US. Current treatment is inadequate as 10-20 percent of patients die from cryptococcal meningitis despite aggressive antifungal therapy, and individuals who survive beyond the initial treatment period must be maintained on life-long therapy to prevent relapse. Because of these therapeutic limitations, antibodies have been considered as prevention and treatment for C. neoformans infection. Anti-capsular monoclonal antibodies can prolong the life of lethally infected mice and increase the effectiveness of antifungal agents in vivo. Previous observations indicate that functions mediated by the constant regions of these antibodies are crucial in determining their protective potential. Consistent with this idea are preliminary studies we have done in genetically deficient mice showing that antibody interactions with certain Fc receptors (FcRs) are important in mediating protection, while the presence of complement may be detrimental to antibody efficacy, particularly in the absence of FcR binding. Over the past several years, we have developed a large library of recombinant antibodies with a variety of different functional properties. We will now graft anti-cryptococcal variable regions onto these antibodies to examine, both alone and in combination, the contribution of such characteristics as FcR binding, complement activation, avidity and half life to efficacy in an animal model of infection with C. neoformans. We will first confirm the functional properties of these antibodies in vitro by testing FcR binding, antibody-dependant cell mediated cytotoxicity (ADCC), and complement activation and determine their pharmacokinetics in vivo. We will then test in vivo efficacy against infection with C. neoformans. Specifically, we will investigate whether antibody efficacy depends on i) in vivo persistence, ii) ability to activate complement, iii) engagement of FcRs or iv) effective cross-linking of surface antigen. The experiments proposed here are designed to explore the hypothesis that antibodies with different constellations of functional properties will have differing degrees of efficacy. Murine infection with C. neoformans is a particularly relevant system because a murine monoclonal antibody is currently undergoing Phase I evaluation for the treatment of cryptococcal meningitis in AIDS patients. If this trial proves promising, the experiments proposed will provide the basis for selecting the best therapeutic candidates for further study. A clear definition of what properties correlate with efficacy should allow us to move forward in designing effective therapeutic antibodies for treatment of disease in humans. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
Studies 47
•
Project Title: MECHANISMS OF ISCHEMIC NEONATAL BRAIN INJURY Principal Investigator & Institution: Ferriero, Donna M. Professor; Neurology; University of California San Francisco 500 Parnassus Ave San Francisco, CA 94122 Timing: Fiscal Year 2001; Project Start 01-APR-1997; Project End 24-SEP-2002 Summary: Support is requested to continue a multidisciplinary program that was begun in 1993 under the auspices of a P2O from NINDS. Through the study of a variety of pathological states such as perinataI asphyxia, neonatal stroke and neonatal infection, patterns and mechanisms of ischemic neonatal brain injury will be elucidated. It is the hypothesis of this proposal that the integrity of the blood brain barrier, cerebral perfusion, excitatory amino acid release availability of neurotrophic factors and substrates of intermediary metabolism, are critically important factors in the pathogenesis of neonatal brain injury. Through an integration of human research and basic science research we plan to study the role of these factors in the pathogenesis of neonatal ischemic brain injury. Taking what we observe in the human condition, we will develop new animal models and techniques, as well as use existing animal models and tissue culture paradigms with established methodology to unravel mechanisms. Through continuous in situ monitoring of injury viaMRI/MRS and near infrared spectroscopy(NIRS), we will be better equipped to study these mechanisms and meet our ultimate goal of providing therapies in the nursery for ischemic brain injury. Each project is conceptually interrelated and utilizes the scientific core for a centralized facility for all experimental manipulations. The programs four projects are 1) MRI predictors of outcome after perinatal asphyxia in humans, 2) Fructose bisphosphate in asphyxial brain injury 3) Neurotrophins in neonatal hypoxic-ischemic brain injury and 4) Mediators of ischemic brain injury in neonatal meningitis. Through these varied approaches we will investigate the cellular, molecular and physiological mechanisms of hypoxia/ischemia in the developing nervous system. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: MECHANISMS OF PYRIDOXAL-5'-PHOSPHATE DEPENDENT ENZYMES Principal Investigator & Institution: Phillips, Robert S. Professor; Chemistry; University of Georgia 617 Boyd, Gsrc Athens, GA 306027411 Timing: Fiscal Year 2001; Project Start 01-SEP-1989; Project End 01-MAY-2004 Summary: (adapted from applicant's abstract): The investigators are studying the mechanism of pyridoxal-5'-phosphate-dependent enzymes that break or form carboncarbon bonds. These enzymes include tryptophan indole-lyase, tyrosine phenol-lyase, tryptophan synthase, bacterial and human kynureninases, and aspartate betadecarboxylase. They are evaluating the reaction mechanism of tyrosine phenol-lyase and tryptophan indole-lyase. The investigators are determining the roles of specific amino acids in catalysis and reaction specificity by both site-directed mutagenesis and by synthesis of a C-terminal peptide containing unnatural amino acids. The investigators are probing the mechanism of the reaction of these enzymes by various kinetic techniques, including rapid scanning stopped flow spectrophotometry and rapid chemical quench. They will design, synthesize, and evaluate novel inhibitors of tryptophan indole-lyase that may be useful in the treatment of Haemophilus influenzae meningitis. The potent competitive inhibitors of kynureninase that they are designing and synthesizing, based on their studies of the bacterial enzyme, have been patented and are undergoing studies to evaluate their potential in the treatment of neurological disorders such as stroke. The investigators will determine and compare the structure
48 Meningitis
and reaction mechanism of bacterial and human kynureninases as well as aspartate beta-decarboxylase. More information on the structure and mechanism of kynureninases mat lead to the design of other more selective and potent inhibitors. The central role of pyridoxal-5'phosphate-dependent enzymes in the metabolism of amino acids and amines and in the biosynthesis of important bioactive metabolites, makes them attractive targets for the design of mechanism-based inhibitors which may be useful for drugs. Thus the results of this research are likely to make a significant contribution to the goal of improving health care for Americans in the future. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MELANOGENESIS IN CRYPTOCOCCUS NEOFORMANS Principal Investigator & Institution: Nosanchuk, Joshua; Medicine; Yeshiva University 500 W 185Th St New York, NY 10033 Timing: Fiscal Year 2001; Project Start 01-JUL-1998; Project End 30-JUN-2003 Summary: Melanin synthesis has been associated with virulence for a variety of microbial pathogens. However, little is known about either melanogenesis or the structure of melanin. The experimental system that Dr. Nosanchuk will study is that of Cryptococcus neoformans, a pathogenic fungus which causes life-threatening meningitis in 5-10 percent of patients with AIDS. This system has several unique advantages for the study of melanin and virulence, including the fact that melanized and non-melanized cells can be easily generated by simply growing the organism with or without a variety of phenoloxidase substrates. In addition, melanogenesis in C. neoformans is catalyzed by a single enzyme. Dr. Nosanchuk proposes a novel approach to the study of melanin and melanogenesis C. neoformans by applying the technology of phage display libraries to identify melanin-binding peptides that will comprise unique reagents for the study of melanin. Furthermore, murine monoclonal antibodies (mAbs) will be generated that bind melanin. Melanin-binding peptides and mAbs will be used to study melanization in vitro and in vivo. The objectives are to determine whether melanogenesis occurs in vivo and to obtain information on the structure of melanin. Four specific aims are proposed: 1. To identify peptides which bind melanin; 2. To study the antibody response to melanin and generate melanin-binding mAbs; 3. To explore the structure of melanin using biochemistry, phage display peptide libraries and mAbs; and 4. To use peptides and mAbs to study C. neoformans melanogenesis in vivo and in vitro. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: MENINGOCOCCAL LIPOOLIGOSACCHARIDE & MUCOSAL PATHOGENESIS Principal Investigator & Institution: Stephens, David S. Director; Medicine; Emory University 1784 North Decatur Road Atlanta, GA 30322 Timing: Fiscal Year 2001; Project Start 01-JAN-1993; Project End 31-DEC-2002 Summary: The long-term objectives of this research program are to help define the genetic, structural and pathogenic basis of meningococcal endotoxin (lipoligosaccharide[LOS]). The recent dramatic increases in meningococcal infections in part of the United States and the emergency of penicillin-resistant meningococcal, emphasize pathogenesis. The principle investigator s approach utilized novel genetic techniques for meningococcal(e.g., Tn916 mutagenesis), biochemical and physical analysis of LOS structure; and human tissue assays to assemble a detailed model of meningococcal LOS and to provide insights into how Los influences pathogenesis. This
Studies 49
application is directed at understanding the structural-functional relationship of the meningococcal LOS inner core, Flu (GlcNAc) Hep2KD02LipidA. LOS inner core structure is predicted to influence LOS assembly, human immune recognition of the meningococcus and interactions with soluble and cellular human proteins. In Specific Aim 1, genetic determinants that are responsible for LOS inner core oligosaccharide chain synthesis and heterogeneity in serogroup B meningococcal will be characterized: (1) by investigation of the ace (alpha chain elongation) operon which contains the UDPGlu: heptosyl (ll) lipooligosaccharide alpha 1, 2 N- acetylglucosamine transferase (rfaK) and the putative UDP-Glu heptosyl (1) lipooligosaccharide beta 1, 4 glucosyltransferase (IgtF); (2) by study of alpha chain initiation, and additions of phosphate derivatives and saccharides to Hepll; and (3) by understanding the deep rough Tn916 mutant 469 (KD02LipidA) at both genetic and structural levels. In Specific Aim 2, the role of Los in two important events that occur during group B meningococcal infection will be investigated. They propose that the LOS inner core, in particular the Hepll structure, facilitates group B meningococcal entry into human nasopharyngeal epithelial cells. In addition, genetically and structurally defined LOS mutants will be used to determine how expression of hep2KD02-Lipid A LOS enhances sensitivity of encapsulated meningococcal to killing by classical pathway complement-mediate mechanisms of human serum. Such data has application to the design of meningococcal vaccines currently in development (e.g. inclusion of truncated LOS molecules in outer membrane vesicle vaccines), and should provide insights into the unique features of meningococcal endotoxin. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MIMETICS MENINGITIDIS
OF
CAPSULAR
EPITOPES
OF
NEISSERIA
Principal Investigator & Institution: Granoff, Dan M. Senior Scientist; Children's Hospital & Res Ctr at Oakland Research Center at Oakland Oakland, CA 94609 Timing: Fiscal Year 2001; Project Start 01-APR-2000; Project End 31-MAR-2005 Summary: Description (Adapted from the applicant's abstract) The long-term objective of this study is to increase our understanding of the immunologic properties of molecular mimetics of a bacterial polysaccharide that also is an autoantigen. Mimetics can act as antigens, bind to antibody receptors on B cells, and elicit serum antibody responses to the nominal antigen. Yet, little is understood about the properties of antigenic mimetics that contribute to their immunogenicity. Nor is much known about the quality of the antibody response with respect to conferring protection against a pathogen. Neisseria meningitidis group B (NmB) polysaccharide is an excellent model to investigate these questions. NmB is a major cause of meningitis and sepsis. The mechanism of protection is well defined (serum antibody), and reliable assays exist for measurement of antibody binding to the polysaccharide antigen, functional antibody against the bacteria, and passive protection in an infant rat model of bacteremia. Efforts to develop a NmB vaccine have been hampered by poor immunogenicity of the polysaccharide capsule, which cross-reacts with host polysialic acid. The PI's laboratory has prepared a panel of murine monoclonal antibodies (Mabs) that react with capsular polysaccharide epitopes on NmB that are distinct from host polysialic acid. These Mabs are bactericidal and confer passive protection in animal models. The PI's hypothesis is that mimetic antigens identified by these Mabs will be able to elicit protective anticapsular antibody responses that are specific for the pathogen, avoiding the risk of autoantibody. Further, that the best mimetics will be those that adopt relatively stable conformations. To search for such mimetics, the PI proposes to screen phage libraries
50 Meningitis
displaying independently folding peptides, or search for constrained protein mimetics within immunoglobulin scaffolds (single chain variable (ScFv) anti-idiotypes). The mimetics will be investigated for their ability to elicit anticapsular antibody responses. The Ig isotype, antibody functional activity to the bacteria, and immunoglobulin variable region gene usage in response to the mimetics, will be compared to that elicited by the nominal antigen. A central question will be whether a mimetic identified with a Mab that reacts specifically with encapsulated NmB strains, but not with host polysialic acid, will elicit protective antibody responses without autoantibody activity. Additional questions will be whether the repertoire of the antibody response to the mimetic is similar or different than that elicited by the nominal polysaccharide, and what effect, if any, the antibody repertoire may have on protection. Taken together, the data will provide important information on the properties of mimetic antigens with chemical structures that are distinct from that of the nominal polysaccharide antigen. The results also may identify new candidate molecules for inclusion in a future vaccine for prevention of NmB disease. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MOLECULAR POLYSIALYTRANSFERASES
MECHANISMS
OF
ALPHA
2,8-
Principal Investigator & Institution: Troy, Frederic A. Professor; Biological Chemistry; University of California Davis Sponsored Programs, 118 Everson Hall Davis, CA 95616 Timing: Fiscal Year 2001; Project Start 01-MAY-1998; Project End 30-APR-2004 Summary: The 2,8-linked polysialic acid (polySia) glycotope is involved in cell migration and cell adhesion and thus plays a central role in the regulation of mammalian developmental processes. It is also an important tumor-associated oncodevelopmental antigen on a number of human cancers. On neurotropic E. coli K1 and Neisseria meningitidis Gp.B, the polySia capsule is a neurovirulent determinant associated with neonatal meningitis in humans. Therefore, it is important to understand the molecular mechanism of polySia chain synthesis, and how synthesis is controlled. These are the long-term objectives of our studies. The enzymes responsible for synthesis of polySia ar the CMP-Sia: 2,8 polysialytransferase (polySTs), designated PST and STX in mammals and NeuS in E. coli K1. There is no primary sequence homology between the mammalian and bacterial polySTs, yet all three catalyze synthesis of identical polySia chains. A key hypothesis to be tested is that PST, STX and NeuS achieve the same catalytic functions by rearranging conserved amino acid motifs spatially in their active sites to bind CMP-Sia and initiate polySia chain synthesis while bound to the enzyme. The Specific Aims of this grant are three-fold. Aim 1 will characterize by biochemical methods the length of the polySia chains synthesized by membrane-bond and soluble constructs of PST and STX derived from transfected N-CAM(+) and (-) cells. The nature of the potential reducing terminus in N-CAM (-)/polySia(+) transfected cells will als be determined. Aim 2 includes structure-function studies that will investigate the structural basis for polysialylation. Active site cysteine and conserved basic amino acid motifs implicated in catalysis and processivity will be studied by site-directed mutagenesis. Aim 3 will use in vitro reconstitution experiments to determine, "how many enzymes does it take to synthesize polySia?". Successful completion of these studies will provide basic information for understanding the molecular mechanism of polysialylation, and the critical domains of the polySTs involved. This will also have important implications for basic studies relating to neural development and plasticity, neoplastic disease and molecular microbiology and pathogenesis, and provide a necessary framework for future studies.
Studies 51
Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MUCOSAL DEFENSE BY IGA AGAINST S PNEUMONIAE Principal Investigator & Institution: Janoff, Edward N. Professor; Medicine; University of Minnesota Twin Cities 200 Oak Street Se Minneapolis, MN 554552070 Timing: Fiscal Year 2001; Project Start 01-MAR-2001; Project End 28-FEB-2006 Summary: (adapted from the investigator's abstract): Streptococcus pneumoniae is a common invasive mucosal pathogen. Local and systemic manifestations range from asymptomatic colonization, to sinusitis and otitis media, to community-acquired pneumonia, bacteremia, and meningitis, resulting in up to 40,0000 deaths/year in the US alone. The local host and bacterial factors that determine whether S. pneumoniae causes no disease, mucosal disease, or invasive disease are not well-characterized. We propose to characterize the mechanisms of control of pneumococcal infections operative at the initial steps in their pathogenesis from nasopharyngeal colonization to aspiration into upper respiratory mucosae and alveoli, prior to alveolar injury and invasion into tissue and blood. We have shown that IgA reactive with pneumococcal capsular polysaccharide (PPS) mediates killing by neutrophils by both complement-dependent and -independent conditions. IgA and IgG may both contribute to defense of the lower respiratory tract by initiating killing by macrophages and neutrophils and by inhibiting adherence to epithelial cells. We will characterize the molecular and biochemical features of PPS-specific Ig which determine their functional role, their effective interactions with local phagocytic cells, as well as the adaptive mechanisms of the organism which may subvert these protective mechanisms. Hypotheses: (1) Molecular and biochemical characteristics of capsule-specific IgA and IgG (e.g., mutation rates of immunoglobulin genes (VH), momeric, polymeric, and secretory structure of IgA, avidity, and pattern of IgA glycosylation) determine their functional efficiency to inhibit adherence and mediate killing by phagocytes. (2) Bacterial virulence factors (e.g., IgA1 protease, choline-binding protein A, and phase variation) subvert the ability of PPSspecific IgA to control S. pneumoniae. (3) The local host environment (e.g., complement, C-reactive protein) determines the phagocytes' ability of IgA and IgG to initiate killing of S. pneumoniae. The specific objectives of this proposal are designed to illuminate the unique features of the local host-pathogen interaction and defense against these extremely common and serious mucosal infections with S. pneumoniae in children and adults. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: NATURAL ANTIBODY AGAINST GROUP B STREPTOCCOUS IN MICE Principal Investigator & Institution: Butko, Peter; Chemistry and Biochemistry; University of Southern Mississippi Box 1, Southern Sta Hattiesburg, MS 39406 Timing: Fiscal Year 2001; Project Start 01-APR-2001; Project End 31-MAR-2004 Summary: (Verbatim from Applicant's Abstract): Group B streptococcus (GBS, Streptococcus agalactiae) is the most common cause of neonatal sepsis and meningitis in the USA. A humoral factor has been discovered in normal mouse serum which protects the animals against GBS infection. It is hypothesized that the protective factor is natural IgM antibody. Two goals of the proposed research are: (i) To confirm that the antibody is of the IgM type and that it is protective against experimental GBS infections in vivo; (ii) to identify the antigenic target for this antibody on the bacterial surface. To these aims, several clinical isolates and mutant strains of GBS, in combination with in
52 Meningitis
vitro enzyme-linked immunosorbent assays (ELISA) and in vivo mouse protection experiments will be utilized. Results obtained with mice as animal model may open a new avenue of investigation into possible role of natural antibodies in human immunity to GBS infection and bacterial infection in general, with possible implications for immunotherapy. The results also may provide impetus to the research on the antigenic targets on GBS, possibly other than the capsular polysaccharide, which would have implications for current GBS vaccine efforts. A non-scientific goal of this project is to increase the intensity of health-related undergraduate research and teaching in a midsize rural university with no medical school and to increase diversity in the work force in the academic research and medicine. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: NICOTINE & IMMUNOPATHOGENESIS OF CRYPTOCOCCAL MENINGITIS Principal Investigator & Institution: Sopori, Mohan L. Senior Scientist and Director; Lovelace Biomedical & Environmental Res Environmental Research Inst Albuquerque, NM 87185 Timing: Fiscal Year 2003; Project Start 01-SEP-2003; Project End 31-MAY-2008 Summary: (provided by applicant): Opportunistic infections of the central nervous system are common complication in acquired immunodeficiency syndrome (AIDS) patients. Cryptococcus neoformans (Cne) is an encapsulated yeast that causes often fatal cryptococcal meningoencephalitis (CM) in 7-30% of AIDS patients. While highly active anti-retroviral therapy has successfully decreased the incidence of many opportunistic infections, it is less effective in decreasing the incidence of opportunistic fungal infections in advanced AIDS patients. The host's response to Cne is a complex interplay between the innate and adaptive immunities. In animal models, the inability to increase the brain levels of proinflammatory cytokines or promote leukocyte migration into the brain is typically associated with lethal CM. Thus, "proinflammatory" responses are required to contain Cne infection in the central nervous system. Epidemiological studies show that cigarette smoking is a significant risk factor in cryptococcosis and other opportunistic fungal infections, and >85% of AIDS patients with cryptococcosis are cigarette smokers. However, the mechanism by which smoking affects the pathogenesis of Cne is totally unknown. We have demonstrated that cigarette smoke suppresses the immune system, and nicotine (NT) is a major immunosuppressive component of cigarette smoke that causes T cell anergy and inhibits the inflammatory responses. Our preliminary studies suggest that chronic NT treatment inhibits chemokinesis/chemotaxis and the migration of leukocytes to the site of inflammation, decreases brain IL-1beta expression in response to an inflammatory stimuli such as turpentine and Cne, and promotes growth and early dissemination of Cne into the brain. Therefore, we hypothesize that cigarette smoke/NT modulates both the innate and adaptive immune responses to Cne, thus facilitating its dissemination to the brain and the development CM. To test this hypothesis and to identify mechanism(s) by which NT facilitates brain infection by Cne, the following studies are proposed: 1. To investigate the effects of NT on Cne-induced innate immunity, including the expression of proinflammatory cytokines/chemokines in the brain and the response of leukocytes to cytokines/chemokines that are affected by Cne, to establish the kinetics of Cne and leukocyte migration into the brain and the development of CM, and to examine the effects of NT on the Cne-induced fever response. 2. To ascertain the effects on the adaptive immune responses including generation of anti-Cne antibodies, proliferative and delayed-type hypersensitivity responses to cryptococcal antigens, and generation of
Studies 53
cytotoxic T cells to immunodominant epitopes of Cne proteins, as well as to evaluate the protective function of T cells that migrate into the brain after Cne infection. 3. To investigate the mechanisms by which NT suppresses the migration of leukocytes toward the site of infection. These studies, we believe, will delineate the mechanism(s) by which smoking/NT encourages dissemination of Cne and, perhaps, other fungal infections into the brain of AIDS patients, and identify potential therapeutic targets for treatment of CM. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: PATHOGENESIS OF CRYPTOCOCCAL MENINGOENCEPHALITIS Principal Investigator & Institution: Lee, Sunhee C. Professor; Pathology; Yeshiva University 500 W 185Th St New York, NY 10033 Timing: Fiscal Year 2001; Project Start 16-DEC-1998; Project End 30-NOV-2002 Summary: (Adapted from Applicant's Abstract) Cryptococcal meningoencephalitis is caused by Cryptococcus neoformans, an encapsulated fungus which is ubiquitous in urban environments. Infection is thought to occur via the respiratory system following inhalation of C. neoformans. The respiratory infection is often transient or inapparent, but subsequent systemic cryptococcoses often result in cryptococcal meningoencephalitis, the classical presentation of cryptococcoses. Cryptococcal meningitis is incurable in patients with AIDS, despite antifungal treatments. The hypothesis to be tested in this proposal is that microglia and astrocytes can function as effector cells in cryptococcal meningoencephalitis and that modulation of their effector function by cytokines and opsonins may modify the course and the outcome of cryptococcal infection. The first Specific Aim will study the interaction of microglia with C. neoformans, and the role of cytokines and capspule-specific antibodies in modifying the interaction. Particular emphasis will be placed on the role of mAbs developed in this Institution that have been shown to offer protective immunity in murine infection. In the second Specific Aim, the fate of C. neoformans- infected microglia will be determined, since evidence suggests phagocyte killing as a novel mechanism of host injury induced by C. neoformans. The hypotheses to be tested include that the mode of phagocyte death can determine the fate of organisms. By defining the host cell parameters that successfully lead to killing of C. neoformans, the applicants hope to be able to optimize the therapy. In the third Specific Aim, interactions of C. neoformans and HIV-1 in microglia will be determined. Since most patients with cryptococcal meningitis also harbor HIV-1 virus in the CNS, it will be of paramount importance to examine the role of HIV-1 in modifying antifungal effector mechanisms exerted by microglia. In the fourth Specific Aim, they will test the hypothesis that C. neoformans alter the cytokine and chemokine milieu in the CNS which, in turn, modulates antifungal and antiviral activity of microglia and astrocytes. The last Specific Aim will define the role of nitric oxide synthase in anticryptococcal activity in human CNS and in culture. Specifically, they will determine if cytokine-activated astrocytes can synergize with microglia to promote intracellular killing by providing nitric oxide. These experiments will use human brain cells thus permitting the direct correlation of the observed results to potential therapeutic intervention in man. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: PHOSPHOLIPASE REGULATION OF MONOCYTE CHEMOTAXIS TO MCP-1 Principal Investigator & Institution: Cathcart, Martha K. Member; Molecular Medicine; Cleveland Clinic Lerner Col/Med-Cwru Cleveland, OH 44195
54 Meningitis
Timing: Fiscal Year 2003; Project Start 01-JUL-2003; Project End 30-JUN-2007 Summary: (provided by applicant): Monocytes are major participants in inflammatory responses and are mediators of chronic inflammation. Monocyte chemotactic factor 1 (MCP-1) is a critical chemotactic factor involved in attracting monocytes from the blood into tissues. This chemotactic cytokine has been shown to be a particularly important for the extravasation of monocytes into vessel walls in atherogenesis. Atherosclerosis-prone mice, when rendered deficient in either MCP-1 or its receptor, CCR2, develop significantly less atherosclerosis than their normal counterparts. Furthermore, MCP-1 has also been associated with a series of other chronic human inflammatory diseases including rheumatoid arthritis, viral meningitis, psoriasis, and inflammatory bowel disease. To date, we have a very cursory understanding of the signal transduction pathways regulating the chemotactic response of monocytes to MCP-I. In this application we propose experiments to elucidate the pathways regulating this central inflammatory process. Recent studies from our laboratory have identified a novel role for phospholipases A2 in regulating monocyte chemotaxis. When primary monocytes are rendered deficient in the expression of either cPLA2 or iPLA2 they fail to respond to the chemotactic stimulus of MCP-I. These pathways appear to operate independently in regulating the chemotactic response. It is clear that lipid signaling pathways are integral regulators of this monocyte chemotactic response. In this proposal we present a research plan to investigate how these PEA2 pathways regulate chemotaxis. In Aim 1 we will determine how these phospholipases relate to the few other pathways that have been identified in regulating MCP-l-induced monocyte chemotaxis and in the process we will explore the best approaches for selectively intervening in this process. We will examine the contributions of phospholipase D and AA metabolites in regulating chemotaxis and will explore the role of phospholipases in influencing cytoskeletal rearrangement and other cell processes involved in monocytic responses to MCP-1. These studies will significantly advance our understanding of this key inflammatory event. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: PLECONARIL (VP63843) THERAPY--INFANTS W/ ENTEROVIRAL MEN Principal Investigator & Institution: Edwards, Kathryn M.; Vanderbilt University 3319 West End Ave. Nashville, TN 372036917 Timing: Fiscal Year 2001 Summary: HYPOTHESIS: STUDY OBJECTIVES: A) VIROLOGIC EFFICACY- PRIMARY OBJECTIVE of this investigation is to determine if administration of pleconaril to infants w/enteroviral meningitis results in more rapid clearance of virus from various body sites. B) SAFETY- determine the safety of administration of pleconaril to infants w/enteroviral meningitis. The DAIDS Pediatric Toxicity Tables will be utilized. C) PHARMACOKINETICS- the pharmarmacokinetics of pleconaril administered to infants over a seven day period will be defined as a function of age. D) CLINICAL EFFICACYthe effects of pleconaril on resolution of meningitis symptoms will be assessed. SPECIFIC AIMS: STUDY ENDPOINTS: A) PRIMARY- Percentage of patients shedding virus (as detected by viral culture) from the oropharynx (i.e. throat) four days after beginning study drug. B) SECONDARY- 1) Duration (in days) of non-polio enteroviral shedding from any site, as detected by viral culture and/or PCR. 2) Resolution of meningitis symptoms (Appendix III). 3) Safety (see Section IX.D.4 for list of safety labs). 4) Pleconaril pharmacokinetics. C) TERTIARY- Development of viral resistance to pleconaril during course of viral shedding. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
Studies 55
•
Project Title: PRETARGETING STRATEGIES MALIGNANCY RADIOIMMUNOTHERAPY
FOR
CENTRAL
NERVOUS
Principal Investigator & Institution: Zalutsky, Michael R. Professor; Duke University Durham, NC 27706 Timing: Fiscal Year 2001 Summary: The overall objective of this proposal is to improve the clinical utility of radiolabeled monoclonal antibodies (MAbs) for the treatment of CNS tumors. Our hypothesis is that the efficacy of radioimmunotherapy is critically dependent on the type of nuclide and MAb labeling method that are used. During the past few years, we have developed novel strategies for labeling MAbs with the radioimmunotherapy and emits beta-particles with a maximum range in tissue of 102 mm. Astatine-211 decays by the emission of alpha-particles, which have a range of only a few cell diameters and a higher relative biological effectiveness than beta-particles. This nuclide might be ideal for the treatment of neoplastic maningitis. Fluorine-18 sis a positron emitter, and MAbs labeled with 18F offer the attractive possibility of using positron emission tomography (PET) to quantitate the distribution of labeled MAbs. PET imaging could provide more accurate dosimetry for both tumor and normal tissues and greatly facilitate radioimmunotherapy planning. The goal of this work is to be able to transfer our radiohalogenation technologies to the clinical domain as expeditiously as possible. These studies will be performed using chimeric Mel-14 and its fragments. This MAb was selected because of its potential utility for the treatment of gliomas and melanomas, particularly via intratumoral and intrathecal delivery. In addition, the selection of chimeric Mel-14 is supported by the encouraging results obtained in extensive preclinical work and clinical pilot studies that we have performed with murine Mel-14 F(ab')2. The specific aims of this project are: a) to label intact chimeric Mel-14 IgG and its fragments with 131I, 211At, and 18F using N-succinimidyl [131I] iodobenzoate, [211At] astatobenzoate, and [18F] fluorobenzoate, respectively, without compromising immunoreactivity; b) to determine the pharmacokinetics of radiohalogenated intact chimeric Mel-14 and its fragments in subcutaneous, intracranial, and neoplastic meningitis human tumor xenograft models; c) to investigate the in vitro radiotoxicity of 131I- and 211At-labeled intact chimeric mel-14 and its fragments in human tumor 2 cell lines; d) to evaluate the toxicity of 131I- and 211At-labeled intact chimeric Mel-14 and its fragments in normal and athymic mice; and e) to determine the therapeutic potential of intact chimeric Mel-14 and its fragments labeled with equitoxic doses of 131I and 211At in subcutaneous, intracranial, and neoplastic meningitis human tumor xenograft models. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: PROLONGED THROMBOPLASTIN TIME IN FEBRILE CHILDREN Principal Investigator & Institution: Willwerth, Ben M.; Children's Hospital (Boston) Boston, MA 021155737 Timing: Fiscal Year 2001 Summary: The hypothesis for this study is that the prolongation of the partial thromboplastin time (PTT) is caused by a lupus anticoagulant, which is likely produced in response to viral infections. The study will attempt to identify the cause of prolongation of the PTT in children with fever and petechiae, and may help the scientific community better understand the interaction between viral and bacterial infections and the human clotting system. Background: Children with fever and petechiae are known to be at increased risk for serious bacterial infections, including bacteremia, sepsis, and
56 Meningitis
meningitis. Previous studies have attempted to identify the incidence of and risk factors for serious bacterial illnes in these children. A recent study found that only 2% of children with fever and petechiae had bacteremia or sepsis. They noted that prothrombin time (PT) or PTT was prolonged in 28% of children with fever and petechiae. Though these children were not noted to have bleeding problems related to their prolonged coagulation times, this finding suggested that the source of the fever and petechiae in these children interacts with the human clotting system in a fashion that the investigators have yet to identify. The study will include 3 distinct patient populations: 1) children with fever and petechiae without bacteremia or sepsis; 2) children with fever without petechiae; and 3) children with neither fever nor petechiae. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: REGIONAL AGT DEPELTION OF CNS AND LEPTOMENINGEAL TUMORS Principal Investigator & Institution: Friedman, Henry S. Professor; Pediatrics; Duke University Durham, NC 27706 Timing: Fiscal Year 2002; Project Start 01-FEB-2002; Project End 31-JAN-2005 Summary: (provided by applicant) Central nervous system (CNS) neoplasms which either arise in the brain or metastasize from an extraneural primary site, are highly malignant tumors refractory to all conventional therapy. Similarly, patients with neoplastic meningitis from virtually any tumor such as melanoma, sarcoma or breast carcinoma do poorly, with mean survival following leptomeningeal spread measured in months. The major impediment to successful treatment is de novo or acquired resistance to chemotherapy. Temozolomide is an imidazole tetrazinone similar to dacarbazine, requiring conversion to the active methylating agent MTIC. Methylating agents, including temozolomide, produce cytotoxicity due to a lethal cycle of mismatch repair following cellular misrecognition of O(6)-methylguanine. Recent preclinical and clinical studies have confirmed the activity of temoxolomide in the treatment of malignant glioma. Unfortunately, the majority of patients ultimately display resistance to temozolomide. The two primary mechanisms of resistance to temozolomide and other alkylating agents are the enzyme O(6)-alkylguanine-DNA alkyltransferase (AGT) and a deficiency in the DNA mismatch repair pathway. Of these two mechanisms, AGT plays a primary role in resistance to temozolomide by removing the alkyl groups from the O(6) position of guanine, in effect reversing the cytotoxic lesion of temozolomide. The sensitivity of tumor cell lines to temozolomide and the alkylating agent BCNU can be correlated with AGT levels. Regional therapy of CNS parenchymal or leptomeningeal neoplasms with intratumoral or intrathecal administration respectively, offers the potential benefit of enhancing delivery to the target neoplasm while minimizing delivery and hence toxicity to systemic organs. We have previously demonstrated the activity and modest toxicity of intrathecal temozolomide in the treatment of athymic rats bearing subarachnoid AGT-human malignant gliom xenografts. We have extended these results and demonstrated the activity and safety of temozolomide delivered by intracerebral microinfusion in the treatment of malignant gliomas intracranially in athymic nude rats. The specific aims of this proposal are: 1. To define the role of intratumoral O(6)-BG and other AGT inhibitors in enhancing systemic or intratumoral temozolomide therapy of malignant glioma; 2. To define the role of intrathecal AGT inhibitors in enhancing system or intrathecal temozolomide therapy of neoplastic meningitis. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
Studies 57
•
Project Title: REGULATION OF THE (POLY) SIALIC ACID VIRULENCE FACTOR Principal Investigator & Institution: Vimr, Eric R. Associate Professor; Animal Sciences; University of Illinois Urbana-Champaign Henry Administration Bldg Champaign, IL 61820 Timing: Fiscal Year 2001; Project Start 01-JUL-1998; Project End 31-MAY-2003 Summary: The broad objective of this proposal is to increase our understanding of bacterial polysaccharide synthesis in pathogenic microorganisms. The K1 antigen, or polysialic acid capsule is a homopolymer of alpha2,8- linked sialyl residues. Synthesis of the capsule depends on about 15 genes of the kps pathogenicity locus that is organized into at least two convergently transcribed operons, one of which is controlled by the thermoregulated kpsF promoter. The anti-recognition functions of sialic acids (antiphagocytosis; inhibition of antibody-independent complement fixation; molecular mimicry of host antigens) make these unique nine- carbon carboxy sugar acids important determinants of virulence in diverse human and animal pathogens. Escherichia coli K1 is a leading cause of neonatal meningitis and a frequent cause of urinary tract infections in children and bacteremia in adults. Vaccination against these diseases may not always be practical, and conventional drug therapy is problematic. Alternative or improved therapies may emerge from a better understanding of capsular polysaccharide expression. Objectives of the application are to understand the molecular mechanisms of capsule thermoregulation and sialic acid precursor biosynthesis. This information is necessary for construction of defined mutants that will allow us to unambiguously determine the association between capsule and lipopolysaccharide O antigen during disease. To accomplish these objectives, we will pursue three specific aims. First, thermoregulation will be investigated with an in vitro transcription system designed to determine the intrinsic sensitivity of the kpsF promoter to temperature. The role of a positive regulator will be determined by isolation and characterization of mutants that no longer regulate the kpsF promoter. Second, the origin of sialic acid biosynthetic precursor, N- acetylmannosamine, will be determined by genetic and biochemical approaches. Finally, the role of the capsule and its association with O antigen will be determined using defined mutants in an animal model of E. coli K1 meningitis and bacteremia. At the completion of this research, we expect to have clearly delineated the relative contributions of cell surface polysaccharides to pathogenesis. We also expect to have identified specific new targets for potential therapeutic developments aimed at blocking capsule expression in vivo. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: ROLE OF COMPLEMENT PROTEINS IN E. COLI MENINGITIS Principal Investigator & Institution: Nemani, Prasadarao V.; Children's Hospital Los Angeles 4650 Sunset Blvd Los Angeles, CA 90027 Timing: Fiscal Year 2002; Project Start 01-APR-2002; Project End 31-MAR-2004 Summary: (provided by applicant): Neonatal E. coli K1 meningitis is the most common serious infection of the central nervous system with unchanged rates of mortality and morbidity. Survivors of this disease suffer a number of complications including mental retardation and speech impairment. Limited knowledge about the pathogenesis and pathophysiology of this disease hampered the efforts to develop new therapeutic strategies for the prevention. For example, most cases of E. coli K1 meningitis occur via hematogenous spread, but it is unclear how the circulating E. coli evades the hostdefense mechanisms. The investigator's studies have shown that outer membrane protein A (OmpA) of E. coli contributes to resistance to serum bactericidal activity. In
58 Meningitis
addition, OmpA interacts with a brain specific 95 kDa receptor for E. coli invasion of the blood-brain barrier (BBB). The E. coli invasion of the BBB was significantly reduced in the presence of adult human serum (AHS) when compared to cord blood serum (CBS) using the investigator's in vitro model of the BBB, the cultured brain microvascular endothelial cells (BMEC). His data further showed that OmpA binds to C4-binding protein, a complement fluid phase regulator, in significant quantities from AHS when compared to CBS. A compelling observation is that the binding of C4-binding protein to OmpA blocked the E. coli invasion of BMEC, suggesting that it is competing with the OmpA-receptor. The investigator hypothesized that binding of C4BP to OmpA blokcs the E. coli invasion of BMEC and that low levlels of C4BP may contribute to the susceptibility of neonates to E. coli meningitis. He will pursue this hypothesis by study of the following specific aims. 1. To determine the binding site of C4BP on OmpA that blocks E. coli invasion of BMEC, and 2. To assess the effect of anti-OmpA antibody, OmpA-peptides, and C4BP-peptides on E. coli invasion of BMEC in the newborn rat model of hematogenous meningitis. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: ROLE OF TRAJ IN NEONATAL E. COLI SEPSIS AND MENINGITIS Principal Investigator & Institution: Badger, Julie L.; Children's Hospital Los Angeles 4650 Sunset Blvd Los Angeles, CA 90027 Timing: Fiscal Year 2003; Project Start 01-APR-2003; Project End 31-MAR-2008 Summary: (provided by applicant): Despite the use of modern therapeutics and diagnostic measures, neonatal bacterial sepsis and meningitis continues to be a disease with unacceptable rates of morbidity and mortality. The fatality rate of this disease is 1575 percent; furthermore, approximately 50 percent of meningitis survivors have significant neurological and developmental abnormalities. The primary, route of infection for E. coli K1 (the most common causative agent of gram-negative meningitis) is oral. Following intestinal colonization, bacteria translocate through the GI tract to extra-intestinal sites of mesenteric lymph nodes (MLN), liver, spleen, and the blood. E. coli K1 then multiply systemically within the bloodstream reaching a necessary threshold of bacteremia to gain access to the central nervous system (CNS). Recently we identified an E. coli K1 plasmid-encoded blood-brain barrier (BBB) invasion gene, traJ, with homology to traJ of various F-like plasmid tra operons. Our preliminary data indicate that the traJ mutation specifically attenuates dissemination from the MLN to the liver, spleen, blood, and the CNS in the neonatal rat. In addition, although animals orally infected with the traJ mutant demonstrated a decrease or no recoverable bacteria in the liver or spleen, these tissues showed a significant inflammatory response. In vitro studies determined that the traJ mutant is taken-up less by macrophages and shows a loss of a 55 kDa-secreted protein. The central hypothesis of this application is that TraJ controls the expression of a set of genes whose products (i.e., 55 kDa secreted protein) are involved in E. coli K1 dissemination, systemic infection and crossing the BBB, and these events within the disease process occur via TraJ-dependent interactions with professional phagocytes. The following proposed experiments are designed to test and substantiate our hypotheses. We aim to 1) Elucidate the genetic and molecular characteristics of the traJ region and plasmid, evaluate the ability of the endogenous plasmid to self-transfer, and determine the potential role of the traJ-containing plasmid in E. coli K1 neonatal rat virulence, 2) Evaluate the function of the TraJ-regulated proteins (i.e., 55 kDa-secreted protein) in E. coli K1 systemic dissemination and meningitis, and 3) Determine the mechanism of TraJ-dependent host inflammatory response in the neonatal rat. Improved knowledge of molecular mechanisms for early
Studies 59
systemic dissemination and the exact interplay of the host inflammatory response during these events will assist in achieving our long-term goal of identifying novel rational approaches to development of new treatments and preventive strategies for E. coli K1 sepsis and meningitis. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: SIGNAL TRANSDUCTION AND VIRULENCE IN C NEOFORMANS Principal Investigator & Institution: Alspaugh, Andrew J,. Assistant Professor; Medicine; Duke University Durham, NC 27706 Timing: Fiscal Year 2001; Project Start 01-JUL-1998; Project End 30-JUN-2002 Summary: Dr. Alspaugh is a clinical/research fellow in the division of Infectious Diseases at Duke University. he is pursuing a career in academic medicine with a specific, scientific focus in the pathogenesis of infectious diseases. He has previous research experience in molecular genetics and in the immunology of cryptococcal infections. After his clinical infectious disease training, he has been working under the mentorship of Joseph Heitman and John Perfect studying signal transduction pathways in the human fungal pathogen Cryptococcus neoformans, and has identified that certain signaling elements are associated with pathogenicity in this organism. In his current environment at Duke, which includes regular interaction with other investigators interested in studying pathogenic fungi, he has a unique opportunity to continue his development as a research physician. He will be an active participant in both the Division of Infectious Disease as well as the Departments of Genetics and Pharmacology. Elements of signal transduction pathways are remarkably conserved from fungi to man. Dr. Alspaugh is especially interested in those signaling pathways which are activated in pathogens in response to host factors and which are associated with pathogenicity. Recently, heterotrimeric G- proteins have been identified as signaling elements essential for pathogenicity in the plant fungal pathogens Cryphonectria parasitica and Ustilago maydis. By homologous recombination, Dr. Alspaugh created mutant strains of the human pathogen Cryptococcus neoformans with a functional deletion of GPA1, the gene encoding a G alpha protein homolog. The gpa1 mutant cells were defective in mating and in the ability to express two well-established virulence traits, polysaccharide capsule and melanin. In a rabbit model of cryptococcal meningitis, the gpa1 mutant cells were markedly attenuated for virulence. Reintroduction of the wild-type GPA1 gene suppressed all of the mutant phenotypes, as did the addition of cAMP to the mutant cells. These findings implicate a novel signaling pathway in C. neoformans in which the GPA1 proteins transmits several external signals into the cell and, by regulating cAMP levels, regulates the important cellular processes of mating and pathogenicity. Dr. Alspaugh plans to further evaluate this signaling pathway, identifying upstream receptors and downstream molecules, to beer understand the process of pathogenicity in this organism and other fungi. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: SIGNAL TRANSDUCTION PATHWAYS REGULATING VIRULENCE Principal Investigator & Institution: Heitman, Joseph B. Professor; Duke University Durham, NC 27706 Timing: Fiscal Year 2001; Project Start 01-MAR-2001; Project End 28-FEB-2002 Summary: Fungal infections are increasing as a result of AIDS, transplantation, and high dose chemotherapy. However, existing antifungal agents are limited to amphotericin B, azoles, and flucytosine, and drug resistant isolates are emerging. We propose to
60 Meningitis
elucidate signal transduction cascades regulating virulence of Cryptococcus neoformans, the leading cause of fungal meningitis and a common opportunistic pathogen. Several features make C. neoformans an ideal model fungal pathogen. The organism exists as haploid cells with a defined sexual cycle. Gene disruption by homologous recombination is now possible, and established animal models permit analyses of mutant strains and candidate drugs in a virulence setting. These advances provide tools to elucidate signaling cascades regulating virulence traits of this organism, including capsule and melanin production in response to host signals, and to explore the association between virulence and MATalpha mating type. We have discovered that the G protein Gpa1 is required for mating and capsule and melanin production in C. neoformans. gpa 1 mutant strains are avirulent in an animal mode of cryptococcal meningitis. The phenotypes of gpa 1 mutant cells are suppressed by cAMP, suggesting Gpa1 regulates an adenylyl cyclase/cAMP/protein kinase A cascade. We have cloned C. neoformans homologs of Ras1, the PKA catalytic subunit and the Sch9 kinase, which are known to regulate an analogous G protein/cAMP dependent signaling pathway that regulates pseudohyphal differentiation in S. cerevisiae. In both S. cerevisiae and C. albicans, a MAP kinase signaling pathway also regulates filamentation and virulence. We and others have identified components of a homologous MAP kinase cascade in C. neoformans. Our studies reveal mutants lacking the G beta protein Gpb1, the MAP kinase Cpk1, or the STE12 transcription factor homolog have mating defects and virulence studies with these mutants are in progress. We propose to delineate the MAP kinase and G protein/cAMP dependent signaling cascades regulating C. neoformans virulence to understand regulation of pathogenesis and to identify novel antifungal drug targets. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: STATUS EPILEPTICUS OUTCOMES IN THE UNITED STATES Principal Investigator & Institution: Trevathan, N E. Neurology; Washington University Lindell and Skinker Blvd St. Louis, MO 63130 Timing: Fiscal Year 2001; Project Start 09-JUL-2001; Project End 30-JUN-2002 Summary: (taken from abstract) Status epilepticus (SE) is a common, life- threatening medical emergency that is experienced by about 150,000 people in the United States (US) each year, with up to 40,000 SE-associated deaths. In spite of treatments that are often effective, systematic emergency diagnostic and therapeutic protocols for SE are lacking in most hospitals. Unless diagnostic and therapeutic interventions are specifically directed to subpopulations of patients who will benefit most, it is unlikely that significant improvements in the care of patients with SE will be achieved rapidly. Data from the National Inpatient Sample (NIS) of the Healthcare Cost and Utilization Project (HCUP-3) have been recently used to describe the general characteristics of inpatients in the US with SE, and to demonstrate that SE increases the odds of all-cause mortality among inpatients in the US after controlling for co-morbid conditions and other potential confounding variables. Stroke, closed head injury, bacterial meningitis, and viral encephalitis are among the most common significant co-morbidities among hospitalized patients with SE. The long-term goals of our research are to: (a) Characterize the sub- populations of hospitalized patients in the US at highest risk for developing SE, and identify those inpatients who experience a significant increase in the odds of death associated with SE; (b) Propose a systematic intervention strategy for SE diagnosis and treatment for these sub-populations that minimizes medical errors, enhances rapid Diagnosis, and improves clinical outcomes; and (c) Study the effectiveness of the new proposed SE diagnostic and therapeutic delivery system among
Studies 61
hospitalized patients. During this one-year grant period, we will extend our initial analyses of SE using the NIS HCUP-3, 1988-1997, to achieve the following Specific Aims: (1) Using the NIS data we will determine the frequency, the trends in frequency, and the geographic variations of SE among hospitalized patients in the US with bacterial meningitis, viral encephalitis, closed head injury, and/or stroke; (2) Using the NIS data, we will determine the impact of SE on the odds of death, controlling for potential confounding variables, among inpatients in the US with bacterial meningitis, viral encephalitis, closed head injury, and/or stroke; (3) Using the NIS data, we will conduct four separate analyses to determine the factors that increase the odds of developing SE among inpatients with bacterial meningitis, viral encephalitis, closed head injuries, and/or stroke. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: STRUCTURAL ANALYSIS OF ENTEROVIRUS CELL ENTRY PATHWAYS Principal Investigator & Institution: Hogle, James M. Professor; Biological Chem & Molecular Pharm; Harvard University (Medical School) Medical School Campus Boston, MA 02115 Timing: Fiscal Year 2002; Project Start 01-DEC-1983; Project End 31-MAR-2007 Summary: (provided by applicant): Over the past 10 years poliovirus and its close relatives (Coxsackieviruses, echoviruses and rhinoviruses) have emerged as model systems for probing the cell-entry mechanisms of nonenveloped viruses. These viruses are responsible for a variety of human diseases including: common colds, summer flu, poliomyelitis, encephalitis, meningitis, and a variety of cardiomyopathies. In previous funding periods several forms of poliovirus relevant to cell entry have been characterized by a combination of biochemical and structural studies. These studies together with work in other laboratories have led to a working model for the cell entry process that has striking similarities to models for the cell entry of enveloped viruses. The model frames the cell entry process in terms of several specific structural questions: 1) How does receptor binding lead to conformational changes that are required for subsequent steps in cell entry? 2) What is the sequence of conformational changes that ultimately leads to cell entry and the release of the viral RNA? 3) What is the role of the membrane in the formation of the virus receptor complex and the induction of conformational changes? 4) What is the nature of the interaction of the virus with the cell membrane that leads to the internalization of the RNA? 5) How is the RNA released from the particle and into the cell? In the coming funding period the questions will be addressed by a combination of structural and biochemical studies. Existing structures of the poliovirus/receptor complex and cell entry intermediates will be extended to the highest possible resolution using a combination of cryoelectron microscopy and x-ray crystallography. Conditions for stabilizing additional cell-entry intermediates in the poliovirus cell entry pathway will be optimized, and these intermediates will be characterized by cryoelectron microscopy and biochemical studies. The structure of the complex of echovirus 11 with its receptor DAF (CD55) will be determined by cryoelectron microscopy. Receptor-decorated liposomes will be used as a simple in vitro model system for biochemical studies of the early events in cell entry. This system also will be used to characterize the structure of the poliovirus/Pvr complex in the context of the membrane, to characterize the structure of the A particle/membrane complex, and to characterize structures responsible for release of the viral RNA by cryoelectron microscopy. These studies will provide a series of snapshots of the virus in the process
62 Meningitis
of entering the cell that will serve as a context for the development of more detailed models of the cell entry mechanism of polio and related viruses. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: STRUCTURAL STUDIES OF BACTERIAL HYALURONATE LYASE ENZYME Principal Investigator & Institution: Jedrzejas, Mark J. Microbiology; University of Alabama at Birmingham Uab Station Birmingham, AL 35294 Timing: Fiscal Year 2001; Project Start 01-JAN-1999; Project End 08-MAY-2001 Summary: The objective of this research proposal is to develop a better understanding of the structural properties and mechanism of action of S. pneumoniae hyaluronate lyase enzyme. The long term objective is to better understand the mechanism of invasion of host tissue and the penetration of host defenses by S. pneumoniae and other Grampositive bacteria. Such understanding may lead to the development of new antibacterial therapeutic agents. S. pneumoniae is the most common cause of fatal pneumonia in the elderly, and it is one of the most common causes of middle ear infections and meningitis in children. The present vaccine consists of a mixture of 23 different capsular polysaccharides. While this vaccine is very effective in young adults, it is only about 60 percent effective in the elderly. In children less than 2 years of age the vaccine is ineffective and is not recommended due to the inability of this age group to mount an antibody response to the penumococcal polysaccharides. Antimicrobial drugs such as penicillin have diminished the risk of pneumococcal disease. However, in most parts of this country, up to 35 percent of pneumococcal strains are now resistant to penicillin and the frequency of multidrug resistant strains is steadily increasing. It has been recently suggested that certain pneumococcal proteins such as hyaluronate lyase, pneumolysin, and pneumococcal surface protein A (PspA) could be used as potential vaccine or drug targets for development of new cure. Hyaluronate lyase is a major surface protein of S. pneumoniae with possibly antigenetically variable properties that might be essential for full pneumococcal virulence. Thus, hyaluronate lyase might represent one of the best alternatives for a pneumococcal vaccine or drug target especially when combined with other pneumococcal virulence factors such as PspA or pneumolysin. We have expressed in E. coli, purified, and crystallized fully active forms of hyaluronate lyase enzyme from S. pneumoniae and Group B Streptococcus. The specific aims of the research proposed in this application are directed towards: a) the determinatin of the crystal structure of the hyaluronate lyase enzyme; b) thoroughly characterizing the properties and mapping the active site of this enzyme utilizing oligonucleotide mediated site directed mutagenesis. The results will enhance our knowledge about mechanisms involved in the action of the enzyme and in the pathogenesis of S. pneumoniae bacteria. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: STRUCTURE/FUNCTION OF BACTERIAL ADHESION PILI Principal Investigator & Institution: Bullitt, Esther S. Assistant Professor; Biophysics; Boston University Medical Campus 715 Albany St, 560 Boston, MA 02118 Timing: Fiscal Year 2001; Project Start 01-MAY-1998; Project End 30-APR-2003 Summary: The aim of this research is to understand the structure and assembly of adhesion pili found on pathogenic bacteria, thereby providing insight into how the architecture of these pili supports their role as a virulence factor. Bacterial survival and colonization require attachment of the bacteria to hosts. In many stains, this process is initiated and maintained by pili; in Escherichia coli that cause pyelonephritis, adhesion
Studies 63
and virulence depend on P-pili. Hib-pili expressed on the surface of Haemophilus influenzae mediate H. flu's colonization of the upper respiratory tract, and thus its ability to cause diseases such as childhood meningitis, otitis media, and pneumonia of the elderly. As bacteria become more resistant to traditional antibiotics, it is important to develop new therapies against bacterial infections. Structural information about adhesion pili will provide a basis for future rational design of new therapies to prevent bacterial binding or to remove pathogenic bacteria bound to the human host. The proposed research addresses this long-term goal through structural studies of bacterial adhesion pili. These studies focus on: 1) electron microscopy and three-dimensional (3D) helical reconstruction of P-pili preserved in vitreous ice and of Hib-pili negative stain, 2) controlled damage/recovery of pili to investigate the possibility of re-formation of intact helical filaments, 3) investigation of the 3-D structure of P-pili with mutant structural proteins (pilins), to examine regions of the PapA pilin essential for their assembly into tightly coiled helical filaments, 4) bacterial attachment assays, to assess the effect of mutations and the effect of damage on bacterial binding, and 5) in vitro reconstitution of hetero-pilin polymers from chaperone-pilin complexes, to improve our understanding of the bioassembly process of a prototypical macromolecule. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: STUDY OF S PNEUMONIAE VIRULENCE GENE REGULATION Principal Investigator & Institution: Camilli, Andrew; Associate Professor; Molecular Biol & Microbiology; Tufts University Boston Boston, MA 02111 Timing: Fiscal Year 2002; Project Start 15-SEP-2002; Project End 14-SEP-2004 Summary: (provided by applicant): The overall goal of our research is to understand the pathogenicity of Streptococcus pneumoniae, the most common cause of bacteremia, bacterial meningitis, otitis media and community-acquired pneumonia in the U.S.A. Current capsule-based vaccines, which only contain a subset of the capsular types in circulation, do not provide adequate protection from pneumonia and otitis media, which account for the majority of S. pneumoniae morbidity. Despite more than a century of research, understanding of S. pneumoniae virulence factors is limited. Furthermore, almost nothing is known concerning the regulation of S. pneumoniae virulence factors during infection. These limitations, plus an increasing incidence of antibiotic-resistance mandate increased study of the pathogenicity of this organism. We have completed a large-scale screen that resulted in the identification of 233 genes that are essential in a murine model of pneumonia. Additionally, we tested the importance of each of these genes in murine models of bacteremia and nasopharygeal carriage. Included among these novel virulence factors are 21 surface proteins, and 20 putative regulators that we hypothesize coordinate tissue-specific virulence gene expression. The first goal of the proposed work is to gain an understanding of both the regulation and mechanisms of action of two factors hypothesized to localize to the bacterial surface and interact with host components. Mutational analyses and virulence assays will be combined to define their interacting domains. The second goal is to identify major virulence gene regulons and their modes of coordination during infection. Five putative transcription factors identified in our screen will be placed under inducible expression, and the subset of genes regulated by each will be determined by transcriptional profiling on microarrays. For selected genes, the level of expression during nasopharyngeal carriage in mice and humans will be determined using quantitative RTPCR. The requirement for each cognate regulator for expression of these virulence genes during infection of mice will be confirmed. These studies will enhance our knowledge and understanding of S. pneumoniae-host interactions and virulence mechanisms, and
64 Meningitis
will constitute the first broad study of S. pneumoniae virulence gene regulation. These studies will aid in the development of novel vaccines, and will suggest new targets for antimicrobial drug development. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: SUBSTANCE P, NO & MICROGLIA IN CNS INFLAMMATION Principal Investigator & Institution: Nathan, Barnett R. Neurology; University of Virginia Charlottesville Box 400195 Charlottesville, VA 22904 Timing: Fiscal Year 2001; Project Start 01-SEP-1999; Project End 31-AUG-2004 Summary: In the next 5 years I plan to study in vitro and in vivo the interactions of microglia, macrophages, substance P and nitric oxide as well as the effect of these substances on mitochondrial function. Substance P (SP) has effects as a pain mediator in the spinal cord and has vasoactive properties. It also plays a significant role in the pathogenesis of neurogenic inflammation, being released from peripheral nerve terminals and causing precapillary vasodilatation, postcapillary plasma extravasation and histamine release. Nitric oxide (NO) is known to play a role in bacterial meningitis and also has immunomodulatory and vasoactive properties. Peripheral blood macrophages and central nervous system (CNS) microglia share similar immunogenic properties and may be derived from the same cell line. Microglia are suspected to play a role in the pathophysiology of a wide variety of inflammatory CNS diseases and the mediators for this microglial induced injury may be modulators such as substance P and nitric oxide. The underlying hypothesis which provides the framework for all of the proposed studies is that substance P (SP), nitric oxide(NO) and microglia play a central role in the pathophysiology of bacterial meningitis (BM) and other acute CNS inflammatory conditions. The overall goal of this application is to investigate the effects of SP and NO on macrophage and microglia functions in in vitro and in vivo systems. This overall goal will be approached by addressing the following specific hypotheses. Hypothesis 1: Substance P plays a central role in bacterial meningitis, both through its direct immunomodulatory effects and through its effects on nitric oxide. In stimulated phagocytic cells there is an upregulation of preprotachykinin and SP receptor message. Hypothesis 2: Nitric oxide plays a central role in the pathophysiology of bacterial meningitis. There is upregulation of inducible nitric oxide synthase (iNOS) message resulting in increased production of NO. SP modulates iNOS via inhibition of iNOS message. Hypothesis 3: Both the resident and transient phagocytic cells in the CNS (microglia and macrophages) participate in the pathophysiology of bacterial meningitis. SP and NO modulate their effects in CNS inflammation via these cells. Hypothesis 4: The ultimate site for the effects of SP and NO may be the mitochondrial respiratory chain enzymes of these phagocytic cells. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: THE NEUROPATHY
ROLE
OF
NUTRITION
IN
VIRUS-INDUCED
OPTIC
Principal Investigator & Institution: Beck, Melinda A. Associate Professor; Pediatrics; University of North Carolina Chapel Hill Office of Sponsored Research Chapel Hill, NC 27599 Timing: Fiscal Year 2003; Project Start 15-APR-1999; Project End 31-MAR-2007 Summary: (provided by applicant): Coxsackievirus A9 (CA9) and a variant, impaired in replication but persistently present in CSF over several months, were isolated from patients' CSF specimens during an epidemic of optic and peripheral neuropathy in Cuba
Studies 65
in the early 1990's. The epidemic was clearly related to dietary deficiencies in several nutrients, including the antioxidants selenium, vitamin E, and lycopene. We are studying these isolates in the context of our previous work in mice, which demonstrated that deficiency of selenium or vitamin E can lead to increased severity of both Coxsackievirus B3 myocarditis and influenza pneumonia, with concomitant mutations in the viral genome. These mutations are reproducible, and the mutant strains have increased virulence for mice with normal nutriture. We hypothesize that host nutritional deficiencies induced mutations in CA9, leading to a new viral variant with altered pathogenic potential. We have completed genomic sequence analysis of three Cuban CA9 isolates from neuropathy patients and of five meningitis isolates from before the epidemic. Phylogenetic analysis shows the neuropathy isolates to be different, with a unique mutation near the active site of 2a protease that may contribute to the altered capsid proteins previously demonstrated in the variant virus. Using homologous regions among the CA9 already sequenced, we designed improved primers for sequencing the variant, which required special methods for RNA isolation because of apparent instability and/or very limited quantity. We have produced full-length cDNA from the variant, and sequences in the 5' non-translated region are consistent with a CA9 not identical to the other isolates. Using electron microscopy, we have demonstrated typical picornavirus virions in thin sections of CA9, but not of the variant, although the latter produces abundant viral antigen as demonstrated by immunofluorescence with homologous antiserum. We have produced mutations in CB3 by in vitro exposure to hydrogen peroxide in cell culture, and we will now apply the methods developed to CA9. In this continuation proposal, our objectives are 1) to characterize the quasispecies populations of the CA9 and variant isolates from Cuban patients; 2) to determine the role of the 2a protease and other mutations in altering the capsid proteins and replication patterns of the variant; 3) to determine the effects of repeated passage of CA9 and variant viruses in cells exposed to, or protected from, oxidative stress; and 4) to study the capsid morphology of the variant by comparing it to normal CA9 using cryo-electron microscopy. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: TNFGAMMA PERMEABILITY
EFFECTS
ON
BLOOD
BRAIN
BARRIER
Principal Investigator & Institution: Miller, Donald W. Associate Professor; Pharmaceutical Sciences; University of Nebraska Medical Center Omaha, NE 681987835 Timing: Fiscal Year 2001; Project Start 01-JUL-1997; Project End 30-APR-2003 Summary: (Adapted from Applicant's Abstract): Tumor necrosis factor-alpha (TNF-a) is a cytokine released in response to inflammatory events in the body. The increased levels of TNF-a in the central nervous system observed in conditions such as multiple sclerosis, bacterial meningitis, viral infections and brain ischemia suggest that the cytokine may be involved in the pathogenesis of these diseases. A major cellular target for TNF-a is the endothelium, where increases in coagulant activity, cell adhesiveness and vascular permeability are observed. Indeed, exogenous administration of TNF-a produces significant increases in blood-brain barrier (BBB) permeability. Therefore, understanding the mechanisms through which TNF-a produces changes in the permeability of brain microvessel endothelial cells that form the BBB, may provide insight into the cause and effective treatment of inflammatory events within the central nervous system. The proposed studies will examine the effects of TNF-a on BBB permeability on two distinct levels. First, primary cultured bovine brain microvessel endothelial cells (BBMEC) will be used as an in vitro model of the BBB to examine the
66 Meningitis
cellular factors involved in the permeability effects of TNF-a. The hypothesis to be examined is that inhibition of actin stress filament formation in the cells will prevent increases in BBMEC monolayer permeability observed with TNF-a. The specific aims for the in vitro studies will be to evaluate the effects that 1) inhibition of Rho-mediated GTP binding proteins, 2) alterations in cyclic nucleotide signaling pathways, and 3) inhibition of arachidonic acid metabolism has on TNF-alpha-induced changes in actin filament formation and BBMEC monolayer permeability. Secondly, the effects of TNF-a on BBB will be evaluated in vivo. The hypothesis for the in vivo studies is that changes in BBB permeability observed under inflammatory conditions in the brain are directly correlated to the amount of TNF-a released. For these studies, microdialysis probes will be implanted into the cortex of rats. The specific aims for the in vivo portion of the proposal are to 1) determine the dose-response relationship between cortically administered TNF-a and increases in BBB permeability, and 2) correlate the endogenous release of TNF-a following cortical injection of bacterial toxin or cerebral blood flow occlusion with changes in BBB permeability. Microdialysis probes will be used to deliver exogenous TNF-a to specific sites in the cortex as well as sampling endogenously released TNF-a. Together, the proposed studies will provide a better understanding of the mechanisms involved in TNF-a effects on BBB permeability. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: TRANSCRIPTIONAL BIOSYNTHESIS
REGULATION
OF
GBS
CAPSULE
Principal Investigator & Institution: Cieslewicz, Michael J. Medicine; Harvard University (Medical School) Medical School Campus Boston, MA 02115 Timing: Fiscal Year 2001; Project Start 01-FEB-2001 Summary: (provided by applicant): Streptococcus agalactiae (Group B Streptococcus or GBS) is a common cause of neonatal pneumonia, sepsis and meningitis. Acapsular GBS mutants exhibit decreased virulence in mice suggesting that the capsular polysaccharide is a major virulence factor. Strains of GBS are found to express nine different capsule serotypes, Ia, Ib and II-VIII. We have focused our study on one of the most important in GBS capsule serotypes in human infection, type Ia. The GBS operon that directs synthesis of the type Ia capsule consists of 16 genes and is predicted to contain two promoters. The first promoter is upstream of the first gene, cpsIaA. A second, downstream promoter is predicted to lie upstream of cpsIaE. A non-polar cpsIaA deletion mutant exhibits decreased capsule expression at the surface of the cell, yet individual capsule chains in the cpsIaA deletion mutant and its parent wild-type strain are the same molecular size. Additionally, transcription of genes downstream of cpsIaA is down-regulated in a cpsIaA deletion mutant. These results are suggestive of CpsIaA acting as a transcriptional activator. In this proposal we will determine the transcriptional organization and relative promoter strength of the type Ia GBS capsule operon. In addition, we will determine if CpsIaA directly modulates transcription of the type Ia capsule genes. Experiments outlined in this proposal will lead to a better understanding of transcriptional regulation of GBS capsule biosynthesis. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: TRANSGENIC MOUSE MODEL FOR ECHOVIRUS PATHOGENESIS Principal Investigator & Institution: Racaniello, Vincent R. Professor; Microbiology; Columbia University Health Sciences New York, NY 10032 Timing: Fiscal Year 2001; Project Start 01-JUN-2001; Project End 30-APR-2005
Studies 67
Summary: (provided by applicant): Animal viruses initiate their replicative cycles by attaching to a cellular membrane receptor, followed by entry into the cell. Identification of the poliovirus receptor, Pvr, was essential for the establishment of a transgenic mouse model for poliomyelitis. Although a great deal is known about the pathogenesis of poliovirus infection, relatively little is understood about how echoviruses cause disease. Echoviruses are important human pathogens and are responsible for aseptic meningitis, neonatal sepsis, myocarditis, exanthemas, respiratory illness and gastrointestinal disease. Because most echovirus strains only replicate in humans, a mouse model has not been available for studying echovirus pathogenesis. The object of work in this proposal is to isolate transgenic mice that express human cell receptors for echovirus, to establish a new animal model for studying echovirus pathogenesis. We propose to isolate transgenic mice that express VLA-2, a heterodimeric integrin consisting of alpha2 and beta1 subunits, which is known to be the cell receptor for echovirus types 1 and 8. Three specific aims are planned. First, human cDNA encoding the alpha2 and beta1 subunits of VLA-2 will be placed under the transcriptional control of the human betaactin promoter, and used to establish transgenic mice that express both proteins. Second, tissues and organs of VLA-2 transgenic mice will be examined by Northern and Western blot analysis and immunohistochemistry for expression of VLA-2 RNA and protein. Third, the susceptibility of VLA-2 transgenic mice to echovirus type 1 infection by different routes, as well as the location of virus replication after inoculation, will be determined. In addition, the ability of echovirus to spread from muscle and intestine to the central nervous system by axonal transport will be determined. Fourth, experiments will be done to determine if an immune response is mounted during echovirus 1 infection of VLA-2 transgenic mice. Knock-out mice will be used to study the role of the immune response in limiting or exacerbating echovirus pathogenesis. Transgenic animal models would enable studies on the sites of echovirus replication, the mechanisms of viral spread, and the basis of echovirus tissue tropism. Establishment of a small animal model may yield information about echovirus pathogenesis that could stimulate development of echovirus vaccines or antiviral drugs. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: TREATING SEPSIS WITH PAF ACETYLHYDROLASE Principal Investigator & Institution: Prescott, Stephen M. H.A. & Edna Benning Presidential Profess; Intermountain Reg Cancer Netwk; University of Utah 200 S University St Salt Lake City, UT 84112 Timing: Fiscal Year 2001; Project Start 01-JUL-2001; Project End 30-JUN-2004 Summary: In this application we propose to test if removal of PAF and related phospholipids reduces the mortality associated with certain forms of sepsis. To test this hypothesis, we will examine the effect of administration of recombinant PAF acetylhydrolase, the enzyme that inactivates PAF and related phospholipids, to animals undergoing sepsis. We will use survival as the endpoint but will also characterize the response to enzyme administration by comparing cytokine levels in animals treated with placebo or with the recombinant protein. We will utilize two experimental models of sepsis: cecal ligation and puncture and sepsis induced by injection of Neisseria meningitidis. As a clinical corollary, we will determine the levels of PAF acetylhydrolase activity and cytokine levels in the plasma of patients undergoing sepsis and meningococcemia. An important goal of these studies, in addition to testing the potential of PAF acetylhydrolase as a therapeutic agent, is to identify patient groups that are likely to benefit the most from PAF acetylhydrolase administration. Recent clinical studies have failed to demonstrate that anti-inflammatory or immunomodulatory agents
68 Meningitis
have beneficial effects in the treatment of sepsis. A possible explanation for this observation is that the patient population studied included subjects in whom a variety of different mechanisms resulted in sepsis. This may have precluded the ability of the agent(s) tested to show a beneficial effect in a limited group of patients because such effects would be lost in the analysis of the entire patient group. Our hypothesis is that the definition of sub-populations with similar etiologies will be a key factor in our understanding of sepsis. This approach will facilitate identification of markers to characterize the evolution and outcome of the disease as well as identify novel therapies. For example, patients suffering from meningococcemia-related sepsis can be identified as a homogeneous sub-population of septic patients. The studies proposed here may facilitate the molecular identification and treatment of populations that can significantly benefit from PAF acetylhydrolase administration. These studies will be carried out primarily in Brazil, as an extension of NIH SCOR grant P50 HL50153 (Project 5). They constitute an ideal complement to the studies currently being performed by Drs. Prescott and Stafforini, who are the Principal Investigator and Project Director of Project 5 of the SCOR in Acute Lung Injury, respectively. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: TREATMENT FOR GBS COLONIZATION IN PREGNANT WOMEN Principal Investigator & Institution: Bhatt, Bakul M.; Biomedical Development Corporation 500 Sandau, Ste 200 San Antonio, TX 78216 Timing: Fiscal Year 2001; Project Start 20-SEP-1997; Project End 31-MAY-2004 Summary: (Adapted from Applicant's Abstract): The goal of this project is to further develop Iocide, a novel iodine-based antimicrobial technology, for use as a topical bacteriocide for group B streptococci (GBS) in the vaginal tract of pregnant women during the intrapartum period. GBS is the leading cause of neonatal bacterial disease and death, and most frequently occurs in neonates as sepsis, meningitis, and pneumonia. Despite clinical advances to date, GBS continues to be a major cause of illness and death among newborns. Due to the limitations of current clinical strategies, a need exists for alternate approaches to prevent GBS-related neonatal disease. The following specific aims have been designed to achieve this goal: 1) to optimize the formulation of the Iocide vaginal gel, 2) to determine the effective range of Iocide in vitro, 3) to demonstrate safety and efficacy to the Iocide in animals, and 4) to determine safety and efficacy of Iocide in human clinical trials. PROPOSED COMMERCIAL APPLICATION: NOT AVAILABLE Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: TUBERCULOSIS IMMUNITY IN YOUNG CHILDREN Principal Investigator & Institution: Lewinsohn, Deborah A.; Oregon Health & Science University Portland, OR 972393098 Timing: Fiscal Year 2003; Project Start 15-MAY-2003; Project End 30-APR-2007 Summary: (provided by applicant): Tuberculosis (TB) is one of the most important causes of infectious morbidity and mortality worldwide. Young children are more likely to contract infection with and develop severe disease from the causative agent Mycobacterium tuberculosis (Mtb). These clinical observations likely reflect fundamental differences in the immune systems of young children and adults. Critical differences relevant to TB immunity include the propensity for infants and young children to develop TH2-type CD4+ T cells in response to immunogens, deficiencies in the development of TH1-type T cells in response to pathogens, and deficiencies in
Studies 69
macrophage and dendritic cell (DC) function. We propose to systematically define, in young children (less than or equal to 10 years of age), these important differences relevant to the successful containment of Mtb infection. The specific aims are: 1) To determine if severity of disease following Mtb infection in young children is associated with TH2-type Mtb-specific immunity, and conversely, if absence of disease following Mtb infection is associated with TH 1-type Mtb-specific immunity. 2) To determine if immunologic immaturity is associated with the development of TH2-type Mtb-specific immunity following Mtb infection, and conversely if immunologic maturity is associated with the development of TH 1-type Mtb-specific immunity following Mtb infection. 3) To evaluate aspects of innate immunity relevant to Mtb infection by characterizing the phenotype and function of macrophages and DC from cord blood derived from healthy neonates in comparison to macrophage and DC function in healthy adults. These studies may contribute to a more complete understanding of TB immunity in young children, and hence 'facilitate the development of an improved TB vaccine for this vulnerable population. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: USING BIOCHEMICAL MARKERS TO DETECT ABUSIVE HEAD TRAUMA Principal Investigator & Institution: Berger, Rachel P. Professor; Children's Hosp Pittsburgh/Upmc Hlth Sys of Upmc Health Systems Pittsburgh, PA 15213 Timing: Fiscal Year 2003; Project Start 14-APR-2003; Project End 31-MAR-2008 Summary: (provided by applicant): Child abuse is a leading cause of serious traumatic brain injury (TBI) in infants and young children. Proper diagnosis of abusive head trauma (AHT) is difficult even for experienced, astute physicians. Misdiagnosis is common and can have catastrophic medical consequences for patients. Aside from increased awareness, there are currently no established strategies or diagnostic tests to help physicians properly identify AHT. A screening test that could alert physicians to the possibility of AHT and thereby aid in proper and timely diagnosis, could have an enormous impact. Biochemical markers of brain injury are released from the brain after TBI and diffuse into cerebrospinal fluid (CSF) and/or serum, where their concentrations can be measured. CSF and serum concentrations of three of these biochemical markers -neuron-specific enolase (NSE), S100B, and myelin-basic protein (MBP) - are sensitive indicators of mild, moderate and severe TBI in adults and children. These markers may therefore have the potential to act as diagnostic adjuncts to complement physician acumen in properly diagnosing AHT. Specific Aim 1 is to determine the sensitivity and specificity of serum NSE concentrations for detecting AHT in infants at increased risk of AHT and to determine whether the use of a panel of NSE, S100B and MBP improves sensitivity or specificity when compared with NSE as a single marker. Specific Aim 2 is to determine whether increases in CSF and serum NSE, S100B and/or MBP are specific to TBI or whether their concentrations can be affected by four non-traumatic neurological insults: hypoxic-ischemic encephalopathy, meningitis, progressive encephalopathy and seizures. The candidate is a pediatrician at Children's Hospital of Pittsburgh (CHP). This Mentored Career Development Award will allow the candidate to pursue a unique and highly integrated mentored program in pediatric neurotrauma and child abuse. Pittsburgh is an ideal environment for this type of program because of the resources of CHP, the Safar Center for Resuscitation Research and The Child Advocacy Center. Dr. Patrick Kochanek, the primary mentor for this award, is internationally recognized for his work in the field of pediatric TBI, has served as a
70 Meningitis
mentor on multiple K awards and is the PI of an NICHD-funded training grant (T32) in pediatric neurointensive care. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: VIRULENCE GENES HAEMOPHILUS INFLUENZAE Principal Investigator & Institution: Smith, Arnold L. Professor and Chair; Molecular Microbiol and Immun; University of Missouri Columbia 310 Jesse Hall Columbia, MO 65211 Timing: Fiscal Year 2002; Project Start 15-SEP-2002; Project End 16-SEP-2002 Summary: (provided by applicant): Haemophilus influenzae is a human-restricted bacterium which can exist as an upper respiratory commensal, but also cause focal and/or systemic disease. More than 95 percent of the nasopharyngeal isolates lack capsules and are not serotypeable, and cause focal infections, while encapsulated (and rare nontypeable) strains cause sepsis and meningitis. The genome of both commensal and pathogenic isolates is 250 kb (on average) larger than the avirulent laboratory strain (Rd KW2O) whose genome sequence was published in 1995. We have found that the genome of strain Rd KW2O is a "scaffold" on which genes, gene clusters and operons encoding virulence factors are inserted, usually at the Haemophilus-specific DNA uptake sites. Using differential hybridization we will identify those DNA loci that permit nasopharyngeal colonization by commensals, and the additional putative virulence loci in pathogenic isolates. Each of these DNA fragments and the flanking DNA, will be sequenced until the Rd KW2O scaffold is identified. All sequence information will be posted on the UW Genome Center web site. Using strict criteria for homology (not conventional criteria) putative virulence genes will either be deleted or mutated and the virulence of the mutant compared to the parent in a relevant in vitro and/or in vivo infection model. For example a putative adhesin present in a lower respiratory tract isolate could be tested with human respiratory epithelial cell lines, and with primary human respiratory epithelium growing at an air-liquid interface in tissue culture. One unique isolate, an untypeable strain causing meningitis in an immunocompetent child immunized with a Hib-conjugate vaccine appears to be a member of a clade; we wish to confirm the preliminary finding and initiate a global database (in collaboration with the MLST Haemophilus Center) for these vaccine-failure isolates. With an understanding of the molecular mechanisms of colonization versus infection, strategies for prevention and intervention can be devised. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: MENINGITIS
VORICONAZOLE
IN
SUPPRESSION
OF
CRYPTOCOCCAL
Principal Investigator & Institution: Muschatt, David M.; Tulane University of Louisiana New Orleans, LA 70118 Timing: Fiscal Year 2001 Summary: Among persons with advanced HIV infection, cryptococcal meningitis remains the most common invasive fungal infection and fourth most common opportunistic infection. AIDS-associated cryptococcal meningitis also is not easily treatable. In most instances, patients require life-long suppressive treatment because current anti-fungal therapy rarely eradicates the infection. Therefore, the purpose of this study is to determine if voriconazole, a research medicine, is safe, effective and tolerated as a suppressive treatment for cryptococcal meningitis. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
Studies 71
•
Project Title: VP 63843 IN TREATMENT OF ENTEROVIRAL MENINGITIS IN ADOLESCENTS&ADULTS Principal Investigator & Institution: Young, Kelly D.; Harbor-Ucla Research & Educ Inst 1124 W Carson St Torrance, CA 90502 Timing: Fiscal Year 2001 Summary: This abstract is not available. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
E-Journals: PubMed Central3 PubMed Central (PMC) is a digital archive of life sciences journal literature developed and managed by the National Center for Biotechnology Information (NCBI) at the U.S. National Library of Medicine (NLM).4 Access to this growing archive of e-journals is free and unrestricted.5 To search, go to http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=Pmc, and type “meningitis” (or synonyms) into the search box. This search gives you access to full-text articles. The following is a sample of items found for meningitis in the PubMed Central database: •
A critical role for neutralizing-antibody-producing B cells, CD4 + T cells, and interferons in persistent and acute infections of mice with lymphocytic choriomeningitis virus: Implications for adoptive immunotherapy of virus carriers. by Planz O, Ehl S, Furrer E, Horvath E, Brundler MA, Hengartner H, Zinkernagel RM. 1997 Jun 24; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=21252
•
A cryptic cause of cryptococcal meningitis. by Cheung MC, Rachlis AR, Shumak SL. 2003 Feb 18; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=143553
•
A role for pneumolysin but not neuraminidase in the hearing loss and cochlear damage induced by experimental pneumococcal meningitis in guinea pigs. by Winter AJ, Comis SD, Osborne MP, Tarlow MJ, Stephen J, Andrew PW, Hill J, Mitchell TJ. 1997 Nov; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=175634
•
A Uropathogenicity Island Contributes to the Pathogenicity of Escherichia coli Strains That Cause Neonatal Meningitis. by Houdouin V, Bonacorsi S, Brahimi N, Clermont O, Nassif X, Bingen E. 2002 Oct; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=128312
3 4
Adapted from the National Library of Medicine: http://www.pubmedcentral.nih.gov/about/intro.html.
With PubMed Central, NCBI is taking the lead in preservation and maintenance of open access to electronic literature, just as NLM has done for decades with printed biomedical literature. PubMed Central aims to become a world-class library of the digital age. 5 The value of PubMed Central, in addition to its role as an archive, lies in the availability of data from diverse sources stored in a common format in a single repository. Many journals already have online publishing operations, and there is a growing tendency to publish material online only, to the exclusion of print.
72 Meningitis
•
Ability of Escherichia coli isolates that cause meningitis in newborns to invade epithelial and endothelial cells. by Meier C, Oelschlaeger TA, Merkert H, Korhonen TK, Hacker J. 1996 Jul; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=174088
•
Activity of LY333328 in Experimental Meningitis Caused by a Streptococcus pneumoniae Strain Susceptible to Penicillin. by Gerber J, Smirnov A, Wellmer A, Ragheb J, Prange J, Schutz E, Wettich K, Kalich S, Nau R. 2001 Jul; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=90624
•
Amphotericin B Colloidal Dispersion Combined with Flucytosine with or without Fluconazole for Treatment of Murine Cryptococcal Meningitis. by Diamond DM, Bauer M, Daniel BE, Leal MA, Johnson D, Williams BK, Thomas AM, Ding JC, Najvar L, Graybill JR, Larsen RA. 1998 Mar; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=105493
•
An Alternative Animal Model for Comparison of Treatments for Cryptococcal Meningitis. by Najvar LK, Bocanegra R, Graybill JR. 1999 Feb; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=89093
•
Antimicrobial Resistance in Haemophilus influenzae Isolated during PopulationBased Surveillance for Meningitis in Salvador, Brazil. by Reis JN, Lima JB, Ribeiro GS, Corderio SM, Salgado K, Reis MG, Ko AI. 2002 Nov; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=128747
•
Antimicrobial Susceptibilities of Group B Streptococci Isolated between 1992 and 1996 from Patients with Bacteremia or Meningitis. by Fernandez M, Hickman ME, Baker CJ. 1998 Jun; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=105636
•
Aseptic meningitis after treatment with amoxicillin. by Czerwenka W, Gruenwald C, Conen D. 1999 Jun 5; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=27894
•
Aseptic meningitis in Germany associated with echovirus type 13. by Diedrich S, Schreier E. 2001; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=57743
•
Aspergillus Meningitis: Diagnosis by Non-Culture-Based Microbiological Methods and Management. by Verweij PE, Brinkman K, Kremer HP, Kullberg BJ, Meis JF. 1999 Apr; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=88672
•
Bactericidal activity against cephalosporin-resistant Streptococcus pneumoniae in cerebrospinal fluid of children with acute bacterial meningitis. by Klugman KP, Friedland IR, Bradley JS. 1995 Sep; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=162869
Studies 73
•
Bactericidal activity against intermediately cephalosporin-resistant Streptococcus pneumoniae in cerebrospinal fluid of children with bacterial meningitis treated with high doses of cefotaxime and vancomycin. by Doit C, Barre J, Cohen R, Bonacorsi S, Bourrillon A, Bingen EH. 1997 Sep; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=164066
•
Blockade of NMDA receptor subtype NR2B prevents seizures but not apoptosis of dentate gyrus neurons in bacterial meningitis in infant rats. by Kolarova A, Ringer R, Tauber MG, Leib SL. 2003; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=212551
•
BMS-284756 in Experimental Cephalosporin-Resistant Pneumococcal Meningitis. by Rodriguez-Cerrato V, Ghaffar F, Saavedra J, Michelow IC, Hardy RD, Iglehart J, Olsen K, McCracken GH Jr. 2001 Nov; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=90788
•
Cerebrospinal fluid bactericidal activity against cephalosporin-resistant Streptococcus pneumoniae in children with meningitis treated with high-dosage cefotaxime. by Friedland IR, Klugman KP. 1997 Sep; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=164030
•
Cerebrospinal fluid penetration of amikacin in children with community-acquired bacterial meningitis. by Gaillard JL, Silly C, Le Masne A, Mahut B, Lacaille F, Cheron G, Abadie V, Hubert P, Matha V, Coustere C. 1995 Jan; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=162520
•
Characterization of a Laboratory-Derived, High-Level Ampicillin-Resistant Salmonella enterica Serovar Typhimurium Strain That Caused Meningitis in an Infant. by Chiu CH, Chu C, Su LH, Wu WY, Wu TL. 2002 May; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=127154
•
Characterization of Mycobacterium tuberculosis Complex Isolates from the Cerebrospinal Fluid of Meningitis Patients at Six Fever Hospitals in Egypt. by Cooksey RC, Abbadi SH, Woodley CL, Sikes D, Wasfy M, Crawford JT, Mahoney F. 2002 May; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=130952
•
Cheap vaccine needed for Africa's meningitis epidemic. by Maskalyk J. 2002 Nov 12; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=134309
•
Clindamycin therapy of experimental meningitis caused by penicillin- and cephalosporin-resistant Streptococcus pneumoniae. by Paris MM, Shelton S, Trujillo M, Hickey SM, McCracken GH Jr. 1996 Jan; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=163069
•
Cochlear implant recipients at risk for meningitis. by Wooltorton E. 2002 Sep 17; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=122034
74 Meningitis
•
Combination therapy with fluconazole and flucytosine in the murine model of cryptococcal meningitis. by Nguyen MH, Najvar LK, Yu CY, Graybill JR. 1997 May; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=163860
•
Comparative Efficacies of Terbinafine and Fluconazole in Treatment of Experimental Coccidioidal Meningitis in a Rabbit Model. by Sorensen KN, Sobel RA, Clemons KV, Calderon L, Howell KJ, Irani PR, Pappagianis D, Williams PL, Stevens DA. 2000 Nov; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=101607
•
Comparative Genomics Identifies the Genetic Islands That Distinguish Neisseria meningitidis, the Agent of Cerebrospinal Meningitis, from Other Neisseria Species. by Perrin A, Bonacorsi S, Carbonnelle E, Talibi D, Dessen P, Nassif X, Tinsley C. 2002 Dec; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=133019
•
Comparative In Vitro Killing Activities of Meropenem, Imipenem, Ceftriaxone, and Ceftriaxone plus Vancomycin at Clinically Achievable Cerebrospinal Fluid Concentrations against Penicillin-Resistant Streptococcus pneumoniae Isolates from Children with Meningitis. by Fitoussi F, Doit C, Benali K, Bonacorsi S, Geslin P, Bingen E. 1998 Apr; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=105574
•
Comparison of Fluconazole and Itraconazole in a Rabbit Model of Coccidioidal Meningitis. by Sorensen KN, Sobel RA, Clemons KV, Pappagianis D, Stevens DA, Williams PL. 2000 Jun; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=89905
•
Concentrations of Cefpirome in Cerebrospinal Fluid of Children with Bacterial Meningitis after a Single Intravenous Dose. by Friedland IR, Sultan E, Lehr KH, Lenfant B. 1998 Jan; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=105484
•
Critical role for a high-affinity chemokine-binding protein in [gamma]-herpesvirus -induced lethal meningitis. by van Berkel V, Levine B, Kapadia SB, Goldman JE, Speck SH, IV HW. 2002 Apr 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=150927
•
Critical Role for Alpha/Beta and Gamma Interferons in Persistence of Lymphocytic Choriomeningitis Virus by Clonal Exhaustion of Cytotoxic T Cells. by Ou R, Zhou S, Huang L, Moskophidis D. 2001 Sep 15; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=115086
•
Critical Role for Glial Cells in the Propagation and Spread of Lymphocytic Choriomeningitis Virus in the Developing Rat Brain. by Bonthius DJ, Mahoney J, Buchmeier MJ, Karacay B, Taggard D. 2002 Jul; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=136288
Studies 75
•
Decreased Virulence of a Pneumolysin-Deficient Strain of Streptococcus pneumoniae in Murine Meningitis. by Wellmer A, Zysk G, Gerber J, Kunst T, von Mering M, Bunkowski S, Eiffert H, Nau R. 2002 Nov; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=130334
•
Detection by PCR of Enteroviruses in Cerebrospinal Fluid during a Summer Outbreak of Aseptic Meningitis in Switzerland. by Gorgievski-Hrisoho M, Schumacher JD, Vilimonovic N, Germann D, Matter L. 1998 Sep; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=105134
•
Detection of JC Virus in Cerebrospinal Fluid (CSF) Samples from Patients with Progressive Multifocal Leukoencephalopathy but Not in CSF Samples from Patients with Herpes Simplex Encephalitis, Enteroviral Meningitis, or Multiple Sclerosis. by Bogdanovic G, Priftakis P, Hammarin AL, Soderstrom M, Samuelson A, LewensohnFuchs I, Dalianis T. 1998 Apr; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=104707
•
Detection of Leptospira DNA in Patients with Aseptic Meningitis by PCR. by Romero EC, Billerbeck AE, Lando VS, Camargo ED, Souza CC, Yasuda PH. 1998 May; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=104853
•
Dexamethasone in adults with bacterial meningitis. by Suh KN. 2003 Mar 18; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=154925
•
Diagnosis of Meningococcal Meningitis by Broad-Range Bacterial PCR with Cerebrospinal Fluid. by Kotilainen P, Jalava J, Meurman O, Lehtonen OP, Rintala E, Seppala OP, Eerola E, Nikkari S. 1998 Aug; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=105011
•
Differences in Affinity of Binding of Lymphocytic Choriomeningitis Virus Strains to the Cellular Receptor [alpha]-Dystroglycan Correlate with Viral Tropism and Disease Kinetics. by Smelt SC, Borrow P, Kunz S, Cao W, Tishon A, Lewicki H, Campbell KP, Oldstone MB. 2001 Jan 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=113937
•
Dissemination of Lymphocytic Choriomeningitis Virus from the Gastric Mucosa Requires G Protein-Coupled Signaling. by Yin C, Djavani M, Schenkel AR, Schmidt DS, Pauza CD, Salvato MS. 1998 Nov; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=110272
•
Effect of fluconazole on fungicidal activity of flucytosine in murine cryptococcal meningitis. by Larsen RA, Bauer M, Weiner JM, Diamond DM, Leal ME, Ding JC, Rinaldi MG, Graybill JR. 1996 Sep; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=163494
•
Effect of severity of meningitis on fungicidal activity of flucytosine combined with fluconazole in a murine model of cryptococcal meningitis. by Ding JC, Bauer M,
76 Meningitis
Diamond DM, Leal MA, Johnson D, Williams BK, Thomas AM, Najvar L, Graybill JR, Larsen RA. 1997 Jul; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=163965 •
Effects of Polysaccharide Fucoidin on Cerebrospinal Fluid Interleukin-1 and Tumor Necrosis Factor Alpha in Pneumococcal Meningitis in the Rabbit. by Granert C, Raud J, Waage A, Lindquist L. 1999 May; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=115939
•
Efficacies of BMS 284756 against Penicillin-Sensitive, Penicillin-Resistant, and Quinolone-Resistant Pneumococci in Experimental Meningitis. by Cottagnoud P, Acosta F, Cottagnoud M, Pfister M, Tauber MG. 2002 Jan; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=126974
•
Efficacy of Gatifloxacin in Experimental Escherichia coli Meningitis. by Lutsar I, Friedland IR, Jafri HS, Wubbel L, Ng W, Ghaffar F, McCracken GH Jr. 1999 Jul; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=89371
•
Efficacy of Intravenous Liposomal Amphotericin B (AmBisome) against Coccidioidal Meningitis in Rabbits. by Clemons KV, Sobel RA, Williams PL, Pappagianis D, Stevens DA. 2002 Aug; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=127346
•
Enhanced Virus Clearance by Early Inducible Lymphocytic Choriomeningitis VirusNeutralizing Antibodies in Immunoglobulin-Transgenic Mice. by Seiler P, Kalinke U, Rulicke T, Bucher EM, Bose C, Zinkernagel RM, Hengartner H. 1998 Mar; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=109522
•
Enzyme Immunoassay Detecting Teichoic and Lipoteichoic Acids versus Cerebrospinal Fluid Culture and Latex Agglutination for Diagnosis of Streptococcus pneumoniae Meningitis. by Stuertz K, Merx I, Eiffert H, Schmutzhard E, Mader M, Nau R. 1998 Aug; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=105046
•
Evaluation of an In-House-Developed Radioassay Kit for Antibody Detection in Cases of Pulmonary Tuberculosis and Tuberculous Meningitis. by Kameswaran M, Shetty K, Ray MK, Jaleel MA, Kadival GV. 2002 Sep; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=120075
•
Evaluation of CP-99,219, a new fluoroquinolone, for treatment of experimental penicillin- and cephalosporin-resistant pneumococcal meningitis. by Paris MM, Hickey SM, Trujillo M, Shelton S, McCracken GH Jr. 1995 Jun; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=162720
Studies 77
•
Evaluation of Moxifloxacin, a New 8-Methoxyquinolone, for Treatment of Meningitis Caused by a PenicillinResistant Pneumococcus in Rabbits. by Ostergaard C, Klitmoller Sorensen T, Dahl Knudsen J, Frimodt-Moller N. 1998 Jul; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=105670
•
Evaluation of PCR Using TRC4 and IS6110 Primers in Detection of Tuberculous Meningitis. by Narayanan S, Parandaman V, Narayanan PR, Venkatesan P, Girish C, Mahadevan S, Rajajee S. 2001 May; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=88071
•
Evaluation of T-3811ME (BMS-284756), a New Des-F(6)-Quinolone, for Treatment of Meningitis Caused by Penicillin-Resistant Streptococcus pneumoniae in Rabbits. by Takahata M, Yamada H, Morita T, Furubou S, Minami S, Todo Y, Watanabe Y, Narita H. 2002 Jun; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=127215
•
Failure To Detect Muramic Acid in Normal Rat Tissues but Detection in Cerebrospinal Fluids from Patients with Pneumococcal Meningitis. by Kozar MP, Krahmer MT, Fox A, Gray BM. 2000 Aug; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=98412
•
Fit genotypes and escape variants of subgroup III Neisseria meningitidis during three pandemics of epidemic meningitis. by Zhu P, van der Ende A, Falush D, Brieske N, Morelli G, Linz B, Popovic T, Schuurman IG, Adegbola RA, Zurth K, Gagneux S, Platonov AE, Riou JY, Caugant DA, Nicolas P, Achtman M. 2001 Apr 24; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=33193
•
Garenoxacin (BMS-284756) and Moxifloxacin in Experimental Meningitis Caused by Vancomycin-Tolerant Pneumococci. by Rodriguez-Cerrato V, McCoig CC, Saavedra J, Barton T, Michelow IC, Hardy RD, Bowlware K, Iglehart J, Katz K, McCracken GH Jr. 2003 Jan; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=148949
•
Gemifloxacin Is Effective in Experimental Pneumococcal Meningitis. by Smirnov A, Wellmer A, Gerber J, Maier K, Henne S, Nau R. 2000 Mar; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=89762
•
Gemifloxacin Is Efficacious against Penicillin-Resistant and Quinolone-Resistant Pneumococci in Experimental Meningitis. by Cottagnoud P, Acosta F, Cottagnoud M, Tauber MG. 2002 May; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=127126
•
Gentamicin Increases the Efficacy of Vancomycin against Penicillin-Resistant Pneumococci in the Rabbit Meningitis Model. by Cottagnoud P, Gerber CM, Cottagnoud M, Tauber MG. 2002 Jan; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=127013
78 Meningitis
•
Group B streptococcal [beta]-hemolysin/cytolysin activates neutrophil signaling pathways in brain endothelium and contributes to development of meningitis. by Doran KS, Liu GY, Nizet V. 2003 Sep 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=182187
•
High doses of cefotaxime in treatment of adult meningitis due to Streptococcus pneumoniae with decreased susceptibilities to broad-spectrum cephalosporins. by Viladrich PF, Cabellos C, Pallares R, Tubau F, Martinez-Lacasa J, Linares J, Gudiol F. 1996 Jan; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=163086
•
High Frequency of Virus-Specific Interleukin-2-Producing CD4 + T Cells and Th1 Dominance during Lymphocytic Choriomeningitis Virus Infection. by Varga SM, Welsh RM. 2000 May 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=111961
•
Identification of Regions of the Escherichia coli Chromosome Specific for Neonatal Meningitis-Associated Strains. by Bonacorsi SP, Clermont O, Tinsley C, Le Gall I, Beaudoin JC, Elion J, Nassif X, Bingen E. 2000 Apr; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=97390
•
Immunocytochemical Method for Early Laboratory Diagnosis of Tuberculous Meningitis. by Sumi MG, Mathai A, Reuben S, Sarada C, Radhakrishnan VV. 2002 Mar; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=119925
•
Impaired responsiveness to gamma interferon of macrophages infected with lymphocytic choriomeningitis virus clone 13: susceptibility to histoplasmosis. by Villarete L, de Fries R, Kolhekar S, Howard D, Ahmed R, Wu-Hsieh B. 1995 Apr; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=173176
•
Influence of dexamethasone on efficacy of ceftriaxone and vancomycin therapy in experimental pneumococcal meningitis. by Cabellos C, Martinez-Lacasa J, Martos A, Tubau F, Fernandez A, Viladrich PF, Gudiol F. 1995 Sep; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=162903
•
Inhibition of Escherichia coli-Induced Meningitis by Carboxyfullerence. by Tsao N, Kanakamma PP, Luh TY, Chou CK, Lei HY. 1999 Sep; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=89460
•
Inhibition of Leukocyte Entry into the Brain by the Selectin Blocker Fucoidin Decreases Interleukin-1 (IL-1) Levels but Increases IL-8 Levels in Cerebrospinal Fluid during Experimental Pneumococcal Meningitis in Rabbits. by Ostergaard C, YiengKow RV, Benfield T, Frimodt-Moller N, Espersen F, Lundgren JD. 2000 Jun; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=97550
Studies 79
•
Interleukin-10 Negatively Regulates Local Cytokine and Chemokine Production but Does Not Influence Antibacterial Host Defense during Murine Pneumococcal Meningitis. by Zwijnenburg PJ, van der Poll T, Florquin S, Roord JJ, van Furth AM. 2003 Apr; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=152042
•
Intrathecal Administration of Single-Chain Immunotoxin, LMB-7 [B3(Fv)- PE38], Produces Cures of Carcinomatous Meningitis in a Rat Model. by Pastan IH, Archer GE, McLendon RE, Friedman HS, Fuchs HE, Wang Q, Pai LH, Herndon J, Bigner DD. 1995 Mar 28; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=42299
•
Intrathecal production of interleukin-12 and gamma interferon in patients with bacterial meningitis. by Kornelisse RF, Hack CE, Savelkoul HF, van der Pouw Kraan TC, Hop WC, van Mierlo G, Suur MH, Neijens HJ, de Groot R. 1997 Mar; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=175063
•
Intrathecal synthesis of immunoglobulin G and Mycobacterium tuberculosis-specific humoral immune response in tuberculous meningitis. by Cho TY, Park SC, Cho SN, Lee HR, Kim SK, Kim SK, Lee BI. 1995 May; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=170160
•
Invasive Fungal Sinusitis and Meningitis Due to Arthrographis kalrae in a Patient with AIDS. by Chin-Hong PV, Sutton DA, Roemer M, Jacobson MA, Aberg JA. 2001 Feb; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=87827
•
Killing activity of cefpirome against penicillin-resistant Streptococcus pneumoniae isolates from patients with meningitis in a pharmacodynamic model simulating the cerebrospinal fluid concentration profile. by Fitoussi F, Doit C, Sandin A, Pechinot A, Kazmierczack A, Geslin P, Bingen E. 1995 Nov; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=162984
•
Laboratory Diagnosis and Genetic Analysis of an Echovirus 30-Associated Outbreak of Aseptic Meningitis in Taiwan in 2001. by Wang JR, Tsai HP, Huang SW, Kuo PH, Kiang D, Liu CC. 2002 Dec; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=154609
•
Light eye colour linked to deafness after meningitis. by Cullington HE. 2001 Mar 10; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=26552
•
Long-Term CD4 Th1 and Th2 Memory following Acute Lymphocytic Choriomeningitis Virus Infection. by Whitmire JK, Asano MS, Murali-Krishna K, Suresh M, Ahmed R. 1998 Oct; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=110189
80 Meningitis
•
Management of meningitis caused by penicillin-resistant Streptococcus pneumoniae. by Paris MM, Ramilo O, McCracken GH Jr. 1995 Oct; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=162908
•
Management of meningitis caused by penicillin-resistant Streptococcus pneumoniae. by Bhattacharya S. 1996 Mar; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=163213
•
Matrix Metalloproteinases Contribute to Brain Damage in Experimental Pneumococcal Meningitis. by Leib SL, Leppert D, Clements J, Tauber MG. 2000 Feb; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=97183
•
Meningitis and cochlear implantation. by Papsin BC. 2003 Feb 4; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=140462
•
Meningitis Due to Mixed Infection with Penicillin-Resistant and PenicillinSusceptible Strains of Streptococcus pneumoniae. by Chaves F, Campelo C, Sanz F, Otero JR. 2003 Jan; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=149642
•
Meningitis Due to Streptococcus salivarius. by Idigoras P, Valiente A, Iglesias L. 2001 Aug; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=88286
•
Meningitis in infancy in England and Wales: follow up at age 5 years. by Bedford H, de Louvois J, Halket S, Peckham C, Hurley R, Harvey D. 2001 Sep 8; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=48156
•
Microscopic Examination and Broth Culture of Cerebrospinal Fluid in Diagnosis of Meningitis. by Dunbar SA, Eason RA, Musher DM, Clarridge JE III. 1998 Jun; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=104888
•
Modeling of Transfer Kinetics at the Serum-Cerebrospinal Fluid Barrier in Rabbits with Experimental Meningitis: Application to Grepafloxacin. by Pfister M, Zhang L, Hammarlund-Udenaes M, Sheiner LB, Gerber CM, Tauber MG, Cottagnoud P. 2003 Jan; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=149016
•
Modulation of Release of Proinflammatory Bacterial Compounds by Antibacterials: Potential Impact on Course of Inflammation and Outcome in Sepsis and Meningitis. by Nau R, Eiffert H. 2002 Jan; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=118062
•
Molecular and Functional Dissection of the H-2Db-Restricted Subdominant Cytotoxic T-Cell Response to Lymphocytic Choriomeningitis Virus. by Hudrisier D, Riond J, Gairin JE. 2001 Mar 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=114831
Studies 81
•
Molecular Epidemiological Study of Haemophilus influenzae Serotype b Strains Obtained from Children with Meningitis in Japan. by Mitsuda T, Kuroki H, Ishikawa N, Imagawa T, Ito S, Miyamae T, Mori M, Uehara S, Yokota S. 1999 Aug; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=85279
•
Molecular Identification and Epidemiological Tracing of Pasteurella multocida Meningitis in a Baby. by Boerlin P, Siegrist HH, Burnens AP, Kuhnert P, Mendez P, Pretat G, Lienhard R, Nicolet J. 2000 Mar; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=86385
•
Molecular Identification of Staphylococcus lugdunensis in a Patient with Meningitis. by Kaabia N, Scauarda D, Lena G, Drancourt M. 2002 May; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=130937
•
Moxifloxacin in the Therapy of Experimental Pneumococcal Meningitis. by Schmidt H, Dalhoff A, Stuertz K, Trostdorf F, Chen V, Schneider O, Kohlsdorfer C, Bruck W, Nau R. 1998 Jun; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=105611
•
Multicenter Evaluation of the Amplicor Enterovirus PCR Test with Cerebrospinal Fluid from Patients with Aseptic Meningitis. by van Vliet KE, Glimaker M, Lebon P, Klapper PE, Taylor CE, Ciardi M, van der Avoort HG, Diepersloot RJ, Kurtz J, Peeters MF, Cleator GM, van Loon AM. 1998 Sep; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=105179
•
Neisseria meningitidis Serogroups W135 and A Were Equally Prevalent among Meningitis Cases Occurring at the End of the 2001 Epidemics in Burkina Faso and Niger. by Taha MK, Parent du Chatelet I, Schlumberger M, Sanou I, Djibo S, de Chabalier F, Alonso JM. 2002 Mar; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=120283
•
Neutralization of Macrophage Inflammatory Protein 2 (MIP-2) and MIP-1[alpha] Attenuates Neutrophil Recruitment in the Central Nervous System during Experimental Bacterial Meningitis. by Diab A, Abdalla H, Li HL, Shi FD, Zhu J, Hojberg B, Lindquist L, Wretlind B, Bakhiet M, Link H. 1999 May; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=116008
•
Once-daily gentamicin therapy for experimental Escherichia coli meningitis. by Ahmed A, Paris MM, Trujillo M, Hickey SM, Wubbel L, Shelton SL, McCracken GH Jr. 1997 Jan; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=163658
•
One Case Each of Recurrent Meningitis and Hemoperitoneum Infection with Ralstonia mannitolilytica. by Vaneechoutte M, De Baere T, Wauters G, Steyaert S, Claeys G, Vogelaers D, Verschraegen G. 2001 Dec; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=88597
82 Meningitis
•
PCR-Enzyme Immunoassay for Detection of Streptococcus pneumoniae DNA in Cerebrospinal Fluid Samples from Patients With Culture-Negative Meningitis. by Cherian T, Lalitha MK, Manoharan A, Thomas K, Yolken RH, Steinhoff MC. 1998 Dec; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=105248
•
Persistent Virus Infection despite Chronic Cytotoxic T-Lymphocyte Activation in Gamma Interferon-Deficient Mice Infected with Lymphocytic Choriomeningitis Virus. by Bartholdy C, Christensen JP, Wodarz D, Thomsen AR. 2000 Nov 15; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=110904
•
Pharmacodynamics and bactericidal activity of ceftriaxone therapy in experimental cephalosporin-resistant pneumococcal meningitis. by Lutsar I, Ahmed A, Friedland IR, Trujillo M, Wubbel L, Olsen K, McCracken GH Jr. 1997 Nov; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=164137
•
Pharmacodynamics and Bactericidal Activity of Moxifloxacin in Experimental Escherichia coli Meningitis. by Rodriguez-Cerrato V, McCoig CC, Michelow IC, Ghaffar F, Jafri HS, Hardy RD, Patel C, Olsen K, McCracken GH Jr. 2001 Nov; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=90787
•
Pharmacodynamics of Gatifloxacin in Cerebrospinal Fluid in Experimental Cephalosporin-Resistant Pneumococcal Meningitis. by Lutsar I, Friedland IR, Wubbel L, McCoig CC, Jafri HS, Ng W, Ghaffar F, McCracken GH Jr. 1998 Oct; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=105913
•
Pharmacodynamics of Vancomycin for the Treatment of Experimental Penicillin- and Cephalosporin-Resistant Pneumococcal Meningitis. by Ahmed A, Jafri H, Lutsar I, McCoig CC, Trujillo M, Wubbel L, Shelton S, McCracken GH Jr. 1999 Apr; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=89220
•
Pneumococcal pneumolysin and H2O2 mediate brain cell apoptosis during meningitis. by Braun JS, Sublett JE, Freyer D, Mitchell TJ, Cleveland JL, Tuomanen EI, Weber JR. 2002 Jan 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=150815
•
Population-Based Survey of Antimicrobial Susceptibility and Serotype Distribution of Streptococcus pneumoniae from Meningitis Patients in Salvador, Brazil. by Reis JN, Cordeiro SM, Coppola SJ, Salgado K, Carvalho MG, Teixeira LM, Thompson TA, Facklam RR, Reis MG, Ko AI. 2002 Jan; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=120107
•
Postneurosurgical Meningitis Due to Proteus penneri with Selection of a CeftriaxoneResistant Isolate: Analysis of Chromosomal Class A [beta]-Lactamase HugA and its LysR-Type Regulatory Protein HugR. by Liassine N, Madec S, Ninet B, Metral C, Fouchereau-Peron M, Labia R, Auckenthaler R. 2002 Jan; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=126972
Studies 83
•
Potential role of nitric oxide in the pathophysiology of experimental bacterial meningitis in rats. by Buster BL, Weintrob AC, Townsend GC, Scheld WM. 1995 Oct; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=173539
•
Pretreatment with Granulocyte Colony-Stimulating Factor Attenuates the Inflammatory Response but Not the Bacterial Load in Cerebrospinal Fluid during Experimental Pneumococcal Meningitis in Rabbits. by Ostergaard C, Benfield T, Gesser B, Kharazmi A, Frimodt-Moller N, Espersen F, Lundgren JD. 1999 Jul; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=116528
•
Prospective randomized comparison of cefepime and cefotaxime for treatment of bacterial meningitis in infants and children. by Saez-Llorens X, Castano E, Garcia R, Baez C, Perez M, Tejeira F, McCracken GH Jr. 1995 Apr; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=162657
•
Quinolone antibiotics in therapy of experimental pneumococcal meningitis in rabbits. by Nau R, Schmidt T, Kaye K, Froula JL, Tauber MG. 1995 Mar; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=162589
•
Randomized comparison of meropenem with cefotaxime for treatment of bacterial meningitis. Meropenem Meningitis Study Group. by Klugman KP, Dagan R. 1995 May; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=162697
•
Rapid Diagnosis of Tuberculous Meningitis by a Dot Immunobinding Assay To Detect Mycobacterial Antigen in Cerebrospinal Fluid Specimens. by Sumi MG, Mathai A, Sarada C, Radhakrishnan VV. 1999 Dec; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=85846
•
Rapid Real-Time PCR for Determination of Penicillin Susceptibility in Pneumococcal Meningitis, Including Culture-Negative Cases. by Kearns AM, Graham C, Burdess D, Heatherington J, Freeman R. 2002 Feb; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=153399
•
Recruitment Times, Proliferation, and Apoptosis Rates during the CD8 + T-Cell Response to Lymphocytic Choriomeningitis Virus. by De Boer RJ, Oprea M, Antia R, Murali-Krishna K, Ahmed R, Perelson AS. 2001 Nov 15; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=114648
•
Rhodotorula glutinis-Related Meningitis. by Lanzafame M, De Checchi G, Parinello A. 2001 Jan; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=87748
84 Meningitis
•
Rifampin Followed by Ceftriaxone for Experimental Meningitis Decreases Lipoteichoic Acid Concentrations in Cerebrospinal Fluid and Reduces Neuronal Damage in Comparison to Ceftriaxone Alone. by Gerber J, Pohl K, Sander V, Bunkowski S, Nau R. 2003 Apr; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=152510
•
Role of an Intact Splenic Microarchitecture in Early Lymphocytic Choriomeningitis Virus Production. by Muller S, Hunziker L, Enzler S, Buhler-Jungo M, Di Santo JP, Zinkernagel RM, Mueller C. 2002 Mar; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=153806
•
Role of IS6110-Targeted PCR, Culture, Biochemical, Clinical, and Immunological Criteria for Diagnosis of Tuberculous Meningitis. by Caws M, Wilson SM, Clough C, Drobniewski F. 2000 Sep; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=87341
•
Roles of proinflammatory and anti-inflammatory cytokines in pathophysiology of bacterial meningitis and effect of adjunctive therapy. by van Furth AM, Roord JJ, van Furth R. 1996 Dec; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=174464
•
Selective Loss of Natural Killer T Cells by Apoptosis following Infection with Lymphocytic Choriomeningitis Virus. by Hobbs JA, Cho S, Roberts TJ, Sriram V, Zhang J, Xu M, Brutkiewicz RR. 2001 Nov 15; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=114656
•
Severe community-acquired meningitis. by Boisson C, Arnaud S, Vialet R, Martin C. 1999; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=137234
•
Simultaneous Detection of Neisseria meningitidis, Haemophilus influenzae, and Streptococcus pneumoniae in Suspected Cases of Meningitis and Septicemia Using Real-Time PCR. by Corless CE, Guiver M, Borrow R, Edwards-Jones V, Fox AJ, Kaczmarski EB. 2001 Apr; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=87969
•
Streptococcal Meningitis Resulting from Contact with an Infected Horse. by Downar J, Willey BM, Sutherland JW, Mathew K, Low DE. 2001 Jun; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=88147
•
Streptococcus bovis Meningitis in an Infant. by Grant RJ, Whitehead TR, Orr JE. 2000 Jan; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=88753
•
Streptococcus pneumoniae Causes Experimental Meningitis following Intranasal and Otitis Media Infections via a Nonhematogenous Route. by Marra A, Brigham D. 2001 Dec; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=98817
Studies 85
•
Successful treatment of cryptococcal meningitis with amphotericin B colloidal dispersion: report of four cases. by Valero G, Graybill JR. 1995 Nov; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=162993
•
Synergy between Trovafloxacin and Ceftriaxone against Penicillin-Resistant Pneumococci in the Rabbit Meningitis Model and In Vitro. by Cottagnoud P, Acosta F, Cottagnoud M, Neftel K, Tauber MG. 2000 Aug; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=90034
•
Systemic Neutralization of Interleukin-8 Markedly Reduces Neutrophilic Pleocytosis during Experimental Lipopolysaccharide-Induced Meningitis in Rabbits. by Dumont RA, Car BD, Voitenok NN, Junker U, Moser B, Zak O, O'Reilly T. 2000 Oct; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=101534
•
The 1998 Senegal Epidemic of Meningitis Was Due to the Clonal Expansion of A:4:P1.9, Clone III-1, Sequence Type 5 Neisseria meningitidis Strains. by Nicolas P, Raphenon G, Guibourdenche M, Decousset L, Stor R, Gaye AB. 2000 Jan; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=88695
•
The Cellular Form of Human Fibronectin as an Adhesion Target for the S Fimbriae of Meningitis-Associated Escherichia coli. by Saren A, Virkola R, Hacker J, Korhonen TK. 1999 May; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=116024
•
The Polysaccharide Fucoidin Inhibits the Antibiotic-Induced Inflammatory Cascade in Experimental Pneumococcal Meningitis. by Granert C, Raud J, Lindquist L. 1998 May; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=104518
•
The Three Major Spanish Clones of Penicillin-Resistant Streptococcus pneumoniae Are the Most Common Clones Recovered in Recent Cases of Meningitis in Spain. by Enright MC, Fenoll A, Griffiths D, Spratt BG. 1999 Oct; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=85530
•
The Virus-Specific and Allospecific Cytotoxic T-Lymphocyte Response to Lymphocytic Choriomeningitis Virus Is Modified in a Subpopulation of CD8 + T Cells Coexpressing the Inhibitory Major Histocompatibility Complex Class I Receptor Ly49G2. by Peacock CD, Lin MY, Ortaldo JR, Welsh RM. 2000 Aug 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=112220
•
Thymic Tolerance to Only One Viral Protein Reduces Lymphocytic Choriomeningitis Virus-Induced Immunopathology and Increases Survival in Perforin-Deficient Mice. by von Herrath M, Coon B, Homann D, Wolfe T, Guidotti LG. 1999 Jul; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=112653
86 Meningitis
•
Travel warning: eosinophilic meningitis caused by rat lungworm. by Weir E. 2002 Apr 30; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=102360
•
Trovafloxacin in Combination with Vancomycin against Penicillin-Resistant Pneumococci in the Rabbit Meningitis Model. by Rodoni D, Hanni F, Gerber CM, Cottagnoud M, Neftel K, Tauber MG, Cottagnoud P. 1999 Apr; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=89237
•
Trovafloxacin in treatment of rabbits with experimental meningitis caused by highlevel penicillin-resistant Streptococcus pneumoniae. by Kim YS, Liu Q, Chow LL, Tauber MG. 1997 May; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=163879
•
Use of IMiD3, a Thalidomide Analog, as an Adjunct to Therapy for Experimental Tuberculous Meningitis. by Tsenova L, Mangaliso B, Muller G, Chen Y, Freedman VH, Stirling D, Kaplan G. 2002 Jun; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=127267
•
Use of Lytic Bacteriophage for Control of Experimental Escherichia coli Septicemia and Meningitis in Chickens and Calves. by Barrow P, Lovell M, Berchieri A Jr. 1998 May; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=104512
•
Use of Roche AMPLICOR Mycobacterium tuberculosis PCR in Early Diagnosis of Tuberculous Meningitis. by Bonington A, Strang JI, Klapper PE, Hood SV, Rubombora W, Penny M, Willers R, Wilkins EG. 1998 May; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=104809
•
Variation in the structure of glucuronoxylomannan in isolates from patients with recurrent cryptococcal meningitis. by Cherniak R, Morris LC, Belay T, Spitzer ED, Casadevall A. 1995 May; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=173241
•
YKL-40 Is Elevated in Cerebrospinal Fluid from Patients with Purulent Meningitis. by Ostergaard C, Johansen JS, Benfield T, Price PA, Lundgren JD. 2002 May; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=119997
The National Library of Medicine: PubMed One of the quickest and most comprehensive ways to find academic studies in both English and other languages is to use PubMed, maintained by the National Library of Medicine.6
6
PubMed was developed by the National Center for Biotechnology Information (NCBI) at the National Library of Medicine (NLM) at the National Institutes of Health (NIH). The PubMed database was developed in conjunction with publishers of biomedical literature as a search tool for accessing literature citations and linking to full-text
Studies 87
The advantage of PubMed over previously mentioned sources is that it covers a greater number of domestic and foreign references. It is also free to use. If the publisher has a Web site that offers full text of its journals, PubMed will provide links to that site, as well as to sites offering other related data. User registration, a subscription fee, or some other type of fee may be required to access the full text of articles in some journals. To generate your own bibliography of studies dealing with meningitis, simply go to the PubMed Web site at http://www.ncbi.nlm.nih.gov/pubmed. Type “meningitis” (or synonyms) into the search box, and click “Go.” The following is the type of output you can expect from PubMed for meningitis (hyperlinks lead to article summaries): •
A 10-week old infant with meningitis. Author(s): Colby CE, Steinbach WJ, Haiman AK. Source: Clinical Pediatrics. 2001 March; 40(3): 155-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11307961&dopt=Abstract
•
A 35-year-old man with recurrent aseptic meningitis. Author(s): Chang DZ, Correia NG, Khurana P, Tuthill RJ, Taege AJ. Source: Cleve Clin J Med. 2001 March; 68(3): 199-201, 205-6. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11263848&dopt=Abstract
•
A 59-year-old woman with tuberculous meningitis masked by hepatic encephalopathy. Author(s): Carmichael MG, Thompson JC, Buttolph TB, Hooke JA. Source: Military Medicine. 2003 March; 168(3): 266-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12685697&dopt=Abstract
•
A case of anthrax meningitis. Author(s): Albayrak F, Memikoglu O, Kurt O, Cokca F, Birengel S, Tekeli E. Source: Scandinavian Journal of Infectious Diseases. 2002; 34(8): 627-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12238584&dopt=Abstract
•
A case of non-O:1 Vibrio cholerae septicemia with meningitis, cerebral abscess and unilateral hydrocephalus in a preterm baby. Author(s): Ismail EA, Shafik MH, Al-Mutairi G. Source: European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology. 2001 August; 20(8): 598600. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11681447&dopt=Abstract
journal articles at Web sites of participating publishers. Publishers that participate in PubMed supply NLM with their citations electronically prior to or at the time of publication.
88 Meningitis
•
A case of pneumococcal meningitis. Author(s): Crozier I, Morrow JD, Morgan H. Source: Tenn Med. 2000 October; 93(10): 379-80. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11026815&dopt=Abstract
•
A case of rheumatoid meningitis positive for perinuclear antineutrophil cytoplasmic antibody. Author(s): Funauchi M, Yoo BS, Sugiyama M, Ikoma S, Ohno M, Kinoshito K, Hamada K, Kanamaru A. Source: Annals of the Rheumatic Diseases. 2000 December; 59(12): 1001-2. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11153479&dopt=Abstract
•
A clinical manifestation of AIDS with cryptococcal meningitis in Equatorial Guinea. Author(s): Wang W, Carm AR. Source: Trop Doct. 2001 October; 31(4): 221-2. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11676062&dopt=Abstract
•
A clinical study of chronic morbidity in children following pyogenic meningitis. Author(s): George CN, Letha S, Bai SS. Source: Indian Pediatrics. 2002 July; 39(7): 663-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12147894&dopt=Abstract
•
A cluster of children with lyme meningitis presenting to one emergency department in a Boston suburb. Author(s): Bowen AP. Source: Journal of Emergency Nursing: Jen : Official Publication of the Emergency Department Nurses Association. 2002 August; 28(4): 355-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12122414&dopt=Abstract
•
A comparative evaluation of dot immunobinding assay (Dot-Iba) and polymerase chain reaction (PCR) for the laboratory diagnosis of tuberculous meningitis. Author(s): Sumi MG, Mathai A, Reuben S, Sarada C, Radhakrishnan VV, Indulakshmi R, Sathish M, Ajaykumar R, Manju YK. Source: Diagnostic Microbiology and Infectious Disease. 2002 January; 42(1): 35-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11821169&dopt=Abstract
•
A critical review of control strategies against meningococcal meningitis epidemics in sub-Saharan African countries. Author(s): Chippaux JP, Debois H, Saliou P. Source: Infection. 2002 August; 30(4): 216-24. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12236565&dopt=Abstract
Studies 89
•
A cryptic cause of cryptococcal meningitis. Author(s): Cheung MC, Rachlis AR, Shumak SL. Source: Cmaj : Canadian Medical Association Journal = Journal De L'association Medicale Canadienne. 2003 February 18; 168(4): 451-2. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12591788&dopt=Abstract
•
A hospital outbreak of aseptic meningitis due to echovirus type 30 in Antalya, Turkey. Author(s): Akman S, Ozkaya E, Colak D, Daloglu H. Source: Turk J Pediatr. 2002 July-September; 44(3): 237-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12405436&dopt=Abstract
•
A newer approach for the laboratory diagnosis of tuberculous meningitis. Author(s): Mathai A, Radhakrishnan VV, George SM, Sarada C. Source: Diagnostic Microbiology and Infectious Disease. 2001 April; 39(4): 225-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11404064&dopt=Abstract
•
A novel, multiple drug-resistant, serotype 24F strain of Streptococcus pneumoniae that caused meningitis in patients in Naples, Italy. Author(s): Pantosti A, Gherardi G, Conte M, Faella F, Dicuonzo G, Beall B. Source: Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America. 2002 July 15; 35(2): 205-8. Epub 2002 June 19. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12087529&dopt=Abstract
•
A phase II trial of intra-cerebrospinal fluid alpha interferon in the treatment of neoplastic meningitis. Author(s): Chamberlain MC. Source: Cancer. 2002 May 15; 94(10): 2675-80. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12173336&dopt=Abstract
•
A prospective study of AIDS-associated cryptococcal meningitis in Thailand treated with high-dose amphotericin B. Author(s): Pitisuttithum P, Tansuphasawadikul S, Simpson AJ, Howe PA, White NJ. Source: The Journal of Infection. 2001 November; 43(4): 226-33. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11869059&dopt=Abstract
90 Meningitis
•
A randomized, double-blind, placebo-controlled trial of acetazolamide for the treatment of elevated intracranial pressure in cryptococcal meningitis. Author(s): Newton PN, Thai le H, Tip NQ, Short JM, Chierakul W, Rajanuwong A, Pitisuttithum P, Chasombat S, Phonrat B, Maek-A-Nantawat W, Teaunadi R, Lalloo DG, White NJ. Source: Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America. 2002 September 15; 35(6): 769-72. Epub 2002 August 26. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12203177&dopt=Abstract
•
A retrospective clinical, laboratory and outcome analysis in 43 cases of acute aseptic meningitis. Author(s): Nowak DA, Boehmer R, Fuchs HH. Source: European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies. 2003 May; 10(3): 271-80. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12752401&dopt=Abstract
•
A revised clinical method for assessment of severity of acute bacterial meningitis. Author(s): Akpede GO, Jalo I, Dawodu SO. Source: Annals of Tropical Paediatrics. 2002 March; 22(1): 33-44. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11926048&dopt=Abstract
•
A season of aseptic meningitis in Germany: epidemiologic, clinical and diagnostic aspects. Author(s): Bottner A, Daneschnejad S, Handrick W, Schuster V, Liebert UG, Kiess W. Source: The Pediatric Infectious Disease Journal. 2002 December; 21(12): 1126-32. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12488662&dopt=Abstract
•
A uropathogenicity island contributes to the pathogenicity of Escherichia coli strains that cause neonatal meningitis. Author(s): Houdouin V, Bonacorsi S, Brahimi N, Clermont O, Nassif X, Bingen E. Source: Infection and Immunity. 2002 October; 70(10): 5865-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12228319&dopt=Abstract
•
Absolute neutrophil count in aseptic and bacterial meningitis related to time of lumbar puncture. Author(s): Straussberg R, Harel L, Nussinovitch M, Amir J. Source: Pediatric Neurology. 2003 May; 28(5): 365-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12878298&dopt=Abstract
•
Actinomycotic meningitis: report of a case. Author(s): Chotmongkol V, Panthavasit J, Chuesakoolvanich K. Source: J Med Assoc Thai. 2002 June; 85(6): 739-41. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12322850&dopt=Abstract
Studies 91
•
Acute bacterial meningitis as a complication of otitis media and related mortality factors. Author(s): Geyik MF, Kokoglu OF, Hosoglu S, Ayaz C. Source: Yonsei Medical Journal. 2002 October; 43(5): 573-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12402369&dopt=Abstract
•
Acute bacterial meningitis in adults. A 12-year review. Author(s): Hussein AS, Shafran SD. Source: Medicine; Analytical Reviews of General Medicine, Neurology, Psychiatry, Dermatology, and Pediatrics. 2000 November; 79(6): 360-8. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11144034&dopt=Abstract
•
Acute bacterial meningitis in children admitted to a rural Kenyan hospital: increasing antibiotic resistance and outcome. Author(s): Mwangi I, Berkley J, Lowe B, Peshu N, Marsh K, Newton CR. Source: The Pediatric Infectious Disease Journal. 2002 November; 21(11): 1042-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12442027&dopt=Abstract
•
Acute community-acquired meningitis and encephalitis. Author(s): Saltman DC. Source: The Medical Journal of Australia. 2002 September 2; 177(5): 277; Author Reply 277. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12197828&dopt=Abstract
•
Acute disseminated encephalomyelitis associated with Pasteurella multocida meningitis. Author(s): Proulx NL, Freedman MS, Chan JW, Toye B, Code CC. Source: The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques. 2003 May; 30(2): 155-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12774957&dopt=Abstract
•
Acute meningitis due to Toscana virus infection among patients from both the Spanish Mediterranean region and the region of Madrid. Author(s): Echevarria JM, de Ory F, Guisasola ME, Sanchez-Seco MP, Tenorio A, Lozano A, Cordoba J, Gobernado M. Source: Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology. 2003 January; 26(1): 79-84. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12589837&dopt=Abstract
92 Meningitis
•
Acute meningoencephalitis and meningitis due to primary HIV infection. Author(s): Newton PJ, Newsholme W, Brink NS, Manji H, Williams IG, Miller RF. Source: Bmj (Clinical Research Ed.). 2002 November 23; 325(7374): 1225-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12446542&dopt=Abstract
•
Acute motor axonal Guillain-Barre syndrome after Salmonella typhimurium bacteremia and cryptococcal meningitis in AIDS. Author(s): Blanche P, Passeron A, Gombert B, Ginsburg C, Chapuis L, Salmon D, Sicard D. Source: Journal of Neurology. 2001 April; 248(4): 334-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11374102&dopt=Abstract
•
Acute severe spinal cord dysfunction in bacterial meningitis in adults: MRI findings suggest extensive myelitis. Author(s): Roos KL. Source: Archives of Neurology. 2001 May; 58(5): 717-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11346365&dopt=Abstract
•
Acute severe spinal cord dysfunction in bacterial meningitis in adults: MRI findings suggest extensive myelitis. Author(s): Kastenbauer S, Winkler F, Fesl G, Schiel X, Ostermann H, Yousry TA, Pfister HW. Source: Archives of Neurology. 2001 May; 58(5): 806-10. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11346376&dopt=Abstract
•
Acute ST-segment elevation in Neisseria meningitis. Author(s): Gach O, Lancellotti P, Pierard LA. Source: Acta Cardiol. 2001 October; 56(5): 327-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11712830&dopt=Abstract
•
Acute urinary retention as an unusual manifestation of aseptic meningitis. Author(s): Zenda T, Soma R, Muramoto H, Hayase H, Orito M, Okada T, Mabuchi H, Okino S. Source: Intern Med. 2002 May; 41(5): 392-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12058890&dopt=Abstract
•
Adenosine deaminase levels in cerebrospinal fluid and serum in the diagnosis of tubercular meningitis. Author(s): Chaturvedi P, Vaidya J, Harinath BC, Pramanick B. Source: Journal of Tropical Pediatrics. 2000 December; 46(6): 378-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11191154&dopt=Abstract
Studies 93
•
Adult community acquired bacterial meningitis in a Singaporean teaching hospital. A seven-year overview (1993-2000). Author(s): Chan YC, Wilder-Smith A, Ong BK, Kumarasinghe G, Wilder-Smith E. Source: Singapore Med J. 2002 December; 43(12): 632-6. Erratum In: Singapore Med J. 2003 January; 44(1): 50. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12693768&dopt=Abstract
•
Adult Enterobacter meningitis: a high incidence of coinfection with other pathogens and frequent association with neurosurgical procedures. Author(s): Huang CR, Lu CH, Chang WN. Source: Infection. 2001 March-April; 29(2): 75-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11339479&dopt=Abstract
•
Adult onset spontaneous CSF otorrhea with oval window fistula and recurrent meningitis: MRI findings. Author(s): Rupa V, Job A, Rajshekhar V. Source: Otolaryngology and Head and Neck Surgery. 2001 March; 124(3): 344-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11241007&dopt=Abstract
•
Adults with meningitis caused by viridans streptococci. Author(s): Lu CH, Chang WN, Chang HW. Source: Infection. 2001 December; 29(6): 305-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11787829&dopt=Abstract
•
Amoxicillin-induced aseptic meningitis. Author(s): Wittmann A, Wooten GF. Source: Neurology. 2001 November 13; 57(9): 1734. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11706130&dopt=Abstract
•
An epidemic of aseptic meningitis due to coxsackievirus B5 in Nara prefecture, Japan: an epidemiological analysis by PCR-RFLP. Author(s): Kitahori Y, Inoue Y, Maruhashi Y, Adachi O, Imai S. Source: Japanese Journal of Infectious Diseases. 2003 April; 56(2): 75-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12824693&dopt=Abstract
•
An indigenous leucocyte esterase test along with Pandy's test for the diagnosis of bacterial meningitis. Author(s): Locham KK, Sodhi M, Jindal G. Source: Indian Pediatrics. 2002 June; 39(6): 602-3; Author Reply 603-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12084964&dopt=Abstract
94 Meningitis
•
An indigenous leucocyte esterase test along with Pandy's test for the diagnosis of bacterial meningitis. Author(s): Srivastava RK, Gupta S, Bhargava M, Kumar N, Upadhyay P, Puliyel JM. Source: Indian Pediatrics. 2001 November; 38(11): 1281-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11721069&dopt=Abstract
•
An infant with group B streptococcal meningitis. Author(s): Listernick R. Source: Pediatric Annals. 2002 November; 31(11): 699-703. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12455478&dopt=Abstract
•
An infant with meningitis and unexplained coagulopathy. Author(s): Siegfried B. Source: Clinical Pediatrics. 2002 October; 41(8): 625-6; Discussion 626-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12403383&dopt=Abstract
•
An open label trial of sustained-release cytarabine (DepoCyt) for the intrathecal treatment of solid tumor neoplastic meningitis. Author(s): Jaeckle KA, Batchelor T, O'Day SJ, Phuphanich S, New P, Lesser G, Cohn A, Gilbert M, Aiken R, Heros D, Rogers L, Wong E, Fulton D, Gutheil JC, Baidas S, Kennedy JM, Mason W, Moots P, Russell C, Swinnen LJ, Howell SB. Source: Journal of Neuro-Oncology. 2002 May; 57(3): 231-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12125986&dopt=Abstract
•
An outbreak of Aseptic Meningitis due to echovirus type 30 in two cities of Turkey. Author(s): Ozkaya E, Hizel K, Uysal G, Akman S, Terzioglu S, Kuyucu N. Source: European Journal of Epidemiology. 2003; 18(8): 823-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12974559&dopt=Abstract
•
An outbreak of echovirus 13 meningitis in central Israel. Author(s): Somekh E, Cesar K, Handsher R, Hanukoglu A, Dalal I, Ballin A, Shohat T. Source: Epidemiology and Infection. 2003 April; 130(2): 257-62. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12729194&dopt=Abstract
•
An outbreak of eosinophilic meningitis caused by Angiostrongylus cantonensis in travelers returning from the Caribbean. Author(s): Slom TJ, Cortese MM, Gerber SI, Jones RC, Holtz TH, Lopez AS, Zambrano CH, Sufit RL, Sakolvaree Y, Chaicumpa W, Herwaldt BL, Johnson S. Source: The New England Journal of Medicine. 2002 February 28; 346(9): 668-75. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11870244&dopt=Abstract
Studies 95
•
An outbreak of meningitis caused by Angiostrongylus cantonensis in Kaohsiung. Author(s): Tsai TH, Liu YC, Wann SR, Lin WR, Lee SJ, Lin HH, Chen YS, Yen MY, Yen CM. Source: J Microbiol Immunol Infect. 2001 March; 34(1): 50-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11321128&dopt=Abstract
•
An unusual cause of acute bacterial meningitis. Author(s): Stephenson I, Wiselka MJ. Source: Postgraduate Medical Journal. 2001 December; 77(914): 791, 800-1. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11723327&dopt=Abstract
•
An unusual serotype of Salmonella from a case of meningitis in a neonate. Author(s): Ghadage DP, Bal AM. Source: Indian J Pediatr. 2001 November; 68(11): 1088. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11770251&dopt=Abstract
•
Anthrax meningitis: case report and review. Author(s): Tasyaran MA, Deniz O, Ertek M, Cetin K. Source: Scandinavian Journal of Infectious Diseases. 2002; 34(1): 66-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11874170&dopt=Abstract
•
Anthrax meningitis: case report. Author(s): Yorgancigil B, Demirci M, Unlu M, Sevuk E, Doganay M. Source: International Journal of Infectious Diseases : Ijid : Official Publication of the International Society for Infectious Diseases. 2001; 5(4): 220-1. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11953221&dopt=Abstract
•
Antibiotic guidelines and antibiotic use in adult bacterial meningitis in The Netherlands. Author(s): van de Beek D, de Gans J, Spanjaard L, Vermeulen M, Dankert J. Source: The Journal of Antimicrobial Chemotherapy. 2002 April; 49(4): 661-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11909840&dopt=Abstract
•
Antibiotic susceptibility and serotype distribution of 240 Streptococcus pneumoniae causing meningitis in Belgium 1997-2000. Author(s): Verhaegen J, Vandecasteele SJ, Vandeven J, Verbiest N, Lagrou K, Peetermans WE. Source: Acta Clin Belg. 2003 January-February; 58(1): 19-26. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12723258&dopt=Abstract
96 Meningitis
•
Antifungal therapy for treatment of cryptococcal meningitis. Author(s): Yao Z, Liao W, Wen H. Source: Chin Med J (Engl). 2000 February; 113(2): 178-80. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11775548&dopt=Abstract
•
Antimicrobial resistance in Haemophilus influenzae isolated during populationbased surveillance for meningitis in Salvador, Brazil. Author(s): Reis JN, Lima JB, Ribeiro GS, Corderio SM, Salgado K, Reis MG, Ko AI. Source: Antimicrobial Agents and Chemotherapy. 2002 November; 46(11): 3641-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12384381&dopt=Abstract
•
Antimicrobial resistance patterns of Haemophilus influenzae isolated from patients with meningitis in Sao Paulo, Brazil. Author(s): Casagrande ST, Vicente EJ, Landgraf IM, Kobata AM. Source: Brazilian Journal of Medical and Biological Research = Revista Brasileira De Pesquisas Medicas E Biologicas / Sociedade Brasileira De Biofisica. [et Al.]. 2000 March; 33(3): 295-300. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10719380&dopt=Abstract
•
Approach to acute bacterial meningitis. Minireview. Author(s): Tabbarah ZA. Source: J Med Liban. 2001 January-February; 49(1): 18-21. Review. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11910960&dopt=Abstract
•
Appropriateness of a pneumococcal conjugate vaccine in Brazil: potential impact of age and clinical diagnosis, with emphasis on meningitis. Author(s): Brandileone MC, de Andrade AL, Di Fabio JL, Guerra ML, Austrian R. Source: The Journal of Infectious Diseases. 2003 April 15; 187(8): 1206-12. Epub 2003 March 26. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12695999&dopt=Abstract
•
Aseptic meningitis after intraventricular administration of gentamicin. Author(s): Haase KK, Lapointe M, Haines SJ. Source: Pharmacotherapy. 2001 January; 21(1): 103-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11191728&dopt=Abstract
•
Aseptic meningitis after spinal anesthesia in an infant. Author(s): Abouleish A, Nguyen NC, Mayhew JF. Source: Anesthesiology. 2000 April; 92(4): 1200-1. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10754646&dopt=Abstract
Studies 97
•
Aseptic meningitis and optic neuritis preceding varicella-zoster progressive outer retinal necrosis in a patient with AIDS. Author(s): Franco-Paredes C, Bellehemeur T, Merchant A, Sanghi P, DiazGranados C, Rimland D. Source: Aids (London, England). 2002 May 3; 16(7): 1045-9. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11953471&dopt=Abstract
•
Aseptic meningitis as a delayed neurologic complication of murine typhus. Author(s): Vallejo-Maroto I, Garcia-Morillo S, Wittel MB, Stiefel P, Miranda M, Pamies E, Aparicio R, Carneado J. Source: Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases. 2002 December; 8(12): 826-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12519359&dopt=Abstract
•
Aseptic meningitis associated with rofecoxib. Author(s): Bonnel RA, Villalba ML, Karwoski CB, Beitz J. Source: Archives of Internal Medicine. 2002 March 25; 162(6): 713-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11911727&dopt=Abstract
•
Aseptic meningitis due to administration of intravenous immunoglobulin with an unusually high number of leukocytes in cerebrospinal fluid. Author(s): Obando I, Duran I, Martin-Rosa L, Cano JM, Garcia-Martin FJ. Source: Pediatric Emergency Care. 2002 December; 18(6): 429-32. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12488836&dopt=Abstract
•
Aseptic meningitis in a child after systemic treatment with high dose cytarabine. Author(s): Pease CL, Horton TM, McClain KL, Kaplan SL. Source: The Pediatric Infectious Disease Journal. 2001 January; 20(1): 87-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11176579&dopt=Abstract
•
Aseptic meningitis in a large MMR vaccine campaign (590,609 people) in Curitiba, Parana, Brazil, 1998. Author(s): Arruda WO, Kondageski C. Source: Revista Do Instituto De Medicina Tropical De Sao Paulo. 2001 SeptemberOctober; 43(5): 301-2. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11696855&dopt=Abstract
•
Aseptic meningitis in children--the Singapore experience. Author(s): Tee WS, Choong CT, Lin RV, Ling AE. Source: Ann Acad Med Singapore. 2002 November; 31(6): 756-60. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12520830&dopt=Abstract
98 Meningitis
•
Aseptic meningitis in Germany associated with echovirus type 13. Author(s): Diedrich S, Schreier E. Source: Bmc Infectious Diseases [electronic Resource]. 2001; 1(1): 14. Epub 2001 September 14. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11591222&dopt=Abstract
•
Aseptic meningitis related to valacyclovir. Author(s): Fobelo MJ, Corzo Delgado JE, Romero Alonso A, Gomez-Bellver MJ. Source: The Annals of Pharmacotherapy. 2001 January; 35(1): 128-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11197578&dopt=Abstract
•
Aseptic meningitis. Author(s): Narchi H. Source: Pediatrics. 2001 February; 107(2): 451. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11246643&dopt=Abstract
•
Assessment of antibody responses to antigens of Mycobacterium tuberculosis and Cysticercus cellulosae in cerebrospinal fluid of chronic meningitis patients for definitive diagnosis as TBM/NCC by passive hemagglutination and immunoblot assays. Author(s): Katti MK. Source: Fems Immunology and Medical Microbiology. 2002 March 25; 33(1): 57-61. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11985970&dopt=Abstract
•
Association of tumour necrosis factor alpha & malnutrition with outcome in children with acute bacterial meningitis. Author(s): Hemalatha R, Bhaskaram P, Balakrishna N, Saraswathi I. Source: The Indian Journal of Medical Research. 2002 February; 115: 55-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12138665&dopt=Abstract
•
Atypical presentation of tuberculosis meningitis: a case report. Author(s): Souza RD, Franklin D, Simpson J, Kerr F. Source: Scott Med J. 2002 February; 47(1): 14-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11980292&dopt=Abstract
•
Audit of suspected meningitis in a district in 1996-1997 and in 1999. Author(s): Ejidokun OO, Linnane J, Ramaiah SR. Source: Commun Dis Public Health. 2002 March; 5(1): 27-32. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12070973&dopt=Abstract
Studies 99
•
Bacillus cereus bacteremia and meningitis in immunocompromised children. Author(s): Gaur AH, Patrick CC, McCullers JA, Flynn PM, Pearson TA, Razzouk BI, Thompson SJ, Shenep JL. Source: Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America. 2001 May 15; 32(10): 1456-62. Epub 2001 April 20. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11317247&dopt=Abstract
•
Bacillus cereus meningitis complicating cerebrospinal fluid fistula repair and spinal drainage. Author(s): Marshman LA, Hardwidge C, Donaldson PM. Source: British Journal of Neurosurgery. 2000 December; 14(6): 580-2. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11272043&dopt=Abstract
•
Bacteremia and meningitis caused by a macrolide-sensitive strain of Streptococcus pneumoniae during treatment with azithromycin. Author(s): Lisby G, Brasholt MS, Teglbjerg MS. Source: Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America. 2001 August 1; 33(3): 415-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11438918&dopt=Abstract
•
Bacterial and mycobacterial meningitis in HIV-positive compared with HIV-negative patients in an internal medicine ward in Libreville, Gabon. Author(s): Nkoumou MO, Betha G, Kombila M, Clevenbergh P. Source: Journal of Acquired Immune Deficiency Syndromes (1999). 2003 March 1; 32(3): 345-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12626897&dopt=Abstract
•
Bacterial meningitis in aging adults. Author(s): Choi C. Source: Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America. 2001 October 15; 33(8): 1380-5. Epub 2001 September 05. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11550119&dopt=Abstract
•
Bacterial meningitis in Angola. Author(s): Bernardino L, Magalhaes J, Simoes MJ, Monteiro L. Source: Lancet. 2003 May 3; 361(9368): 1564-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12737901&dopt=Abstract
•
Bacterial meningitis in childhood at the Children's Hospital of Pittsburgh: 1988-1998. Author(s): Neuman HB, Wald ER. Source: Clinical Pediatrics. 2001 November; 40(11): 595-600. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11758958&dopt=Abstract
100 Meningitis
•
Bacterial meningitis in children. Author(s): Saez-Llorens X, McCracken GH Jr. Source: Lancet. 2003 June 21; 361(9375): 2139-48. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12826449&dopt=Abstract
•
Bacterial meningitis in children: critical care needs. Author(s): Singhi S, Singhi P, Baranwal AK. Source: Indian J Pediatr. 2001 August; 68(8): 737-47. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11563252&dopt=Abstract
•
Bacterial meningitis in Malawian adults: pneumococcal disease is common, severe, and seasonal. Author(s): Gordon SB, Walsh AL, Chaponda M, Gordon MA, Soko D, Mbwvinji M, Molyneux ME, Read RC. Source: Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America. 2000 July; 31(1): 53-7. Epub 2000 July 11. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10913396&dopt=Abstract
•
Bacterial meningitis in Saudi Arabia: the impact of Haemophilus influenzae type b vaccination. Author(s): Almuneef M, Alshaalan M, Memish Z, Alalola S. Source: Journal of Chemotherapy (Florence, Italy). 2001 April; 13 Suppl 1: 34-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11434527&dopt=Abstract
•
Bacterial meningitis of an infant with Currarino triad. Author(s): Chou IC, Mak SC, Lin TP, Chi CS, Pen HC. Source: Acta Paediatr Taiwan. 2002 September-October; 43(5): 288-90. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12607487&dopt=Abstract
•
Bacterial meningitis secondary to a transethmoidal encephalocele presenting to the emergency department. Author(s): Schwartz MD, Shaw GJ. Source: The Journal of Emergency Medicine. 2002 August; 23(2): 171-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12359286&dopt=Abstract
•
Bacterial meningitis. Appeal to thwart deadly outbreak. Author(s): Vogel G. Source: Science. 2002 October 11; 298(5592): 339. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12376673&dopt=Abstract
Studies 101
•
Bacterial meningitis: current controversies in approaches to treatment. Author(s): Williams AJ, Nadel S. Source: Cns Drugs. 2001; 15(12): 909-19. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11735611&dopt=Abstract
•
Bacterial meningitis--problems on many fronts. Author(s): Ruef C. Source: Infection. 2000 January-February; 28(1): 1-2. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10697782&dopt=Abstract
•
Bacterial penetration across the blood-brain barrier during the development of neonatal meningitis. Author(s): Huang SH, Stins MF, Kim KS. Source: Microbes and Infection / Institut Pasteur. 2000 August; 2(10): 1237-44. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11008113&dopt=Abstract
•
Bactericidal activity in cerebrospinal fluid by treating meningitis caused by Stomatococcus mucilaginosus with rifampicin, cefotaxime and vancomycin in a neutropenic child. Author(s): Skogen PG, Kolmannskog S, Bergh K. Source: Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases. 2001 January; 7(1): 39-42. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11284946&dopt=Abstract
•
Bactericidal antibody response to Neisseria meningitidis serogroup B in patients with bacterial meningitis: effect of immunization with an outer membrane protein vaccine. Author(s): Milagres LG, Gorla MC, Rebelo MC, Barroso DE. Source: Fems Immunology and Medical Microbiology. 2000 August; 28(4): 319-27. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10891656&dopt=Abstract
•
Bacteriologic outcome of children with cefotaxime- or ceftriaxone-susceptible and nonsusceptible Streptococcus pneumoniae meningitis. Author(s): Olivier C, Cohen R, Begue P, Floret D. Source: The Pediatric Infectious Disease Journal. 2000 October; 19(10): 1015-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11055609&dopt=Abstract
•
Bacteriological diagnosis of Streptococcus suis meningitis. Author(s): Durand F, Perino CL, Recule C, Brion JP, Kobish M, Guerber F, Croize J. Source: European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology. 2001 July; 20(7): 519-21. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11561816&dopt=Abstract
102 Meningitis
•
Benefits of management strategy adjustments during an outbreak of enterovirus meningitis in adults. Author(s): Tattevin P, Minjolle S, Arvieux C, Clayessen V, Colimon R, Bouget J, Michelet C. Source: Scandinavian Journal of Infectious Diseases. 2002; 34(5): 359-61. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12069020&dopt=Abstract
•
Bilateral basal ganglia infarctions in a patient with Streptococcus pneumoniae meningitis. Author(s): Johkura K, Nishiyama T, Kuroiwa Y. Source: European Neurology. 2002; 48(2): 123-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12187007&dopt=Abstract
•
Bilateral endogenous Klebsiella pneumoniae endophthalmitis associated with meningitis-useful vision regained after treatment: case report. Author(s): Liao SB, Yang KJ, Lai CC, Chen TL, Lee SC. Source: Changgeng Yi Xue Za Zhi. 2000 September; 23(9): 566-71. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11092147&dopt=Abstract
•
Bilateral panophthalmitis as the initial presentation of meningococcal meningitis in an infant. Author(s): Gartaganis SP, Eliopoulou MJ, Georgakopoulos CD, Koliopoulos JX, Mela EK. Source: J Aapos. 2001 August; 5(4): 260-1. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11507588&dopt=Abstract
•
Bilateral vestibular failure as a unique presenting sign in carcinomatous meningitis: case report. Author(s): Pollak L, Milo R, Kossych V, Rabey MJ, Shapira E. Source: Journal of Neurology, Neurosurgery, and Psychiatry. 2001 May; 70(5): 704-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11336037&dopt=Abstract
•
Biofilm on ventriculo-peritoneal shunt tubing as a cause of treatment failure in coccidioidal meningitis. Author(s): Davis LE, Cook G, Costerton JW. Source: Emerging Infectious Diseases. 2002 April; 8(4): 376-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11971770&dopt=Abstract
•
Bipolaris spicifera meningitis complicating a neurosurgerical procedure. Author(s): Latham RH. Source: Scandinavian Journal of Infectious Diseases. 2000; 32(1): 102-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10716091&dopt=Abstract
Studies 103
•
Brainstem auditory evoked potentials in tubercular meningitis and their correlation with radiological findings. Author(s): Kalita J, Misra UK. Source: Neurology India. 2001 March; 49(1): 51-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11303242&dopt=Abstract
•
Breakthrough Streptococcus pneumoniae meningitis during clarithromycin therapy for acute otitis media. Author(s): Bochud PY, Calandra T, Moreillon P, Baumgartner JD, Yersin B. Source: European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology. 2001 February; 20(2): 1367. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11305469&dopt=Abstract
•
Breast cancer relapsing as carcinomatous meningitis. Author(s): Gaur S. Source: Southern Medical Journal. 2003 July; 96(7): 728. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12940338&dopt=Abstract
•
Broad-range bacterial polymerase chain reaction for early detection of bacterial meningitis. Author(s): Saravolatz LD, Manzor O, VanderVelde N, Pawlak J, Belian B. Source: Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America. 2003 January 1; 36(1): 40-5. Epub 2002 December 12. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12491200&dopt=Abstract
•
Burden of meningitis and other severe bacterial infections of children in africa: implications for prevention. Author(s): Peltola H. Source: Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America. 2001 January; 32(1): 64-75. Epub 2000 December 11. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11112673&dopt=Abstract
•
Can a clinical decision rule decrease antibiotic use in viral meningitis? Author(s): Chitkara MB, Ryan LM, Stockwell D, Wiedermann BL. Source: Archives of Pediatrics & Adolescent Medicine. 2002 December; 156(12): 1195-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12444829&dopt=Abstract
•
Carcinomatous meningitis in a patient with metastatic breast cancer. Author(s): Lauby G. Source: Clin Lab Sci. 2001 Summer; 14(3): 141-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11517623&dopt=Abstract
104 Meningitis
•
Carcinomatous meningitis: are surgeryand gamma knife radiosurgery treatment risk factors? Author(s): Mahajan A, Borden J, Tsai JS. Source: Journal of Neurosurgery. 2002 December; 97(5 Suppl): 441-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12507072&dopt=Abstract
•
Carcinomatous Meningitis: it does not have to be a death sentence. Author(s): Sagar SM. Source: Oncology (Huntingt). 2002 February; 16(2): 237-43; Discussion 244, 249-50. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11866138&dopt=Abstract
•
Case reports of viral meningitis/encephalitis. Author(s): Norwood C, Naponick JJ, Burton S, Varoqua S, Morris J, Kuizon D. Source: J La State Med Soc. 2003 May-June; 155(3): 154-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12873102&dopt=Abstract
•
Case Reports. Chronic and acute Aspergillus meningitis. Author(s): Moling O, Lass-Floerl C, Verweij PE, Porte M, Boiron P, Prugger M, Gebert U, Corradini R, Vedovelli C, Rimenti G, Mian P. Source: Mycoses. 2002 December; 45(11-12): 504-11. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12472730&dopt=Abstract
•
Case Reports. Pulmonary cryptococcosis associated with cryptococcal meningitis in non-AIDS patients. Author(s): Zhu LP, Shi YZ, Weng XH, Muller FM. Source: Mycoses. 2002 April; 45(3-4): 111-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12000513&dopt=Abstract
•
Caspase-3 mediates hippocampal apoptosis in pneumococcal meningitis. Author(s): Gianinazzi C, Grandgirard D, Imboden H, Egger L, Meli DN, Bifrare YD, Joss PC, Tauber MG, Borner C, Leib SL. Source: Acta Neuropathologica. 2003 May; 105(5): 499-507. Epub 2003 February 12. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12677451&dopt=Abstract
•
Cause and timing of death following meningitis in adults. Author(s): Vandecasteele SJ, Verhaegen J, Peetermans WE. Source: Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America. 2002 March 15; 34(6): 878-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11850873&dopt=Abstract
Studies 105
•
Cavernous sinus syndrome secondary to tuberculous meningitis. Author(s): Hui AC, Wong WS, Wong KS. Source: European Neurology. 2002; 47(2): 125-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11844904&dopt=Abstract
•
Cefepime in the empiric treatment of meningitis in children. Author(s): Saez-Llorens X, O'Ryan M. Source: The Pediatric Infectious Disease Journal. 2001 March; 20(3): 356-61. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11303850&dopt=Abstract
•
Cefepime is efficacious against penicillin- and quinolone-resistant pneumococci in experimental meningitis. Author(s): Cottagnoud P, Acosta F, Cottagnoud M, Tauber MG. Source: The Journal of Antimicrobial Chemotherapy. 2002 February; 49(2): 327-30. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11815575&dopt=Abstract
•
Cerebral blood flow, oxidative metabolism and cerebrovascular carbon dioxide reactivity in patients with acute bacterial meningitis. Author(s): Moller K, Strauss GI, Thomsen G, Larsen FS, Holm S, Sperling BK, Skinhoj P, Knudsen GM. Source: Acta Anaesthesiologica Scandinavica. 2002 May; 46(5): 567-78. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12027852&dopt=Abstract
•
Cerebrospinal fluid lysozyme level for the diagnosis of tuberculous meningitis in children. Author(s): Mishra OP, Batra P, Ali Z, Anupurba S, Das BK. Source: Journal of Tropical Pediatrics. 2003 February; 49(1): 13-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12630714&dopt=Abstract
•
Cerebrospinal fluid penetration and pharmacokinetic/pharmacodynamic parameters of intravenously administered colistin in a case of multidrug-resistant Acinetobacter baumannii meningitis. Author(s): Jimenez-Mejias ME, Pichardo-Guerrero C, Marquez-Rivas FJ, Martin-Lozano D, Prados T, Pachon J. Source: European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology. 2002 March; 21(3): 212-4. Epub 2002 March 19. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11957024&dopt=Abstract
106 Meningitis
•
Characterization of a laboratory-derived, high-level ampicillin-resistant Salmonella enterica serovar Typhimurium strain that caused meningitis in an infant. Author(s): Chiu CH, Chu C, Su LH, Wu WY, Wu TL. Source: Antimicrobial Agents and Chemotherapy. 2002 May; 46(5): 1604-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11959613&dopt=Abstract
•
Characterization of Mycobacterium tuberculosis complex isolates from the cerebrospinal fluid of meningitis patients at six fever hospitals in Egypt. Author(s): Cooksey RC, Abbadi SH, Woodley CL, Sikes D, Wasfy M, Crawford JT, Mahoney F. Source: Journal of Clinical Microbiology. 2002 May; 40(5): 1651-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11980936&dopt=Abstract
•
Childhood bacterial meningitis in Bulgaria: a population-based retrospective study in six regions during 1992-96. Author(s): Kojouharova M, Gatcheva N, Setchanova L, Mechandjieva V; Bulgarian Hib Study Team. Source: International Journal of Infectious Diseases : Ijid : Official Publication of the International Society for Infectious Diseases. 2003 June; 7(2): 109-12. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12839711&dopt=Abstract
•
Chip-based diagnostics for meningitis and food poisoning. Author(s): Clayton J. Source: Drug Discovery Today. 2002 June 15; 7(12): 637-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12110234&dopt=Abstract
•
Chloramphenicol or ceftriaxone, or both, as treatment for meningitis in developing countries? Author(s): Duke T, Michael A, Mokela D, Wal T, Reeder J. Source: Archives of Disease in Childhood. 2003 June; 88(6): 536-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12765927&dopt=Abstract
•
Chronic meningitis presenting with acute obstructive hydrocephalus. Author(s): Birkhahn RH, Sweeny AH, Lopez O. Source: The Journal of Emergency Medicine. 2002 February; 22(2): 175-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11858923&dopt=Abstract
•
Chronic meningitis. Author(s): Tan TQ. Source: Seminars in Pediatric Infectious Diseases. 2003 April; 14(2): 131-9. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12881801&dopt=Abstract
Studies 107
•
Chronic meningitis: still a diagnostic challenge. Author(s): Hildebrand J, Aoun M. Source: Journal of Neurology. 2003 June; 250(6): 653-60. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12796824&dopt=Abstract
•
Chronicle of an outbreak foretold: meningococcal meningitis W135 in Burkina Faso. Author(s): Decosas J, Koama JB. Source: The Lancet Infectious Diseases. 2002 December; 2(12): 763-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12467693&dopt=Abstract
•
Citrobacter koseri (diversus) meningitis in an otherwise healthy adolescent. Author(s): Prais D, Nussinovitch M, Harel L, Amir J. Source: Scandinavian Journal of Infectious Diseases. 2003; 35(3): 202-4. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12751719&dopt=Abstract
•
Citrobacter koseri pneumonia and meningitis in an infant. Author(s): Aller SC, Chusid MJ. Source: The Journal of Infection. 2002 July; 45(1): 65-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12217738&dopt=Abstract
•
Cladosporium bantianum meningitis in a neonate. Author(s): Banerjee TK, Patwari AK, Dutta R, Anand VK, Chabra A. Source: Indian J Pediatr. 2002 August; 69(8): 721-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12356227&dopt=Abstract
•
Claims of equivalence in randomized controlled trials of the treatment of bacterial meningitis in children. Author(s): Krysan DJ, Kemper AR. Source: The Pediatric Infectious Disease Journal. 2002 August; 21(8): 753-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12192164&dopt=Abstract
•
Classification of Ralstonia pickettii biovar 3/'thomasii' strains (Pickett 1994) and of new isolates related to nosocomial recurrent meningitis as Ralstonia mannitolytica sp. nov. Author(s): De Baere T, Steyaert S, Wauters G, Des Vos P, Goris J, Coenye T, Suyama T, Verschraegen G, Vaneechoutte M. Source: International Journal of Systematic and Evolutionary Microbiology. 2001 March; 51(Pt 2): 547-58. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11321101&dopt=Abstract
108 Meningitis
•
Clearance of 14-3-3 protein from cerebrospinal fluid heralds the resolution of bacterial meningitis. Author(s): Bonora S, Zanusso G, Raiteri R, Monaco S, Rossati A, Ferrari S, Boffito M, Audagnotto S, Sinicco A, Rizzuto N, Concia E, Di Perri G. Source: Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America. 2003 June 1; 36(11): 1492-5. Epub 2003 May 16. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12766846&dopt=Abstract
•
Clinical data and cerebrospinal fluid findings in Lyme meningitis versus aseptic meningitis. Author(s): Tuerlinckx D, Bodart E, Garrino MG, de Bilderling G. Source: European Journal of Pediatrics. 2003 March; 162(3): 150-3. Epub 2003 January 21. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12655417&dopt=Abstract
•
Clinical outcomes of meningitis caused by Streptococcus pneumoniae in the era of antibiotic resistance. Author(s): Fiore AE, Moroney JF, Farley MM, Harrison LH, Patterson JE, Jorgensen JH, Cetron M, Kolczak MS, Breiman RF, Schuchat A. Source: Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America. 2000 January; 30(1): 71-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10619736&dopt=Abstract
•
Clinical predictors of bacterial meningitis in infants and young children in The Gambia. Author(s): Weber MW, Herman J, Jaffar S, Usen S, Oparaugo A, Omosigho C, Adegbola RA, Greenwood BM, Mulholland EK. Source: Tropical Medicine & International Health : Tm & Ih. 2002 September; 7(9): 72231. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12225501&dopt=Abstract
•
Clinical study of 44 cases of Staphylococcus aureus meningitis. Author(s): Pintado V, Meseguer MA, Fortun J, Cobo J, Navas E, Quereda C, Corral I, Moreno S. Source: European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology. 2002 December; 21(12): 864-8. Epub 2002 December 10. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12525921&dopt=Abstract
Studies 109
•
Clonally related penicillin-nonsusceptible Streptococcus pneumoniae serotype 14 from cases of meningitis in Salvador, Brazil. Author(s): Ko AI, Reis JN, Coppola SJ, Gouveia EL, Cordeiro SM, Lobo TS, Pinheiro RM, Salgado K, Ribeiro Dourado CM, Tavares-Neto J, Rocha H, Galvao Reis M, Johnson WD Jr, Riley LW. Source: Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America. 2000 January; 30(1): 78-86. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10619737&dopt=Abstract
•
Coccidioidal meningitis: incidental diagnosis 3 y after ventriculo-peritoneal shunt placement for hydrocephalus. Author(s): Almoujahed MO, Johnson LB, Gehring R, Khatib R. Source: Scandinavian Journal of Infectious Diseases. 2002; 34(2): 142-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11928851&dopt=Abstract
•
Coccidioidomycosis meningitis and syndrome of inappropriate antidiuretic hormone. Author(s): Webb M, Ziauddin A, Okusa MD. Source: The American Journal of the Medical Sciences. 2002 September; 324(3): 155-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12240713&dopt=Abstract
•
Cochlear implant recipients at risk for meningitis. Author(s): Wooltorton E. Source: Cmaj : Canadian Medical Association Journal = Journal De L'association Medicale Canadienne. 2002 September 17; 167(6): 670. Erratum In: Cmaj. 2003 February 4; 168(3): 257. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12358204&dopt=Abstract
•
Cochlear implants and meningitis: update and recommendations for prevention. Author(s): Bluestone CD. Source: The Pediatric Infectious Disease Journal. 2003 May; 22(5): 477-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12792395&dopt=Abstract
•
Cochlear implants carry risk of meningitis, agencies warn. Author(s): Josefson D. Source: Bmj (Clinical Research Ed.). 2002 August 10; 325(7359): 298. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12169502&dopt=Abstract
•
Cochlear malformations, meningitis, and cochlear implants: what have we learned? Author(s): Bluestone CD. Source: Otology & Neurotology : Official Publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology. 2003 March; 24(2): 349-50. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12621357&dopt=Abstract
110 Meningitis
•
Cognitive impairment in adults with good recovery after bacterial meningitis. Author(s): van de Beek D, Schmand B, de Gans J, Weisfelt M, Vaessen H, Dankert J, Vermeulen M. Source: The Journal of Infectious Diseases. 2002 October 1; 186(7): 1047-52. Epub 2002 September 13. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12232850&dopt=Abstract
•
Comamonas testosteroni meningitis in a patient with recurrent cholesteatoma. Author(s): Arda B, Aydemir S, Yamazhan T, Hassan A, Tunger A, Serter D. Source: Apmis : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica. 2003 April; 111(4): 474-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12780521&dopt=Abstract
•
Community-acquired bacterial meningitis in adults: the epidemiology, timing of appropriate antimicrobial therapy, and prognostic factors. Author(s): Lu CH, Huang CR, Chang WN, Chang CJ, Cheng BC, Lee PY, Lin MW, Chang HW. Source: Clinical Neurology and Neurosurgery. 2002 September; 104(4): 352-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12140104&dopt=Abstract
•
Community-acquired spontaneous bacterial meningitis in adult diabetic patients: an analysis of clinical characteristics and prognostic factors. Author(s): Huang CR, Lu CH, Chang HW, Lee PY, Lin MW, Chang WN. Source: Infection. 2002 December; 30(6): 346-50. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12478323&dopt=Abstract
•
Community-acquired spontaneous Klebsiella pneumoniae meningitis in adult cirrhotic patients with and without diabetes. Author(s): Chang WN, Lu CH, Wu JJ, Lei CB, Huang CR. Source: European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology. 2003 April; 22(4): 271-3. Epub 2003 March 22. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12687413&dopt=Abstract
•
Comparative genomics identifies the genetic islands that distinguish Neisseria meningitidis, the agent of cerebrospinal meningitis, from other Neisseria species. Author(s): Perrin A, Bonacorsi S, Carbonnelle E, Talibi D, Dessen P, Nassif X, Tinsley C. Source: Infection and Immunity. 2002 December; 70(12): 7063-72. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12438387&dopt=Abstract
Studies 111
•
Comparison of mixed cell culture containing genetically engineered BGMK and CaCo-2 cells (Super E-Mix) with RT-PCR and conventional cell culture for the diagnosis of enterovirus meningitis. Author(s): Buck GE, Wiesemann M, Stewart L. Source: Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology. 2002 July; 25 Suppl 1: S13-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12091077&dopt=Abstract
•
Computerised tomographic study of tuberculous meningitis in children. Author(s): De JK, Bagchi S, Bhadra UK, Chatterjee SN, Munshi AK. Source: J Indian Med Assoc. 2002 October; 100(10): 603-4, 606. Erratum In: J Indian Med Assoc. 2002 November; 100(11): 678. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12452514&dopt=Abstract
•
Concurrent meningitis/serious bacterial infection in an infant hospitalized with respiratory syncytial virus. Author(s): McGregor RS, Tung J. Source: Archives of Pediatrics & Adolescent Medicine. 2002 October; 156(10): 1055; Author Reply 1056-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12361455&dopt=Abstract
•
Corticosteroid treatment of eosinophilic meningitis. Author(s): Chotmongkol V, Sawanyawisuth K, Thavornpitak Y. Source: Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America. 2000 September; 31(3): 660-2. Epub 2000 September 26. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11017811&dopt=Abstract
•
Corticosteroids for everyone with meningitis? Author(s): Tunkel AR, Scheld WM. Source: The New England Journal of Medicine. 2002 November 14; 347(20): 1613-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12432049&dopt=Abstract
•
Corticosteroids in acute bacterial meningitis. Author(s): van de Beek D, de Gans J, McIntyre P, Prasad K. Source: Cochrane Database Syst Rev. 2003; (3): Cd004305. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12918010&dopt=Abstract
•
Cranial CT before lumbar puncture in suspected meningitis. Author(s): Segal S. Source: The New England Journal of Medicine. 2002 April 18; 346(16): 1248-51; Author Reply 1248-51. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11963944&dopt=Abstract
112 Meningitis
•
Cranial CT before lumbar puncture in suspected meningitis. Author(s): Kastenbauer S, Winkler F, Pfister HW. Source: The New England Journal of Medicine. 2002 April 18; 346(16): 1248-51; Author Reply 1248-51. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11961158&dopt=Abstract
•
Cranial CT before lumbar puncture in suspected meningitis. Author(s): Tokuda Y, Nakazato N. Source: The New England Journal of Medicine. 2002 April 18; 346(16): 1248-51; Author Reply 1248-51. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11963943&dopt=Abstract
•
Cranial CT before lumbar puncture in suspected meningitis. Author(s): Tattevin P, Bruneel F, Regnier B. Source: The New England Journal of Medicine. 2002 April 18; 346(16): 1248-51; Author Reply 1248-51. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11963945&dopt=Abstract
•
Cranial CT before lumbar puncture in suspected meningitis. Author(s): Bruzzi JF, Brennan DD. Source: The New England Journal of Medicine. 2002 April 18; 346(16): 1248-51; Author Reply 1248-51. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11963942&dopt=Abstract
•
Cranial Doppler ultrasonography as a predictor of neurologic sequelae in infants with bacterial meningitis. Author(s): Okten A, Ahmetoglu A, Dilber E, Dinc H, Kalyoncu M, Ciftcibais K, Yaris N. Source: Investigative Radiology. 2002 February; 37(2): 86-90. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11799332&dopt=Abstract
•
C-reactive protein concentrations in cerebral spinal fluid in gram-positive and gramnegative bacterial meningitis. Author(s): Rajs G, Finzi-Yeheskel Z, Rajs A, Mayer M. Source: Clinical Chemistry. 2002 March; 48(3): 591-2. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11861461&dopt=Abstract
•
Cryptococcal lymphadenitis and meningitis in human immunodeficiency virus infection--a case report. Author(s): Das BP, Panda PL, Mallik RN, Das B. Source: Indian J Pathol Microbiol. 2002 July; 45(3): 349-51. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12785184&dopt=Abstract
Studies 113
•
Cryptococcal meningitis and sarcoidosis. Author(s): Ross JJ, Katz JD. Source: Scandinavian Journal of Infectious Diseases. 2002; 34(12): 937-9. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12587633&dopt=Abstract
•
Cryptococcal meningitis caused by Cryptococcus neoformans var. gattii, serotype C, in AIDS patients in Soweto, South Africa. Author(s): Karstaedt AS, Crewe-Brown HH, Dromer F. Source: Medical Mycology : Official Publication of the International Society for Human and Animal Mycology. 2002 February; 40(1): 7-11. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11860015&dopt=Abstract
•
Cryptococcal meningitis during front-line chemotherapy for acute lymphoblastic leukemia. Author(s): Urbini B, Castellini C, Rondelli R, Prete A, Pierinelli S, Pession A. Source: Haematologica. 2000 October; 85(10): 1103-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11025610&dopt=Abstract
•
Cryptococcal meningitis following autologous stem cell transplantation in a patient with multiple myeloma. Author(s): Mendpara SD, Ustun C, Kallab AM, Mazzella FM, Bilodeau PA, Jillella AP. Source: Bone Marrow Transplantation. 2002 August; 30(4): 259-60. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12203144&dopt=Abstract
•
Cryptococcal meningitis in a child with acute lymphoblastic leukemia. Author(s): Mavinkurve-Groothuis AM, Bokkerink JP, Verweij PE, Veerman AJ, Hoogerbrugge PM. Source: The Pediatric Infectious Disease Journal. 2003 June; 22(6): 576. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12799518&dopt=Abstract
•
Cryptococcal meningitis in a neonate. Author(s): Kaur R, Mittal N, Rawat D, Mathur MD. Source: Scandinavian Journal of Infectious Diseases. 2002; 34(7): 542-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12195885&dopt=Abstract
•
Cryptococcal meningitis in a patient with systemic immunosuppression 13 years after liver transplantation. Author(s): Hermann W, Gunther P, Berrouschot J, Kuhn HJ, Wagner A. Source: Intensive Care Medicine. 2002 October; 28(10): 1500. Epub 2002 August 17. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12373479&dopt=Abstract
114 Meningitis
•
Cryptococcal meningitis in pediatric AIDS. Author(s): Kaur R, Rawat D, Kakkar M, Monga R, Sharma VK. Source: Journal of Tropical Pediatrics. 2003 April; 49(2): 124-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12729297&dopt=Abstract
•
Cryptococcal meningitis in pediatric systemic lupus erythematosus. Author(s): Liou J, Chiu C, Tseng C, Chi C, Fu L. Source: Mycoses. 2003 April; 46(3-4): 153-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12870207&dopt=Abstract
•
Cryptococcal meningitis: an analysis among 5,521 consecutive organ transplant recipients. Author(s): Wu G, Vilchez RA, Eidelman B, Fung J, Kormos R, Kusne S. Source: Transplant Infectious Disease : an Official Journal of the Transplantation Society. 2002 December; 4(4): 183-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12535260&dopt=Abstract
•
Cryptococcal meningitis: implications for the otologist. Author(s): Low WK. Source: Orl; Journal for Oto-Rhino-Laryngology and Its Related Specialties. 2002 January-February; 64(1): 35-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11891396&dopt=Abstract
•
Cryptococcus neoformans causing meningitis in AIDS patients. Author(s): Menezes EA, Monteiro MN, Angelo MR, Santos CD, Freire CC, Cunha FA. Source: Revista Da Sociedade Brasileira De Medicina Tropical. 2002 September-October; 35(5): 537-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12621679&dopt=Abstract
•
Cryptococcus neoformans var. gattii meningitis in Singapore. Author(s): Koh TH, Tan AL, Lo YL, Oh H. Source: Medical Mycology : Official Publication of the International Society for Human and Animal Mycology. 2002 April; 40(2): 221-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12058737&dopt=Abstract
•
Current concepts in the pathogenesis of meningitis caused by Streptococcus pneumoniae. Author(s): Meli DN, Christen S, Leib SL, Tauber MG. Source: Current Opinion in Infectious Diseases. 2002 June; 15(3): 253-7. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12015459&dopt=Abstract
Studies 115
•
Current options for the treatment of neoplastic meningitis. Author(s): Cokgor I, Friedman AH, Friedman HS. Source: Journal of Neuro-Oncology. 2002 October; 60(1): 79-88. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12416549&dopt=Abstract
•
Current pharmacotherapy of pneumococcal meningitis. Author(s): Aronin SI. Source: Expert Opinion on Pharmacotherapy. 2002 February; 3(2): 121-9. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11829726&dopt=Abstract
•
Current treatment approaches for neoplastic meningitis: nursing management of patients receiving intrathecal DepoCyt. Author(s): Craig C. Source: Oncology Nursing Forum. 2000 September; 27(8): 1225-30; Quiz 1231-2. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11013903&dopt=Abstract
•
Cytokine profiles in HIV seropositive patients with tuberculous meningitis. Author(s): Patel VB, Bhigjee AI, Bill PL, Connolly CA. Source: Journal of Neurology, Neurosurgery, and Psychiatry. 2002 November; 73(5): 598-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12397163&dopt=Abstract
•
D- and L-lactate in rabbit and human bacterial meningitis. Author(s): Wellmer A, Prange J, Gerber J, Zysk G, Lange P, Michel U, Eiffert H, Nau R. Source: Scandinavian Journal of Infectious Diseases. 2001; 33(12): 909-13. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11868764&dopt=Abstract
•
Decreased susceptibility to extended-spectrum cephalosporins of a penicillinsusceptible Streptococcus pneumoniae in meningitis. Author(s): De Champs C, Constantin JM, Bonnet R, Guelon D, Goldstein F, Sirot J. Source: Infection. 2000 January-February; 28(1): 58-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10697797&dopt=Abstract
•
Delayed diagnosis of meningitis caused by beta-haemolytic group G. Streptococcus in an older woman. Author(s): Luyx C, Vanpee D, Glupczynski Y, Swine C, Gillet JB. Source: The Journal of Emergency Medicine. 2001 November; 21(4): 393-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11728766&dopt=Abstract
116 Meningitis
•
Dependency of cerebral blood flow on mean arterial pressure in patients with acute bacterial meningitis. Author(s): Moller K, Larsen FS, Qvist J, Wandall JH, Knudsen GM, Gjorup IE, Skinhoj P. Source: Critical Care Medicine. 2000 April; 28(4): 1027-32. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10809277&dopt=Abstract
•
Dermal sinus presenting as group B streptococcal meningitis. Author(s): Reimer CM, Sharma G, Grelinger BA. Source: Archives of Neurology. 2001 May; 58(5): 820-1. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11346379&dopt=Abstract
•
Designing meningitis vaccines. Author(s): Buttery JP, Moxon ER. Source: Journal of the Royal College of Physicians of London. 2000 March-April; 34(2): 163-8. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10816873&dopt=Abstract
•
Detection of antibody to Mycobacterium tuberculosis protein antigens in the cerebrospinal fluid of patients with tuberculous meningitis. Author(s): Chandramuki A, Lyashchenko K, Kumari HB, Khanna N, Brusasca P, Gourie-Devi M, Satishchandra P, Shankar SK, Ravi V, Alcabes P, Kanaujia GV, Gennaro ML. Source: The Journal of Infectious Diseases. 2002 September 1; 186(5): 678-83. Epub 2002 August 05. Erratum In: J Infect Dis. 2003 January 1; 187(1): 163. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12195355&dopt=Abstract
•
Detection of Neisseria meningitidis in cerebrospinal fluid samples from suspicious cases of meningococcal meningitis using polymerase chain reaction and counterimmunoelectrophoresis. Author(s): De Gaspari EN. Source: Rev Argent Microbiol. 2000 April-June; 32(2): 97-103. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10885010&dopt=Abstract
•
Development and evaluation of a broad-range PCR-ELISA assay with Borrelia burgdorferi and Streptococcus pneumoniae as model organisms for reactive arthritis and bacterial meningitis. Author(s): Fischer-Romero C, Luthy-Hottenstein J, Altwegg M. Source: Journal of Microbiological Methods. 2000 March; 40(1): 79-88. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10739346&dopt=Abstract
Studies 117
•
Development and validation of a multivariable predictive model to distinguish bacterial from aseptic meningitis in children in the post-Haemophilus influenzae era. Author(s): Nigrovic LE, Kuppermann N, Malley R. Source: Pediatrics. 2002 October; 110(4): 712-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12359784&dopt=Abstract
•
Dexamethasone in acute bacterial meningitis. Author(s): Principi N, Esposito S. Source: Lancet. 2002 November 16; 360(9345): 1610; Author Reply 1610-1. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12443642&dopt=Abstract
•
Dexamethasone in acute bacterial meningitis. Author(s): Obaro SK. Source: Lancet. 2002 November 16; 360(9345): 1609-10; Author Reply 1610-1. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12443641&dopt=Abstract
•
Dexamethasone in adults with bacterial meningitis. Author(s): Tancredi DN, Binder WD. Source: The New England Journal of Medicine. 2003 March 6; 348(10): 954-7; Author Reply 954-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12622125&dopt=Abstract
•
Dexamethasone in adults with bacterial meningitis. Author(s): Tabas JA, Chambers HF. Source: The New England Journal of Medicine. 2003 March 6; 348(10): 954-7; Author Reply 954-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12621141&dopt=Abstract
•
Dexamethasone in adults with bacterial meningitis. Author(s): Joffe AR. Source: The New England Journal of Medicine. 2003 March 6; 348(10): 954-7; Author Reply 954-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12622128&dopt=Abstract
•
Dexamethasone in adults with bacterial meningitis. Author(s): Abril V, Ortega E. Source: The New England Journal of Medicine. 2003 March 6; 348(10): 954-7; Author Reply 954-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12622126&dopt=Abstract
118 Meningitis
•
Dexamethasone in adults with bacterial meningitis. Author(s): Poshkus M, Obaro S. Source: The New England Journal of Medicine. 2003 March 6; 348(10): 954-7; Author Reply 954-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12622127&dopt=Abstract
•
Dexamethasone in adults with bacterial meningitis. Author(s): de Gans J, van de Beek D; European Dexamethasone in Adulthood Bacterial Meningitis Study Investigators. Source: The New England Journal of Medicine. 2002 November 14; 347(20): 1549-56. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12432041&dopt=Abstract
•
Dexamethasone therapy for bacterial meningitis in adults: a double blind placebo control study. Author(s): Gijwani D, Kumhar MR, Singh VB, Chadda VS, Soni PK, Nayak KC, Gupta BK. Source: Neurology India. 2002 March; 50(1): 63-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11960154&dopt=Abstract
•
Dexamethasone treatment in childhood bacterial meningitis in Malawi: a randomised controlled trial. Author(s): Molyneux EM, Walsh AL, Forsyth H, Tembo M, Mwenechanya J, Kayira K, Bwanaisa L, Njobvu A, Rogerson S, Malenga G. Source: Lancet. 2002 July 20; 360(9328): 211-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12133656&dopt=Abstract
•
Dexamethasone use in adult meningococcal meningitis. Author(s): Hui L, Tokeshi J. Source: Hawaii Med J. 2000 July; 59(7): 308-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10961042&dopt=Abstract
•
Diabetes insipidus as a complication of cryptococcal meningitis in an HIV-infected patient. Author(s): Juffermans NP, Verbon A, Van der Poll T. Source: Scandinavian Journal of Infectious Diseases. 2002; 34(5): 397-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12069031&dopt=Abstract
•
Diabetes insipidus due to Streptococcus pneumoniae meningitis. Author(s): Franco-Paredes C, Evans J, Jurado R. Source: Archives of Internal Medicine. 2001 April 23; 161(8): 1114-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11322848&dopt=Abstract
Studies 119
•
Diagnosing and prognosticating acute meningitis in young infants within 24 hours of admission. Author(s): See KC, Tay SK, Low PS. Source: Ann Acad Med Singapore. 2001 September; 30(5): 503-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11603134&dopt=Abstract
•
Diagnosing bacterial meningitis after the Haemophilus influenzae vaccine: still a challenge. Author(s): Frohna JG, Park SM, Gopal S. Source: Archives of Pediatrics & Adolescent Medicine. 2001 December; 155(12): 1307-10. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11732948&dopt=Abstract
•
Diagnosing postneurosurgical meningitis. Author(s): Johnson JR. Source: Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America. 2000 May; 30(5): 836-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10816158&dopt=Abstract
•
Diagnosis and management of increased intracranial pressure in patients with AIDS and cryptococcal meningitis. The NIAID Mycoses Study Group and AIDS Cooperative Treatment Groups. Author(s): Graybill JR, Sobel J, Saag M, van Der Horst C, Powderly W, Cloud G, Riser L, Hamill R, Dismukes W. Source: Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America. 2000 January; 30(1): 47-54. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10619732&dopt=Abstract
•
Diagnosis and outcome of acute bacterial meningitis in early childhood. Author(s): Chinchankar N, Mane M, Bhave S, Bapat S, Bavdekar A, Pandit A, Niphadkar KB, Dutta A, Leboulleux D. Source: Indian Pediatrics. 2002 October; 39(10): 914-21. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12428036&dopt=Abstract
•
Diagnosis and treatment of bacterial meningitis. Author(s): El Bashir H, Laundy M, Booy R. Source: Archives of Disease in Childhood. 2003 July; 88(7): 615-20. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12818910&dopt=Abstract
120 Meningitis
•
Diagnosis of acute bacterial meningitis in children at a district hospital in subSaharan Africa. Author(s): Berkley JA, Mwangi I, Ngetsa CJ, Mwarumba S, Lowe BS, Marsh K, Newton CR. Source: Lancet. 2001 June 2; 357(9270): 1753-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11403812&dopt=Abstract
•
Diagnosis of adult tuberculous meningitis by use of clinical and laboratory features. Author(s): Thwaites GE, Chau TT, Stepniewska K, Phu NH, Chuong LV, Sinh DX, White NJ, Parry CM, Farrar JJ. Source: Lancet. 2002 October 26; 360(9342): 1287-92. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12414204&dopt=Abstract
•
Diagnosis of bacterial meningitis. Author(s): Enwere G, Obaro S. Source: Lancet. 2001 November 3; 358(9292): 1549-50. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11705597&dopt=Abstract
•
Diagnostic criteria for Tuberculous Meningitis. Author(s): Seth R, Sharma U. Source: Indian J Pediatr. 2002 April; 69(4): 299-303. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12019549&dopt=Abstract
•
Diagnostic performance of amplified Mycobacterium Tuberculosis direct test in the cerebrospinal fluid of children with tuberculosis meningitis. Author(s): Yaramis A. Source: Pediatrics. 2000 July; 106(1 Pt 1): 162. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10939912&dopt=Abstract
•
Diagnostic utility of cerebrospinal fluid studies in patients with clinically suspected tuberculous meningitis. Author(s): Hooker JA, Muhindi DW, Amayo EO, Mc'ligeyo SO, Bhatt KM, Odhiambo JA. Source: The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union against Tuberculosis and Lung Disease. 2003 August; 7(8): 787-96. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12921156&dopt=Abstract
Studies 121
•
Diagnostic value of cytokine assays in cerebrospinal fluid in culture-negative, polymerase chain reaction-positive bacterial meningitis. Author(s): Lorino G, Angeletti S, Gherardi G, De Cesaris M, Gherardi L, Battistoni F, Filadoro F, Dicuonzo G. Source: European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology. 2000 May; 19(5): 388-92. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10898144&dopt=Abstract
•
Differences in laboratory findings for cerebrospinal fluid specimens obtained from patients with meningitis or encephalitis due to herpes simplex virus (HSV) documented by detection of HSV DNA. Author(s): Simko JP, Caliendo AM, Hogle K, Versalovic J. Source: Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America. 2002 August 15; 35(4): 414-9. Epub 2002 July 17. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12145725&dopt=Abstract
•
Diffuse meningeal involvement in tubercular meningitis. Author(s): Roy J, Paul S, Mitra S, Gangopadhyay PK. Source: Neurology India. 2001 June; 49(2): 216. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11447455&dopt=Abstract
•
Diplopia in a patient with carcinomatous meningitis: a case report and review of the literature. Author(s): Chang AK. Source: The Journal of Emergency Medicine. 2002 November; 23(4): 351-4. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12480013&dopt=Abstract
•
Discontinuation of secondary prophylaxis for cryptococcal meningitis in HIVinfected patients responding to highly active antiretroviral therapy. Author(s): Martinez E, Garcia-Viejo MA, Marcos MA, Perez-Cuevas JB, Blanco JL, Mallolas J, Miro JM, Gatell JM. Source: Aids (London, England). 2000 November 10; 14(16): 2615-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11101078&dopt=Abstract
•
Discontinuation of secondary prophylaxis for cryptococcal meningitis in human immunodeficiency virus-infected patients treated with highly active antiretroviral therapy: a prospective, multicenter, randomized study. Author(s): Vibhagool A, Sungkanuparph S, Mootsikapun P, Chetchotisakd P, Tansuphaswaswadikul S, Bowonwatanuwong C, Ingsathit A. Source: Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America. 2003 May 15; 36(10): 1329-31. Epub 2003 May 02. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12746781&dopt=Abstract
122 Meningitis
•
Discrepancies between brain CT imaging and severely raised intracranial pressure proven by ventriculostomy in adults with pneumococcal meningitis. Author(s): Winkler F, Kastenbauer S, Yousry TA, Maerz U, Pfister HW. Source: Journal of Neurology. 2002 September; 249(9): 1292-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12242556&dopt=Abstract
•
Disseminated gonococcal infection and meningitis. Author(s): Mofredj A, Baraka D, Madec Y, Lemaitre P. Source: The American Journal of Medicine. 2000 July; 109(1): 71-2. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10991742&dopt=Abstract
•
Distinguishing between chemical and bacterial meningitis in patients who have undergone neurosurgery. Author(s): Brown EM, de Louvois J, Bayston R, Lees PD, Pople IK; British Society for Antimicrobial Chemotherapy Working Party on Neurosurgical Infections. Source: Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America. 2002 February 15; 34(4): 556-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11797188&dopt=Abstract
•
Does dexamethasone affect ceftriazone penetration into cerebrospinal fluid in adult bacterial meningitis. Author(s): Buke AC, Cavusoglu C, Karasulu E, Karakartal G. Source: International Journal of Antimicrobial Agents. 2003 May; 21(5): 452-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12727079&dopt=Abstract
•
Double blind placebo-controlled trial of pleconaril in infants with enterovirus meningitis. Author(s): Abzug MJ, Cloud G, Bradley J, Sanchez PJ, Romero J, Powell D, Lepow M, Mani C, Capparelli EV, Blount S, Lakeman F, Whitley RJ, Kimberlin DW; National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. Source: The Pediatric Infectious Disease Journal. 2003 April; 22(4): 335-41. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12690273&dopt=Abstract
•
Drug companies asked to deliver on a low-cost meningitis vaccine. Author(s): Ahmad K. Source: The Lancet Infectious Diseases. 2002 November; 2(11): 650. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12409033&dopt=Abstract
•
Drug-induced aseptic meningitis. Author(s): Nettis E, Calogiuri G, Colanardi MC, Ferrannini A, Tursi A. Source: Current Drug Targets. Immune, Endocrine and Metabolic Disorders. 2003 June; 3(2): 143-9. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12769786&dopt=Abstract
Studies 123
•
Drug-induced aseptic meningitis: diagnosis and management. Author(s): Jolles S, Sewell WA, Leighton C. Source: Drug Safety : an International Journal of Medical Toxicology and Drug Experience. 2000 March; 22(3): 215-26. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10738845&dopt=Abstract
•
Duodenal ulcer perforation in a twenty-month-old: an unusual complication of Haemophilus influenzae type B meningitis. Author(s): Sykora J, Jana T, Renata P, Frantisek S, Vladimir S, Jana V, Petr H. Source: Journal of Pediatric Gastroenterology and Nutrition. 2002 September; 35(3): 3668. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12352530&dopt=Abstract
•
Duration of echovirus 30 excretion in stools from patients with aseptic meningitis. Author(s): Takao S, Komazawa Y, Fukuda S, Shimazu Y, Noda M, Tokumoto S. Source: Japanese Journal of Infectious Diseases. 2000 June; 53(3): 132-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10957714&dopt=Abstract
•
Dutch consider following UK on vaccines after meningitis scare. Author(s): Sheldon T. Source: Bmj (Clinical Research Ed.). 2001 September 1; 323(7311): 470. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11532831&dopt=Abstract
•
E. coli invasion of brain microvascular endothelial cells as a pathogenetic basis of meningitis. Author(s): Kim KS. Source: Subcell Biochem. 2000; 33: 47-59. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10804851&dopt=Abstract
•
Early management of suspected bacterial meningitis and meningococcal septicaemia in adults. Author(s): Heyderman RS, Lambert HP, O'Sullivan I, Stuart JM, Taylor BL, Wall RA. Source: The Journal of Infection. 2003 February; 46(2): 75-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12634067&dopt=Abstract
•
Early prediction of neurological sequelae or death after bacterial meningitis. Author(s): Oostenbrink R, Moons KG, Derksen-Lubsen G, Grobbee DE, Moll HA. Source: Acta Paediatrica (Oslo, Norway : 1992). 2002; 91(4): 391-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12061353&dopt=Abstract
124 Meningitis
•
Echovirus 30 meningitis: a new cause for cerebral venous thrombosis? Author(s): Rabaud Ch, Ghiringelli CB, Dauendorffer JN, May T. Source: The Journal of Infection. 2002 January; 44(1): 53. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11972424&dopt=Abstract
•
Echovirus 30 outbreak of aseptic meningitis in Turkey. Author(s): Uysal G, Ozkaya E, Guven A. Source: The Pediatric Infectious Disease Journal. 2000 May; 19(5): 490. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10819358&dopt=Abstract
•
Efavirenz-based regimen as treatment of advanced AIDS with cryptococcal meningitis. Author(s): Sungkanuparph S, Vibhagool A, Mootsikapun P, Chetchotisakd P, Tansuphaswaswadikul S, Bowonwatanuwong C, Chantratita W. Source: Journal of Acquired Immune Deficiency Syndromes (1999). 2003 May 1; 33(1): 118-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12792366&dopt=Abstract
•
Effect of methyl prednisolone on sensory motor functions in tuberculous meningitis. Author(s): Kalita J, Misra UK. Source: Neurology India. 2001 September; 49(3): 267-71. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11593244&dopt=Abstract
•
Effect of short-term hyperventilation on cerebral blood flow autoregulation in patients with acute bacterial meningitis. Author(s): Moller K, Skinhoj P, Knudsen GM, Larsen FS. Source: Stroke; a Journal of Cerebral Circulation. 2000 May; 31(5): 1116-22. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10797174&dopt=Abstract
•
Effectiveness of incidence thresholds for detection and control of meningococcal meningitis epidemics in northern Togo. Author(s): Kaninda AV, Belanger F, Lewis R, Batchassi E, Aplogan A, Yakoua Y, Paquet C. Source: International Journal of Epidemiology. 2000 October; 29(5): 933-40. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11034981&dopt=Abstract
•
Efficiency of cefepime in postoperative meningitis attributable to Enterobacter aerogenes. Author(s): Rousseau JM, Soullie B, Villevielle T, Koeck JL. Source: The Journal of Trauma. 2001 May; 50(5): 971. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11379596&dopt=Abstract
Studies 125
•
Electroencephalographic abnormalities in aseptic meningitis and noninfectious headache. A comparative study. Author(s): Pollak L, Klein C, Schiffer J, Flechter S, Rabey J. Source: Headache. 2001 January; 41(1): 79-83. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11168607&dopt=Abstract
•
Elevated cerebrospinal fluid levels of glutamate in children with bacterial meningitis as a predictor of the development of seizures or other adverse outcomes. Author(s): Ma W, Shang-Feaster G, Okada PJ, Kernie SG. Source: Pediatric Critical Care Medicine : a Journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies. 2003 April; 4(2): 170-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12749647&dopt=Abstract
•
Eleven-month-old with recurrent bacterial and aseptic meningitis. Author(s): Slavin KA, Kohl S. Source: The Pediatric Infectious Disease Journal. 2000 February; 19(2): 175, 178-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10694015&dopt=Abstract
•
Emergency management of meningitis. Author(s): Charlton R. Source: Journal of the Royal Society of Medicine. 2000 August; 93(8): 450. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10983518&dopt=Abstract
•
Emergency management of meningitis. Author(s): Heyderman RS, Klein NJ. Source: Journal of the Royal Society of Medicine. 2000 May; 93(5): 225-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10884763&dopt=Abstract
•
Emergency vaccination against epidemic meningitis in Ghana: implications for the control of meningococcal disease in West Africa. Author(s): Woods CW, Armstrong G, Sackey SO, Tetteh C, Bugri S, Perkins BA, Rosenstein NE. Source: Lancet. 2000 January 1; 355(9197): 30-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10615888&dopt=Abstract
•
Empirical treatment of adult postsurgical nosocomial meningitis. Author(s): De Bels D, Korinek AM, Bismuth R, Trystram D, Coriat P, Puybasset L. Source: Acta Neurochirurgica. 2002 October; 144(10): 989-95. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12382127&dopt=Abstract
126 Meningitis
•
Employment of broad-range 16S rRNA PCR to detect aetiological agents of infection from clinical specimens in patients with acute meningitis--rapid separation of 16S rRNA PCR amplicons without the need for cloning. Author(s): Xu J, Millar BC, Moore JE, Murphy K, Webb H, Fox AJ, Cafferkey M, Crowe MJ. Source: Journal of Applied Microbiology. 2003; 94(2): 197-206. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12534811&dopt=Abstract
•
Encephalitis without meningitis due to sandfly fever virus serotype toscana. Author(s): Dionisio D, Valassina M, Ciufolini MG, Vivarelli A, Esperti F, Cusi MG, Marchi A, Mazzoli F, Lupi C. Source: Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America. 2001 April 15; 32(8): 1241-3. Epub 2001 March 27. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11283818&dopt=Abstract
•
Endoscopic lamina terminalis fenestration for treatment of hydrocephalus due to tuberculous meningitis. Case illustration. Author(s): Nakao N, Itakura T. Source: Journal of Neurosurgery. 2003 July; 99(1): 187. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12854766&dopt=Abstract
•
Endoscopic third ventriculostomy in tuberculous meningitis. Author(s): Figaji AA, Fieggen AG, Peter JC. Source: Child's Nervous System : Chns : Official Journal of the International Society for Pediatric Neurosurgery. 2003 April; 19(4): 217-25. Epub 2003 April 05. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12682756&dopt=Abstract
•
Endoscopic third ventriculostomy in tuberculous meningitis. Author(s): Siomin V, Constantini S. Source: Child's Nervous System : Chns : Official Journal of the International Society for Pediatric Neurosurgery. 2003 June; 19(5-6): 269. Epub 2003 May 28. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12774170&dopt=Abstract
•
Enterococcal meningitis in an infant complicating congenital cutis aplasia. Author(s): Suara RO, Dermody TS. Source: The Pediatric Infectious Disease Journal. 2000 July; 19(7): 668-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10917233&dopt=Abstract
•
Enterococcal nosocomial meningitis in children. Author(s): Krcmery V Jr, Filka J, Krupova Y, Mateicka F. Source: Journal of Chemotherapy (Florence, Italy). 2000 February; 12(1): 109-11. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10768523&dopt=Abstract
Studies 127
•
Enterococcus faecalis meningitis after spinal anesthesia. Author(s): Tortosa JA, Hernandez-Palazon J. Source: Anesthesiology. 2000 March; 92(3): 909. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10719988&dopt=Abstract
•
Enterococcus faecalis: an unusual cause of meningitis in HIV-infected patients. Author(s): Sharma A, Mong MS, Minamoto G. Source: Aids Read. 2002 December; 12(12): 540-2. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12521008&dopt=Abstract
•
Enteroviral meningitis in Northern Jordan: prevalence and association with clinical findings. Author(s): Meqdam MM, Khalousi MM, Al-Shurman A. Source: Journal of Medical Virology. 2002 February; 66(2): 224-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11782931&dopt=Abstract
•
Enteroviral meningitis with a petechial rash in three children. Author(s): Sukhai RN, Munneke R. Source: European Journal of Pediatrics. 2002 April; 161(4): 226-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12014394&dopt=Abstract
•
Enteroviral meningitis. Cost of illness and considerations for the economic evaluation of potential therapies. Author(s): Parasuraman TV, Frenia K, Romero J. Source: Pharmacoeconomics. 2001 January; 19(1): 3-12. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11252544&dopt=Abstract
•
Enterovirus meningitis in adults in 1999-2000 and evaluation of clinical management. Author(s): Peigue-Lafeuille H, Croquez N, Laurichesse H, Clavelou P, Aumaitre O, Schmidt J, Maillet-Vioud M, Henquell C, Archimbaud C, Bailly JL, Chambon M. Source: Journal of Medical Virology. 2002 May; 67(1): 47-53. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11920817&dopt=Abstract
•
Enzootic Angiostrongylus cantonensis in rats and snails after an outbreak of human eosinophilic meningitis, Jamaica. Author(s): Lindo JF, Waugh C, Hall J, Cunningham-Myrie C, Ashley D, Eberhard ML, Sullivan JJ, Bishop HS, Robinson DG, Holtz T, Robinson RD. Source: Emerging Infectious Diseases. 2002 March; 8(3): 324-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11927033&dopt=Abstract
128 Meningitis
•
Eosinophilic meningitis caused by Angiostrongylus cantonensis associated with eating raw snails: correlation of brain magnetic resonance imaging scans with clinical findings. Author(s): Tsai HC, Liu YC, Kunin CM, Lai PH, Lee SS, Chen YS, Wann SR, Lin WR, Huang CK, Ger LP, Lin HH, Yen MY. Source: Am J Trop Med Hyg. 2003 March; 68(3): 281-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12685630&dopt=Abstract
•
Eosinophilic meningitis caused by Angiostrongylus cantonensis: report of 17 cases. Author(s): Tsai HC, Liu YC, Kunin CM, Lee SS, Chen YS, Lin HH, Tsai TH, Lin WR, Huang CK, Yen MY, Yen CM. Source: The American Journal of Medicine. 2001 August; 111(2): 109-14. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11498063&dopt=Abstract
•
Eosinophilic meningitis due to Angiostrongylus cantonensis in a returned traveler: case report and review of the literature. Author(s): Lo Re V 3rd, Gluckman SJ. Source: Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America. 2001 November 1; 33(9): E112-5. Epub 2001 September 24. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11568860&dopt=Abstract
•
Eosinophilic meningitis due to Angiostrongylus cantonensis. Author(s): Ellis-Pegler R, Parry G. Source: Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America. 2002 September 15; 35(6): 777-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12203184&dopt=Abstract
•
Eosinophilic meningitis due to Gnathostoma spinigerum. Author(s): Lo Re V 3rd, Gluckman SJ. Source: The Journal of Infection. 2002 August; 45(2): 117-20. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12217718&dopt=Abstract
•
Eosinophilic meningitis in a neonate. Author(s): Hewett FA 2nd, Hendley JO. Source: Clinical Pediatrics. 2002 May; 41(4): 269-71. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12043718&dopt=Abstract
•
Eosinophilic meningitis. Author(s): Lo Re V 3rd, Gluckman SJ. Source: The American Journal of Medicine. 2003 February 15; 114(3): 217-23. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12637136&dopt=Abstract
Studies 129
•
Epidemic typhus meningitis in the southwestern United States. Author(s): Massung RF, Davis LE, Slater K, McKechnie DB, Puerzer M. Source: Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America. 2001 March 15; 32(6): 979-82. Epub 2001 Mar 09. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11247722&dopt=Abstract
•
Epidemiology and diagnosis of meningitis: results of a five-year prospective, population-based study. Author(s): Jolly K, Stewart G. Source: Commun Dis Public Health. 2001 June; 4(2): 124-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11525000&dopt=Abstract
•
Epidemiology of bacterial meningitis among children in Brazil, 1997-1998. Author(s): Weiss DP, Coplan P, Guess H. Source: Revista De Saude Publica. 2001 June; 35(3): 249-55. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11486147&dopt=Abstract
•
Epidemiology of childhood bacterial meningitis in Poland. Incidence of bacterial meningitis with special reference to Haemophilus influenzae type b among children 0-59 months old in the former Kielce and Bydgoszcz districts in Poland in 1998-1999. Author(s): Zielinski A, Tomaszunas-Blaszczyk J, Kuklinska D. Source: European Journal of Epidemiology. 2001; 17(8): 779-82. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12086097&dopt=Abstract
•
Epidemiology of Haemophilus influenzae type b meningitis in Manila, Philippines, 1994 to 1996. Author(s): Limcangco MR, Salole EG, Armour CL. Source: The Pediatric Infectious Disease Journal. 2000 January; 19(1): 7-11. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10643843&dopt=Abstract
•
Epidemiology of meningitis and bacteraemia due to Streptococcus pneumoniae in The Netherlands. Author(s): Spanjaard L, van der Ende A, Rumke H, Dankert J, van Alphen L. Source: Acta Paediatr Suppl. 2000 December; 89(435): 22-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11194792&dopt=Abstract
•
Epidemiology of meningitis due to Haemophilus influenzae type b in children in Bulgaria: a prospective, population-based surveillance study. Author(s): Kojouharova M, Gatcheva N, Setchanova L, Robertson SE, Wenger JD. Source: Bulletin of the World Health Organization. 2002; 80(9): 690-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12378285&dopt=Abstract
130 Meningitis
•
Epidemiology of meningococcal meningitis in Angola, 1994-2000. Author(s): Gaspar M, Leite F, Brumana L, Felix B, Stella AA. Source: Epidemiology and Infection. 2001 December; 127(3): 421-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11811874&dopt=Abstract
•
Epidemiology of neonatal meningitis in Qatar. Author(s): El-Said MF, Bessisso MS, Janahi MA, Habob LH, El-Shafie SS. Source: Saudi Med J. 2002 July; 23(7): 789-92. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12174226&dopt=Abstract
•
Erythema migrans after ceftriaxone treatment of aseptic meningitis caused by Borrelia burgdorferi. Author(s): Jhaveri R, Cherry JD, Phillips S, Korb J. Source: The Pediatric Infectious Disease Journal. 2001 October; 20(10): 1010-2. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11642622&dopt=Abstract
•
Escherichia coli O18:K1:H7 isolates from patients with acute cystitis and neonatal meningitis exhibit common phylogenetic origins and virulence factor profiles. Author(s): Johnson JR, Delavari P, O'Bryan TT. Source: The Journal of Infectious Diseases. 2001 February 1; 183(3): 425-34. Epub 2000 December 20. Erratum In: J Infect Dis 2001 May 15; 183(10): 1546. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11133374&dopt=Abstract
•
Estimating incidence of bacterial meningitis with capture-recapture method, Lazio Region, Italy. Author(s): Faustini A, Fano V, Sangalli M, Ferro S, Celesti L, Contegiacomo P, Renzini V, Perucci CA. Source: European Journal of Epidemiology. 2000; 16(9): 843-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11297227&dopt=Abstract
•
Etiologic spectrum and pattern of antimicrobial drug susceptibility in bacterial meningitis in Sokoto, Nigeria. Author(s): Emele FE. Source: Acta Paediatrica (Oslo, Norway : 1992). 2000 August; 89(8): 942-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10976835&dopt=Abstract
•
Evaluation of an in-house-developed radioassay kit for antibody detection in cases of pulmonary tuberculosis and tuberculous meningitis. Author(s): Kameswaran M, Shetty K, Ray MK, Jaleel MA, Kadival GV. Source: Clinical and Diagnostic Laboratory Immunology. 2002 September; 9(5): 987-93. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12204948&dopt=Abstract
Studies 131
•
Evaluation of brainstem auditory evoked response audiometry findings in children with tuberculous meningitis at admission. Author(s): Topcu I, Cureoglu S, Yaramis A, Tekin M, Oktay F, Osma U, Meric F, Katar S. Source: Auris, Nasus, Larynx. 2002 January; 29(1): 11-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11772484&dopt=Abstract
•
Evaluation of enterovirus serological tests IgM-EIA and complement fixation in patients with meningitis, confirmed by detection of enteroviral RNA by RT-PCR in cerebrospinal fluid. Author(s): Terletskaia-Ladwig E, Metzger C, Schalasta G, Enders G. Source: Journal of Medical Virology. 2000 June; 61(2): 221-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10797378&dopt=Abstract
•
Evaluation of free radical status in CSF in childhood meningitis. Author(s): Ray G, Aneja S, Jain M, Batra S. Source: Annals of Tropical Paediatrics. 2000 June; 20(2): 115-20. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10945061&dopt=Abstract
•
Evaluation of PCR using TRC(4) and IS6110 primers in detection of tuberculous meningitis. Author(s): Narayanan S, Parandaman V, Narayanan PR, Venkatesan P, Girish C, Mahadevan S, Rajajee S. Source: Journal of Clinical Microbiology. 2001 May; 39(5): 2006-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11326036&dopt=Abstract
•
Evaluation of polymerase chain reaction (PCR) for diagnosing Haemophilus influenzae b meningitis. Author(s): Singhi SC, Mohankumar D, Singhi PD, Sapru S, Ganguly NK. Source: Annals of Tropical Paediatrics. 2002 December; 22(4): 347-53. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12530285&dopt=Abstract
•
Evaluation of surveillance thresholds for prediction of meningitis epidemics using ongoing surveillance data at the district level, in Niger. Author(s): de Chabalier F, Hassane A, Chippaux JP. Source: Trans R Soc Trop Med Hyg. 2000 May-June; 94(3): 251-2. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10974990&dopt=Abstract
•
Experimental meningitis in the rat: protection by uric acid at human physiological blood concentrations. Author(s): Kastenbauer S, Koedel U, Becker BF, Pfister HW. Source: European Journal of Pharmacology. 2001 August 10; 425(2): 149-52. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11502281&dopt=Abstract
132 Meningitis
•
Expression of death-related proteins in dentate granule cells in human bacterial meningitis. Author(s): Gerber J, Bruck W, Stadelmann C, Bunkowski S, Lassmann H, Nau R. Source: Brain Pathology (Zurich, Switzerland). 2001 October; 11(4): 422-31. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11556687&dopt=Abstract
•
Expression of matrix metalloproteinases, sICAM-1 and IL-8 in CSF from children with meningitis. Author(s): Shapiro S, Miller A, Lahat N, Sobel E, Lerner A. Source: Journal of the Neurological Sciences. 2003 January 15; 206(1): 43-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12480084&dopt=Abstract
•
Expression of vascular endothelial growth factor in tuberculous meningitis. Author(s): Matsuyama W, Hashiguchi T, Umehara F, Matsuura E, Kawabata M, Arimura K, Maruyama I, Osame M. Source: Journal of the Neurological Sciences. 2001 May 1; 186(1-2): 75-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11412875&dopt=Abstract
•
Failure of cefotaxime and meropenem to eradicate meningitis caused by an intermediately susceptible Streptococcus pneumoniae strain. Author(s): Vandecasteele SJ, Verhaegen J, Colaert J, Van Caster A, Devlieger H. Source: European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology. 2001 October; 20(10): 7512. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11757981&dopt=Abstract
•
Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid. Author(s): Maniu CV, Hellinger WC, Chu SY, Palmer R, Alvarez-Elcoro S. Source: Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America. 2001 September 1; 33(5): 745-8. Epub 2001 August 06. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11486298&dopt=Abstract
•
Failure To detect muramic acid in normal rat tissues but detection in cerebrospinal fluids from patients with Pneumococcal meningitis. Author(s): Kozar MP, Krahmer MT, Fox A, Gray BM. Source: Infection and Immunity. 2000 August; 68(8): 4688-98. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10899874&dopt=Abstract
Studies 133
•
False-positive pneumococcal antigen test in meningitis diagnosis. Author(s): Alonso-Tarres C, Cortes-Lletget C, Casanova T, Domenech A. Source: Lancet. 2001 October 13; 358(9289): 1273-4. Erratum In: Lancet 2002 July 27; 360(9329): 344. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11675095&dopt=Abstract
•
Familial outbreak of disseminated multidrug-resistant tuberculosis and meningitis. Author(s): Sofia M, Maniscalco M, Honore N, Molino A, Mormile M, Heym B, Cole ST. Source: The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union against Tuberculosis and Lung Disease. 2001 June; 5(6): 551-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11409583&dopt=Abstract
•
Fast duplex one-step RT-PCR for rapid differential diagnosis of entero- or toscana virus meningitis. Author(s): Valassina M, Valentini M, Valensin PE, Cusi MG. Source: Diagnostic Microbiology and Infectious Disease. 2002 July; 43(3): 201-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12106953&dopt=Abstract
•
Fatal meningitis and encephalitis due to Bartonella henselae bacteria. Author(s): Gerber JE, Johnson JE, Scott MA, Madhusudhan KT. Source: J Forensic Sci. 2002 May; 47(3): 640-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12051353&dopt=Abstract
•
Fatal septicemia and meningitis due to Morganella morganii in a patient with Hodgkin's disease. Author(s): Samonis G, Anatoliotaki M, Apostolakou H, Souglakos J, Georgoulias V. Source: Scandinavian Journal of Infectious Diseases. 2001; 33(7): 553-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11515771&dopt=Abstract
•
Fatal subarachnoid hemorrhage complicating actinomycotic meningitis. Author(s): Koda Y, Seto Y, Takeichi S, Kimura H. Source: Forensic Science International. 2003 July 8; 134(2-3): 169-71. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12850413&dopt=Abstract
•
Feculent meningitis: polymicrobial meningitis in colorectal surgery. Author(s): Garcia-Lechuz JM, Hernangomez S, San Juan R, Bouza E. Source: Diagnostic Microbiology and Infectious Disease. 2000 November; 38(3): 169-70. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11109015&dopt=Abstract
134 Meningitis
•
Fever interval before diagnosis, prior antibiotic treatment, and clinical outcome for young children with bacterial meningitis. Author(s): Bonsu BK, Harper MB. Source: Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America. 2001 February 15; 32(4): 566-72. Epub 2001 Feb 09. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11181119&dopt=Abstract
•
Findings in a patient with herpes simplex viral meningitis associated with acute retinal necrosis syndrome. Author(s): Tada Y, Negoro K, Morimatsu M, Makino H, Nishida T. Source: Ajnr. American Journal of Neuroradiology. 2001 August; 22(7): 1300-2. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11498417&dopt=Abstract
•
First epidemic of aseptic meningitis due to echovirus type 13 among Spanish children. Author(s): Trallero G, Casas I, Avellon A, Perez C, Tenorio A, De La Loma A. Source: Epidemiology and Infection. 2003 April; 130(2): 251-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12729193&dopt=Abstract
•
First epidemic of echovirus 16 meningitis in Cuba. Author(s): Sarmiento L, Mas P, Goyenechea A, Palomera R, Morier L, Capo V, Quintana I, Santin M. Source: Emerging Infectious Diseases. 2001 September-October; 7(5): 887-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11747705&dopt=Abstract
•
Fit genotypes and escape variants of subgroup III Neisseria meningitidis during three pandemics of epidemic meningitis. Author(s): Zhu P, van der Ende A, Falush D, Brieske N, Morelli G, Linz B, Popovic T, Schuurman IG, Adegbola RA, Zurth K, Gagneux S, Platonov AE, Riou JY, Caugant DA, Nicolas P, Achtman M. Source: Proceedings of the National Academy of Sciences of the United States of America. 2001 April 24; 98(9): 5234-9. Epub 2001 Apr 03. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11287631&dopt=Abstract
•
Flaccid quadriplegia from tonsillar herniation in pneumococcal meningitis. Author(s): Ropper AH, Kanis KB. Source: Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia. 2000 July; 7(4): 339-41. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10938617&dopt=Abstract
Studies 135
•
Fluconazole treatment of coccidioidal meningitis in children: two case reports and a review of the literature. Author(s): Saitoh A, Homans J, Kovacs A. Source: The Pediatric Infectious Disease Journal. 2000 December; 19(12): 1204-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11144385&dopt=Abstract
•
Fluconazole-resistant cryptococcal meningitis. Author(s): Momoff N, Parrish A. Source: South African Medical Journal. Suid-Afrikaanse Tydskrif Vir Geneeskunde. 2003 June; 93(6): 444. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12916384&dopt=Abstract
•
Fluid-attenuated inversion-recovery imaging of cerebral infarction associated with tuberculous meningitis. Author(s): Nogami K, Nomura S, Kashiwagi S, Kato S, Yamashita K, Ito H. Source: Computerized Medical Imaging and Graphics : the Official Journal of the Computerized Medical Imaging Society. 2000 September-October; 24(5): 333-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10940611&dopt=Abstract
•
Follistatin (FS) in human cerebrospinal fluid and regulation of FS expression in a mouse model of meningitis. Author(s): Michel U, Ebert S, Schneider O, Shintani Y, Bunkowski S, Smirnov A, Stringaris A, Gerber J, Bruck W, Nau R. Source: European Journal of Endocrinology / European Federation of Endocrine Societies. 2000 December; 143(6): 809-16. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11124865&dopt=Abstract
•
Frequent association with neurosurgical conditions in adult Proteus mirabilis meningitis: report of five cases. Author(s): Chang WN, Tsai YC, Chien CC, Huang CR, Lu CH. Source: Clinical Neurology and Neurosurgery. 2002 May; 104(2): 121-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11932041&dopt=Abstract
•
Frosted branch angitis associated with aseptic meningitis. Author(s): Johkura K, Hara A, Hattori T, Hasegawa O, Kuroiwa Y. Source: European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies. 2000 March; 7(2): 241. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10809950&dopt=Abstract
•
Fungal meningitis. Author(s): Gottfredsson M, Perfect JR. Source: Seminars in Neurology. 2000; 20(3): 307-22. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11051295&dopt=Abstract
136 Meningitis
•
Fusobacterium necrophorum: a rare cause of meningitis in children. Author(s): Voie H, Turid M, Wathne KO. Source: Scandinavian Journal of Infectious Diseases. 2002; 34(7): 543-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12195886&dopt=Abstract
•
Gastric linitis adenocarcinoma and carcinomatous meningitis: an infrequent but aggressive association--report of four cases. Author(s): Delaunoit T, Boige V, Belloc J, Elias D, Lasser P, Duvillard P, Ducreux M. Source: Annals of Oncology : Official Journal of the European Society for Medical Oncology / Esmo. 2001 June; 12(6): 869-71. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11484967&dopt=Abstract
•
Gemifloxacin is efficacious against penicillin-resistant and quinolone-resistant pneumococci in experimental meningitis. Author(s): Cottagnoud P, Acosta F, Cottagnoud M, Tauber MG. Source: Antimicrobial Agents and Chemotherapy. 2002 May; 46(5): 1607-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11959614&dopt=Abstract
•
Genetic diversity of echovirus 30 during a meningitis outbreak, demonstrated by direct molecular typing from cerebrospinal fluid. Author(s): Bailly JL, Brosson D, Archimbaud C, Chambon M, Henquell C, PeigueLafeuille H. Source: Journal of Medical Virology. 2002 December; 68(4): 558-67. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12376964&dopt=Abstract
•
Genetic predisposition and sensorineural hearing loss following bacterial meningitis: is there a link? Author(s): Jayarajan V, Patton MA, Rajenderkumar D. Source: The Journal of Infection. 2002 April; 44(3): 210. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12099760&dopt=Abstract
•
Gonococcal meningitis and intra-abdominal abscess in the presence of a ventriculoperitoneal shunt. Author(s): Lin MF, Lau YJ, Hu BS, Shi ZY, Lin YH. Source: Scandinavian Journal of Infectious Diseases. 2000; 32(5): 567-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11055670&dopt=Abstract
•
Gram negative meningitis resulting from rupture of a spinal epidural abscess into the subarachnoid space. Author(s): Lodhi S, Mozaffar T, Sarwari AR. Source: J Pak Med Assoc. 2000 November; 50(11): 393-4. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11126818&dopt=Abstract
Studies 137
•
Group a streptococcal meningitis in adults: report of 41 cases and a review of the literature. Author(s): van de Beek D, de Gans J, Spanjaard L, Sela S, Vermeulen M, Dankert J. Source: Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America. 2002 May 1; 34(9): E32-6. Epub 2002 April 04. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11941569&dopt=Abstract
•
Group A streptococcal meningitis with an infected BCG scar. Author(s): Melzer M, Joashi U, Murdoch I, Gransden W. Source: Journal of the Royal Society of Medicine. 2000 December; 93(12): 641. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11193065&dopt=Abstract
•
Group A streptococcal meningitis: report of a case and review of literature since 1976. Author(s): Shetty AK, Frankel LR, Maldonado Y, Falco DA, Lewis DB. Source: Pediatric Emergency Care. 2001 December; 17(6): 430-4. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11753187&dopt=Abstract
•
Group B streptococcal beta-hemolysin/cytolysin activates neutrophil signaling pathways in brain endothelium and contributes to development of meningitis. Author(s): Doran KS, Liu GY, Nizet V. Source: The Journal of Clinical Investigation. 2003 September; 112(5): 736-44. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12952922&dopt=Abstract
•
Group B streptococcal meningitis complicating elective abortion: report of 2 cases. Author(s): Deziel PJ, McGuire N, Brown PD. Source: Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America. 2000 November; 31(5): E23-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11073784&dopt=Abstract
•
Group B streptococcal meningitis in adults: recent increase in Southeast Asia. Author(s): Wilder-Smith E, Chow KM, Kay R, Ip M, Tee N. Source: Aust N Z J Med. 2000 August; 30(4): 462-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10985511&dopt=Abstract
•
Group B streptococcus meningitis in an HIV-positive adult: case report and review. Author(s): Guerin JM, Mofredj A, Leibinger F, Ekherian JM, Raskine L. Source: Scandinavian Journal of Infectious Diseases. 2000; 32(2): 215-7. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10826913&dopt=Abstract
138 Meningitis
•
Group C streptococcal meningitis in infancy. Author(s): Jenkins EL, McGuire W. Source: Acta Paediatrica (Oslo, Norway : 1992). 2000 September; 89(9): 1141-2. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11071100&dopt=Abstract
•
Group C streptococcal meningitis: case report and review of the literature. Author(s): Shah SS, Matthews RP, Cohen C. Source: The Pediatric Infectious Disease Journal. 2001 April; 20(4): 445-8. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11332674&dopt=Abstract
•
Group-A streptococcal meningitis in an adult, secondary to purulent otitis media. Author(s): Cohen-Kerem R, Lavon H. Source: The Journal of Laryngology and Otology. 2002 July; 116(7): 541-2. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12238676&dopt=Abstract
•
Guidelines for managing acute bacterial meningitis. Author(s): Moller K, Skinhoj P. Source: Bmj (Clinical Research Ed.). 2000 May 13; 320(7245): 1290. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10807603&dopt=Abstract
•
Haemophilus influenzae meningitis in Catalonia, Spain: epidemiology and bacteriologic characteristics. Author(s): Latorre C, Pineda V, Juncosa T, Munoz C, Dominguez A, Bou R, Fontanals D, Sanfeliu I, Pons I, Margall N, Sanchez F, Pericas R, Lobera E; H. influenzae invasive disease working group. Source: Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases. 2000 May; 6(5): 279-82. Erratum In: Clin Microbiol Infect 2000 October; 6(10): 573. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11168129&dopt=Abstract
•
Haemophilus influenzae type b meningitis in a fully immunized 2-year-old. Author(s): McCann WA, Frank MM, Cox F, Ownby DR. Source: Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology. 2002 June; 88(6): 551-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12086360&dopt=Abstract
•
Haemophilus influenzae type b meningitis with subdural effusion: a case report. Author(s): Chan PC, Lu CY, Lee PI, Yang TY, Chen RT, Ho YH, Yang SC, Lee CY, Huang L. Source: J Microbiol Immunol Infect. 2002 March; 35(1): 61-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11950123&dopt=Abstract
Studies 139
•
Haemophilus influenzae type b meningitis: how much better is prevention than cure? Author(s): Duke T. Source: P N G Med J. 2002 September-December; 45(3-4): 213-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12968792&dopt=Abstract
•
Haemophilus influenzae type b still remains a leading cause of meningitis among unvaccinated children--a prospective CSF analysis study. Author(s): Uduman SA, Adeyemi E, El-Khadir A, Jose K, Benedict S, Bener A. Source: Journal of Tropical Pediatrics. 2000 December; 46(6): 331-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11191142&dopt=Abstract
•
Hearing in children after meningococcal meningitis. Author(s): Drake R, Dravitski J, Voss L. Source: Journal of Paediatrics and Child Health. 2000 June; 36(3): 240-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10849224&dopt=Abstract
•
Hearing preservation mastoidectomy in otogenic meningitis secondary to an enlarged vestibular aqueduct. Case report. Author(s): Saliba I, Moukheiber A, Wanna G, Moukarzel N, Nehme A, Mansour S. Source: J Med Liban. 2000 September-October; 48(5): 327-32. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12489589&dopt=Abstract
•
Henoch-Schonlein purpura following meningitis C vaccination. Author(s): Courtney PA, Patterson RN, Lee RJ. Source: Rheumatology (Oxford, England). 2001 March; 40(3): 345-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11285387&dopt=Abstract
•
Hepatocyte growth factor levels in cerebrospinal fluid: a comparison between acute bacterial and nonbacterial meningitis. Author(s): Nayeri F, Nilsson I, Hagberg L, Brudin L, Roberg M, Soderstrom C, Forsberg P. Source: The Journal of Infectious Diseases. 2000 June; 181(6): 2092-4. Epub 2000 May 26. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10837201&dopt=Abstract
•
Herpes zoster and aseptic meningitis in a previously healthy child. Author(s): Szinnai G, Farron F, Bar G, Heininger U. Source: European Journal of Pediatrics. 2003 June; 162(6): 434-5. Epub 2003 April 08. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12684902&dopt=Abstract
140 Meningitis
•
Hospital-acquired meningitis in patients undergoing craniotomy: incidence, evolution, and risk factors. Author(s): Reichert MC, Medeiros EA, Ferraz FA. Source: American Journal of Infection Control. 2002 May; 30(3): 158-64. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11988710&dopt=Abstract
•
How college nurses managed the meningitis C campaign. Author(s): Halligan E. Source: Nurs Times. 2000 November 30-December 6; 96(48): 38-9. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11965995&dopt=Abstract
•
Human herpesvirus 7-associated meningitis and optic neuritis in a patient after allogeneic stem cell transplantation. Author(s): Yoshikawa T, Yoshida J, Hamaguchi M, Kubota T, Akimoto S, Ihira M, Nishiyama Y, Asano Y. Source: Journal of Medical Virology. 2003 July; 70(3): 440-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12767008&dopt=Abstract
•
Hydrocephalus in coccidioidal meningitis: case report and review of the literature. Author(s): Romeo JH, Rice LB, McQuarrie IG. Source: Neurosurgery. 2000 September; 47(3): 773-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10981768&dopt=Abstract
•
Hydrocephalus internus--first manifestation of chronic meningitis due to Listeria monocytogenes. Author(s): Grafe G, Handrik W, Geyer C. Source: European Journal of Pediatric Surgery : Official Journal of Austrian Association of Pediatric Surgery. [et Al] = Zeitschrift Fur Kinderchirurgie. 2001 December; 11 Suppl 1: S46-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11848049&dopt=Abstract
•
Hypothermia attenuates beta1 integrin expression on extravasated neutrophils in an animal model of meningitis. Author(s): Rowin ME, Xue V, Irazuzta J. Source: Inflammation. 2001 June; 25(3): 137-44. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11403204&dopt=Abstract
•
Iatrogenic meningitis: an increasing role for resistant viridans streptococci? Case report and review of the last 20 years. Author(s): Yaniv LG, Potasman I. Source: Scandinavian Journal of Infectious Diseases. 2000; 32(6): 693-6. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11200384&dopt=Abstract
Studies 141
•
Iatrogenic meningitis: the case for face masks. Author(s): Baer ET. Source: Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America. 2000 August; 31(2): 519-21. Epub 2000 August 28. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10987715&dopt=Abstract
•
Iatrogenic Streptococcus salivarius meningitis after spinal anaesthesia: need for strict application of standard precautions. Author(s): Couzigou C, Vuong TK, Botherel AH, Aggoune M, Astagneau P. Source: The Journal of Hospital Infection. 2003 April; 53(4): 313-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12660130&dopt=Abstract
•
ICD-10 mild cognitive disorder following meningitis due to neurosarcoidosis. Author(s): Pruter C, Kunert HJ, Hoff P. Source: Psychopathology. 2001 November-December; 34(6): 326-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11847493&dopt=Abstract
•
Identification of resource use and associated costs for viral meningitis. Author(s): Parasuraman TV, Deverka PA, Toscani MR. Source: Manag Care. 2000 January; 9(1): 41-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10977664&dopt=Abstract
•
Identification of viridans streptococcal species causing bacterial meningitis in adults in Taiwan. Author(s): Chang WN, Wu JJ, Huang CR, Tsai YC, Chien CC, Lu CH. Source: European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology. 2002 May; 21(5): 393-6. Epub 2002 May 07. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12072926&dopt=Abstract
•
IL-6 may be the key mediator in trimethoprim-induced systemic adverse reaction and aseptic meningitis: a reply to Muller et al. Author(s): Antonen JA, Saha HH, Hurme M, Pasternack AI. Source: Clinical Nephrology. 2001 June; 55(6): 489-90. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11434363&dopt=Abstract
•
Images in clinical medicine. Neoplastic meningitis. Author(s): Grossman SA, Celano P. Source: The New England Journal of Medicine. 2001 February 15; 344(7): 494. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11172191&dopt=Abstract
142 Meningitis
•
Imaging of cranial meningitis and ventriculitis. Author(s): Kanamalla US, Ibarra RA, Jinkins JR. Source: Neuroimaging Clin N Am. 2000 May; 10(2): 309-31. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10775954&dopt=Abstract
•
Immunisation. School nurses burnt out by meningitis C campaign. Author(s): Coombes R. Source: Nurs Times. 2000 June 22-28; 96(25): 13. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11962968&dopt=Abstract
•
Immunization campaign targets influenza, meningitis, tetanus. Author(s): Traynor K. Source: American Journal of Health-System Pharmacy : Ajhp : Official Journal of the American Society of Health-System Pharmacists. 2001 September 15; 58(18): 1685-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11571808&dopt=Abstract
•
Immunocytochemical method for early laboratory diagnosis of tuberculous meningitis. Author(s): Sumi MG, Mathai A, Reuben S, Sarada C, Radhakrishnan VV. Source: Clinical and Diagnostic Laboratory Immunology. 2002 March; 9(2): 344-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11874875&dopt=Abstract
•
Immunodiagnosis of human eosinophilic meningitis using an antigen of Angiostrongylus cantonensis L5 with molecular weight 204 kD. Author(s): Chye SM, Chang JH, Yen CM. Source: Acta Tropica. 2000 February 25; 75(1): 9-17. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10708002&dopt=Abstract
•
Immunodiagnosis of tuberculous meningitis: rapid detection of mycobacterial antigens in cerebrospinal fluid by reverse passive hemagglutination assay and their characterization by Western blotting. Author(s): Katti MK. Source: Fems Immunology and Medical Microbiology. 2001 July; 31(1): 59-64. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11476983&dopt=Abstract
•
Impact of Haemophilus influenzae type b (Hib) conjugate vaccines on Haemophilus influenzae meningitis in Wisconsin. Author(s): Enders PJ, Trepka MJ, Davis JP. Source: Wmj. 2000 August; 99(5): 45-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11043070&dopt=Abstract
Studies 143
•
Impact of HIV infection on meningitis in Harare, Zimbabwe: a prospective study of 406 predominantly adult patients. Author(s): Hakim JG, Gangaidzo IT, Heyderman RS, Mielke J, Mushangi E, Taziwa A, Robertson VJ, Musvaire P, Mason PR. Source: Aids (London, England). 2000 July 7; 14(10): 1401-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10930155&dopt=Abstract
•
Impact of human immunodeficiency virus type 1 infection on the epidemiology and outcome of bacterial meningitis in South African children. Author(s): Madhi SA, Madhi A, Petersen K, Khoosal M, Klugman KP. Source: International Journal of Infectious Diseases : Ijid : Official Publication of the International Society for Infectious Diseases. 2001; 5(3): 119-25. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11724667&dopt=Abstract
•
Impact of rapid polymerase chain reaction results on management of pediatric patients with enteroviral meningitis. Author(s): Robinson CC, Willis M, Meagher A, Gieseker KE, Rotbart H, Glode MP. Source: The Pediatric Infectious Disease Journal. 2002 April; 21(4): 283-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12075757&dopt=Abstract
•
Impetigo neonatorum associated with late onset group B streptococcal meningitis. Author(s): Guha A, Eisenhut M, Shears P, Dalzell M. Source: The Journal of Infection. 2003 August; 47(2): 185-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12860158&dopt=Abstract
•
In vivo therapy of neoplastic meningitis with methotrexate and 5. Author(s): Kassis AI, Dahman BA, Adelstein SJ. Source: Acta Oncologica (Stockholm, Sweden). 2000; 39(6): 731-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11130012&dopt=Abstract
•
Incidence of Haemophilus influenzae type b meningitis in Mie prefecture, Japan. Author(s): Nakano T, Ihara T, Kamiya H, Yabu Y, Kuwabara H, Iwade Y, Sugiyama A. Source: Pediatrics International : Official Journal of the Japan Pediatric Society. 2001 June; 43(3): 323-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11380936&dopt=Abstract
•
Increase of in vitro amoxycillin bactericidal activity by clavulanic acid against Neisseria meningitis using time-kill curves. Author(s): Anta ML, Gimenez MJ, Alou L, Gomez-Lus ML, Laguna B, Aguilar L, Prieto J. Source: International Journal of Antimicrobial Agents. 2002 March; 19(3): 249-50. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11932151&dopt=Abstract
144 Meningitis
•
Increased serum concentrations of tissue plasminogen activator correlate with an adverse clinical outcome in patients with bacterial meningitis. Author(s): Winkler F, Kastenbauer S, Koedel U, Pfister HW. Source: Journal of Neurology, Neurosurgery, and Psychiatry. 2002 October; 73(4): 456. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12235321&dopt=Abstract
•
Index of suspicion. Case 1. Diagnosis: TB meningitis. Author(s): Alshaar M. Source: Pediatrics in Review / American Academy of Pediatrics. 2001 July; 22(7): 245-50. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11435626&dopt=Abstract
•
Indications for the immunological evaluation of patients with meningitis. Author(s): Overturf GD. Source: Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America. 2003 January 15; 36(2): 189-94. Epub 2002 December 31. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12522751&dopt=Abstract
•
Infantile Salmonella meningitis associated with gecko-keeping. Author(s): Cyriac J, Wozniak ER. Source: Commun Dis Public Health. 2000 March; 3(1): 66-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10743325&dopt=Abstract
•
Infected cephalohematoma complicated with meningitis: report of one case. Author(s): Huang CS, Cheng KJ, Huang CB. Source: Acta Paediatr Taiwan. 2002 July-August; 43(4): 217-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12238911&dopt=Abstract
•
Infectious disease. Shortage of meningitis vaccine forces triage in Burkina Faso. Author(s): Vogel G. Source: Science. 2003 March 7; 299(5612): 1499-501. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12624241&dopt=Abstract
•
Infliximab-induced aseptic meningitis. Author(s): Kashyap AS, Kashyap S. Source: Lancet. 2002 April 6; 359(9313): 1252. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11955573&dopt=Abstract
•
Infliximab-induced aseptic meningitis. Author(s): Marotte H, Charrin JE, Miossec P. Source: Lancet. 2001 November 24; 358(9295): 1784. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11734240&dopt=Abstract
Studies 145
•
Initial presentation of systemic lupus erythematosus masquerading as bacterial meningitis. Author(s): Dong J, Suwanvecho S, Chen L, Keung YK. Source: The Journal of the American Board of Family Practice / American Board of Family Practice. 2001 November-December; 14(6): 470-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11757892&dopt=Abstract
•
Initial treatment with amphotericin B plus rifampin in the acute treatment of cryptococcal meningitis in aids. Author(s): Chotmongkol V, Methawasin K. Source: Southeast Asian J Trop Med Public Health. 2001 December; 32(4): 776-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12041553&dopt=Abstract
•
Interleukin 6 may be an important mediator of trimethoprim-induced systemic adverse reaction resembling aseptic meningitis. Author(s): Antonen J, Hulkkonen J, Pasternack A, Hurme M. Source: Archives of Internal Medicine. 2000 July 10; 160(13): 2066-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10888991&dopt=Abstract
•
Interleukin-1beta and tumor necrosis factor-alpha in cerebrospinal fluid of children with bacterial meningitis. Author(s): Tang RB, Lee BH, Chung RL, Chen SJ, Wong TT. Source: Child's Nervous System : Chns : Official Journal of the International Society for Pediatric Neurosurgery. 2001 August; 17(8): 453-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11508533&dopt=Abstract
•
Interleukin-8 levels in children with bacterial, tuberculous and aseptic meningitis. Author(s): Yilmaz E, Gurgoze MK, Ilhan N, Dogan Y, Aydinoglu H. Source: Indian J Pediatr. 2002 March; 69(3): 219-21. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12003295&dopt=Abstract
•
Interventricular methotrexate therapy for carcinomatous meningitis due to breast cancer: a case with leukoencephalopathy. Author(s): Hara H, Igarashi A, Yano Y, Yashiro T, Ueno E, Aiyoshi Y. Source: Breast Cancer. 2000; 7(3): 247-51. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11029806&dopt=Abstract
•
Intracranial Salmonella infections: meningitis, subdural collections and brain abscess. A series of six surgically managed cases with follow-up results. Author(s): Mahapatra AK, Pawar SJ, Sharma RR. Source: Pediatric Neurosurgery. 2002 January; 36(1): 8-13. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11818740&dopt=Abstract
146 Meningitis
•
Intradural, eextramedullary tuberculoma of the spinal cord as a complication of tuberculous meningitis. Author(s): Skendros P, Kamaria F, Kontopoulos V, Tsitouridis I, Sidiropoulos L. Source: Infection. 2003 March; 31(2): 115-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12682818&dopt=Abstract
•
Intramuscular ceftriaxone in the treatment of childhood meningitis due to Haemophilus influenzae type F. Author(s): Ratka A, Erramouspe J. Source: The Annals of Pharmacotherapy. 2001 January; 35(1): 36-40. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11197583&dopt=Abstract
•
Intraoperative intracranial pressure monitoring in pneumococcal meningitis. Author(s): Vavilala MS, Lam AM. Source: Anesthesia and Analgesia. 2000 January; 90(1): 107-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10624987&dopt=Abstract
•
Intrathecal administration of vancomycin for coagulase-negative staphylococcal meningitis in a patient with blunt head injury: case report. Author(s): Kawamoto H, Inagawa T, Ikawa F, Sakamoto S, Urabe S. Source: The Journal of Trauma. 2002 November; 53(5): 1010-2. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12435961&dopt=Abstract
•
Intrathecal amphotericin in the management of coccidioidal meningitis. Author(s): Stevens DA, Shatsky SA. Source: Seminars in Respiratory Infections. 2001 December; 16(4): 263-9. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11740828&dopt=Abstract
•
Intrathecal chemotherapy in carcinomatous meningitis from breast cancer. Author(s): Orlando L, Curigliano G, Colleoni M, Fazio N, Nole F, Martinelli G, Cinieri S, Graffeo R, Peruzzotti G, Goldhirsch A. Source: Anticancer Res. 2002 September-October; 22(5): 3057-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12530042&dopt=Abstract
•
Intrathecal synthesis of complement components C3c and C4 in the central nervous system infections with signs of the acute serous meningitis syndrome. Author(s): Tatomirovic Z, Bokun R, Bokonjic D. Source: Vojnosanit Pregl. 2002 May-June; 59(3): 265-70. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12132240&dopt=Abstract
Studies 147
•
Intrathecal treatment of neoplastic meningitis due to breast cancer with a slow-release formulation of cytarabine. Author(s): Jaeckle KA, Phuphanich S, Bent MJ, Aiken R, Batchelor T, Campbell T, Fulton D, Gilbert M, Heros D, Rogers L, O'Day SJ, Akerley W, Allen J, Baidas S, Gertler SZ, Greenberg HS, LaFollette S, Lesser G, Mason W, Recht L, Wong E, Chamberlain MC, Cohn A, Glantz MJ, Gutheil JC, Maria B, Moots P, New P, Russell C, Shapiro W, Swinnen L, Howell SB. Source: British Journal of Cancer. 2001 January; 84(2): 157-63. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11161370&dopt=Abstract
•
Intravenous methylprednisolone for aseptic meningitis in Vogt-Koyanagi-Harada syndrome. Author(s): Solaro C, Messmer Uccelli M. Source: European Neurology. 2000; 44(2): 129-30. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10965172&dopt=Abstract
•
Intraventricular haemorrhage due to ruptured posterior inferior cerebellar artery aneurysm in tuberculous meningitis. Author(s): Griffiths SJ, Sgouros S, James G, John P. Source: Child's Nervous System : Chns : Official Journal of the International Society for Pediatric Neurosurgery. 2000 December; 16(12): 872-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11156304&dopt=Abstract
•
Intussusception associated with bacterial meningitis. Author(s): Crushell E, Flanagan O, Devins M, Dunne K, Gleeson J. Source: Archives of Disease in Childhood. 2001 July; 85(1): 56-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11420203&dopt=Abstract
•
Invasive fungal sinusitis and meningitis due to Arthrographis kalrae in a patient with AIDS. Author(s): Chin-Hong PV, Sutton DA, Roemer M, Jacobson MA, Aberg JA. Source: Journal of Clinical Microbiology. 2001 February; 39(2): 804-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11158158&dopt=Abstract
•
Is vaccination against meningitis useful? The findings of an investigation in the Sherbrooke region, Quebec. Author(s): De Wals P, Allard MA, Guindon K, Mayrand L, Simard S, Black R. Source: Can Commun Dis Rep. 2002 April 15; 28(8): 61-3. English, French. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11974427&dopt=Abstract
148 Meningitis
•
Isolated cerebrospinal fluid eosinophilia due to Streptococcus bovis meningitis in an infant. Author(s): Al-Arishi H, Frayha HH, Yaneza AL, Al Hifzi IS. Source: International Journal of Infectious Diseases : Ijid : Official Publication of the International Society for Infectious Diseases. 2002 December; 6(4): 323-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12725215&dopt=Abstract
•
Isolated cryptococcal sphenoid sinusitis with septicemia, meningitis, and subsequent skull base osteomyelitis in an immunocompetent patient. Author(s): Prendiville S, Bielamowicz SA, Hawrych A, Deeb ZE. Source: Otolaryngology and Head and Neck Surgery. 2000 September; 123(3): 277-9. Erratum In: Otolaryngol Head Neck Surg 2000 November; 123(5): 668. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10964305&dopt=Abstract
•
Isolated vestibular ossification after meningitis associated with sensorineural hearing loss. Author(s): Reeck JB, Lalwani AK. Source: Otology & Neurotology : Official Publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology. 2003 July; 24(4): 576-81. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12851548&dopt=Abstract
•
Isolation and characterization of vancomycin-tolerant Streptococcus pneumoniae from the cerebrospinal fluid of a patient who developed recrudescent meningitis. Author(s): McCullers JA, English BK, Novak R. Source: The Journal of Infectious Diseases. 2000 January; 181(1): 369-73. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10608791&dopt=Abstract
•
Isolation of echovirus type 13 from patients of aseptic meningitis. Author(s): Keino M, Kanno M, Hirasawa K, Watari T, Mikawa M, Saito K, Kato K, Katayose M, Yoshida H. Source: Japanese Journal of Infectious Diseases. 2001 December; 54(6): 249-50. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11862012&dopt=Abstract
•
Isoniazid resistance, mycobacterial genotype and outcome in Vietnamese adults with tuberculous meningitis. Author(s): Thwaites GE, Chau TT, Caws M, Phu NH, Chuong LV, Sinh DX, Drobniewski F, White NJ, Parry CM, Farrar JJ. Source: The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union against Tuberculosis and Lung Disease. 2002 October; 6(10): 865-71. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12365572&dopt=Abstract
Studies 149
•
Issues arising from two related cases of childhood tuberculous meningitis. Author(s): Leung WC, Tregoning D. Source: Public Health. 2000 January; 114(1): 57-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10787028&dopt=Abstract
•
JMM, past and present. Meningitis cerebro-spinalis epidemica. Author(s): Ganten D, Weber JR. Source: Journal of Molecular Medicine (Berlin, Germany). 2001 May; 79(4): 159-60. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11409705&dopt=Abstract
•
Kingella endocarditis and meningitis in a patient with SLE and associated antiphospholipid syndrome. Author(s): Wolak T, Abu-Shakra M, Flusser D, Liel-Cohen N, Buskila D, Sukenik S. Source: Lupus. 2000; 9(5): 393-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10878736&dopt=Abstract
•
Klebsiella meningitis in adults: clinical features, prognostic factors and therapeutic outcomes. Author(s): Lu CH, Chang WN, Chang HW. Source: Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia. 2002 September; 9(5): 533-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12383410&dopt=Abstract
•
Klebsiella pneumoniae meningitis in thalassemia major patients. Author(s): Li CK, Shing MM, Chik KW, Lee V, Yuen PM. Source: Pediatric Hematology and Oncology. 2001 April-May; 18(3): 229-32. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11293293&dopt=Abstract
•
Klebsiella pneumoniae meningitis: timing of antimicrobial therapy and prognosis. Author(s): Fang CT, Chen YC, Chang SC, Sau WY, Luh KT. Source: Qjm : Monthly Journal of the Association of Physicians. 2000 January; 93(1): 4553. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10623782&dopt=Abstract
•
Laboratory diagnosis and genetic analysis of an echovirus 30-associated outbreak of aseptic meningitis in Taiwan in 2001. Author(s): Wang JR, Tsai HP, Huang SW, Kuo PH, Kiang D, Liu CC. Source: Journal of Clinical Microbiology. 2002 December; 40(12): 4439-44. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12454133&dopt=Abstract
150 Meningitis
•
Labyrinthine dysplasia, meningitis, and sensorineural deafness: a complex relationship. Author(s): Rashad UM, Flood LM, El-Hmd KA, Hawthorne MR. Source: The Journal of Otolaryngology. 2000 April; 29(2): 110-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10819110&dopt=Abstract
•
Lack of sensitivity of the latex agglutination test to detect bacterial antigen in the cerebrospinal fluid of patients with culture-negative meningitis. Author(s): Tarafdar K, Rao S, Recco RA, Zaman MM. Source: Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America. 2001 August 1; 33(3): 406-8. Epub 2001 June 21. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11438913&dopt=Abstract
•
Late-developing cerebral arteropathy after pyogenic meningitis. Author(s): Palacio S, Hart RG, Vollmer DG, Kagan-Hallet K. Source: Archives of Neurology. 2003 March; 60(3): 431-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12633156&dopt=Abstract
•
Legacy of bacterial meningitis in infancy. Many children continue to suffer functionally important deficits. Author(s): Grimwood K. Source: Bmj (Clinical Research Ed.). 2001 September 8; 323(7312): 523-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11546680&dopt=Abstract
•
Lesson of the week: Recurrent bacterial meningitis: the need for sensitive imaging. Author(s): Carrol ED, Latif AH, Misbah SA, Flood TJ, Abinun M, Clark JE, Pugh RE, Cant AJ. Source: Bmj (Clinical Research Ed.). 2001 September 1; 323(7311): 501-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11532847&dopt=Abstract
•
Leukemic meningitis in B-cell chronoc lymphocytic leukemia: resolution following intrathecal methotrexate. Author(s): Marmont AM. Source: Blood. 2000 July 15; 96(2): 776-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10950515&dopt=Abstract
•
Leukocyte aggregation score in meningitis and its relationship with cerebrospinal fluid soluble selectin and soluble ICAM-1 levels. Author(s): Uysal G, Tulek N, Ozhan B. Source: Journal of Tropical Pediatrics. 2000 December; 46(6): 381-2. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11191156&dopt=Abstract
Studies 151
•
Levels of matrix metalloproteinase-9 within cerebrospinal fluid in a rabbit model of coccidioidal meningitis and vasculitis. Author(s): Williams PL, Leib SL, Kamberi P, Leppert D, Sobel RA, Bifrare YD, Clemons KV, Stevens DA. Source: The Journal of Infectious Diseases. 2002 December 1; 186(11): 1692-5. Epub 2002 November 01. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12447750&dopt=Abstract
•
Levels of three inflammation markers, C-reactive protein, serum amyloid A protein and procalcitonin, in the serum and cerebrospinal fluid of patients with meningitis. Author(s): Shimetani N, Shimetani K, Mori M. Source: Scandinavian Journal of Clinical and Laboratory Investigation. 2001; 61(7): 56774. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11763415&dopt=Abstract
•
Light eye colour linked to deafness after meningitis. Author(s): Cullington HE. Source: Bmj (Clinical Research Ed.). 2001 March 10; 322(7286): 587. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11238154&dopt=Abstract
•
Limits of detection of Mycobacterium tuberculosis in spiked cerebrospinal fluid using the polymerase chain reaction in tuberculous meningitis. Author(s): Baran J Jr, Riederer KM, Khatib R. Source: European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology. 2000 January; 19(1): 47-50. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10706180&dopt=Abstract
•
Listeria meningitis after treatment with infliximab. Author(s): Kamath BM, Mamula P, Baldassano RN, Markowitz JE. Source: Journal of Pediatric Gastroenterology and Nutrition. 2002 April; 34(4): 410-2. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11930099&dopt=Abstract
•
Listeria meningitis in children: report of two cases. Author(s): Economou M, Karyda S, Kansouzidou A, Kavaliotis J. Source: Infection. 2000 March-April; 28(2): 121-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10782402&dopt=Abstract
•
Listeria monocytogenes meningitis during the incubation period of hepatitis A disease. Author(s): Boga AS, Montero RB, Garcia FS, Valcarcel GR. Source: The Pediatric Infectious Disease Journal. 2000 March; 19(3): 265-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10749478&dopt=Abstract
152 Meningitis
•
Listeria monocytogenes meningitis in a patient with chronic hepatitis C infection, treated by interferon alfa and ribavirin. Author(s): Vander T, Medvedovsky M, Hallevy C, Golzman G, Herishanu Y. Source: The Journal of Infection. 2003 January; 46(1): 70-1. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12504615&dopt=Abstract
•
Listeria monocytogenes meningitis: serotype distribution and patient characteristics in The Netherlands, 1976-95. Author(s): Aouaj Y, Spanjaard L, van Leeuwen N, Dankert J. Source: Epidemiology and Infection. 2002 June; 128(3): 405-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12113484&dopt=Abstract
•
Long term follow up after meningitis in infancy: behaviour of teenagers. Author(s): Halket S, de Louvois J, Holt DE, Harvey D. Source: Archives of Disease in Childhood. 2003 May; 88(5): 395-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12716708&dopt=Abstract
•
Long term outcome of neonatal meningitis. Author(s): Stevens JP, Eames M, Kent A, Halket S, Holt D, Harvey D. Source: Archives of Disease in Childhood. Fetal and Neonatal Edition. 2003 May; 88(3): F179-84. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12719389&dopt=Abstract
•
Long term response in a patient with neoplastic meningitis secondary to melanoma treated with (131)I-radiolabeled antichondroitin proteoglycan sulfate Mel-14 F(ab')(2): a case study. Author(s): Cokgor I, Akabani G, Friedman HS, Friedman AH, Zalutsky MR, Zehngebot LM, Provenzale JM, Guy CD, Wikstrand CJ, Bigner DD. Source: Cancer. 2001 May 1; 91(9): 1809-13. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11335907&dopt=Abstract
•
Longitudinal outcomes of Haemophilus influenzae meningitis in school-age children. Author(s): Taylor HG, Schatschneider C, Minich NM. Source: Neuropsychology. 2000 October; 14(4): 509-18. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11055253&dopt=Abstract
•
Long-term follow up of childhood tuberculous meningitis. Author(s): Schoeman J, Wait J, Burger M, van Zyl F, Fertig G, van Rensburg AJ, Springer P, Donald P. Source: Developmental Medicine and Child Neurology. 2002 August; 44(8): 522-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12206617&dopt=Abstract
Studies 153
•
Long-term follow-up of children with bacterial meningitis with emphasis on behavioural characteristics. Author(s): Berg S, Trollfors B, Hugosson S, Fernell E, Svensson E. Source: European Journal of Pediatrics. 2002 June; 161(6): 330-6. Epub 2002 April 25. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12029452&dopt=Abstract
•
Long-Term outcome of neonatal Citrobacter koseri (diversus) meningitis treated with imipenem/meropenem and surgical drainage. Author(s): Straussberg R, Harel L, Amir J. Source: Infection. 2001 October; 29(5): 280-2. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11688908&dopt=Abstract
•
Long-term outcomes of childhood meningitis. Author(s): Fellick JM, Thomson AP. Source: Hosp Med. 2002 May; 63(5): 274-7. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12066345&dopt=Abstract
•
Low cerebrospinal fluid beta-amyloid 42 in patients with acute bacterial meningitis and normalization after treatment. Author(s): Sjogren M, Gisslen M, Vanmechelen E, Blennow K. Source: Neuroscience Letters. 2001 November 13; 314(1-2): 33-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11698140&dopt=Abstract
•
Low sensitivity of polymerase chain reaction for diagnosis of tuberculous meningitis in southeastern Brazil. Author(s): Brienze VM, Tonon AP, Pereira FJ, Liso E, Tognola WA, dos Santos MA, Ferreira MU. Source: Revista Da Sociedade Brasileira De Medicina Tropical. 2001 July-August; 34(4): 389-93. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11562736&dopt=Abstract
•
Low sensitivity of serum procalcitonin in bacterial meningitis in adults. Author(s): Hoffmann O, Reuter U, Masuhr F, Holtkamp M, Kassim N, Weber JR. Source: Scandinavian Journal of Infectious Diseases. 2001; 33(3): 215-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11303813&dopt=Abstract
•
Lumbar puncture in pediatric bacterial meningitis: defining the time interval for recovery of cerebrospinal fluid pathogens after parenteral antibiotic pretreatment. Author(s): Kanegaye JT, Soliemanzadeh P, Bradley JS. Source: Pediatrics. 2001 November; 108(5): 1169-74. Erratum In: Pediatrics 2002 September; 110(3): 651. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11694698&dopt=Abstract
154 Meningitis
•
Lumbar punctures and meningitis. Author(s): Kvalsvig AJ, Unsworth DJ. Source: Pediatrics. 2002 November; 110(5): 1028; Author Reply 1028. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12415049&dopt=Abstract
•
Lumbar punctures and meningitis. Author(s): Arkava T, Luszczak M. Source: Pediatrics. 2002 November; 110(5): 1028; Author Reply 1028. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12415048&dopt=Abstract
•
Lymphomatous meningitis of the Burkitt type presenting with multiple cranial neuropathies. Author(s): Grassi MA, Lee AG. Source: American Journal of Ophthalmology. 2002 March; 133(3): 424-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11860991&dopt=Abstract
•
Malignant meningitis secondary to ovarian carcinoma: an unusual occurrence. Author(s): Chung P, Allerton R. Source: Clin Oncol (R Coll Radiol). 2001; 13(2): 112-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11373871&dopt=Abstract
•
Management of an outbreak of meningococcal meningitis in a Sudanese refugee camp in Northern Uganda. Author(s): Santaniello-Newton A, Hunter PR. Source: Epidemiology and Infection. 2000 February; 124(1): 75-81. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10722133&dopt=Abstract
•
Management of bacterial meningitis in adults. Author(s): Cohen J. Source: Bmj (Clinical Research Ed.). 2003 May 10; 326(7397): 996-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12742897&dopt=Abstract
•
Management of meningitis in children with oral fluid restriction or intravenous fluid at maintenance volumes: a randomised trial. Author(s): Duke T, Mokela D, Frank D, Michael A, Paulo T, Mgone J, Kurubi J. Source: Annals of Tropical Paediatrics. 2002 June; 22(2): 145-57. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12070950&dopt=Abstract
Studies 155
•
Management of pneumococcal meningitis. Author(s): Kaplan SL. Source: The Pediatric Infectious Disease Journal. 2002 June; 21(6): 589-91; Discussion 613-4. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12182395&dopt=Abstract
•
Markers of oxidative injury in the cerebrospinal fluid of a premature infant with meningitis and periventricular leukomalacia. Author(s): Inder T, Mocatta T, Darlow B, Spencer C, Senthilmohan R, Winterbourn CC, Volpe JJ. Source: The Journal of Pediatrics. 2002 May; 140(5): 617-21. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12032532&dopt=Abstract
•
Maternal group B streptococcal meningitis in the postpartum period. Author(s): Ravindranth NT, O'Driscoll J. Source: Journal of Obstetrics and Gynaecology : the Journal of the Institute of Obstetrics and Gynaecology. 2003 January; 23(1): 79. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12647708&dopt=Abstract
•
Matrix metalloproteinase (MMP)-8 and MMP-9 in cerebrospinal fluid during bacterial meningitis: association with blood-brain barrier damage and neurological sequelae. Author(s): Leppert D, Leib SL, Grygar C, Miller KM, Schaad UB, Hollander GA. Source: Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America. 2000 July; 31(1): 80-4. Epub 2000 July 14. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10913401&dopt=Abstract
•
Matrix metalloproteinase-9 in pneumococcal meningitis: activation via an oxidative pathway. Author(s): Meli DN, Christen S, Leib SL. Source: The Journal of Infectious Diseases. 2003 May 1; 187(9): 1411-5. Epub 2003 April 15. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12717622&dopt=Abstract
•
Matrix metalloproteinases: multifunctional effectors of inflammation in multiple sclerosis and bacterial meningitis. Author(s): Leppert D, Lindberg RL, Kappos L, Leib SL. Source: Brain Research. Brain Research Reviews. 2001 October; 36(2-3): 249-57. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11690622&dopt=Abstract
156 Meningitis
•
Media management of a community outbreak of meningococcal meningitis. Author(s): Singleton CD, Fey R, Appleby C. Source: Commun Dis Public Health. 2000 December; 3(4): 267-70. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11280256&dopt=Abstract
•
Meningeal carcinomatosis in lung cancer. Case 2. Carcinomatous meningitis. Author(s): Janne PA, Janicek MJ, Brown F. Source: Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 2000 August; 18(15): 2927-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10920142&dopt=Abstract
•
Meningitis A conjugate vaccine comes on stream. Author(s): Ahmad K. Source: The Lancet Infectious Diseases. 2003 May; 3(5): 263. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12726961&dopt=Abstract
•
Meningitis after spinal anaesthesia. Author(s): Whiteside J. Source: Anesthesia and Analgesia. 2000 September; 91(3): 763-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10960420&dopt=Abstract
•
Meningitis and cochlear implantation. Author(s): Papsin BC. Source: Cmaj : Canadian Medical Association Journal = Journal De L'association Medicale Canadienne. 2003 February 4; 168(3): 256-7; Author Reply 257. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12566326&dopt=Abstract
•
Meningitis and cochlear implantation. Author(s): O'Donoghue G, Balkany T, Cohen N, Lenarz T, Lustig L, Niparko J. Source: Otology & Neurotology : Official Publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology. 2002 November; 23(6): 823-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12438839&dopt=Abstract
•
Meningitis and encephalitis in children. An update. Author(s): Bonthius DJ, Karacay B. Source: Neurologic Clinics. 2002 November; 20(4): 1013-38, Vi-Vii. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12616679&dopt=Abstract
Studies 157
•
Meningitis and endocarditis caused by group B streptococcus in a human immunodeficiency virus (HIV) infected patient. Author(s): Civljak R, Lisic M, Begovac J, Maretic T, Planinc D. Source: Croatian Medical Journal. 2001 October; 42(5): 572-5. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11596176&dopt=Abstract
•
Meningitis and septicaemia in a child caused by non-typable Haemophilus influenzae biotype III. Author(s): Kay SE, Nack Z, Jenner BM. Source: The Medical Journal of Australia. 2001 November 5; 175(9): 484-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11758078&dopt=Abstract
•
Meningitis and shunt infection caused by anaerobic bacteria in children. Author(s): Brook I. Source: Pediatric Neurology. 2002 February; 26(2): 99-105. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11897473&dopt=Abstract
•
Meningitis articles spark painful memories. Author(s): Andrews J. Source: Nurs N Z. 2001 August; 7(7): 4. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12012840&dopt=Abstract
•
Meningitis C immunisation is low among young people who are not in education. Author(s): Booth L, Naracott E, Greenslade J. Source: Bmj (Clinical Research Ed.). 2000 March 18; 320(7237): 805. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10720386&dopt=Abstract
•
Meningitis C vaccine (North American vaccine). Author(s): Lattanzi M, Del Giudice G. Source: Curr Opin Investig Drugs. 2002 January; 3(1): 51-3. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12054072&dopt=Abstract
•
Meningitis C vaccine uptake by British undergraduates. Author(s): Thirlaway K, Lukman H. Source: Commun Dis Public Health. 2003 June; 6(2): 157-60. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12889298&dopt=Abstract
158 Meningitis
•
Meningitis carcinomatosa originating from an alpha fetoprotein-producing gastric cancer. Author(s): Tsujikawa T, Tsukamoto H, Itoh A, Andoh A, Sasaki M, Koyama S, Fujiyama Y, Bamba T. Source: Intern Med. 2000 March; 39(3): 223-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10772124&dopt=Abstract
•
Meningitis caused by Streptococcus pyogenes in an intravenous drug user. Author(s): Robson D, Cadwgan AM, Laing RB. Source: The Journal of Infection. 2002 November; 45(4): 276-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12423620&dopt=Abstract
•
Meningitis complicating an occult infected nasal epidermoid cyst in a child. Author(s): Hsu ML, Chen CY, Lien YH, Wang CC, Yuh YS, Chen SJ. Source: Journal of Neuroimaging : Official Journal of the American Society of Neuroimaging. 2002 April; 12(2): 187-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11977917&dopt=Abstract
•
Meningitis concerns. Immunization recommended for group C type among children under five, teens and young adults. Author(s): Fletcher M. Source: Can Nurse. 2002 January; 98(1): 10. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11845548&dopt=Abstract
•
Meningitis due to acute otitis media and arachnoid granulations. Author(s): Perry BP, Rubinstein JT. Source: The Annals of Otology, Rhinology, and Laryngology. 2000 September; 109(9): 877-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11007094&dopt=Abstract
•
Meningitis due to Capnocytophaga canimorsus after receipt of a dog bite: case report and review of the literature. Author(s): Le Moal G, Landron C, Grollier G, Robert R, Burucoa C. Source: Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America. 2003 February 1; 36(3): E42-6. Epub 2003 January 13. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12539089&dopt=Abstract
•
Meningitis due to mixed infection with penicillin-resistant and penicillin-susceptible strains of Streptococcus pneumoniae. Author(s): Chaves F, Campelo C, Sanz F, Otero JR. Source: Journal of Clinical Microbiology. 2003 January; 41(1): 512-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12517910&dopt=Abstract
Studies 159
•
Meningitis due to Neisseria subflava: case report and review. Author(s): Baraldes MA, Domingo P, Barrio JL, Pericas R, Gurgui M, Vazquez G. Source: Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America. 2000 March; 30(3): 615-7. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10722463&dopt=Abstract
•
Meningitis due to penicillin-resistant Neisseria meningitidis in a 20-year-old man. Author(s): Ben RJ, Wang CC, Chu ML. Source: J Formos Med Assoc. 2001 October; 100(10): 696-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11760376&dopt=Abstract
•
Meningitis due to Salmonella in preterm neonates. Author(s): Totan M, Kucukoduk S, Dagdemir A, Dilber C. Source: Turk J Pediatr. 2002 January-March; 44(1): 45-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11858379&dopt=Abstract
•
Meningitis due to Streptococcus salivarius. Author(s): Idigoras P, Valiente A, Iglesias L, Trieu-Cout P, Poyart C. Source: Journal of Clinical Microbiology. 2001 August; 39(8): 3017. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11499393&dopt=Abstract
•
Meningitis due to viridans streptococci. Author(s): Watanakunakorn C. Source: Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America. 2000 January; 30(1): 238-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10619783&dopt=Abstract
•
Meningitis following cochlear implantation: pathomechanisms, clinical symptoms, conservative and surgical treatments. Author(s): Arnold W, Bredberg G, Gstottner W, Helms J, Hildmann H, Kiratzidis T, Muller J, Ramsden RT, Roland P, Walterspiel JN. Source: Orl; Journal for Oto-Rhino-Laryngology and Its Related Specialties. 2002 November-December; 64(6): 382-9. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12499760&dopt=Abstract
•
Meningitis following stapedotomy: a rare and early complication. Author(s): Nielsen TR, Thomsen J. Source: The Journal of Laryngology and Otology. 2000 October; 114(10): 781-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11127151&dopt=Abstract
160 Meningitis
•
Meningitis four years after treatment of macroprolactinoma. Author(s): Wood R, Sandeman DD, Gawne-Cain ML, Holt RI. Source: Journal of the Royal Society of Medicine. 2002 October; 95(10): 501-2. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12356971&dopt=Abstract
•
Meningitis in a girl with recurrent otitis media caused by Streptococcus pyogenes-otitis media has to be treated appropriately. Author(s): Steppberger K, Adams I, Deutscher J, Muller H, Kiess W. Source: Infection. 2001 October; 29(5): 286-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11688910&dopt=Abstract
•
Meningitis in Africa--tackling W135. Author(s): Chonghaile CN. Source: Lancet. 2002 December 21-28; 360(9350): 2054-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12504411&dopt=Abstract
•
Meningitis in infancy in England and Wales: follow up at age 5 years. Author(s): Bedford H, de Louvois J, Halket S, Peckham C, Hurley R, Harvey D. Source: Bmj (Clinical Research Ed.). 2001 September 8; 323(7312): 533-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11546697&dopt=Abstract
•
Meningitis in pediatric patients. Author(s): Lozon MM. Source: Air Medical Journal. 2002 March-April; 21(2): 9-11. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11896364&dopt=Abstract
•
Meningitis propagation in southern Tanzania: the role of a village video show. Author(s): Jahn A, Kudzala A, Kitundu H, Lyamuya E, Razum O. Source: Tropical Medicine & International Health : Tm & Ih. 2001 October; 6(10): 839-41. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11679132&dopt=Abstract
•
Meningitis seasonal pattern in Africa and detection of epidemics: a retrospective study in Niger, 1990-98. Author(s): de Chabalier F, Djingarey MH, Hassane A, Chippaux JP. Source: Trans R Soc Trop Med Hyg. 2000 November-December; 94(6): 664-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11198652&dopt=Abstract
•
Meningitis vaccination programme prompts needless scare. Author(s): Dixon B. Source: Current Biology : Cb. 2000 October 19; 10(20): R726. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11069092&dopt=Abstract
Studies 161
•
Meningitis, life and death, and why we do what we do. Author(s): Nice RA. Source: Journal of American College Health : J of Ach. 2002 May; 50(6): 313. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12701658&dopt=Abstract
•
Meningitis, pathogenicity near criticality: the epidemiology of meningococcal disease as a model for accidental pathogens. Author(s): Stollenwerk N, Jansen VA. Source: Journal of Theoretical Biology. 2003 June 7; 222(3): 347-59. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12732481&dopt=Abstract
•
Meningitis. Outcome of a complex interaction. Author(s): Vogel U. Source: Lancet. 2001 December; 358 Suppl: S43. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11784592&dopt=Abstract
•
Meningitis. The fears, the facts. Author(s): Myers F. Source: Rn. 2000 November; 63(11): 52-7; Quiz 58. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11147011&dopt=Abstract
•
Meningitis. The worst days of my life. Author(s): Schwarzbeck D, Reng CM. Source: Lancet. 2001 December; 358 Suppl: S44. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11784593&dopt=Abstract
•
Meningitis: a rash diagnosis. Author(s): Glennie L. Source: Nurs Times. 2000 March 23-29; 96(12): 44-5. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11310020&dopt=Abstract
•
Meningitis--viral versus bacterial. Author(s): Haruda FD. Source: Pediatrics. 2003 August; 112(2): 447-8; Author Reply 447-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12897308&dopt=Abstract
•
Meningococcal disease in Slovenia (1993-1999): serogroups and susceptibility to antibiotics. Slovenian Meningitis Study Group. Author(s): Cizman M, Gubina M, Paragi M, Beovic B, Lesnicar G. Source: International Journal of Antimicrobial Agents. 2001 January; 17(1): 27-31. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11137645&dopt=Abstract
162 Meningitis
•
Meningococcal infections and meningitis: what is new? Author(s): Kumar RK. Source: The Australian Journal of Rural Health. 2000 December; 8(6): 318-21. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11894791&dopt=Abstract
•
Meningococcal meningitis epidemic. A new role for single-dose oily chloramphenicol. Author(s): Hussein AA, Abdel Rahman SI. Source: Saudi Med J. 2002 July; 23(7): 797-801. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12174228&dopt=Abstract
•
Meningococcal meningitis in Africa. Author(s): Fonkoua MC. Source: The American Journal of Nursing. 2002 December; 102(12): 17. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12489542&dopt=Abstract
•
Meningococcal meningitis outbreak control strategies. Author(s): Ahlawat S, Kumar R, Roy P, Varma S, Sharma BK. Source: J Commun Dis. 2000 December; 32(4): 264-74. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11668937&dopt=Abstract
•
Meningococcus-not just meningitis. Author(s): Matich MD. Source: N Z Med J. 2000 June 23; 113(1112): 260. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10914517&dopt=Abstract
•
Methicillin-resistant Staphylococcus aureus meningitis: has the time come for an alternative to vancomycin? Author(s): Pagani L, Petrosillo N, Viale P. Source: Infection. 2002 June; 30(3): 181-2; Author Reply 183. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12120949&dopt=Abstract
•
Microbiologic features of adult community-acquired bacterial meningitis in Taiwan. Author(s): Fang CT, Chang SC, Hsueh PR, Chen YC, Sau WY, Luh KT. Source: J Formos Med Assoc. 2000 April; 99(4): 300-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10870313&dopt=Abstract
•
Migraine-like headache in bacterial meningitis. Author(s): Lampl C, Yazdi K, Buzath A, Klingler D. Source: Cephalalgia : an International Journal of Headache. 2000 October; 20(8): 738-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11167904&dopt=Abstract
Studies 163
•
Mild cognitive impairment after viral meningitis in adults. Author(s): Sittinger H, Muller M, Schweizer I, Merkelbach S. Source: Journal of Neurology. 2002 May; 249(5): 554-60. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12021945&dopt=Abstract
•
Mixed infection in adult bacterial meningitis. Author(s): Chang WN, Lu CH, Huang CR, Chuang YC. Source: Infection. 2000 January-February; 28(1): 8-12. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10697784&dopt=Abstract
•
Modulation of nuclear factor-kappaB activation and decreased markers of neurological injury associated with hypothermic therapy in experimental bacterial meningitis. Author(s): Irazuzta JE, Pretzlaff RK, Zingarelli B, Xue V, Zemlan F. Source: Critical Care Medicine. 2002 November; 30(11): 2553-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12441769&dopt=Abstract
•
Modulation of release of proinflammatory bacterial compounds by antibacterials: potential impact on course of inflammation and outcome in sepsis and meningitis. Author(s): Nau R, Eiffert H. Source: Clinical Microbiology Reviews. 2002 January; 15(1): 95-110. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11781269&dopt=Abstract
•
Molecular analysis and experimental virulence of French and North American Escherichia coli neonatal meningitis isolates: identification of a new virulent clone. Author(s): Bonacorsi S, Clermont O, Houdouin V, Cordevant C, Brahimi N, Marecat A, Tinsley C, Nassif X, Lange M, Bingen E. Source: The Journal of Infectious Diseases. 2003 June 15; 187(12): 1895-906. Epub 2003 May 29. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12792866&dopt=Abstract
•
Molecular analysis of the CDR3 encoding region of the immunoglobulin heavy chain locus in cerebrospinal fluid cells as a diagnostic tool in lymphomatous meningitis. Author(s): Storch-Hagenlocher B, Haas J, Vogt-Schaden ME, Bentz M, Hoffmann LA, Biessmann A, Wildemann B. Source: Annals of Neurology. 2000 February; 47(2): 211-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10665492&dopt=Abstract
•
Molecular detection and identification of an enterovirus during an outbreak of aseptic meningitis. Author(s): Siafakas N, Georgopoulou A, Markoulatos P, Spyrou N, Stanway G. Source: Journal of Clinical Laboratory Analysis. 2001; 15(2): 87-95. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11291111&dopt=Abstract
164 Meningitis
•
Molecular epidemiology of serogroup a meningitis in Moscow, 1969 to 1997. Author(s): Achtman M, van der Ende A, Zhu P, Koroleva IS, Kusecek B, Morelli G, Schuurman IG, Brieske N, Zurth K, Kostyukova NN, Platonov AE. Source: Emerging Infectious Diseases. 2001 May-June; 7(3): 420-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11384519&dopt=Abstract
•
Molecular evolution of human echovirus 9 isolated from patients with aseptic meningitis in northern Kyushu during the summer of 1997. Author(s): Hara K, Kashiwagi T, Ohtsu Y, Masunaga K, Akasu-Tsuji Y, Tsumura N, Kato H, Iwahashi J, Hamada N, Toyoda M, Toyoda T. Source: Microbiol Immunol. 2001; 45(10): 717-20. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11762754&dopt=Abstract
•
Molecular identification and epidemiological tracing of Pasteurella multocida meningitis in a baby. Author(s): Boerlin P, Siegrist HH, Burnens AP, Kuhnert P, Mendez P, Pretat G, Lienhard R, Nicolet J. Source: Journal of Clinical Microbiology. 2000 March; 38(3): 1235-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10699029&dopt=Abstract
•
Molecular identification of Staphylococcus lugdunensis in a patient with meningitis. Author(s): Kaabia N, Scauarda D, Lena G, Drancourt M. Source: Journal of Clinical Microbiology. 2002 May; 40(5): 1824-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11980968&dopt=Abstract
•
Molecular typing and epidemiology of enteroviruses identified from an outbreak of aseptic meningitis in Belgium during the summer of 2000. Author(s): Thoelen I, Lemey P, Van Der Donck I, Beuselinck K, Lindberg AM, Van Ranst M. Source: Journal of Medical Virology. 2003 July; 70(3): 420-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12767006&dopt=Abstract
•
Mononuclear cells and cytokines in the cerebrospinal fluid of echovirus 30 meningitis patients. Author(s): Matsubara T, Matsuoka T, Katayama K, Yoshitomi T, Nishikawa M, Ichiyama T, Furukawa S. Source: Scandinavian Journal of Infectious Diseases. 2000; 32(5): 471-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11055648&dopt=Abstract
Studies 165
•
Moraxella catarrhalis meningitis: a case report. Author(s): Jin Y. Source: Chin Med J (Engl). 2000 April; 113(4): 381-2. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11775241&dopt=Abstract
•
MRI demonstration of unsuspected intraventricular rupture of pyogenic cerebral abscesses in patients being treated for meningitis. Author(s): Kamra P, Vatsal DK, Husain M, Pradhan S, Venkatesh SK, Gupta RK. Source: Neuroradiology. 2002 February; 44(2): 114-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11942361&dopt=Abstract
•
Multidrug-resistant tuberculous meningitis in patients with AIDS. Author(s): Daikos GL, Cleary T, Rodriguez A, Fischl MA. Source: The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union against Tuberculosis and Lung Disease. 2003 April; 7(4): 3948. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12729347&dopt=Abstract
•
Multiple myeloma following an episode of community-acquired pneumococcal bacteraemia or meningitis. Author(s): Gregersen H, Pedersen G, Svendsen N, Thulstrup AM, Sorensen HT, Schonheyder HC. Source: Apmis : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica. 2001 November; 109(11): 797-800. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11900061&dopt=Abstract
•
Mycobacterium tuberculosis meningitis and other etiologies of the aseptic meningitis syndrome. Author(s): Roos KL. Source: Seminars in Neurology. 2000; 20(3): 329-35. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11051297&dopt=Abstract
•
Naegleria meningitis: a rare survival. Author(s): Jain R, Prabhakar S, Modi M, Bhatia R, Sehgal R. Source: Neurology India. 2002 December; 50(4): 470-2. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12577098&dopt=Abstract
166 Meningitis
•
Neisseria meningitidis serogroups W135 and A were equally prevalent among meningitis cases occurring at the end of the 2001 epidemics in Burkina Faso and Niger. Author(s): Taha MK, Parent Du Chatelet I, Schlumberger M, Sanou I, Djibo S, de Chabalier F, Alonso JM. Source: Journal of Clinical Microbiology. 2002 March; 40(3): 1083-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11880446&dopt=Abstract
•
Neisseria sicca meningitis in a woman with nascent pernicious anemia. Author(s): Sartin JS. Source: The American Journal of Medicine. 2000 August 1; 109(2): 175-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11032571&dopt=Abstract
•
Neonatal bacterial meningitis. Author(s): Polin RA, Harris MC. Source: Seminars in Neonatology : Sn. 2001 April; 6(2): 157-72. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11483021&dopt=Abstract
•
Neonatal Candida meningitis. Author(s): Moylett EH. Source: Seminars in Pediatric Infectious Diseases. 2003 April; 14(2): 115-22. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12881799&dopt=Abstract
•
Neonatal coagulase-negative staphylococcal meningitis: a report of two cases. Author(s): Drinkovic D, Pottumarthy S, Knight D, Morris AJ. Source: Pathology. 2002 December; 34(6): 586-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12556001&dopt=Abstract
•
Neonatal meningitis in England and Wales: 10 years on. Author(s): Holt DE, Halket S, de Louvois J, Harvey D. Source: Archives of Disease in Childhood. Fetal and Neonatal Edition. 2001 March; 84(2): F85-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11207221&dopt=Abstract
•
Neonatal meningitis. Author(s): Heath PT, Nik Yusoff NK, Baker CJ. Source: Archives of Disease in Childhood. Fetal and Neonatal Edition. 2003 May; 88(3): F173-8. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12719388&dopt=Abstract
Studies 167
•
Neonatal meningitis. Author(s): Al-Harthi AA, Dagriri KA, Asindi AA, Bello CS. Source: Saudi Med J. 2000 June; 21(6): 550-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11500704&dopt=Abstract
•
Neonatal meningitis: mortality, cerebrospinal fluid, and microbiological findings. Author(s): Nel E. Source: Journal of Tropical Pediatrics. 2000 August; 46(4): 237-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10996987&dopt=Abstract
•
Neonatal salmonella meningitis. Author(s): Nabi G, Khan M. Source: Saudi Med J. 2001 January; 22(1): 78. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11255620&dopt=Abstract
•
Neonatal salmonella meningitis. Author(s): Matthew L, Chandran U. Source: Saudi Med J. 2000 May; 21(5): 498-9. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11500693&dopt=Abstract
•
Neonatal Salmonella meningitis. Author(s): Manzar S. Source: Saudi Med J. 2000 October; 21(10): 989. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11369975&dopt=Abstract
•
Neonatal Salmonella typhimurium meningitis. Author(s): Totan M. Source: Indian J Pediatr. 2001 November; 68(11): 1079-80. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11770247&dopt=Abstract
•
Neonate with late onset Streptococcus bovis meningitis: case report and review of the literature. Author(s): Cheung M, Pelot M, Nadarajah R, Kohl S. Source: The Pediatric Infectious Disease Journal. 2000 September; 19(9): 891-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11001118&dopt=Abstract
•
Neoplastic meningitis. Author(s): Aparicio A, Chamberlain MC. Source: Curr Neurol Neurosci Rep. 2002 May; 2(3): 225-35. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11937001&dopt=Abstract
168 Meningitis
•
Neoplastic meningitis. Author(s): Kim L, Glantz MJ. Source: Curr Treat Options Oncol. 2001 December; 2(6): 517-27. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12057097&dopt=Abstract
•
Neoplastic meningitis: a guide to diagnosis and treatment. Author(s): Chamberlain MC. Source: Current Opinion in Neurology. 2000 December; 13(6): 641-8. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11148663&dopt=Abstract
•
Neoplastic meningitis: diagnosis and treatment considerations. Author(s): Blaney SM, Poplack DG. Source: Medical Oncology (Northwood, London, England). 2000 August; 17(3): 151-62. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10962524&dopt=Abstract
•
Neurocysticercosis presenting as chronic meningitis. Author(s): Hassan KM, Mathew I. Source: J Assoc Physicians India. 2000 September; 48(9): 940. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11198809&dopt=Abstract
•
Neurogenic pulmonary oedema induced by bacterial meningitis: a case report. Author(s): D'Souza R, Kerr F. Source: Scott Med J. 2001 August; 46(4): 115-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11676042&dopt=Abstract
•
Neurologic morbidity after herpes simplex virus type 2 meningitis: a retrospective study of 40 patients. Author(s): Aurelius E, Forsgren M, Gille E, Skoldenberg B. Source: Scandinavian Journal of Infectious Diseases. 2002; 34(4): 278-83. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12064691&dopt=Abstract
•
Neuronal injury in bacterial meningitis: mechanisms and implications for therapy. Author(s): Nau R, Bruck W. Source: Trends in Neurosciences. 2002 January; 25(1): 38-45. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11801337&dopt=Abstract
Studies 169
•
Neuron-specific enolase, nucleotides, nucleosides, purine bases, oxypurines and uric acid concentrations in cerebrospinal fluid of children with meningitis. Author(s): Rodriguez-Nunez A, Cid E, Rodriguez-Garcia J, Camina F, Rodriguez-Segade S, Castro-Gago M. Source: Brain & Development. 2003 March; 25(2): 102-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12581805&dopt=Abstract
•
Neurotoxicity of carbapenem antibiotics: consequences for their use in bacterial meningitis. Author(s): Norrby SR. Source: The Journal of Antimicrobial Chemotherapy. 2000 January; 45(1): 5-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10629006&dopt=Abstract
•
Neurotrophin-3 levels in cerebrospinal fluid from children with bacterial meningitis, viral meningitis, or encephalitis. Author(s): Mizuno Y, Takada H, Urakami K, Ihara K, Kira R, Suminoe A, Ohga S, Aoki T, Hara T. Source: Journal of Child Neurology. 2000 January; 15(1): 19-21. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10641604&dopt=Abstract
•
Neurotrophin-4 and glial cell line-derived neurotrophic factor in cerebrospinal fluid from meningitis/encephalitis patients. Author(s): Tokunaga Y, Kira R, Takahata Y, Gondo K, Mizuno Y, Aoki T, Hara T. Source: Pediatric Neurology. 2002 August; 27(2): 102-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12213609&dopt=Abstract
•
New and old diagnostic markers of meningitis in cerebrospinal fluid (CSF). Author(s): Kleine TO, Zwerenz P, Zofel P, Shiratori K. Source: Brain Research Bulletin. 2003 August 15; 61(3): 287-97. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12909299&dopt=Abstract
•
New onset seizures in HIV-infected patients without intracranial mass lesions or meningitis--a clinical, radiological and SPECT scan study. Author(s): Modi G, Modi M, Martinus I, Vangu M. Source: Journal of the Neurological Sciences. 2002 October 15; 202(1-2): 29-34. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12220689&dopt=Abstract
•
New perspectives on pneumococcal meningitis. Author(s): Aronin SI, Quagliarello VJ. Source: Hosp Pract (Off Ed). 2001 February 15; 36(2): 43-6, 49-50, 51. Review. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11220360&dopt=Abstract
170 Meningitis
•
New rapid antigen test for diagnosis of pneumococcal meningitis. Author(s): Marcos MA, Martinez E, Almela M, Mensa J, Jimenez de Anta MT. Source: Lancet. 2001 May 12; 357(9267): 1499-500. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11377604&dopt=Abstract
•
New therapies and vaccines for bacterial meningitis. Author(s): Foster C, Nadel S. Source: Expert Opinion on Investigational Drugs. 2002 August; 11(8): 1051-60. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12150701&dopt=Abstract
•
NF-kappaB activation in cerebrospinal fluid cells from patients with meningitis. Author(s): Ichiyama T, Isumi H, Yoshitomi T, Nishikawa M, Matsubara T, Furukawa S. Source: Neurological Research. 2002 October; 24(7): 709-12. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12392210&dopt=Abstract
•
Nitric oxide production during bacterial and viral meningitis in children. Author(s): Murawska-Cialowicz E, Szychowska Z, Tr busiewicz B. Source: International Journal of Clinical & Laboratory Research. 2000; 30(3): 127-31. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11196070&dopt=Abstract
•
No evidence of type 1 or type 3 hypersensitivity mechanism in amoxicillin/clavulanic acid induced aseptic meningitis. Author(s): Kastenbauer S, Pfister HW, Wick M. Source: Journal of Neurology, Neurosurgery, and Psychiatry. 2003 May; 74(5): 690-1. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12700328&dopt=Abstract
•
No funds to control meningitis outbreak in Africa. Author(s): Ahmad K. Source: The Lancet Infectious Diseases. 2003 March; 3(3): 119. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12614713&dopt=Abstract
•
Non-01 Vibrio cholerae septicemia and meningitis in a neonate. Author(s): Kerketta JA, Paul AC, Kirubakaran VB, Jesudason MV, Moses PD. Source: Indian J Pediatr. 2002 October; 69(10): 909-10. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12450305&dopt=Abstract
•
Nontraditional dosing of ampicillin-sulbactam for multidrug-resistant Acinetobacter baumannii meningitis. Author(s): Cawley MJ, Suh C, Lee S, Ackerman BH. Source: Pharmacotherapy. 2002 April; 22(4): 527-32. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11939689&dopt=Abstract
Studies 171
•
Nosocomial Acinetobacter meningitis. Author(s): Kralinsky K, Krcmeryova T, Tuharsky J, Krcmery V. Source: The Pediatric Infectious Disease Journal. 2000 March; 19(3): 270-1. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10749482&dopt=Abstract
•
Nosocomial bacterial and fungal meningitis in children; an eight year national survey reporting 101 cases. Pediatric Nosocomial Meningitis Study Group. Author(s): Krcmery V, Paradisi F. Source: International Journal of Antimicrobial Agents. 2000 July; 15(2): 143-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10854811&dopt=Abstract
•
Nosocomial enterobacter meningitis: risk factors, management, and treatment outcomes. Author(s): Parodi S, Lechner A, Osih R, Vespa P, Pegues D. Source: Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America. 2003 July 15; 37(2): 159-66. Epub 2003 Jul 09. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12856206&dopt=Abstract
•
Nosocomial meningitis due to Acinetobacter calcoaceticus in 10 children after ventriculoperitoneal shunt insertion. Author(s): Filka J, Huttova M, Schwartzova D, Kurak M, Krcmeryova T, Tuharsky J, Kralinsky K, Sagat T, Krcmery V Jr. Source: The Journal of Hospital Infection. 2000 January; 44(1): 76-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10633059&dopt=Abstract
•
Nosocomial meningitis due to Pseudomonas aeruginosa in children. Author(s): Kralinsky K, Svetlansky I, Kovacicova G, Filka J, Huttova M, Krcmery V Jr. Source: Journal of Chemotherapy (Florence, Italy). 2000 December; 12(6): 538-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11154042&dopt=Abstract
•
Novel treatment of meningitis caused by multidrug-resistant Mycobacterium tuberculosis with intrathecal levofloxacin and amikacin: case report. Author(s): Berning SE, Cherry TA, Iseman MD. Source: Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America. 2001 February 15; 32(4): 643-6. Epub 2001 Feb 09. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11181130&dopt=Abstract
•
Ocular angiostrongyliasis without meningitis symptoms in Okinawa, Japan. Author(s): Toma H, Matsumura S, Oshiro C, Hidaka T, Sato Y. Source: J Parasitol. 2002 February; 88(1): 211-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12053973&dopt=Abstract
172 Meningitis
•
One case each of recurrent meningitis and hemoperitoneum infection with Ralstonia mannitolilytica. Author(s): Vaneechoutte M, De Baere T, Wauters G, Steyaert S, Claeys G, Vogelaers D, Verschraegen G. Source: Journal of Clinical Microbiology. 2001 December; 39(12): 4588-90. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11724893&dopt=Abstract
•
Optic neuritis complicating west nile virus meningitis in a young adult. Author(s): Gilad R, Lampl Y, Sadeh M, Paul M, Dan M. Source: Infection. 2003 January; 31(1): 55-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12590335&dopt=Abstract
•
Oral wooden stick injury complicated by meningitis and brain abscess. Author(s): Chang CJ, Huang LT, Lui CC, Huang SC. Source: Chang Gung Med J. 2002 April; 25(4): 266-70. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12079161&dopt=Abstract
•
Organ donation from children with meningitis. Author(s): Mirza D, Hastings M, Reyes J, Green M, Healey PJ, Stock P. Source: The Pediatric Infectious Disease Journal. 2003 May; 22(5): 475. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12792392&dopt=Abstract
•
Organ donors with adequately treated bacterial meningitis may be suitable for successful transplantation. Author(s): Paig i JM, Lopez-Navidad A, Lloveras J, Mir M, Orfila A, Quintana S, Vazquez-Sanchez A, Inigo V, Masramon J. Source: Transplantation Proceedings. 2000 February; 32(1): 75-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10700977&dopt=Abstract
•
Osteomyelitis of the odontoid process associated with meningitis and retropharyngeal abscess--case report. Author(s): Kubo S, Takimoto H, Hosoi K, Toyota S, Karasawa J, Yoshimine T. Source: Neurol Med Chir (Tokyo). 2002 October; 42(10): 447-51. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12416570&dopt=Abstract
•
Otogenic meningitis caused by the pneumococci that had acquired resistance to cephalosporins. Author(s): Sakamoto M, Ito K, Sugasawa M, Taniguchi M. Source: Otolaryngology and Head and Neck Surgery. 2001 March; 124(3): 350-1. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11241009&dopt=Abstract
Studies 173
•
Outbreak of aseptic meningitis and mumps after mass vaccination with MMR vaccine using the Leningrad-Zagreb mumps strain. Author(s): da Cunha SS, Rodrigues LC, Barreto ML, Dourado I. Source: Vaccine. 2002 January 15; 20(7-8): 1106-12. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11803071&dopt=Abstract
•
Outbreak of aseptic meningitis associated with echovirus 13. Author(s): Kirschke DL, Jones TF, Buckingham SC, Craig AS, Schaffner W. Source: The Pediatric Infectious Disease Journal. 2002 November; 21(11): 1034-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12442025&dopt=Abstract
•
Outbreak of aseptic meningitis associated with mass vaccination with a urabecontaining measles-mumps-rubella vaccine: implications for immunization programs. Author(s): Dourado I, Cunha S, Teixeira MG, Farrington CP, Melo A, Lucena R, Barreto ML. Source: American Journal of Epidemiology. 2000 March 1; 151(5): 524-30. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10707922&dopt=Abstract
•
Outbreak of aseptic meningitis by echo 4: prevalence of clinical cases among adults. Author(s): Portolani M, Pecorari M, Pietrosemoli P, Bartoletti A, Sabbatini AM, Meacci M, Gennari W, Bazzani E, Beretti F, Guaraldi G. Source: New Microbiol. 2001 January; 24(1): 11-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11209838&dopt=Abstract
•
Outbreak of echovirus 30 meningitis in Wingecarribee Shire, New South Wales. Author(s): Gosbell I, Robinson D, Chant K, Crone S. Source: Commun Dis Intell. 2000 May; 24(5): 121-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11085017&dopt=Abstract
•
Outbreaks of aseptic meningitis associated with echoviruses 9 and 30 and preliminary surveillance reports on enterovirus activity--United States, 2003. Author(s): Centers for Disease Control and Prevention (CDC). Source: Mmwr. Morbidity and Mortality Weekly Report. 2003 August 15; 52(32): 761-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12917581&dopt=Abstract
•
Outbreaks of meningococcal meningitis during Hajj: changing face of an old enemy. Author(s): Khan MA. Source: J Pak Med Assoc. 2003 January; 53(1): 1-3. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12666842&dopt=Abstract
174 Meningitis
•
Outcome of meningitis caused by Streptococcus pneumoniae and Haemophilus influenzae type b in children in The Gambia. Author(s): Goetghebuer T, West TE, Wermenbol V, Cadbury AL, Milligan P, LloydEvans N, Adegbola RA, Mulholland EK, Greenwood BM, Weber MW. Source: Tropical Medicine & International Health : Tm & Ih. 2000 March; 5(3): 207-13. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10747284&dopt=Abstract
•
Outcome of penicillin-nonsusceptible Streptococcus pneumoniae meningitis: a nested case-control study. Author(s): Kellner JD, Scheifele DW, Halperin SA, Lebel MH, Moore D, Le Saux N, Ford-Jones EL, Law B, Vaudry W; Canadian Paediatric Society/Centre for Infectious Disease Prevention and Control Immunization Monitoring Program. Source: The Pediatric Infectious Disease Journal. 2002 October; 21(10): 903-10. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12394810&dopt=Abstract
•
Overwhelming S. pneumonia meningitis after basilar skull fracture: a case report. Author(s): Severyn FA, Fenn J. Source: Air Medical Journal. 2000 July-September; 19(3): 102-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11184480&dopt=Abstract
•
Oxidant and antioxidant activities in childhood meningitis. Author(s): Tsukahara H, Haruta T, Todoroki Y, Hiraoka M, Noiri E, Maeda M, Mayumi M. Source: Life Sciences. 2002 October 25; 71(23): 2797-806. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12383885&dopt=Abstract
•
Oxidative stress in bacterial meningitis in humans. Author(s): Kastenbauer S, Koedel U, Becker BF, Pfister HW. Source: Neurology. 2002 January 22; 58(2): 186-91. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11805243&dopt=Abstract
•
Oxidative stress in childhood meningitis: measurement of 8-hydroxy-2'deoxyguanosine concentration in cerebrospinal fluid. Author(s): Tsukahara H, Haruta T, Ono N, Kobata R, Fukumoto Y, Hiraoka M, Mayumi M. Source: Redox Report : Communications in Free Radical Research. 2000; 5(5): 295-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11145104&dopt=Abstract
•
Paediatric nursing. A brush with meningitis that showed NHS at its best. Author(s): Gaskell C. Source: Nurs Times. 2000 November 23-29; 96(47): 9. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11965785&dopt=Abstract
Studies 175
•
Palmoplantar pustulosis with pustulotic arthroosteitis involving temporal osteomyelitis and meningitis. Author(s): Seno A, Arata J, Matsuura Y, Suemitsu I. Source: The Journal of Dermatology. 2000 April; 27(4): 269-72. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10824492&dopt=Abstract
•
Papilloedema with peripapillary retinal haemorrhages in an acquired immunodeficiency syndrome (AIDS) patient with cryptococcal meningitis. Author(s): Battu RR, Biswas J, Jayakumar N, Madhavan HN, Kumarsamy N, Solomon S. Source: Indian J Ophthalmol. 2000 March; 48(1): 47-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11271934&dopt=Abstract
•
Paradoxical recurrent meningitis following therapy of cryptococcal meningitis: an immune reconstitution syndrome after initiation of highly active antiretroviral therapy. Author(s): King MD, Perlino CA, Cinnamon J, Jernigan JA. Source: International Journal of Std & Aids. 2002 October; 13(10): 724-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12396546&dopt=Abstract
•
Parental perception of educational, behavioural and general health problems in school-age survivors of bacterial meningitis. Author(s): Koomen I, Grobbee DE, Jennekens-Schinkel A, Roord JJ, van Furth AM. Source: Acta Paediatrica (Oslo, Norway : 1992). 2003; 92(2): 177-85. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12710643&dopt=Abstract
•
Passive exposure to tobacco smoke and bacterial meningitis in children. Author(s): Iles K, Poplawski NK, Couper RT. Source: Journal of Paediatrics and Child Health. 2001 August; 37(4): 388-91. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11532060&dopt=Abstract
•
Pasteurella gallinarum neonatal meningitis. Author(s): Ahmed K, Sein PP, Shahnawaz M, Hoosen AA. Source: Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases. 2002 January; 8(1): 55-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11906503&dopt=Abstract
•
Pasteurella multocida meningitis in an adult: case report. Author(s): Armstrong GR, Sen RA, Wilkinson J. Source: Journal of Clinical Pathology. 2000 March; 53(3): 234-5. Erratum In: J Clin Pathol 2000 May; 53(5): 405. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10823146&dopt=Abstract
176 Meningitis
•
Pasteurella multocida meningitis: case report and review of the last 11 y. Author(s): Green BT, Ramsey KM, Nolan PE. Source: Scandinavian Journal of Infectious Diseases. 2002; 34(3): 213-7. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12030400&dopt=Abstract
•
Pathogenesis and pathophysiology of pneumococcal meningitis. Author(s): Koedel U, Scheld WM, Pfister HW. Source: The Lancet Infectious Diseases. 2002 December; 2(12): 721-36. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12467688&dopt=Abstract
•
Pathogenic isolates in meningitis patients in Dar Es Salaam, Tanzania. Author(s): Matee MI, Matre R. Source: East Afr Med J. 2001 September; 78(9): 458-60. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11921576&dopt=Abstract
•
Pathophysiology of bacterial meningitis: mechanism(s) of neuronal injury. Author(s): Scheld WM, Koedel U, Nathan B, Pfister HW. Source: The Journal of Infectious Diseases. 2002 December 1; 186 Suppl 2: S225-33. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12424702&dopt=Abstract
•
Pathophysiology of meningococcal meningitis and septicaemia. Author(s): Pathan N, Faust SN, Levin M. Source: Archives of Disease in Childhood. 2003 July; 88(7): 601-7. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12818907&dopt=Abstract
•
Pattern of meningitis in Al-Ain medical district, United Arab Emirates--a decadal experience (1990-99). Author(s): Mahmoud R, Mahmoud M, Badrinath P, Sheek-Hussein M, Alwash R, Nicol AG. Source: The Journal of Infection. 2002 January; 44(1): 22-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11972414&dopt=Abstract
•
PCR-RFLP based molecular typing of enteroviruses isolated from patients with aseptic meningitis in Korea. Author(s): Lee YS, Kim KS, Chung YS, Cheon DS, Jung SK, Park KS, Na BK, Jee YM, Kim DS, Yoon JD, Song CY, Lee KH. Source: Archives of Virology. 2002 September; 147(9): 1711-20. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12209311&dopt=Abstract
Studies 177
•
Penicillin-resistant pneumococci-implications for management of communityacquired pneumonia and meningitis. Author(s): Ziglam HM, Finch RG. Source: International Journal of Infectious Diseases : Ijid : Official Publication of the International Society for Infectious Diseases. 2002 March; 6 Suppl 1: S14-20. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12044285&dopt=Abstract
•
Penicillin-resistant Streptococcus pneumoniae septic shock and meningitis complicating chronic graft versus host disease: a case report and review of the literature. Author(s): Haddad PA, Repka TL, Weisdorf DJ. Source: The American Journal of Medicine. 2002 August 1; 113(2): 152-5. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12133754&dopt=Abstract
•
Pentoxifylline-induced aseptic meningitis in a patient with mixed connective tissue disease. Author(s): Mathian A, Amoura Z, Piette JC. Source: Neurology. 2002 November 12; 59(9): 1468-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12427911&dopt=Abstract
•
Perceived stress and psychological well-being are associated with antibody status after meningitis C conjugate vaccination. Author(s): Burns VE, Drayson M, Ring C, Carroll D. Source: Psychosomatic Medicine. 2002 November-December; 64(6): 963-70. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12461201&dopt=Abstract
•
Performance after cochlear implantation: a comparison of children deafened by meningitis and congenitally deaf children. Author(s): Mitchell TE, Psarros C, Pegg P, Rennie M, Gibson WP. Source: The Journal of Laryngology and Otology. 2000 January; 114(1): 33-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10789408&dopt=Abstract
•
Pharmacodynamics of gatifloxacin in experimental models of pneumococcal meningitis. Author(s): McCracken GH Jr. Source: Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America. 2000 August; 31 Suppl 2: S45-50. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10984328&dopt=Abstract
•
Pharmacokinetic model for tobramycin in acinetobacter meningitis. Author(s): Chicano-Pia PV, Cercos-Lleti AC, Roma-Sanchez E. Source: The Annals of Pharmacotherapy. 2002 January; 36(1): 83-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11816266&dopt=Abstract
178 Meningitis
•
Phase I clinical trial of intrathecal topotecan in patients with neoplastic meningitis. Author(s): Blaney SM, Heideman R, Berg S, Adamson P, Gillespie A, Geyer JR, Packer R, Matthay K, Jaeckle K, Cole D, Kuttesch N, Poplack DG, Balis FM. Source: Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 2003 January 1; 21(1): 143-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12506183&dopt=Abstract
•
Phylogenetic distribution of virulence-associated genes among Escherichia coli isolates associated with neonatal bacterial meningitis in the Netherlands. Author(s): Johnson JR, Oswald E, O'Bryan TT, Kuskowski MA, Spanjaard L. Source: The Journal of Infectious Diseases. 2002 March 15; 185(6): 774-84. Epub 2002 February 14. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11920295&dopt=Abstract
•
Platelet functions in patients with meningococcal meningitis at the Kenyatta National Hospital, Nairobi. Author(s): Amayo EO, Kayima JK, Joshi MD. Source: East Afr Med J. 2002 August; 79(8): 405-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12638840&dopt=Abstract
•
Pneumococcal antibiotic resistance and rates of meningitis in children. Author(s): Ryan MW, Antonelli PJ. Source: The Laryngoscope. 2000 June; 110(6): 961-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10852513&dopt=Abstract
•
Pneumococcal meningitis in adults: spectrum of complications and prognostic factors in a series of 87 cases. Author(s): Kastenbauer S, Pfister HW. Source: Brain; a Journal of Neurology. 2003 May; 126(Pt 5): 1015-25. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12690042&dopt=Abstract
•
Pneumococcal meningitis in an immunocompetent adult with a cochlear implant. Author(s): Graveriau C, Roman S, Garrigues B, Triglia JM, Stein A. Source: The Journal of Infection. 2003 May; 46(4): 248-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12799152&dopt=Abstract
•
Pneumococcal meningitis in children: relationship of antibiotic resistance to clinical characteristics and outcomes. Author(s): Buckingham SC, McCullers JA, Lujan-Zilbermann J, Knapp KM, Orman KL, English BK. Source: The Pediatric Infectious Disease Journal. 2001 September; 20(9): 837-43. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11734760&dopt=Abstract
Studies 179
•
Pneumococcal meningitis in the intensive care unit: prognostic factors of clinical outcome in a series of 80 cases. Author(s): Auburtin M, Porcher R, Bruneel F, Scanvic A, Trouillet JL, Bedos JP, Regnier B, Wolff M. Source: American Journal of Respiratory and Critical Care Medicine. 2002 March 1; 165(5): 713-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11874820&dopt=Abstract
•
Pneumococcal meningitis masquerading as subarachnoid haemorrhage. Author(s): Chatterjee T, Gowardman JR, Goh TD. Source: The Medical Journal of Australia. 2003 May 19; 178(10): 505-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12741939&dopt=Abstract
•
Pneumococcal meningitis: antibiotics essential but insufficient. Author(s): Davis LE, Greenlee JE. Source: Brain; a Journal of Neurology. 2003 May; 126(Pt 5): 1013-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12690041&dopt=Abstract
•
Pneumococcal pneumolysin and H(2)O(2) mediate brain cell apoptosis during meningitis. Author(s): Braun JS, Sublett JE, Freyer D, Mitchell TJ, Cleveland JL, Tuomanen EI, Weber JR. Source: The Journal of Clinical Investigation. 2002 January; 109(1): 19-27. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11781347&dopt=Abstract
•
Polymerase chain reaction for the laboratory diagnosis of aseptic meningitis and encephalitis. Author(s): Chesky M, Scalco R, Failace L, Read S, Jobim LF. Source: Arquivos De Neuro-Psiquiatria. 2000 September; 58(3B): 836-42. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11018820&dopt=Abstract
•
Polymicrobial meningitis revealing an anterior sacral meningocele in a 23-year-old woman. Author(s): Guerin JM, Leibinger F, Raskine L, Ekherian JM. Source: The Journal of Infection. 2000 March; 40(2): 195-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10841102&dopt=Abstract
•
Polyradiculomyelitis associated with clinically diagnosed tuberculous meningitis. Author(s): Kim BJ, Park MH, Koh SB, Park MK, Park KW, Lee DH. Source: European Neurology. 2001; 46(3): 156-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11598335&dopt=Abstract
180 Meningitis
•
Polysaccharide vaccines for preventing serogroup A meningococcal meningitis. Author(s): Patel M, Lee CK. Source: Cochrane Database Syst Rev. 2001; (3): Cd001093. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11686976&dopt=Abstract
•
Polysaccharide vaccines for preventing serogroup A meningococcal meningitis. Author(s): Patel M. Source: Cochrane Database Syst Rev. 2000; (2): Cd001093. Review. Update In: http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10796590&dopt=Abstract
•
Population-based surveillance for bacterial meningitis in the Dominican Republic: implications for control by vaccination. Author(s): Gomez E, Peguero M, Sanchez J, Castellanos PL, Feris J, Pena C, BrudzinskiLaClaire L, Levine OS. Source: Epidemiology and Infection. 2000 December; 125(3): 549-54. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11218205&dopt=Abstract
•
Population-based survey of antimicrobial susceptibility and serotype distribution of Streptococcus pneumoniae from meningitis patients in Salvador, Brazil. Author(s): Reis JN, Cordeiro SM, Coppola SJ, Salgado K, Carvalho MG, Teixeira LM, Thompson TA, Facklam RR, Reis MG, Ko AI. Source: Journal of Clinical Microbiology. 2002 January; 40(1): 275-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11773131&dopt=Abstract
•
Post spinal meningitis and asepsis. Author(s): Videira RL, Ruiz-Neto PP, Brandao Neto M. Source: Acta Anaesthesiologica Scandinavica. 2002 July; 46(6): 639-46. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12059885&dopt=Abstract
•
Postneurosurgical meningitis due to Proteus penneri with selection of a ceftriaxoneresistant isolate: analysis of chromosomal class A beta-lactamase HugA and its LysRtype regulatory protein HugR. Author(s): Liassine N, Madec S, Ninet B, Metral C, Fouchereau-Peron M, Labia R, Auckenthaler R. Source: Antimicrobial Agents and Chemotherapy. 2002 January; 46(1): 216-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11751137&dopt=Abstract
•
Postsurgical meningitis caused by Bordetella bronchiseptica. Author(s): Belen O, Campos JM, Cogen PH, Jantausch BA. Source: The Pediatric Infectious Disease Journal. 2003 April; 22(4): 380-1. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12712975&dopt=Abstract
Studies 181
•
Posttransplantation Epstein-Barr viral meningitis in a patient with chronic myelogenous leukemia. Author(s): Kanamori H, Fujisawa S, Yamaji S, Tanaka M, Tomita N, Fujimaki K, Ishigatsubo Y. Source: International Journal of Hematology. 2001 December; 74(4): 473-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11794708&dopt=Abstract
•
Post-traumatic meningitis: histomorphological findings, postmortem microbiology and forensic implications. Author(s): Matschke J, Tsokos M. Source: Forensic Science International. 2001 January 15; 115(3): 199-205. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11074175&dopt=Abstract
•
Potential for expansion of the donor pool using liver allografts from donors with bacterial meningitis. Author(s): Issa NC, Patel R. Source: Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society. 2002 October; 8(10): 977-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12360446&dopt=Abstract
•
Predicting outcome in childhood bacterial meningitis: are pneumococci stronger than glutamate? Author(s): Whalen MJ. Source: Pediatric Critical Care Medicine : a Journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies. 2003 April; 4(2): 260-1. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12749667&dopt=Abstract
•
Predicting the outcome of neonatal bacterial meningitis. Author(s): Klinger G, Chin CN, Beyene J, Perlman M. Source: Pediatrics. 2000 September; 106(3): 477-82. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10969090&dopt=Abstract
•
Prediction of bacterial meningitis in children with meningeal signs: reduction of lumbar punctures. Author(s): Oostenbrink R, Moons KG, Donders AR, Grobbee DE, Moll HA. Source: Acta Paediatrica (Oslo, Norway : 1992). 2001 June; 90(6): 611-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11440091&dopt=Abstract
182 Meningitis
•
Predictive value of serum and cerebrospinal fluid procalcitonin levels for the diagnosis of bacterial meningitis. Author(s): Jereb M, Muzlovic I, Hojker S, Strle F. Source: Infection. 2001 August; 29(4): 209-12. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11545482&dopt=Abstract
•
Predictors of bacterial meningitis in the era after Haemophilus influenzae. Author(s): Freedman SB, Marrocco A, Pirie J, Dick PT. Source: Archives of Pediatrics & Adolescent Medicine. 2001 December; 155(12): 1301-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11732947&dopt=Abstract
•
Predictors of inpatient mortality in 190 adult patients with tuberculous meningitis. Author(s): Qureshi HU, Merwat SN, Nawaz SA, Rana AA, Malik A, Mahmud MK, Latif A, Khan A, Sarwari AR. Source: J Pak Med Assoc. 2002 April; 52(4): 159-63. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12174481&dopt=Abstract
•
Predictors of outcome in patients with tuberculous meningitis. Author(s): Hosoglu S, Geyik MF, Balik I, Aygen B, Erol S, Aygencel TG, Mert A, Saltoglu N, Dokmetas I, Felek S, Sunbul M, Irmak H, Aydin K, Kokoglu OF, Ucmak H, Altindis M, Loeb M. Source: The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union against Tuberculosis and Lung Disease. 2002 January; 6(1): 64-70. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11931403&dopt=Abstract
•
Presentation, time to antibiotics, and mortality of patients with bacterial meningitis at an urban county medical center. Author(s): Miner JR, Heegaard W, Mapes A, Biros M. Source: The Journal of Emergency Medicine. 2001 November; 21(4): 387-92. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11728765&dopt=Abstract
•
Prevalence of fungal meningitis among HIV positive & negative subjects in Indore (MP state). Author(s): Jaiswal SP, Hemwani N, Sharma N, Athale S, Chitnis DS. Source: Indian Journal of Medical Sciences. 2002 July; 56(7): 325-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12645168&dopt=Abstract
•
Preventing and treating meningococcal meningitis. Author(s): Michael PA. Source: Medsurg Nursing : Official Journal of the Academy of Medical-Surgical Nurses. 2002 February; 11(1): 9-12; Quiz 13. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11901615&dopt=Abstract
Studies 183
•
Prevention of Haemophilus influenzae type b (Hib) meningitis and emergence of serotype replacement with type a strains after introduction of Hib immunization in Brazil. Author(s): Ribeiro GS, Reis JN, Cordeiro SM, Lima JB, Gouveia EL, Petersen M, Salgado K, Silva HR, Zanella RC, Almeida SC, Brandileone MC, Reis MG, Ko AI. Source: The Journal of Infectious Diseases. 2003 January 1; 187(1): 109-16. Epub 2002 December 13. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12508153&dopt=Abstract
•
Prevention of meningitis: cochlear implants and inner ear abnormalities. Author(s): Bluestone CD. Source: Archives of Otolaryngology--Head & Neck Surgery. 2003 March; 129(3): 279-81. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12622535&dopt=Abstract
•
Prevention, treatment and outcomes of bacterial meningitis in childhood. Author(s): Bedford H. Source: Prof Nurse. 2001 October; 17(2): 100-2. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12030056&dopt=Abstract
•
Prevotella intermedia meningitis associated with cerebrospinal fluid leakage in an adolescent. Author(s): Brook I. Source: The Pediatric Infectious Disease Journal. 2003 August; 22(8): 751-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12938679&dopt=Abstract
•
Primary diffuse leptomeningeal gliomatosis simulating tuberculous meningitis. Author(s): Rees JH, Balakas N, Agathonikou A, Hain SF, Giovanonni G, Panayiotopoulos CP, Luxsuwong M, Revesz T. Source: Journal of Neurology, Neurosurgery, and Psychiatry. 2001 January; 70(1): 120-2. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11118261&dopt=Abstract
•
Primary HIV infection in an adolescent presenting as aseptic meningitis. Author(s): Das BB, Posada R, Mendez H. Source: Indian J Pediatr. 2002 August; 69(8): 731. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12356231&dopt=Abstract
•
Primary Staphylococcus aureus meningitis in an infant. Author(s): Gnanalingham MG, Clarke MA. Source: Journal of the Royal Society of Medicine. 2001 February; 94(2): 86-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11234209&dopt=Abstract
184 Meningitis
•
Problem of timely diagnosis in anthrax meningitis. Author(s): Kanungo R, Kumar A, Bhattacharya S, Dutta TK, Das AK, Badrinath S. Source: J Assoc Physicians India. 2002 July; 50: 913-5. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12126347&dopt=Abstract
•
Prochlorperazine-induced extrapyramidal effects mimicking meningitis in a child. Author(s): Muniz AE. Source: Southern Medical Journal. 2000 June; 93(6): 629-30. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10881788&dopt=Abstract
•
Profile of childhood meningitis in a hospital in South West Saudi Arabia. Author(s): Al-Binali AM, Al-Fifi SH. Source: Saudi Med J. 2002 July; 23(7): 793-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12174227&dopt=Abstract
•
Prognosis of tuberculous meningitis in adults in the era of modern antituberculous chemotherapy. Author(s): Wang JT, Hung CC, Sheng WH, Wang JY, Chang SC, Luh KT. Source: J Microbiol Immunol Infect. 2002 December; 35(4): 215-22. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12542246&dopt=Abstract
•
Prognostic factors in childhood tuberculous meningitis. Author(s): Mahadevan B, Mahadevan S, Serane VT. Source: Journal of Tropical Pediatrics. 2002 December; 48(6): 362-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12521280&dopt=Abstract
•
Prognostic factors in children with purulent meningitis in Turkey. Author(s): Kirimi E, Tuncer O, Arslan S, Atas B, Caksen H, Uner A, Oner AF, Odabas D. Source: Acta Medica Okayama. 2003 February; 57(1): 39-44. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12765223&dopt=Abstract
•
Prognostic value of EEG in neonatal bacterial meningitis. Author(s): Klinger G, Chin CN, Otsubo H, Beyene J, Perlman M. Source: Pediatric Neurology. 2001 January; 24(1): 28-31. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11182277&dopt=Abstract
Studies 185
•
Prospective analysis of 61 cases of enteroviral meningitis: interest of systematic genome detection in cerebrospinal fluid irrespective of cytologic examination results. Author(s): Henquell C, Chambon M, Bailly JL, Alcaraz S, De Champs C, Archimbaud C, Labbe A, Charbonne F, Peigue-Lafeuille H. Source: Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology. 2001 April; 21(1): 29-35. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11255095&dopt=Abstract
•
Prospective validation of a diagnosis model as an aid to therapeutic decision-making in acute meningitis. Author(s): Baty V, Viel JF, Schuhmacher H, Jaeger F, Canton P, Hoen B. Source: European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology. 2000 June; 19(6): 422-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10947216&dopt=Abstract
•
Prospects for prevention of meningococcal meningitis. Author(s): Perkins BA. Source: Lancet. 2001 July 28; 358(9278): 255-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11498206&dopt=Abstract
•
Protection against meningitis-associated central nervous system complications by uric acid. Author(s): Kastenbauer S, Pfister HW. Source: Medical Hypotheses. 2002 May; 58(5): 431. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12199194&dopt=Abstract
•
Psychometric testing in bacterial meningitis: results of a long-term prospective study of infants and children treated between 1973 and 1977. Author(s): Dodge PR, Scaer M, Holmes SJ, Pomeroy SL, Feigin RD. Source: Journal of Child Neurology. 2001 November; 16(11): 854-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11732773&dopt=Abstract
•
Purulent meningitis with unusual diffusion-weighted MRI findings. Author(s): Abe M, Takayama Y, Yamashita H, Noguchi M, Sagoh T. Source: European Journal of Radiology. 2002 October; 44(1): 1-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12350401&dopt=Abstract
•
Quality-of-life-adjusted survival comparison of sustained-release cytosine arabinoside versus intrathecal methotrexate for treatment of solid tumor neoplastic meningitis. Author(s): Cole BF, Glantz MJ, Jaeckle KA, Chamberlain MC, Mackowiak JI. Source: Cancer. 2003 June 15; 97(12): 3053-60. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12784341&dopt=Abstract
186 Meningitis
•
Quinolone treatment for pediatric bacterial meningitis: a comparative study of trovafloxacin and ceftriaxone with or without vancomycin. Author(s): Saez-Llorens X, McCoig C, Feris JM, Vargas SL, Klugman KP, Hussey GD, Frenck RW, Falleiros-Carvalho LH, Arguedas AG, Bradley J, Arrieta AC, Wald ER, Pancorbo S, McCracken GH Jr, Marques SR; Trovan menigitis Study Group. Source: The Pediatric Infectious Disease Journal. 2002 January; 21(1): 14-22. Erratum In: Pediatr Infect Dis J 2002 March; 21(3): 270. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11791092&dopt=Abstract
•
Radiological case of the month. Intracranial hypertension and reduced cerebral blood flow in meningococcal meningitis. Author(s): Ibsen LM. Source: Archives of Pediatrics & Adolescent Medicine. 2002 March; 156(3): 293-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11876677&dopt=Abstract
•
Randomized trial of four vs. seven days of ceftriaxone treatment for bacterial meningitis in children with rapid initial recovery. Author(s): Roine I, Ledermann W, Foncea LM, Banfi A, Cohen J, Peltola H. Source: The Pediatric Infectious Disease Journal. 2000 March; 19(3): 219-22. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10749463&dopt=Abstract
•
Rapid detection of Haemophilus influenzae type b in Bangladeshi children with pneumonia and meningitis by PCR and analysis of antimicrobial resistance. Author(s): Shoma S, Rahman M, Yasmin M. Source: J Health Popul Nutr. 2001 December; 19(4): 268-74. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11855348&dopt=Abstract
•
Rapid diagnosis of acute pyogenic meningitis by a combined PCR dot-blot assay. Author(s): Balganesh M, Lalitha MK, Nathaniel R. Source: Molecular and Cellular Probes. 2000 April; 14(2): 61-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10799266&dopt=Abstract
•
Rapid diagnosis of tuberculous meningitis by a dot-immunobinding assay. Author(s): Sumi MG, Annamma M, Sarada C, Radhakrishnan VV. Source: Acta Neurologica Scandinavica. 2000 January; 101(1): 61-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10660155&dopt=Abstract
•
Rapid diagnosis of tuberculous meningitis by ligase chain reaction amplification. Author(s): Rajo MC, Perez Del Molina ML, Lado Lado FL, Lopez MJ, Prieto E, Pardo F. Source: Scandinavian Journal of Infectious Diseases. 2002; 34(1): 14-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11878290&dopt=Abstract
Studies 187
•
Rapid molecular diagnosis of tuberculous meningitis using the Gen-probe Amplified Mycobacterium Tuberculosis direct test in a large Canadian public health laboratory. Author(s): Chedore P, Jamieson FB. Source: The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union against Tuberculosis and Lung Disease. 2002 October; 6(10): 913-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12365579&dopt=Abstract
•
Rapid real-time PCR for determination of penicillin susceptibility in pneumococcal meningitis, including culture-negative cases. Author(s): Kearns AM, Graham C, Burdess D, Heatherington J, Freeman R. Source: Journal of Clinical Microbiology. 2002 February; 40(2): 682-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11825996&dopt=Abstract
•
Rational antibiotics therapy in bacterial meningitis. Author(s): Dutta AK, Bhatnagar SK. Source: Indian J Pediatr. 2001 July; 68 Suppl 3: S32-9. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11980457&dopt=Abstract
•
Recent increase in meningitis Caused by Neisseria meningitidis serogroups A and W135, Yaounde, Cameroon. Author(s): Fonkoua MC, Taha MK, Nicolas P, Cunin P, Alonso JM, Bercion R, Musi J, Martin PM. Source: Emerging Infectious Diseases. 2002 March; 8(3): 327-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11927034&dopt=Abstract
•
Recurrence of bacterial meningitis in a patient with Crouzon syndrome and pseudomeningocele. Author(s): Ohmori M, Kamio H, Inokuchi K, Tsutsumi H, Fujimura A. Source: Southern Medical Journal. 2002 July; 95(7): 780-1. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12144091&dopt=Abstract
•
Recurrence of pneumococcal meningitis due to primary spontaneous cerebrospinal fluid fistulas. Author(s): Wen HY, Chou ML, Lin KL, Kao PF, Chen JF. Source: Chang Gung Med J. 2001 November; 24(11): 724-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11820653&dopt=Abstract
•
Recurrent aseptic meningitis due to different non-steroidal anti-inflammatory drugs including rofecoxib. Author(s): Ashwath ML, Katner HP. Source: Postgraduate Medical Journal. 2003 May; 79(931): 295-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12782779&dopt=Abstract
188 Meningitis
•
Recurrent aseptic meningitis in a five-year-old Latino boy. Author(s): Ng L, Janner D. Source: The Pediatric Infectious Disease Journal. 2003 April; 22(4): 386-7, 389-90. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12712979&dopt=Abstract
•
Recurrent bacterial meningitis: the search for a cause. Author(s): Harsha WJ, Varon D, Pritchard PB 3rd. Source: J S C Med Assoc. 2002 August; 98(4): 193-5. Review. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12216381&dopt=Abstract
•
Recurrent dermatomal vesicular skin lesions: a clue to diagnosis of herpes simplex virus 2 meningitis. Author(s): Gonzales N, Tyler KL, Gilden DH. Source: Archives of Neurology. 2003 June; 60(6): 868-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12810492&dopt=Abstract
•
Recurrent herpes simplex virus type 2 meningitis: a case report of Mollaret's meningitis. Author(s): Kojima Y, Hashiguchi H, Hashimoto T, Tsuji S, Shoji H, Kazuyama Y. Source: Japanese Journal of Infectious Diseases. 2002 June; 55(3): 85-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12195049&dopt=Abstract
•
Recurrent meningitis due to unrecognised skull fracture. Author(s): Emby D. Source: South African Medical Journal. Suid-Afrikaanse Tydskrif Vir Geneeskunde. 2003 March; 93(3): 160-1. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12768931&dopt=Abstract
•
Recurrent meningitis due to unrecognised skull fracture. Author(s): Ouma JR. Source: South African Medical Journal. Suid-Afrikaanse Tydskrif Vir Geneeskunde. 2002 October; 92(10): 778-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12432796&dopt=Abstract
•
Recurrent meningitis in a seven-year-old girl. Author(s): Nakhla IA, Mansour A, Sultan Y, Frenck W Jr. Source: The Pediatric Infectious Disease Journal. 2002 November; 21(11): 1081, 1093-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12458573&dopt=Abstract
Studies 189
•
Recurrent Pneumococcal bacteraemia and meningitis in an asplenic adult with possible unusual focus. Author(s): Kragsbjerg P, Rydman H. Source: Scandinavian Journal of Infectious Diseases. 2001; 33(9): 706-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11669231&dopt=Abstract
•
Recurrent pneumococcal meningitis in homozygous C3 deficiency. Author(s): Totan M. Source: Indian J Pediatr. 2002 July; 69(7): 625-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12173704&dopt=Abstract
•
Recurrent pyogenic meningitis in a case of transethmoid encephalocele. Author(s): Dhar MC, Chaudhuri S, Basu K, Pain S, Sau TJ, Mitra K. Source: J Assoc Physicians India. 2001 July; 49: 767-8. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11573570&dopt=Abstract
•
Recurrent pyogenic meningitis: an unusual presentation in a case of neurofibromatosis-1. Author(s): Goel D, Jha S, Gupta RK, Hussain M. Source: Pediatric Neurosurgery. 2001 May; 34(5): 242-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11423774&dopt=Abstract
•
Recurrent Streptococcus pneumoniae meningitis. Author(s): Davachi F, Bregu H, Lito G. Source: Journal of Tropical Pediatrics. 2002 August; 48(4): 249-51. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12200990&dopt=Abstract
•
Recurring aseptic meningitis after travel to the tropics: a case of Mollaret's meningitis? Case report with review of the literature. Author(s): Wynants H, Taelman H, Martin JJ, Van den Ende J. Source: Clinical Neurology and Neurosurgery. 2000 June; 102(2): 113-5. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10817900&dopt=Abstract
•
Relationship between penicillin and cephalosporin resistance of Streptococcus pneumoniae strains and its inflammatory activity in the experimental model of meningitis. Author(s): Fernandez A, Cabellos C, Tubau F, Linares J, Viladrich PF, Gudiol F. Source: Medical Microbiology and Immunology. 2001 December; 190(3): 135-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11827202&dopt=Abstract
190 Meningitis
•
Repeated relapses in a meropenem-treated Pseudomonas aeruginosa meningitis. Author(s): Esen S, Leblebicioglu H, Sunbul M, Eroglu C, Leblebcioglu H. Source: Journal of Chemotherapy (Florence, Italy). 2002 October; 14(5): 535-6. Erratum In: J Chemother. 2002 December; 14(6): 642. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12462436&dopt=Abstract
•
Reprogramming the host response in bacterial meningitis: how best to improve outcome? Author(s): van der Flier M, Geelen SP, Kimpen JL, Hoepelman IM, Tuomanen EI. Source: Clinical Microbiology Reviews. 2003 July; 16(3): 415-29. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12857775&dopt=Abstract
•
Reversible acute hydrocephalus complicating Listeria monocytogenes meningitis. Author(s): Frat JP, Veinstein A, Wager M, Burucoa C, Robert R. Source: European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology. 2001 July; 20(7): 512-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11561813&dopt=Abstract
•
Rhodococcus equi nosocomial meningitis cured by levofloxacin and shunt removal. Author(s): Scotton PG, Tonon E, Giobbia M, Gallucci M, Rigoli R, Vaglia A. Source: Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America. 2000 January; 30(1): 223-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10619769&dopt=Abstract
•
Rhodotorula glutinis-related meningitis. Author(s): Lanzafame M, De Checchi G, Parinello A, Trevenzoli M, Cattelan AM. Source: Journal of Clinical Microbiology. 2001 January; 39(1): 410. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11191228&dopt=Abstract
•
Rich nations, poor nations, and bacterial meningitis. Author(s): McCracken GH Jr. Source: Lancet. 2002 July 20; 360(9328): 183. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12133648&dopt=Abstract
•
Rickettsia typhi infection presenting as subacute meningitis. Author(s): Galanakis E, Gikas A, Bitsori M, Sbyrakis S. Source: Journal of Child Neurology. 2002 February; 17(2): 156-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11952082&dopt=Abstract
Studies 191
•
Risk analysis of aseptic meningitis after measles-mumps-rubella vaccination in Korean children by using a case-crossover design. Author(s): Ki M, Park T, Yi SG, Oh JK, Choi B. Source: American Journal of Epidemiology. 2003 January 15; 157(2): 158-65. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12522023&dopt=Abstract
•
Risk and case fatality rate of meningitis in patients with liver cirrhosis. Author(s): Molle I, Thulstrup AM, Svendsen N, Schonheyder HC, Sorensen HT. Source: Scandinavian Journal of Infectious Diseases. 2000; 32(4): 407-10. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10959650&dopt=Abstract
•
Risk factors and prognostic indicators of bacterial meningitis in a cohort of 3580 postneurosurgical patients. Author(s): Federico G, Tumbarello M, Spanu T, Rosell R, Iacoangeli M, Scerrati M, Tacconelli E. Source: Scandinavian Journal of Infectious Diseases. 2001; 33(7): 533-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11515765&dopt=Abstract
•
Risk factors for meningococcal meningitis in northern Ghana. Author(s): Hodgson A, Smith T, Gagneux S, Adjuik M, Pluschke G, Mensah NK, Binka F, Genton B. Source: Trans R Soc Trop Med Hyg. 2001 September-October; 95(5): 477-80. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11706652&dopt=Abstract
•
Risk of bacterial meningitis in children with cochlear implants. Author(s): Reefhuis J, Honein MA, Whitney CG, Chamany S, Mann EA, Biernath KR, Broder K, Manning S, Avashia S, Victor M, Costa P, Devine O, Graham A, Boyle C. Source: The New England Journal of Medicine. 2003 July 31; 349(5): 435-45. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12890842&dopt=Abstract
•
Risk of tuberculosis infection and tuberculous meningitis after discontinuation of Bacillus Calmette-Guerin in Beijing. Author(s): Zhang LX, Tu DH, He GX, Ma ZQ, Nagelkerke NJ, Borgdorff MW, Enarson DA, Broekmans JF. Source: American Journal of Respiratory and Critical Care Medicine. 2000 October; 162(4 Pt 1): 1314-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11029337&dopt=Abstract
•
Role of cerebrospinal fluid shunting for human immunodeficiency virus-positive patients with tuberculous meningitis and hydrocephalus. Author(s): Nadvi SS, Nathoo N, Annamalai K, van Dellen JR, Bhigjee AI. Source: Neurosurgery. 2000 September; 47(3): 644-9; Discussion 649-50. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10981752&dopt=Abstract
192 Meningitis
•
Role of clinical, radiological, and neurophysiological changes in predicting the outcome of tuberculous meningitis: a multivariable analysis. Author(s): Misra UK, Kalita J, Roy AK, Mandal SK, Srivastava M. Source: Journal of Neurology, Neurosurgery, and Psychiatry. 2000 March; 68(3): 300-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10675210&dopt=Abstract
•
Role of dexamethasone in acute bacterial meningitis in adults. Author(s): Ahsan T, Shahid M, Mahmood T, Jabeen R, Jehangir U, Saleem M, Ahmed N, Shaheer A. Source: J Pak Med Assoc. 2002 June; 52(6): 233-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12481630&dopt=Abstract
•
Role of IS6110-targeted PCR, culture, biochemical, clinical, and immunological criteria for diagnosis of tuberculous meningitis. Author(s): Caws M, Wilson SM, Clough C, Drobniewski F. Source: Journal of Clinical Microbiology. 2000 September; 38(9): 3150-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10970348&dopt=Abstract
•
Role of the urokinase plasminogen activator system in patients with bacterial meningitis. Author(s): Winkler F, Kastenbauer S, Koedel U, Pfister HW. Source: Neurology. 2002 November 12; 59(9): 1350-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12427882&dopt=Abstract
•
Safety and efficacy of liposomal amphotericin B in patients with cryptococcal meningitis. Author(s): Kotwani RN, Gokhale PC, Bodhe PV, Kirodian BG, Kshirsagar NA. Source: J Assoc Physicians India. 2001 November; 49: 1086-90. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11868862&dopt=Abstract
•
Safety and efficacy of recombinant granulocyte colony-stimulating factor as an adjunctive therapy for Streptococcus pneumoniae meningitis in non-neutropenic adult patients: a pilot study. Author(s): de Lalla F, Nicolin R, Lazzarini L. Source: The Journal of Antimicrobial Chemotherapy. 2000 November; 46(5): 843-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11062212&dopt=Abstract
•
Salmonella enteritidis meningitis in an infant. Author(s): Gupta N, Gupta P. Source: Indian Pediatrics. 2001 February; 38(2): 205-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11224593&dopt=Abstract
Studies 193
•
Salmonella Group B meningitis 6 weeks after hospitalization in a neonatal care unit. Author(s): Price EH, Workman MR, de Louvois J. Source: The Journal of Hospital Infection. 2001 May; 48(1): 80-1. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11358475&dopt=Abstract
•
Salmonella group B meningitis six weeks after hospitalization in a neonatal care unit. Author(s): Meessen NE, Jansen NJ, Tjhie HT. Source: The Journal of Hospital Infection. 2000 October; 46(2): 160-1. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11049713&dopt=Abstract
•
Salmonella meningitis in adults infected with HIV: case report and review of the literature. Author(s): Leonard MK, Murrow JR, Jurado R, Gaynes R. Source: The American Journal of the Medical Sciences. 2002 May; 323(5): 266-8. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12018670&dopt=Abstract
•
Salmonella meningitis: report of three cases in adults and literature review. Author(s): Karim M, Islam N. Source: Infection. 2002 April; 30(2): 104-8. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12018467&dopt=Abstract
•
Salmonella typhimurium DT104 septicaemia with meningitis in neonatal piglets. Author(s): van der Wolf PJ, Vercammen TJ, Geene JJ, van Exsel AC, Peperkamp NH, Voets MTh, Zeeuwen AA. Source: Vet Q. 2001 November; 23(4): 199-201. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11765240&dopt=Abstract
•
Salmonella virchow meningitis in an adult. Author(s): Gille-Johnson P, Kovamees J, Lindgren V, Aufwerber E, Struve J. Source: Scandinavian Journal of Infectious Diseases. 2000; 32(4): 431-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10959659&dopt=Abstract
•
Seasonal paradox in acute meningitis at Nawabshah. Author(s): Shaikh S, Shaikh RB, Faiz MS. Source: J Coll Physicians Surg Pak. 2003 April; 13(4): 207-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12718775&dopt=Abstract
•
Sensorineural hearing loss following acute bacterial meningitis in non-neonates. Author(s): Cherian B, Singh T, Chacko B, Abraham A. Source: Indian J Pediatr. 2002 November; 69(11): 951-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12503658&dopt=Abstract
194 Meningitis
•
Sepsis and meningitis due to penicillin-resistant viridans streptococci in neutropenic children. Author(s): Tokuda K, Nishi J, Yoshinaga M, Ijichi O, Ikarimoto N, Shii A, Etoh S, Fukushige T, Mogi A, Kawakami K, Miyata K. Source: Pediatrics International : Official Journal of the Japan Pediatric Society. 2000 April; 42(2): 174-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10804736&dopt=Abstract
•
Septic shock, meningitis and adrenal hemorrhages in a twelve-year-old. Toxic shocklike syndrome accompanied by meningitis and bilateral adrenal hemorrhage. Author(s): Hoare S, Bajwa RS, Abinun M. Source: The Pediatric Infectious Disease Journal. 2001 January; 20(1): 89-90, 92. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11176580&dopt=Abstract
•
Septicaemia and meningitis in an infant. Author(s): Arslan S, Bozkurt H, Guducuoglu H, Berktas M, Caksen H, Kurtoglu MG, Akcay G. Source: Journal of Paediatrics and Child Health. 2001 August; 37(4): 414-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11547776&dopt=Abstract
•
Septicaemia and meningitis in neonates and during early infancy in the Goteborg area of Sweden. Author(s): Persson E, Trollfors B, Brandberg LL, Tessin I. Source: Acta Paediatrica (Oslo, Norway : 1992). 2002; 91(10): 1087-92. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12434895&dopt=Abstract
•
Sequelae after bacterial meningitis in childhood. Author(s): Oostenbrink R, Maas M, Moons KG, Moll HA. Source: Scandinavian Journal of Infectious Diseases. 2002; 34(5): 379-82. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12069024&dopt=Abstract
•
Sequential MRI in chronic meningitis during adrenocorticotropic hormone treatment for West syndrome. Author(s): Go T. Source: Child's Nervous System : Chns : Official Journal of the International Society for Pediatric Neurosurgery. 2001 August; 17(8): 497-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11508542&dopt=Abstract
•
Serial study of clinical and CT changes in tuberculous meningitis. Author(s): Ranjan P, Kalita J, Misra UK. Source: Neuroradiology. 2003 May; 45(5): 277-82. Epub 2003 April 10. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12687301&dopt=Abstract
Studies 195
•
Serum C-reactive protein in the differential diagnosis of childhood meningitis. Author(s): Tatara R, Imai H. Source: Pediatrics International : Official Journal of the Japan Pediatric Society. 2000 October; 42(5): 541-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11059546&dopt=Abstract
•
Seven days vs. 10 days ceftriaxone therapy in bacterial meningitis. Author(s): Singhi P, Kaushal M, Singhi S, Ray P. Source: Journal of Tropical Pediatrics. 2002 October; 48(5): 273-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12405169&dopt=Abstract
•
Shortfalls in the use of adenosine deaminase in tuberculous meningitis. Author(s): John MA, Coovadia YM. Source: Trop Doct. 2001 July; 31(3): 138-9. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11444331&dopt=Abstract
•
Short-term antibiotic prophylaxis for the prevention of wound infection and secondary meningitis in acoustic neuroma surgery: a ten-year experience in a regional hospital. Author(s): Minola E, Farina C, Zappone C, Arosio M, Lorenzi N, Mazzoni A. Source: Journal of Chemotherapy (Florence, Italy). 2000 December; 12(6): 521-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11154037&dopt=Abstract
•
Should an India ink test be used to detect cryptococcal meningitis in a low-risk population--primarily in a general acute care setting--or are better stat tests available? Author(s): Koneman EW. Source: Cap Today. 2000 December; 14(12): 62. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11188352&dopt=Abstract
•
Should repeat lumbar punctures be routinely done in neonates with bacterial meningitis?. Results of a survey into clinical practice. Author(s): Agarwal R, Emmerson AJ. Source: Archives of Disease in Childhood. 2001 May; 84(5): 451-2. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11360821&dopt=Abstract
•
Shunt surgery for hydrocephalus complicating cryptococcal meningitis in human immunodeficiency virus-negative patients. Author(s): Liliang PC, Liang CL, Chang WN, Chen HJ, Su TM, Lu K, Lu CH. Source: Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America. 2003 September 1; 37(5): 673-8. Epub 2003 August 12. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12942399&dopt=Abstract
196 Meningitis
•
Significance of cerebrospinal fluid adenosine deaminase isoenzymes in tuberculous (TB) meningitis. Author(s): Schutte CM, Ungerer JP, du Plessis H, van der Meyden CH. Source: Journal of Clinical Laboratory Analysis. 2001; 15(5): 236-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11574950&dopt=Abstract
•
Signs of meningeal irritation at the emergency department: how often bacterial meningitis? Author(s): Oostenbrink R, Moons KG, Theunissen CC, Derksen-Lubsen G, Grobbee DE, Moll HA. Source: Pediatric Emergency Care. 2001 June; 17(3): 161-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11437138&dopt=Abstract
•
Simultaneous detection of Neisseria meningitidis, Haemophilus influenzae, and Streptococcus pneumoniae in suspected cases of meningitis and septicemia using real-time PCR. Author(s): Corless CE, Guiver M, Borrow R, Edwards-Jones V, Fox AJ, Kaczmarski EB. Source: Journal of Clinical Microbiology. 2001 April; 39(4): 1553-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11283086&dopt=Abstract
•
Single photon emission computed tomography in tuberculous meningitis. Author(s): Misra UK, Kalita J, Das BK. Source: Postgraduate Medical Journal. 2000 October; 76(900): 642-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11009579&dopt=Abstract
•
Sinusitis complicated by meningitis: current management. Author(s): Younis RT, Anand VK, Childress C. Source: The Laryngoscope. 2001 August; 111(8): 1338-42. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11568566&dopt=Abstract
•
Specific humoral immunity in mumps meningitis in children. Author(s): Kacprzak-Bergman I, Zaleska I, Jasonek J. Source: Medical Science Monitor : International Medical Journal of Experimental and Clinical Research. 2001 September-October; 7(5): 977-81. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11535945&dopt=Abstract
•
SPECT changes and their correlation with EEG changes in tuberculous meningitis. Author(s): Kalita J, Misra UK, Das BK. Source: Electromyogr Clin Neurophysiol. 2002 January-February; 42(1): 39-44. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11851008&dopt=Abstract
Studies 197
•
Spectrum of clinical and histopathologic responses to intracranial electrodes: from multifocal aseptic meningitis to multifocal hypersensitivity-type meningovasculitis. Author(s): Stephan CL, Kepes JJ, SantaCruz K, Wilkinson SB, Fegley B, Osorio I. Source: Epilepsia. 2001 July; 42(7): 895-901. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11488890&dopt=Abstract
•
Spinal epidermoid tumors: novel approach to aseptic meningitis. Author(s): Kapoor JR, Kapoor R, Buzea C, Gropper MR. Source: Journal of Spinal Disorders & Techniques. 2003 April; 16(2): 193-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12679675&dopt=Abstract
•
Spinal epidural haematoma misdiagnosed as meningitis. Author(s): Hui AC, Wong HT, Lam JM. Source: Hosp Med. 2001 September; 62(9): 571. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11584621&dopt=Abstract
•
Spinal seeding of anaplastic ependymoma mimicking fungal meningitis. A case report and review of the literature. Author(s): Murakami M, Kuratsu J, Takeshima H, Soyama N, Shinojima N, Ushio Y. Source: Journal of Neurosurgical Sciences. 2000 March; 44(1): 46-51; Discussion 51-2. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10961497&dopt=Abstract
•
Spontaneous Escherichia coli meningitis in an adult. Author(s): Mofredj A, Guerin JM, Leibinger F, Mamoudi R. Source: Scandinavian Journal of Infectious Diseases. 2000; 32(6): 699-700. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11200386&dopt=Abstract
•
Spontaneous esophageal perforation presenting as meningitis. Author(s): Jurani CC, Early GL, Roberts SR. Source: The Annals of Thoracic Surgery. 2002 April; 73(4): 1294-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11996275&dopt=Abstract
•
Staphylococcus aureus meningitis in a post splenectomy patient. Author(s): Sharief S, Memon M, Sarwari AR. Source: J Pak Med Assoc. 2000 September; 50(9): 320-1. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11043025&dopt=Abstract
198 Meningitis
•
Staphylococcus aureus meningitis in adults: a clinical comparison of infections caused by methicillin-resistant and methicillin-sensitive strains. Author(s): Chang WN, Lu CH, Wu JJ, Chang HW, Tsai YC, Chen FT, Chien CC. Source: Infection. 2001 October; 29(5): 245-50. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11688900&dopt=Abstract
•
Staphylococcus aureus meningitis in children: a review of 30 community-acquired cases. Author(s): Rodrigues MM, Patrocinio SJ, Rodrigues MG. Source: Arquivos De Neuro-Psiquiatria. 2000 September; 58(3B): 843-51. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11018821&dopt=Abstract
•
Staphylococcus aureus meningitis: experience with cefuroxime treatment during a 16 year period in a Danish region. Author(s): Norgaard M, Gudmundsdottir G, Larsen CS, Schonheyder HC. Source: Scandinavian Journal of Infectious Diseases. 2003; 35(5): 311-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12875516&dopt=Abstract
•
Stenotrophomonas maltophilia meningitis - a rare cause of headache in the ED. Author(s): Spencer MT, Baron BJ. Source: The American Journal of Emergency Medicine. 2001 October; 19(6): 532-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11593485&dopt=Abstract
•
Stenotrophomonas maltophilia meningitis, bacteremia and respiratory infection. Author(s): Platsouka E, Routsi C, Chalkis A, Dimitriadou E, Paniara O, Roussos C. Source: Scandinavian Journal of Infectious Diseases. 2002; 34(5): 391-2. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12069028&dopt=Abstract
•
Still's disease can cause neutrophilic meningitis. Author(s): Blockmans DE, Knockaert DC, Bobbaers HJ. Source: Neurology. 2000 March 14; 54(5): 1203-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10720305&dopt=Abstract
•
Streptococcal meningitis after spinal anesthesia: report of a case. Author(s): Kocamanoglu IS, Sener EB, Tur A, Ustun E, Sahinoglu H. Source: Canadian Journal of Anaesthesia = Journal Canadien D'anesthesie. 2003 March; 50(3): 314-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12620962&dopt=Abstract
Studies 199
•
Streptococcal meningitis in adults: therapeutic outcomes and prognostic factors. Author(s): Lu CH, Chang WN, Chang HW. Source: Clinical Neurology and Neurosurgery. 2001 October; 103(3): 137-42. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11532551&dopt=Abstract
•
Streptococcal meningitis resulting from contact with an infected horse. Author(s): Downar J, Willey BM, Sutherland JW, Mathew K, Low DE. Source: Journal of Clinical Microbiology. 2001 June; 39(6): 2358-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11376093&dopt=Abstract
•
Streptococcus agalactiae meningitis in adults: report of two cases. Author(s): Chotmongkol V, Poonsriaram A. Source: J Med Assoc Thai. 2002 March; 85(3): 385-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12117031&dopt=Abstract
•
Streptococcus bovis meningitis in a healthy adult patient. Author(s): Vilarrasa N, Prats A, Pujol M, Gason A, Viladrich PF. Source: Scandinavian Journal of Infectious Diseases. 2002; 34(1): 61-2. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11874167&dopt=Abstract
•
Streptococcus bovis meningitis in a neonate with Ivemark syndrome. Author(s): Koh TH, Ho S. Source: Scandinavian Journal of Infectious Diseases. 2002; 34(1): 63-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11874168&dopt=Abstract
•
Streptococcus bovis meningitis in an infant. Author(s): Grant RJ, Whitehead TR, Orr JE. Source: Journal of Clinical Microbiology. 2000 January; 38(1): 462-3. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10618145&dopt=Abstract
•
Streptococcus bovis meningitis in an otherwise healthy infant. Author(s): Okumura A, Takahashi H, Ogawa A, Kuno K, Watanabe K. Source: Clinical Pediatrics. 2002 September; 41(7): 523-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12365316&dopt=Abstract
•
Streptococcus intermedius: A cause of lobar pneumonia with meningitis and brain abscesses. Author(s): Khatib R, Ramanathan J, Baran J Jr. Source: Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America. 2000 February; 30(2): 396-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10671350&dopt=Abstract
200 Meningitis
•
Streptococcus mitis-induced meningitis after spinal anesthesia. Author(s): Villevieille T, Vincenti-Rouquette I, Petitjeans F, Koulmann P, Legulluche Y, Rousseau JM, Diraison Y, Brinquin L. Source: Anesthesia and Analgesia. 2000 February; 90(2): 500-1. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10648351&dopt=Abstract
•
Streptococcus pneumoniae sepsis and meningitis during the penicillin prophylaxis era in children with sickle cell disease. Author(s): Hord J, Byrd R, Stowe L, Windsor B, Smith-Whitley K. Source: Journal of Pediatric Hematology/Oncology : Official Journal of the American Society of Pediatric Hematology/Oncology. 2002 August-September; 24(6): 470-2. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12218595&dopt=Abstract
•
Streptococcus sanguis meningitis: report of a case. Author(s): Chotmongkol V, Panthavasit J, Vorachit M. Source: J Med Assoc Thai. 2002 July; 85(7): 839-41. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12296418&dopt=Abstract
•
Streptococcus suis meningitis and septicemia contracted from a wild boar in Germany. Author(s): Rosenkranz M, Elsner HA, Sturenburg HJ, Weiller C, Rother J, Sobottka I. Source: Journal of Neurology. 2003 July; 250(7): 869-70. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12883932&dopt=Abstract
•
Streptococcus suis meningitis, a poacher's risk. Author(s): Halaby T, Hoitsma E, Hupperts R, Spanjaard L, Luirink M, Jacobs J. Source: European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology. 2000 December; 19(12): 943-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11205632&dopt=Abstract
•
Streptococcus zooepidemicus meningitis and bacteraemia. Author(s): Ural O, Tuncer I, Dikici N, Aridogan B. Source: Scandinavian Journal of Infectious Diseases. 2003; 35(3): 206-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12751721&dopt=Abstract
•
Subcortical low intensity on MR images of meningitis, viral encephalitis, and leptomeningeal metastasis. Author(s): Lee JH, Na DG, Choi KH, Kim KJ, Ryoo JW, Lee SY, Suh YL. Source: Ajnr. American Journal of Neuroradiology. 2002 April; 23(4): 535-42. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11950641&dopt=Abstract
Studies 201
•
Subdural empyemas--a rare complication of meningococcal cerebrospinal meningitis in children. Author(s): Bako W, Raczkowska-Kozak J, Liberek A, Gora-Gebka M. Source: Medical Science Monitor : International Medical Journal of Experimental and Clinical Research. 2000 September-October; 6(5): 1008-12. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11208447&dopt=Abstract
•
Subhyaloid or subinternal limiting membrane haemorrhage in meningococcal meningitis. Author(s): Sung VC, Murray DC, Price NJ. Source: The British Journal of Ophthalmology. 2000 October; 84(10): 1206-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11202918&dopt=Abstract
•
Successful treatment of Acanthamoeba meningitis with combination oral antimicrobials. Author(s): Singhal T, Bajpai A, Kalra V, Kabra SK, Samantaray JC, Satpathy G, Gupta AK. Source: The Pediatric Infectious Disease Journal. 2001 June; 20(6): 623-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11419508&dopt=Abstract
•
Successful treatment of coccidioidal meningitis with voriconazole. Author(s): Cortez KJ, Walsh TJ, Bennett JE. Source: Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America. 2003 June 15; 36(12): 1619-22. Epub 2003 Jun 09. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12802765&dopt=Abstract
•
Successful treatment of cryptococcal meningitis with liposomal amphotericin B (LAMP-LRC-1) intolerant to conventional amphotericin B. Author(s): Kirodian BG, Virani AR, Kshirsagar NA. Source: J Assoc Physicians India. 2002 April; 50: 601-2. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12164423&dopt=Abstract
•
Successful treatment of meningitis caused by highly-penicillin-resistant Streptococcus mitis in a leukemic child. Author(s): Jaing TH, Chiu CH, Hung IJ. Source: Chang Gung Med J. 2002 March; 25(3): 190-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12022740&dopt=Abstract
202 Meningitis
•
Successful treatment of multidrug-resistant Acinetobacter baumannii meningitis with intravenous colistin sulfomethate sodium. Author(s): Jimenez-Mejias ME, Becerril B, Marquez-Rivas FJ, Pichardo C, Cuberos L, Pachon J. Source: European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology. 2000 December; 19(12): 970-1. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11205640&dopt=Abstract
•
Successful treatment of multi-resistant Stenotrophomonas maltophilia meningitis with ciprofloxacin in a pre-term infant. Author(s): Lo WT, Wang CC, Lee CM, Chu ML. Source: European Journal of Pediatrics. 2002 December; 161(12): 680-2. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12536991&dopt=Abstract
•
Successful treatment of vancomycin-resistant Enterococcus faecium meningitis with linezolid: case report and literature review. Author(s): Shaikh ZH, Peloquin CA, Ericsson CD. Source: Scandinavian Journal of Infectious Diseases. 2001; 33(5): 375-9. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11440224&dopt=Abstract
•
Successful treatment of vancomycin-resistant Enterococcus meningitis with linezolid. Author(s): Hachem R, Afif C, Gokaslan Z, Raad I. Source: European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology. 2001 June; 20(6): 432-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11476449&dopt=Abstract
•
Successful treatment of vancomycin-resistant enterococcus meningitis with linezolid: case report and review of the literature. Author(s): Steinmetz MP, Vogelbaum MA, De Georgia MA, Andrefsky JC, Isada C. Source: Critical Care Medicine. 2001 December; 29(12): 2383-5. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11801846&dopt=Abstract
•
Successful treatment of ventriculostomy-related meningitis caused by vancomycinresistant Enterococcus with intravenous and intraventricular quinupristin/dalfopristin. Author(s): Williamson JC, Glazier SS, Peacock JE Jr. Source: Clinical Neurology and Neurosurgery. 2002 January; 104(1): 54-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11792478&dopt=Abstract
Studies 203
•
Sudden death in a 35-year-old man with occult malformation of the brain and aseptic meningitis. Author(s): Matschke J, Makrigeorgi-Butera M, Stavrou D. Source: The American Journal of Forensic Medicine and Pathology : Official Publication of the National Association of Medical Examiners. 2003 March; 24(1): 83-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12605005&dopt=Abstract
•
Surveillance of measles-mumps-rubella vaccine-associated aseptic meningitis in Germany. Author(s): Schlipkoter U, Muhlberger N, von Kries R, Weil J. Source: Infection. 2002 December; 30(6): 351-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12478324&dopt=Abstract
•
Survival and sequelae of meningococcal meningitis in Ghana. Author(s): Hodgson A, Smith T, Gagneux S, Akumah I, Adjuik M, Pluschke G, Binka F, Genton B. Source: International Journal of Epidemiology. 2001 December; 30(6): 1440-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11821360&dopt=Abstract
•
Suspected allopurinol-induced aseptic meningitis. Author(s): Greenberg LE, Nguyen T, Miller SM. Source: Pharmacotherapy. 2001 August; 21(8): 1007-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11718488&dopt=Abstract
•
Syphilitic meningitis in HIV-patients with meningeal syndrome: report of two cases and review. Author(s): Carmo RA, Moura AS, Christo PP, Morandi AC, Oliveira MS. Source: The Brazilian Journal of Infectious Diseases : an Official Publication of the Brazilian Society of Infectious Diseases. 2001 October; 5(5): 280-7. Epub 2003 February 21. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11779455&dopt=Abstract
•
Syringomyelia as a complication of tuberculous meningitis. Author(s): Tiamkao S, Tanapaisal C, Kanpittaya J, Jitpimolmard S. Source: J Med Assoc Thai. 2001 January; 84(1): 125-9. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11281491&dopt=Abstract
•
Syringomyelia complicating syphilitic spinal meningitis: a case report. Author(s): Bulundwe KK, Myburgh CJ, Gledhill RF. Source: European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies. 2000 March; 7(2): 231-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10809948&dopt=Abstract
204 Meningitis
•
Targeting effective treatment of bacterial meningitis. 2. Author(s): Raser K, Deziel PJ. Source: Jaapa. 2001 May; 14(5): 26-8, 31-2, 35. Review. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11523337&dopt=Abstract
•
TB PCR in the early diagnosis of tuberculous meningitis: evaluation of the Roche semi-automated COBAS Amplicor MTB test with reference to the manual Amplicor MTB PCR test. Author(s): Bonington A, Strang JI, Klapper PE, Hood SV, Parish A, Swift PJ, Damba J, Stevens H, Sawyer L, Potgieter G, Bailey A, Wilkins EG. Source: Tubercle and Lung Disease : the Official Journal of the International Union against Tuberculosis and Lung Disease. 2000; 80(4-5): 191-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11052908&dopt=Abstract
•
Temozolomide in early stages of newly diagnosed malignant glioma and neoplastic meningitis. Author(s): Friedman HS. Source: Seminars in Oncology. 2000 June; 27(3 Suppl 6): 35-40. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10866348&dopt=Abstract
•
Temporal bone fracture and latent meningitis: temporal bone histopathology study of the month. Author(s): Sudhoff H, Linthicum FH Jr. Source: Otology & Neurotology : Official Publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology. 2003 May; 24(3): 521-2. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12806310&dopt=Abstract
•
The antibiotic and anti-inflammatory treatment of bacterial meningitis in adults: do we have to change our strategies in an era of increasing antibiotic resistance? Author(s): Vandecasteele SJ, Knockaert D, Verhaegen J, Van Eldere J, Peetermans WE. Source: Acta Clin Belg. 2001 July-August; 56(4): 225-33. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11603252&dopt=Abstract
•
The application of the Mancini technique as a diagnostic test in the CSF of tuberculous meningitis patients. Author(s): Kashyap RS, Agarwal NP, Chandak NH, Taori GM, Biswas SK, Purohit HJ, Daginawala HF. Source: Medical Science Monitor : International Medical Journal of Experimental and Clinical Research. 2002 June; 8(6): Mt95-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12070446&dopt=Abstract
Studies 205
•
The changing epidemiology of bacterial meningitis and invasive non-meningitic bacterial disease in scotland during the period 1983-99. Author(s): Kyaw MH, Christie P, Jones IG, Campbell H. Source: Scandinavian Journal of Infectious Diseases. 2002; 34(4): 289-98. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12064693&dopt=Abstract
•
The clinical, radiological and pathological profile of tuberculous meningitis in patients with and without human immunodeficiency virus infection. Author(s): Katrak SM, Shembalkar PK, Bijwe SR, Bhandarkar LD. Source: Journal of the Neurological Sciences. 2000 December 1; 181(1-2): 118-26. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11099721&dopt=Abstract
•
The danger of bacterial meningitis in the adult. 1. Author(s): Raser K, Deziel PJ. Source: Jaapa. 2001 May; 14(5): 16-8, 21-4. Review. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11523336&dopt=Abstract
•
The diagnostic accuracy of Kernig's sign, Brudzinski's sign, and nuchal rigidity in adults with suspected meningitis. Author(s): Thomas KE, Hasbun R, Jekel J, Quagliarello VJ. Source: Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America. 2002 July 1; 35(1): 46-52. Epub 2002 June 05. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12060874&dopt=Abstract
•
The effect of adjuvant steroid treatment on serial cerebrospinal fluid changes in tuberculous meningitis. Author(s): Schoeman JF, Elshof JW, Laubscher JA, Janse van Rensburg A, Donald PR. Source: Annals of Tropical Paediatrics. 2001 December; 21(4): 299-305. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11732147&dopt=Abstract
•
The efficacy of fluconazole 600 mg/day versus itraconazole 600 mg/day as consolidation therapy of cryptococcal meningitis in AIDS patients. Author(s): Mootsikapun P, Chetchotisakd P, Anunnatsiri S, Choksawadphinyo K. Source: J Med Assoc Thai. 2003 April; 86(4): 293-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12757072&dopt=Abstract
•
The emergence of resistant pneumococcal meningitis--implications for empiric therapy. Author(s): McMaster P, McIntyre P, Gilmour R, Gilbert L, Kakakios A, Mellis C. Source: Archives of Disease in Childhood. 2002 September; 87(3): 207-10. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12193427&dopt=Abstract
206 Meningitis
•
The epidemiology of acute meningitis in children in England and Wales. Author(s): Davison KL, Ramsay ME. Source: Archives of Disease in Childhood. 2003 August; 88(8): 662-4. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12876156&dopt=Abstract
•
The EQ-5D and the Health Utilities Index for permanent sequelae after meningitis: a head-to-head comparison. Author(s): Oostenbrink R, A Moll HA, Essink-Bot ML. Source: Journal of Clinical Epidemiology. 2002 August; 55(8): 791-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12384194&dopt=Abstract
•
The future of meningitis vaccines. Author(s): Segal S, Pollard AJ. Source: Hosp Med. 2003 March; 64(3): 161-7. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12669483&dopt=Abstract
•
The impact of an enteroviral RT-PCR assay on the diagnosis of aseptic meningitis and patient management. Author(s): Stellrecht KA, Harding I, Woron AM, Lepow ML, Venezia RA. Source: Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology. 2002 July; 25 Suppl 1: S19-26. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12091078&dopt=Abstract
•
The impact of HIV on meningitis as seen at a South African Academic Hospital (1994 to 1998). Author(s): Schutte CM, Van der Meyden CH, Magazi DS. Source: Infection. 2000 January-February; 28(1): 3-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10697783&dopt=Abstract
•
The impact of new diagnostic methodologies in the management of meningitis in adults at a teaching hospital. Author(s): Chadwick DR, Lever AM. Source: Qjm : Monthly Journal of the Association of Physicians. 2002 October; 95(10): 663-70. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12324638&dopt=Abstract
•
The importance of quickly initiating antibiotic therapy in a 20-year-old man with bacterial meningitis. Author(s): Bridy MA. Source: Journal of Emergency Nursing: Jen : Official Publication of the Emergency Department Nurses Association. 2001 October; 27(5): 437-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11577282&dopt=Abstract
Studies 207
•
The management of bacterial meningitis in children. Author(s): Duke T, Curtis N, Fuller DG. Source: Expert Opinion on Pharmacotherapy. 2003 August; 4(8): 1227-40. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12877633&dopt=Abstract
•
The meningitis mind-bender. Author(s): Parini SM. Source: Nursing Management. 2002 August; 33(8): 21-5; Quiz 26. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12163750&dopt=Abstract
•
The possible role of cerebrospinal fluid adenosine deaminase activity in the diagnosis of tuberculous meningitis in adults. Author(s): Choi SH, Kim YS, Bae IG, Chung JW, Lee MS, Kang JM, Ryu J, Woo JH. Source: Clinical Neurology and Neurosurgery. 2002 January; 104(1): 10-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11792470&dopt=Abstract
•
The potential roles of C-reactive protein and procalcitonin concentrations in the serum and cerebrospinal fluid in the diagnosis of bacterial meningitis. Author(s): Nathan BR, Scheld WM. Source: Curr Clin Top Infect Dis. 2002; 22: 155-65. Review. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12520652&dopt=Abstract
•
The prognostic factors of adult tuberculous meningitis. Author(s): Lu CH, Chang WN, Chang HW. Source: Infection. 2001 December; 29(6): 299-304. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11787828&dopt=Abstract
•
The risk of aseptic meningitis associated with the Leningrad-Zagreb mumps vaccine strain following mass vaccination with measles-mumps-rubella vaccine, Rio Grande do Sul, Brazil, 1997. Author(s): da Silveira CM, Kmetzsch CI, Mohrdieck R, Sperb AF, Prevots DR. Source: International Journal of Epidemiology. 2002 October; 31(5): 978-82. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12435771&dopt=Abstract
•
The role of lumbar puncture in the management of elevated intracranial pressure in patients with AIDS-associated cryptococcal meningitis. Author(s): Antinori S, Ridolfo AL, Gianelli E, Piazza M, Gervasoni C, Monforte AA. Source: Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America. 2000 November; 31(5): 1309-11. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11073737&dopt=Abstract
208 Meningitis
•
The stereochemistry of the amino acid side chain influences the inflammatory potential of muramyl dipeptide in experimental meningitis. Author(s): Cottagnoud P, Gerber CM, Majcherczyk PA, Acosta F, Cottagnoud M, Neftel K, Moreillon P, Tauber MG. Source: Infection and Immunity. 2003 June; 71(6): 3663-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12761158&dopt=Abstract
•
The syndrome of inappropriate secretion of antidiuretic hormone and fluid restriction in meningitis--how strong is the evidence? Author(s): Moller K, Larsen FS, Bie P, Skinhoj P. Source: Scandinavian Journal of Infectious Diseases. 2001; 33(1): 13-26. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11234973&dopt=Abstract
•
The trigeminovascular system in bacterial meningitis. Author(s): Hoffmann O, Dirnagl U, Weber JR. Source: Microscopy Research and Technique. 2001 May 1; 53(3): 188-92. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11301494&dopt=Abstract
•
The use of clinical scales in depicting cerebrovascular complications in bacterial meningitis. Author(s): Merkelbach S, Konig J, Rohn S, Muller M. Source: Journal of Neuroimaging : Official Journal of the American Society of Neuroimaging. 2001 January; 11(1): 25-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11198523&dopt=Abstract
•
The use of ethambutol has lowered the 2-year mortality rate in patients with tuberculous meningitis. Author(s): Lau KK. Source: Hong Kong Medical Journal = Xianggang Yi Xue Za Zhi / Hong Kong Academy of Medicine. 2000 September; 6(3): 329-30. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11025857&dopt=Abstract
•
The use of liver grafts from donors with bacterial meningitis. Author(s): Satoi S, Bramhall SR, Solomon M, Hastings M, Mayer AD, de Goyet JV, Buckels JA, McMaster P, Mirza DF. Source: Transplantation. 2001 September 27; 72(6): 1108-13. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11579309&dopt=Abstract
Studies 209
•
The use of the Internet to inform young international travellers of contact with a case of meningococcal meningitis. Author(s): Buxton JA, Smythe MS, Salzman JR. Source: Can Commun Dis Rep. 2002 March 1; 28(5): 37-40. English, French. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11889906&dopt=Abstract
•
Thoracic myelopathy complicating acute meningococcal meningitis: MRI findings. Author(s): Bhojo AK, Akhter N, Bakshi R, Wasay M. Source: The American Journal of the Medical Sciences. 2002 May; 323(5): 263-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12018669&dopt=Abstract
•
Three cases of bacterial meningitis after spinal and epidural anesthesia. Author(s): Trautmann M, Lepper PM, Schmitz FJ. Source: European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology. 2002 January; 21(1): 43-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11913500&dopt=Abstract
•
Three ECHOvirus serotypes responsible for outbreak of aseptic meningitis in RhoneAlpes region, France. Author(s): Chomel JJ, Antona D, Thouvenot D, Lina B. Source: European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology. 2003 March; 22(3): 191-3. Epub 2003 March 04. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12649719&dopt=Abstract
•
Timely detection of meningococcal meningitis epidemics in Africa. Author(s): Lewis R, Nathan N, Diarra L, Belanger F, Paquet C. Source: Lancet. 2001 July 28; 358(9278): 287-93. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11498215&dopt=Abstract
•
Timing of shunt surgery in childhood tuberculous meningitis with hydrocephalus. Author(s): Kemaloglu S, Ozkan U, Bukte Y, Ceviz A, Ozates M. Source: Pediatric Neurosurgery. 2002 October; 37(4): 194-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12372912&dopt=Abstract
•
Tissue adhesive and postoperative allergic meningitis. Author(s): Kitoh A, Arima Y, Nishigori C, Kikuta K, Miyachi Y. Source: Lancet. 2002 May 11; 359(9318): 1668-70. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12020530&dopt=Abstract
210 Meningitis
•
Toll-like receptor 2 participates in mediation of immune response in experimental pneumococcal meningitis. Author(s): Koedel U, Angele B, Rupprecht T, Wagner H, Roggenkamp A, Pfister HW, Kirschning CJ. Source: Journal of Immunology (Baltimore, Md. : 1950). 2003 January 1; 170(1): 438-44. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12496429&dopt=Abstract
•
Transient elevation of interleukin-16 levels at the initial stage of meningitis in children. Author(s): Suzuki T, Ishiguro A, Shimbo T. Source: Clinical and Experimental Immunology. 2003 March; 131(3): 484-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12605702&dopt=Abstract
•
Trastuzumab for breast cancer-related carcinomatous meningitis. Author(s): Robins HI, Liu G, Hayes L, Mehta M. Source: Clinical Breast Cancer. 2002 January; 2(4): 316. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11899365&dopt=Abstract
•
Travel warning: Eosinophilic meningitis caused by rat lungworm. Author(s): Weir E. Source: Cmaj : Canadian Medical Association Journal = Journal De L'association Medicale Canadienne. 2002 April 30; 166(9): 1184. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12000253&dopt=Abstract
•
Treatment of gram-negative bacterial meningitis in term neonates with third generation cephalosporins plus amikacin. Author(s): Dellagrammaticas HD, Christodoulou C, Megaloyanni E, Papadimitriou M, Kapetanakis J, Kourakis G. Source: Biology of the Neonate. 2000 March; 77(3): 139-46. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10729716&dopt=Abstract
•
Treatment of intracranial hypertension and aspects on lumbar dural puncture in severe bacterial meningitis. Author(s): Grande PO, Myhre EB, Nordstrom CH, Schliamser S. Source: Acta Anaesthesiologica Scandinavica. 2002 March; 46(3): 264-70. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11939916&dopt=Abstract
•
Treatment of intracranial hypertension and aspects on lumbar dural puncture in severe bacterial meningitis. Author(s): Cold GE, Moller K. Source: Acta Anaesthesiologica Scandinavica. 2002 November; 46(10): 1281-5; Author Reply. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12421206&dopt=Abstract
Studies 211
•
Treatment of Salmonella meningitis: two case reports and a review of the literature. Author(s): Owusu-Ofori A, Scheld WM. Source: International Journal of Infectious Diseases : Ijid : Official Publication of the International Society for Infectious Diseases. 2003 March; 7(1): 53-60. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12718811&dopt=Abstract
•
Trimethoprim-induced aseptic meningitis in an adolescent male. Author(s): Redman RC 4th, Miller JB, Hood M, DeMaio J. Source: Pediatrics. 2002 August; 110(2 Pt 1): E26. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12165625&dopt=Abstract
•
Trimethoprim-sulfamethoxazole induced aseptic meningitis in a renal transplant patient. Author(s): Muller MP, Richardson DC, Walmsley SL. Source: Clinical Nephrology. 2001 January; 55(1): 80-4. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11200873&dopt=Abstract
•
Trimethoprim-sulfamethoxazole induced recurrent aseptic meningitis. Author(s): Meng MV, St Lezin M. Source: The Journal of Urology. 2000 November; 164(5): 1664-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11025739&dopt=Abstract
•
Trimethoprim-sulfamethoxazole-induced aseptic meningitis: case report and literature review. Author(s): Capra C, Monza GM, Meazza G, Ramella G. Source: Intensive Care Medicine. 2000 February; 26(2): 212-4. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10784311&dopt=Abstract
•
Triptans reduce the inflammatory response in bacterial meningitis. Author(s): Hoffmann O, Keilwerth N, Bille MB, Reuter U, Angstwurm K, Schumann RR, Dirnagl U, Weber JR. Source: Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism. 2002 August; 22(8): 98896. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12172384&dopt=Abstract
•
Tuberculosis meningitis and attention deficit hyperactivity disorder in children. Author(s): Wait JW, Stanton L, Schoeman JF. Source: Journal of Tropical Pediatrics. 2002 October; 48(5): 294-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12405172&dopt=Abstract
212 Meningitis
•
Tuberculous granulomas in childhood tuberculous meningitis: radiological features and course. Author(s): Ravenscroft A, Schoeman JF, Donald PR. Source: Journal of Tropical Pediatrics. 2001 February; 47(1): 5-12. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11245351&dopt=Abstract
•
Tuberculous meningitis and dystonia. Author(s): Serrano-Duenas M. Source: Movement Disorders : Official Journal of the Movement Disorder Society. 2001 May; 16(3): 582-3. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11391767&dopt=Abstract
•
Tuberculous meningitis associated with urinary tract tuberculosis. Author(s): Chotmongkol V, Kiertiburanakul S. Source: Southeast Asian J Trop Med Public Health. 2001 June; 32(2): 394-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11556594&dopt=Abstract
•
Tuberculous meningitis following correction of kyphosis by spinal osteotomy. A case report. Author(s): Alvarez L, Calvo E. Source: The Journal of Bone and Joint Surgery. American Volume. 2002 June; 84-A(6): 1022-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12063339&dopt=Abstract
•
Tuberculous meningitis in a country with a low incidence of tuberculosis: still a serious disease and a diagnostic challenge. Author(s): Bidstrup C, Andersen PH, Skinhoj P, Andersen AB. Source: Scandinavian Journal of Infectious Diseases. 2002; 34(11): 811-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12578148&dopt=Abstract
•
Tuberculous meningitis in a renal transplant recipient. Author(s): Blaschke S, Steffgen J, Grunewald RW, Muller GA. Source: Journal of Nephrology. 2002 January-February; 15(1): 93-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11936435&dopt=Abstract
•
Tuberculous meningitis in children: clinical features and outcome in 40 cases. Author(s): Paganini H, Gonzalez F, Santander C, Casimir L, Berberian G, Rosanova MT. Source: Scandinavian Journal of Infectious Diseases. 2000; 32(1): 41-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10716076&dopt=Abstract
Studies 213
•
Tuberculous meningitis in children: problem to be addressed effectively with thorough contact tracing. Author(s): Walia R, Hoskyns W. Source: European Journal of Pediatrics. 2000 July; 159(7): 535-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10923231&dopt=Abstract
•
Tuberculous meningitis in infancy. Author(s): Tung YR, Lai MC, Lui CC, Tsai KL, Huang LT, Chang YC, Huang SC, Yang SN, Hung PL. Source: Pediatric Neurology. 2002 October; 27(4): 262-6. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12435563&dopt=Abstract
•
Tuberculous meningitis presenting as sensorineural hearing loss. Author(s): Kotnis R, Simo R. Source: The Journal of Laryngology and Otology. 2001 June; 115(6): 491-2. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11429076&dopt=Abstract
•
Tuberculous meningitis with spinal tuberculous arachnoiditis. Author(s): Poon TL, Ho WS, Pang KY, Wong CK. Source: Hong Kong Medical Journal = Xianggang Yi Xue Za Zhi / Hong Kong Academy of Medicine. 2003 February; 9(1): 59-61. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12547960&dopt=Abstract
•
Tuberculous meningitis with tuberculomata presenting as postpartum pyrexia of unknown origin. Author(s): Chan KH, Ho PL, Cheung RT, Tsang KL, Fong GC, Cheng PW, Ho SL. Source: Hosp Med. 2003 May; 64(5): 306-7. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12789743&dopt=Abstract
•
Tuberculous meningitis. Author(s): Thwaites G, Chau TT, Mai NT, Drobniewski F, McAdam K, Farrar J. Source: Journal of Neurology, Neurosurgery, and Psychiatry. 2000 March; 68(3): 289-99. Review. Erratum In: J Neurol Neurosurg Psychiatry 2000 June; 68(6): 802. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10675209&dopt=Abstract
•
Tuberculous meningitis: a disease of fatal outcome in children. Author(s): Khan IM, Khan S, Laaser U. Source: European Journal of Pediatrics. 2003 April; 162(4): 281-2. Epub 2003 February 21. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12647206&dopt=Abstract
214 Meningitis
•
Tuberculous meningitis: is a 6-month treatment regimen sufficient? Author(s): van Loenhout-Rooyackers JH, Keyser A, Laheij RJ, Verbeek AL, van der Meer JW. Source: The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union against Tuberculosis and Lung Disease. 2001 November; 5(11): 1028-35. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11716339&dopt=Abstract
•
Tuberculous meningitis: pitfalls in diagnosis. Author(s): Joosten AA, van der Valk PD, Geelen JA, Severin WP, Jansen Steur EN. Source: Acta Neurologica Scandinavica. 2000 December; 102(6): 388-94. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11125755&dopt=Abstract
•
Tuberculous radiculomyelitis complicating tuberculous meningitis: case report and review. Author(s): Hernandez-Albujar S, Arribas JR, Royo A, Gonzalez-Garcia JJ, Pena JM, Vazquez JJ. Source: Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America. 2000 June; 30(6): 915-21. Epub 2000 June 14. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10854362&dopt=Abstract
•
Twelve year outcomes following bacterial meningitis: further evidence for persisting effects. Author(s): Grimwood K, Anderson P, Anderson V, Tan L, Nolan T. Source: Archives of Disease in Childhood. 2000 August; 83(2): 111-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10906014&dopt=Abstract
•
Uncomplicated postoperative lipoid meningitis secondary to autologous fat graft necrosis. Author(s): Ricaurte JC, Murali R, Mandell W. Source: Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America. 2000 March; 30(3): 613-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10722462&dopt=Abstract
•
Unilateral facial paralysis occurring in an infant with enteroviral otitis media and aseptic meningitis. Author(s): Hostetler MA, Suara RO, Denison MR. Source: The Journal of Emergency Medicine. 2002 April; 22(3): 267-71. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11932090&dopt=Abstract
Studies 215
•
Unusual presentation of carcinomatous meningitis: case report and review of typical CSF findings. Author(s): Zeller JA, Zunker P, Witt K, Schlueter E, Deuschl G. Source: Neurological Research. 2002 October; 24(7): 652-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12392200&dopt=Abstract
•
Use of intrathecal trastuzumab in a patient with carcinomatous meningitis. Author(s): Laufman LR, Forsthoefel KF. Source: Clinical Breast Cancer. 2001 October; 2(3): 235. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11899418&dopt=Abstract
•
Use of the NOW Streptococcus pneumoniae urinary antigen test in cerebrospinal fluid for rapid diagnosis of pneumococcal meningitis. Author(s): Samra Z, Shmuely H, Nahum E, Paghis D, Ben-Ari J. Source: Diagnostic Microbiology and Infectious Disease. 2003 April; 45(4): 237-40. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12729992&dopt=Abstract
•
Use of universal PCR on cerebrospinal fluid to diagnose bacterial meningitis in culture-negative patients. Author(s): Margall Coscojuela N, Majo Moreno M, Latorre Otin C, Fontanals Amyerich D, Dominguez Garcia A, Prats Pastor G. Source: European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology. 2002 January; 21(1): 67-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11913508&dopt=Abstract
•
Use of ventriculoperitoneal shunts to treat uncontrollable intracranial hypertension in patients who have cryptococcal meningitis without hydrocephalus. Author(s): Liliang PC, Liang CL, Chang WN, Lu K, Lu CH. Source: Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America. 2002 June 15; 34(12): E64-8. Epub 2002 May 17. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12032912&dopt=Abstract
•
Utility of prognostic stratification in adults with community-acquired bacterial meningitis. Author(s): Aronin SI, Quagliarello VJ. Source: Compr Ther. 2001 Spring; 27(1): 72-7. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11280860&dopt=Abstract
216 Meningitis
•
Utility of transcranial Doppler ultrasonography in the diagnosis and follow-up of tuberculous meningitis-related vasculopathy. Author(s): Kilic T, Elmaci I, Ozek MM, Pamir MN. Source: Child's Nervous System : Chns : Official Journal of the International Society for Pediatric Neurosurgery. 2002 April; 18(3-4): 142-6. Epub 2002 March 27. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11981621&dopt=Abstract
•
Uveitis associated with Mycoplasma pneumoniae meningitis. Author(s): Yashar SS, Yashar B, Epstein E, Viani RM. Source: Acta Ophthalmologica Scandinavica. 2001 February; 79(1): 100-1. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11167302&dopt=Abstract
•
Validation of a diagnosis model for differentiating bacterial from viral meningitis in infants and children under 3.5 years of age. Author(s): Jaeger F, Leroy J, Duchene F, Baty V, Baillet S, Estavoyer JM, Hoen B. Source: European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology. 2000 June; 19(6): 418-21. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10947215&dopt=Abstract
•
Value of cerebrospinal fluid leukocyte aggregation in distinguishing the causes of meningitis in children. Author(s): Michelow IC, Nicol M, Tiemessen C, Chezzi C, Pettifor JM. Source: The Pediatric Infectious Disease Journal. 2000 January; 19(1): 66-72. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10643853&dopt=Abstract
•
Vancomycin-resistant Enterococcus faecium meningitis successfully managed with linezolid: case report and review of the literature. Author(s): Zeana C, Kubin CJ, Della-Latta P, Hammer SM. Source: Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America. 2001 August 15; 33(4): 477-82. Epub 2001 July 11. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11462183&dopt=Abstract
•
Varicella zoster meningitis preceeded by thrombophlebitis in a patient with Hodgkin's disease. Author(s): Saif MW, Hamilton JM, Allegra CJ. Source: Leukemia & Lymphoma. 2000 October; 39(3-4): 421-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11342324&dopt=Abstract
•
Varicella-zoster virus meningitis and cerebrospinal fluid HIV RNA. Author(s): Moling O, Rossi P, Rimenti G, Vedovelli C, Mian P. Source: Scandinavian Journal of Infectious Diseases. 2001; 33(5): 398-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11440237&dopt=Abstract
Studies 217
•
Varicella-zoster virus: an overlooked cause of aseptic meningitis. Author(s): Jhaveri R, Sankar R, Yazdani S, Cherry JD. Source: The Pediatric Infectious Disease Journal. 2003 January; 22(1): 96-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12553305&dopt=Abstract
•
Vascular endothelial growth factor in bacterial meningitis: detection in cerebrospinal fluid and localization in postmortem brain. Author(s): van der Flier M, Stockhammer G, Vonk GJ, Nikkels PG, van DiemenSteenvoorde RA, van der Vlist GJ, Rupert SW, Schmutzhard E, Gunsilius E, Gastl G, Hoepelman AI, Kimpen JL, Geelen SP. Source: The Journal of Infectious Diseases. 2001 January 1; 183(1): 149-53. Epub 2000 November 30. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11106541&dopt=Abstract
•
Vascular endothelial growth factor in CSF: a biological marker for carcinomatous meningitis. Author(s): Stockhammer G, Poewe W, Burgstaller S, Deisenhammer F, Muigg A, Kiechl S, Schmutzhard E, Maier H, Felber S, Schumacher P, Gunsilius E, Gastl G. Source: Neurology. 2000 April 25; 54(8): 1670-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10762512&dopt=Abstract
•
Vasculitic complications associated with coccidioidal meningitis. Author(s): Williams PL. Source: Seminars in Respiratory Infections. 2001 December; 16(4): 270-9. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11740829&dopt=Abstract
•
Veillonella parvula meningitis: case report and review of Veillonella infections. Author(s): Bhatti MA, Frank MO. Source: Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America. 2000 September; 31(3): 839-40. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11017846&dopt=Abstract
•
Venous sinus thrombosis after Proteus vulgaris meningitis and concomitant Clostridium abscess formation. Author(s): Bodur H, Colpan A, Gozukucuk R, Akinci E, Cevik MA, Balaban N. Source: Scandinavian Journal of Infectious Diseases. 2002; 34(9): 694-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12374367&dopt=Abstract
•
Ventriculoperitoneal shunting in childhood tuberculous meningitis. Author(s): Lamprecht D, Schoeman J, Donald P, Hartzenberg H. Source: British Journal of Neurosurgery. 2001 April; 15(2): 119-25. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11360374&dopt=Abstract
218 Meningitis
•
Viral meningitis and encephalitis: traditional and emerging viral agents. Author(s): Romero JR, Newland JG. Source: Seminars in Pediatric Infectious Diseases. 2003 April; 14(2): 72-82. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12881794&dopt=Abstract
219
CHAPTER 2. NUTRITION AND MENINGITIS Overview In this chapter, we will show you how to find studies dedicated specifically to nutrition and meningitis.
Finding Nutrition Studies on Meningitis The National Institutes of Health’s Office of Dietary Supplements (ODS) offers a searchable bibliographic database called the IBIDS (International Bibliographic Information on Dietary Supplements; National Institutes of Health, Building 31, Room 1B29, 31 Center Drive, MSC 2086, Bethesda, Maryland 20892-2086, Tel: 301-435-2920, Fax: 301-480-1845, E-mail:
[email protected]). The IBIDS contains over 460,000 scientific citations and summaries about dietary supplements and nutrition as well as references to published international, scientific literature on dietary supplements such as vitamins, minerals, and botanicals.7 The IBIDS includes references and citations to both human and animal research studies. As a service of the ODS, access to the IBIDS database is available free of charge at the following Web address: http://ods.od.nih.gov/databases/ibids.html. After entering the search area, you have three choices: (1) IBIDS Consumer Database, (2) Full IBIDS Database, or (3) Peer Reviewed Citations Only. Now that you have selected a database, click on the “Advanced” tab. An advanced search allows you to retrieve up to 100 fully explained references in a comprehensive format. Type “meningitis” (or synonyms) into the search box, and click “Go.” To narrow the search, you can also select the “Title” field.
7
Adapted from http://ods.od.nih.gov. IBIDS is produced by the Office of Dietary Supplements (ODS) at the National Institutes of Health to assist the public, healthcare providers, educators, and researchers in locating credible, scientific information on dietary supplements. IBIDS was developed and will be maintained through an interagency partnership with the Food and Nutrition Information Center of the National Agricultural Library, U.S. Department of Agriculture.
220 Meningitis
The following information is typical of that found when using the “Full IBIDS Database” to search for “meningitis” (or a synonym): •
A retrospective study on the efficacy and safety of amphotericin B in a lipid emulsion for the treatment of cryptococcal meningitis in AIDS patients. Author(s): Division of Infectious Diseases, Ospedali Riuniti, Bergamo, Italy. Source: Torre, D Banfi, G Tambini, R Speranza, F Zeroli, C Martegani, R Airoldi, M Fiori, G J-Infect. 1998 July; 37(1): 36-8 0163-4453
•
Amphotericin B in a lipid emulsion for the treatment of cryptococcal meningitis in AIDS patients. Author(s): Hopital Bichat-Claude Bernard, Paris, France. Source: Joly, V Geoffray, C Reynes, J Goujard, C Mechali, D Maslo, C Raffi, F Yeni, P JAntimicrob-Chemother. 1996 July; 38(1): 117-26 0305-7453
•
An immunotoxin for the treatment of T-acute lymphoblastic leukemic meningitis: studies in rhesus monkeys. Author(s): Division of Hematology and Oncology, Duke University Medical Center, Durham, NC 27710. Source: Hertler, A A Schlossman, D M Borowitz, M J Poplack, D G Frankel, A E CancerImmunol-Immunother. 1989; 28(1): 59-66 0340-7004
•
An outbreak of eosinophilic meningitis caused by Angiostrongylus cantonensis in travelers returning from the Caribbean. Author(s): Department of Infectious Diseases, Northwestern University Medical School, Chicago, USA. Source: Slom, Trevor J Cortese, Margaret M Gerber, Susan I Jones, Roderick C Holtz, Timothy H Lopez, Adriana S Zambrano, Carlos H Sufit, Robert L Sakolvaree, Yuwaporn Chaicumpa, Wanpen Herwaldt, Barbara L Johnson, Stuart N-Engl-J-Med. 2002 February 28; 346(9): 668-75 1533-4406
•
Aseptic meningitis and optic neuritis preceding varicella-zoster progressive outer retinal necrosis in a patient with AIDS. Author(s): Division of Infectious Diseases, Department of Medicine, Veterans Affairs Medical Center, Emory University School of Medicine, 69 Butler Street, Atlanta, GA 30303, USA. Source: Franco Paredes, Carlos Bellehemeur, Thomas Merchant, Ali Sanghi, Pramod DiazGranados, Carlos Rimland, David AIDS. 2002 May 3; 16(7): 1045-9 0269-9370
•
Bacterial meningitis in children and adults. Changes in community-acquired disease may affect patient care. Author(s): Sunnybrook Health Science Centre, Ontario, Canada.
[email protected] Source: Phillips, E J Simor, A E Postgrad-Med. 1998 March; 103(3): 102-117 0032-5481
•
Bacterial meningitis in children: current concepts of neurologic management. Author(s): Department of Pediatrics, Loma Linda University School of Medicine, California. Source: Ashwal, S Perkin, R M Thompson, J R Schneider, S Tomasi, L G Curr-ProblPediatr. 1994 September; 24(8): 267-84 0045-9380
•
Bacterial meningitis observed in a phase I trial of vinorelbine, cisplatin and thoracic radiotherapy for non-small cell lung cancer: report of a case and discussion on doselimiting toxicity. Author(s): Medical Oncology Division, National Cancer Center Hospital, Tokyo, Japan.
[email protected]
Nutrition 221
Source: Sekine, I Matsuda, T Saisho, T Watanabe, H Yamamoto, N Kunitoh, H Ohe, Y Tamura, T Kodama, T Saijo, N Jpn-J-Clin-Oncol. 2000 September; 30(9): 401-5 0368-2811 •
Catastrophic visual loss due to Cryptococcus neoformans meningitis. Author(s): Center for Infectious Diseases, University of Texas Health Sciences Center, Houston 77030. Source: Rex, J H Larsen, R A Dismukes, W E Cloud, G A Bennett, J E Medicine(Baltimore). 1993 July; 72(4): 207-24 0025-7974
•
Cerebral vasculature is the major target of oxidative protein alterations in bacterial meningitis. Author(s): Institute for Infectious Diseases, University of Berne, Switzerland. Source: Schaper, Manuela Gergely, Suzanne Lykkesfeldt, Jens Zbaren, Jakob Leib, Stephen L Tauber, Martin G Christen, Stephan J-Neuropathol-Exp-Neurol. 2002 July; 61(7): 605-13 0022-3069
•
Cerebrovascular permeability changes during experimental meningitis in the rat. Author(s): Department of Pharmaceutics, School of Pharmacy, University of Buffalo, New York, USA. Source: Boje, K M J-Pharmacol-Exp-Ther. 1995 September; 274(3): 1199-203 0022-3565
•
Could antioxidant therapy reduce the incidence of deafness following bacterial meningitis? Author(s): Department of Pathology, Houston Medical Center, Warner Robins, GA 31093, USA. Source: Maurizi, C P Med-Hypotheses. 1999 January; 52(1): 85-7 0306-9877
•
Craniospinal pachymeningitis. Author(s): Department of Neurosurgery, Hotel-Dieu, Beirut, Lebanon. Source: Nohra, G Maarrawi, J Samaha, E Rizk, T Okais, N Acta-Neurochir-(Wien). 2000; 142(6): 713-4 0001-6268
•
Diabetes insipidus as a hallmark neuroendocrine complication of neonatal meningitis. Author(s): Yale University School of Medicine, New Haven, CT 06520, USA. Source: Cohen, C Rice, E N Thomas, D E Carpenter, T O Curr-Opin-Pediatr. 1998 August; 10(4): 449-52 1040-8703
•
Diagnostic criteria for Tuberculous Meningitis. Author(s): Department of Pediatrics, All India Institute of Medical Sciences, New Delhi.
[email protected] Source: Seth, Rachna Sharma, Usha Indian-J-Pediatr. 2002 April; 69(4): 299-303 0019-5456
•
Epidural complications and a case of malignant meningitis. Author(s): Pembridge Palliative Care Centre, St Charles Hospital, London. Source: Jennings, A L Rothwell, M P Naysmith, A Palliat-Med. 1997 November; 11(6): 483-6 0269-2163
•
Familial outbreak of disseminated multidrug-resistant tuberculosis and meningitis. Author(s): Department of Respiratory Disease, University of Naples Federico II, Italy. Source: Sofia, M Maniscalco, M Honore, N Molino, A Mormile, M Heym, B Cole, S T IntJ-Tuberc-Lung-Dis. 2001 June; 5(6): 551-8 1027-3719
•
Gastric linitis adenocarcinoma and carcinomatous meningitis: an infrequent but aggressive association--report of four cases. Author(s): Service d'Oncologie digestive Medicale, Institut Gustave Roussy, Villejuif, France.
222 Meningitis
Source: Delaunoit, T Boige, V Belloc, J Elias, D Lasser, P Duvillard, P Ducreux, M AnnOncol. 2001 June; 12(6): 869-71 0923-7534 •
Idiopathic hypertrophic cranial pachymeningitis. Author(s): Department of Neurology, Sree Chitra Tirunal Institute for Medical Sciences and Technology, Trivandrum, Kerala, India.
[email protected] Source: Sylaja, P N Cherian, P J Das, C K Radhakrishnan, V V Radhakrishnan, K NeurolIndia. 2002 March; 50(1): 53-9 0028-3886
•
Inhibition of matrix metalloproteinases and tumour necrosis factor alpha converting enzyme as adjuvant therapy in pneumococcal meningitis. Author(s): Institute for Infectious Diseases, University of Bern, Berne, Switzerland.
[email protected] Source: Leib, S L Clements, J M Lindberg, R L Heimgartner, C Loeffler, J M Pfister, L A Tauber, M G Leppert, D Brain. 2001 September; 124(Pt 9): 1734-42 0006-8950
•
Intrathecal administration of amikacin for treatment of meningitis secondary to cephalosporin-resistant Escherichia coli. Author(s): Albany College of Pharmacy, NY 12208. Source: Preston, S L Briceland, L L Ann-Pharmacother. 1993 Jul-August; 27(7-8): 870-3 1060-0280
•
Intrathecal administration of etoposide in the treatment of malignant meningitis: feasibility and pharmacokinetic data. Author(s): Department of Medical Oncology, University Hospital Rotterdam-Dijkzigt, The Netherlands. Source: van der Gaast, A Sonneveld, P Mans, D R Splinter, T A Cancer-ChemotherPharmacol. 1992; 29(4): 335-7 0344-5704
•
Intrathecal chemotherapy in carcinomatous meningitis from breast cancer. Author(s): Division of Medical Oncology, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy.
[email protected] Source: Orlando, L Curigliano, G Colleoni, M Fazio, N Nole, F Martinelli, G Cinieri, S Graffeo, R Peruzzotti, G Goldhirsch, A Anticancer-Res. 2002 Sep-October; 22(5): 3057-9 0250-7005
•
Is nitric oxide involved as a mediator of cerebrovascular changes in the early phase of experimental pneumococcal meningitis? Author(s): Department of Neurology, University of Munich, Germany. Source: Haberl, R L Anneser, F Kodel, U Pfister, H W Neurol-Res. 1994 April; 16(2): 10812 0161-6412
•
Isolated leptomeningeal carcinomatosis (carcinomatous meningitis) after taxaneinduced major remission in patients with advanced breast cancer. Author(s): Department of Medicine, Medical Oncology Unit, Helena-Venizelou Hospital, Athens, Greece.
[email protected] Source: Kosmas, C Malamos, N A Tsavaris, N B Stamataki, M Gregoriou, A Rokana, S Vartholomeou, M Antonopoulos, M J Oncology. 2002; 63(1): 6-15 0030-2414
•
Long-term follow up of childhood tuberculous meningitis. Author(s): Department of Paediatrics and Child Health, Tygerberg Children's Hospital, South Africa.
[email protected] Source: Schoeman, J Wait, J Burger, M van Zyl, F Fertig, G van Rensburg, A J Springer, P Donald, P Dev-Med-Child-Neurol. 2002 August; 44(8): 522-6 0012-1622
Nutrition 223
•
Low levels of LTB4 in cerebrospinal fluid of AIDS patients with cryptococcal meningitis. Author(s): Department of Medicine, University of Milan, Italy. Source: Froldi, M Parma, M Marenzi, R Piona, A Lorini, M Nobile Orazio, E Castagna, A Lazzarin, A J-Clin-Lab-Immunol. 1995; 47(1): 41-7 0141-2760
•
Management of bacterial meningitis. Author(s): Department of Medical Microbiology, University of Liverpool, UK. Source: Hart, C A Cuevas, L E Marzouk, O Thomson, A P Sills, J J-AntimicrobChemother. 1993 July; 32 Suppl A49-59 0305-7453
•
Meningitis in a girl with recurrent otitis media caused by Streptococcus pyogenes-otitis media has to be treated appropriately. Author(s): Children's Hospital, University of Leipzig, Germany.
[email protected] Source: Steppberger, K Adams, I Deutscher, J Muller, H Kiess, W Infection. 2001 October; 29(5): 286-8 0300-8126
•
Migraine-like headache in bacterial meningitis. Author(s): Department of Neurology, Psychiatry and Pain Clinic, General Hospital Linz, Austria.
[email protected] Source: Lampl, C Yazdi, K Buzath, A Klingler, D Cephalalgia. 2000 October; 20(8): 738-9 0333-1024
•
Neurologic evaluation of the patient with acute bacterial meningitis. Author(s): Department of Pediatrics, Loma Linda University School of Medicine, California, USA. Source: Ashwal, S Neurol-Clin. 1995 August; 13(3): 549-77 0733-8619
•
Oxidant and antioxidant activities in childhood meningitis. Author(s): Department of Pediatrics, Faculty of Medicine, Fukui Medical University, Japan.
[email protected] Source: Tsukahara, H Haruta, T Todoroki, Y Hiraoka, M Noiri, E Maeda, M Mayumi, M Life-Sci. 2002 October 25; 71(23): 2797-806 0024-3205
•
Oxidative stress in bacterial meningitis in humans. Author(s): Department of Neurology, Klinikum Grosshadern, Ludwig-Maximilians University, Munich, Germany. Source: Kastenbauer, S Koedel, U Becker, B F Pfister, H W Neurology. 2002 January 22; 58(2): 186-91 0028-3878
•
Pathologic quiz case: progressive diffuse weakness after chemotherapy for large cell lymphoma in a middle-aged woman. Lymphomatous meningitis with neurolymphomatosis. Author(s): Departments of Pathology, University of Utah Hospital, Salt Lake City, Utah, USA. Source: Carey, M J Smith, A G Townsend, J J Arch-Pathol-Lab-Med. 2000 April; 124(4): 645-6 0003-9985
•
Pediatric bacterial meningitis in the emergency department. Author(s): Foote Hospital, Jackson, Michigan, USA. Source: Strawser, D J-Emerg-Nurs. 1997 August; 23(4): 310-5 0099-1767
•
Penicillin therapy of spontaneous streptococcal meningitis in pigs. Author(s): Department of Veterinary Pharmacology, University of Glasgow Veterinary School, Bearsden.
224 Meningitis
Source: McKellar, Q A Baxter, P Taylor, D Bogan, J A Vet-Rec. 1987 October 10; 121(15): 347-50 0042-4900 •
Pentoxifylline-induced aseptic meningitis in a patient with mixed connective tissue disease. Author(s): Internal Medicine Unit, Hopital Pitie-Salpetriere, Paris, France. Source: Mathian, A Amoura, Z Piette, J C Neurology. 2002 November 12; 59(9): 1468-9 0028-3878
•
Phenoxymethyl penicillin potassium as an in-feed medication for pigs with streptococcal meningitis. Source: Johnston, P.I. Henry, N. Boer, R. de Braidwood, J.C. Vet-Rec-J-Br-Vet-Assoc. London : The Association. February 15, 1992. volume 130 (7) page 138-139. 0042-4900
•
Pituitary abscess: an unusual presentation of “aseptic meningitis”. Author(s): Department of Pediatrics, Children's Mercy Hospital, Kansas City, Missouri 64108, USA. Source: Schwartz, I D Zalles, M C Foster, J L Burry, V F J-Pediatr-Endocrinol-Metab. 1995 Apr-June; 8(2): 141-6
•
Pneumococcal meningitis in children: relationship of antibiotic resistance to clinical characteristics and outcomes. Author(s): Department of Pediatrics, University of Tennessee Health Science Center, Le Bonheur Children's Medical Center, Memphis, TN, USA.
[email protected] Source: Buckingham, S C McCullers, J A LuJanuary Zilbermann, J Knapp, K M Orman, K L English, B K Pediatr-Infect-Dis-J. 2001 September; 20(9): 837-43 0891-3668
•
Rapid diagnosis of acute pyogenic meningitis by a combined PCR dot-blot assay. Author(s): Astra Research Centre India, 18th Cross, Malleswaram, Bangalore-560003, India.
[email protected] Source: Balganesh, M Lalitha, M K Nathaniel, R Mol-Cell-Probes. 2000 April; 14(2): 61-9 0890-8508
•
Rational antibiotics therapy in bacterial meningitis. Author(s): Department of Pediatrics, Kalawati Saran Children's Hospital, Lady Hardinge Medical College, New Delhi. Source: Dutta, A K Bhatnagar, S K Indian-J-Pediatr. 2001 July; 68 Suppl 3: S32-9 00195456
•
Recurrent central diabetes insipidus secondary to cryptococcal meningitis. Author(s): Department of Medicine, Brooklyn Veterans Administration Medical Center, New York, USA. Source: Woredekal, Y J-Assoc-Acad-Minor-Phys. 1998; 9(1): 22-4 1048-9886
•
Recurrent herpes simplex virus type 2 meningitis: a case report of Mollaret's meningitis. Author(s): Department of Neurology, University of Occupational and Environmental Health, School of Medicine, Kitakyushu 870-8555, Japan. Source: Kojima, Y Hashiguchi, H Hashimoto, T Tsuji, S Shoji, H Kazuyama, Y Jpn-JInfect-Dis. 2002 June; 55(3): 85-8 1344-6304
•
Recurring aseptic meningitis after travel to the tropics: a case of Mollaret's meningitis? Case report with review of the literature. Author(s): Instituut voor Tropische Geneeskunde, Nationalestraat 155, 2000, Antwerpen, Belgium. Source: Wynants, H Taelman, H Martin, J J Van den Ende, J Clin-Neurol-Neurosurg. 2000 June; 102(2): 113-5 0303-8467
Nutrition 225
•
Risk/benefit in the treatment of children with imipenem-cilastatin for meningitis caused by penicillin-resistant pneumococcus. Author(s): Section of Pediatric Infectious Diseases, University Hospital La Fe, Valencia, Spain. Source: Asensi, F Otero, M C Perez Tamarit, D Rodriguez Escribano, I Cabedo, J L Gresa, S Canton, E J-Chemother. 1993 April; 5(2): 133-4 1120-009X
•
Sequential MRI in chronic meningitis during adrenocorticotropic hormone treatment for West syndrome. Author(s): Department of Pediatrics, Otsu Red Cross Hospital, Japan.
[email protected] Source: Go, T Childs-Nerv-Syst. 2001 August; 17(8): 497-9 0256-7040
•
Spin trapping agent, phenyl N-tert-butylnitrone, reduces nitric oxide production in the rat brain during experimental meningitis. Author(s): Institute for Life Support Technology, Yamagata Public Corporation for the Development of Industry, 2-2-1 Matsuei, Yamagata 990-2473, Japan. Source: Endoh, H Kato, N Fujii, S Suzuki, Y Sato, S Kayama, T Kotake, Y Yoshimura, T Free-Radic-Res. 2001 November; 35(5): 583-91 1071-5762
•
Steroids for treating tuberculous meningitis. Author(s): Neurology, All India Institute of Medical Sciences, Ansarinagar, New Delhi, Delhi, India, 110029.
[email protected] Source: Prasad, K Volmink, J Menon, G R Cochrane-Database-Syst-Revolume 2000; (3): CD002244 1469-493X
•
Successful treatment of resistant cryptococcal meningitis with amphotericin B lipid emulsion after nephrotoxicity with conventional intravenous amphotericin B. Author(s): Department of Medicine, Brighton Health Care, U.K. Source: Leake, H A Appleyard, M N Hartley, J P J-Infect. 1994 May; 28(3): 319-22 01634453
•
The management of cryptococcal meningitis in Papua New Guinea. Author(s): Department of Clinical Sciences, University of Papua New Guinea, Port Moresby, Papua New Guinea. Source: Seaton, R A P-N-G-Med-J. 1996 March; 39(1): 67-73 0031-1480
•
The neurochemical markers in cerebrospinal fluid to differentiate between aseptic and tuberculous meningitis. Author(s): Department of Clinical Neuroscience and Family Medicine, Huddinge University Hospital, Sweden. Source: Qureshi, G A Baig, S M Bednar, I Halawa, A Parvez, S H Neurochem-Int. 1998 February; 32(2): 197-203 0197-0186
•
The use of corticosteroids in the management of bacterial meningitis in adults. Author(s): Department of Internal Medicine, University of Virginia, Charlottesville 22908, USA. Source: Townsend, G C Scheld, W M J-Antimicrob-Chemother. 1996 June; 37(6): 1051-61 0305-7453
•
Transient diabetes insipidus following Escherichia coli meningitis complicated by ventriculoperitoneal shunt. Author(s): Department of Pediatrics, Firat University Medical School, Elazig, Turkey. Source: Kabakus, N Yilmaz, B Aydinoglu, H Serhathoglu, S J-Endocrinol-Invest. 1999 November; 22(10): 800-2 0391-4097
226 Meningitis
•
Transitional cell carcinomatous meningitis after M-VAC (methotrexate, vinblastine, doxorubicin, and cisplatin) chemotherapy. Author(s): Urology Service, Walter Reed Army Medical Center, Washington, D.C. Source: Bishop, J R Moul, J W Maldonado, L McLeod, D G Urology. 1990 October; 36(4): 373-7 0090-4295
•
Tuberculous meningitis. 23 cases from a 12-year period (1976-1987). Author(s): Department of Infectious Diseases, Rigshospitalet, Copenhagen. Source: Jensen, T H Magnussen, P Eriksen, N H Skinhoj, P Dan-Med-Bull. 1990 October; 37(5): 459-62 0907-8916
•
Vasculitic complications associated with coccidioidal meningitis. Author(s): Visalia Medical Clinic, Inc., Visalia, CA. Source: Williams, P L Semin-Respir-Infect. 2001 December; 16(4): 270-9 0882-0546
Federal Resources on Nutrition In addition to the IBIDS, the United States Department of Health and Human Services (HHS) and the United States Department of Agriculture (USDA) provide many sources of information on general nutrition and health. Recommended resources include: •
healthfinder®, HHS’s gateway to health information, including diet and nutrition: http://www.healthfinder.gov/scripts/SearchContext.asp?topic=238&page=0
•
The United States Department of Agriculture’s Web site dedicated to nutrition information: www.nutrition.gov
•
The Food and Drug Administration’s Web site for federal food safety information: www.foodsafety.gov
•
The National Action Plan on Overweight and Obesity sponsored by the United States Surgeon General: http://www.surgeongeneral.gov/topics/obesity/
•
The Center for Food Safety and Applied Nutrition has an Internet site sponsored by the Food and Drug Administration and the Department of Health and Human Services: http://vm.cfsan.fda.gov/
•
Center for Nutrition Policy and Promotion sponsored by the United States Department of Agriculture: http://www.usda.gov/cnpp/
•
Food and Nutrition Information Center, National Agricultural Library sponsored by the United States Department of Agriculture: http://www.nal.usda.gov/fnic/
•
Food and Nutrition Service sponsored by the United States Department of Agriculture: http://www.fns.usda.gov/fns/
Additional Web Resources A number of additional Web sites offer encyclopedic information covering food and nutrition. The following is a representative sample: •
AOL: http://search.aol.com/cat.adp?id=174&layer=&from=subcats
•
Family Village: http://www.familyvillage.wisc.edu/med_nutrition.html
Nutrition 227
•
Google: http://directory.google.com/Top/Health/Nutrition/
•
Healthnotes: http://www.healthnotes.com/
•
Open Directory Project: http://dmoz.org/Health/Nutrition/
•
Yahoo.com: http://dir.yahoo.com/Health/Nutrition/
•
WebMDHealth: http://my.webmd.com/nutrition
•
WholeHealthMD.com: http://www.wholehealthmd.com/reflib/0,1529,00.html
229
CHAPTER 3. ALTERNATIVE MEDICINE AND MENINGITIS Overview In this chapter, we will begin by introducing you to official information sources on complementary and alternative medicine (CAM) relating to meningitis. At the conclusion of this chapter, we will provide additional sources.
National Center for Complementary and Alternative Medicine The National Center for Complementary and Alternative Medicine (NCCAM) of the National Institutes of Health (http://nccam.nih.gov/) has created a link to the National Library of Medicine’s databases to facilitate research for articles that specifically relate to meningitis and complementary medicine. To search the database, go to the following Web site: http://www.nlm.nih.gov/nccam/camonpubmed.html. Select “CAM on PubMed.” Enter “meningitis” (or synonyms) into the search box. Click “Go.” The following references provide information on particular aspects of complementary and alternative medicine that are related to meningitis: •
A placebo-controlled trial of maintenance therapy with fluconazole after treatment of cryptococcal meningitis in the acquired immunodeficiency syndrome. California Collaborative Treatment Group. Author(s): Bozzette SA, Larsen RA, Chiu J, Leal MA, Jacobsen J, Rothman P, Robinson P, Gilbert G, McCutchan JA, Tilles J, et al. Source: The New England Journal of Medicine. 1991 February 28; 324(9): 580-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=1992319&dopt=Abstract
•
Acute confusion, Chinese herbal medicines and tuberculous meningitis. Author(s): Chan JC, Tomlinson B, Kay R, Chan TY, Critchley JA. Source: Aust N Z J Med. 1994 October; 24(5): 590-1. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7848176&dopt=Abstract
•
An outbreak of pneumonia and meningitis caused by a previously undescribed gramnegative bacterium in a hot spring spa.
230 Meningitis
Author(s): Hubert B, de Mahenge A, Grimont F, Richard C, Peloux Y, de Mahenge C, Fleurette J, Grimont PA. Source: Epidemiology and Infection. 1991 October; 107(2): 373-81. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=1936159&dopt=Abstract •
Antiviral activity of higher plants and propionin on lymphocytic choriomeningitis infection. Author(s): Furusawa E, Ramanathan S, Furusawa S, Woo YK, Cutting W. Source: Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N. Y.). 1967 May; 125(1): 234-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=4961253&dopt=Abstract
•
Antiviral activity of higher plants on lymphocytic choriomeningitis infection in vitro and in vivo. Author(s): Furusawa E, Cutting W. Source: Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N. Y.). 1966 May; 122(1): 280-2. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=4957672&dopt=Abstract
•
Aseptic meningitis associated with Ehrlichia canis infection. Author(s): Golden SE. Source: The Pediatric Infectious Disease Journal. 1989 May; 8(5): 335-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2726324&dopt=Abstract
•
Bacillus species pseudomeningitis. Author(s): Lettau LA, Benjamin D, Cantrell HF, Potts DW, Boggs JM. Source: Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America. 1988 September; 9(9): 394-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3171138&dopt=Abstract
•
Bacterial meningitis and lumbar epidural hematoma due to lumbar acupunctures: a case report. Author(s): Chen CY, Liu GC, Sheu RS, Huang CL. Source: Kaohsiung J Med Sci. 1997 May; 13(5): 328-31. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9226976&dopt=Abstract
•
Bacterial meningitis observed in a phase I trial of vinorelbine, cisplatin and thoracic radiotherapy for non-small cell lung cancer: report of a case and discussion on doselimiting toxicity. Author(s): Sekine I, Matsuda T, Saisho T, Watanabe H, Yamamoto N, Kunitoh H, Ohe Y, Tamura T, Kodama T, Saijo N.
Alternative Medicine 231
Source: Japanese Journal of Clinical Oncology. 2000 September; 30(9): 401-5. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11095138&dopt=Abstract •
Balneatrix alpica gen. nov., sp. nov., a bacterium associated with pneumonia and meningitis in a spa therapy center. Author(s): Dauga C, Gillis M, Vandamme P, Ageron E, Grimont F, Kersters K, de Mahenge C, Peloux Y, Grimont PA. Source: Research in Microbiology. 1993 January; 144(1): 35-46. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8327781&dopt=Abstract
•
Binding of mannan-binding protein to various bacterial pathogens of meningitis. Author(s): van Emmerik LC, Kuijper EJ, Fijen CA, Dankert J, Thiel S. Source: Clinical and Experimental Immunology. 1994 September; 97(3): 411-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8082295&dopt=Abstract
•
Capnocytophaga canimorsus meningitis in a newborn: an avoidable infection. Author(s): Rosenman JR, Reynolds JK, Kleiman MB. Source: The Pediatric Infectious Disease Journal. 2003 February; 22(2): 204-5. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12613462&dopt=Abstract
•
Comparison of counterimmunoelectrophoresis, latex agglutination and bacterial culture for the diagnosis of bacterial meningitis using urine, serum and cerebrospinal fluid samples. Author(s): Requejo HI, Nascimento CM, Fahrat CK. Source: Brazilian Journal of Medical and Biological Research = Revista Brasileira De Pesquisas Medicas E Biologicas / Sociedade Brasileira De Biofisica. [et Al.]. 1992; 25(4): 357-67. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=1342212&dopt=Abstract
•
Congenital lymphocytic choriomeningitis virus infection: decade of rediscovery. Author(s): Barton LL, Mets MB. Source: Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America. 2001 August 1; 33(3): 370-4. Epub 2001 July 05. Review. Erratum In: Clin Infect Dis 2001 October 15; 33(8): 1445. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11438904&dopt=Abstract
•
Cryptococcal meningitis in a patient with Hodgkin's lymphoma. Author(s): Rajkumar K, Rajkumar T, Sagar TG, Maitreyan V, Shanta V. Source: J Assoc Physicians India. 1991 October; 39(10): 785. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=1816214&dopt=Abstract
•
Cryptococcal meningitis in Papua New Guinea: ecology and the role of eucalypts. Author(s): Laurenson I, Naraqi S, Howcroft N, Burrows I, Saulei S.
232 Meningitis
Source: The Medical Journal of Australia. 1993 February 1; 158(3): 213. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8450794&dopt=Abstract •
Cryptococcal meningitis. Author(s): Tjia TL, Yeow YK, Tan CB. Source: Journal of Neurology, Neurosurgery, and Psychiatry. 1985 September; 48(9): 853-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=4045478&dopt=Abstract
•
Development of a protocol for early treatment of endemic meningitis in children in Vanuatu. Author(s): Harris M, Carrol K, Carrol C. Source: J Trop Med Hyg. 1991 February; 94(1): 8-14. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=1995940&dopt=Abstract
•
Effect of catalase on regional cerebral blood flow and brain edema during the early phase of experimental pneumococcal meningitis. Author(s): Pfister HW, Kodel U, Dirnagl U, Haberl RL, Ruckdeschel G, Einhaupl KM. Source: The Journal of Infectious Diseases. 1992 December; 166(6): 1442-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=1431262&dopt=Abstract
•
Eosinophilic meningitis beyond the Pacific Basin: the global dispersal of a peridomestic zoonosis caused by Angiostrongylus cantonensis, the nematode lungworm of rats. Author(s): Kliks MM, Palumbo NE. Source: Social Science & Medicine (1982). 1992 January; 34(2): 199-212. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=1738873&dopt=Abstract
•
Eosinophilic meningitis due to Angiostrongylus cantonensis. Author(s): Fuller AJ, Munckhof W, Kiers L, Ebeling P, Richards MJ. Source: The Western Journal of Medicine. 1993 July; 159(1): 78-80. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8123100&dopt=Abstract
•
Further studies of antiviral activity of natural products on lymphocytic choriomeningitis infection. Author(s): Furusawa E, Furusawa S, Ramanathan S, Cutting W. Source: Chemotherapy. 1968; 13(3): 172-80. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=5660664&dopt=Abstract
•
Haemophilus influenzae meningitis: an evolving therapeutic regimen. Author(s): Barkin RM, Greer CC, Schumacher CJ, McIntosh K.
Alternative Medicine 233
Source: Am J Dis Child. 1976 December; 130(12): 1318-21. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=1087110&dopt=Abstract •
Haemopoietic defects in mice infected with lymphocytic choriomeningitis virus. 1. The enhanced x-ray sensitivity of virus infected mice. Author(s): Bro-Jorgensen K, Volkert M. Source: Acta Pathol Microbiol Scand [b] Microbiol Immunol. 1972; 80(6): 845-52. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=4509394&dopt=Abstract
•
Hearing loss and pneumococcal meningitis: an animal model. Author(s): Bhatt S, Halpin C, Hsu W, Thedinger BA, Levine RA, Tuomanen E, Nadol JB Jr. Source: The Laryngoscope. 1991 December; 101(12 Pt 1): 1285-92. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=1766298&dopt=Abstract
•
Hypertrophic chronic pachymeningitis as a localized immune process in the craniocervical region. Author(s): Voller B, Vass K, Wanschitz J, Machold K, Asenbaum S, Hoberstorfer M, Auff E. Source: Neurology. 2001 January 9; 56(1): 107-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11148246&dopt=Abstract
•
Hyperventilation as the initial manifestation of lymphomatous meningitis. Author(s): Karp G, Nahum K. Source: Journal of Neuro-Oncology. 1992 June; 13(2): 173-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=1279132&dopt=Abstract
•
Idiopathic hypertrophic cranial pachymeningitis with accumulation of thallium-201 on single-photon emission CT. Author(s): Nishioka H, Ito H, Haraoka J, Yamada Y, Nojima H. Source: Ajnr. American Journal of Neuroradiology. 1998 March; 19(3): 450-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9541297&dopt=Abstract
•
Imipenem resistance in a case of AIDS with relapsing Pseudomonas meningitis. Author(s): Eng RH, Lynch AM, Smith SM, Ambros RA, Fan-Havard P, Mangia A, Tecson-Tumang F, Cherubin C. Source: Southern Medical Journal. 1990 August; 83(8): 979-80. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2116669&dopt=Abstract
•
Immunodiagnosis of pneumococcal meningitis using immunosorbent assay. Author(s): Requejo HI, das Gracas M, Alkmin A, Landgraf IM.
Dot-enzyme-linked
234 Meningitis
Source: Journal of Tropical Pediatrics. 2001 October; 47(5): 288-90. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11695728&dopt=Abstract •
Incompatibilities of professional and religious ideology: problems of medical management and outcome in a case of pediatric meningitis. Author(s): Redlener IE, Scott CS. Source: Soc Sci Med [med Anthropol]. 1979 April; 13B(2): 89-93. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=505059&dopt=Abstract
•
Intrathecal administration of etoposide in the treatment of malignant meningitis: feasibility and pharmacokinetic data. Author(s): van der Gaast A, Sonneveld P, Mans DR, Splinter TA. Source: Cancer Chemotherapy and Pharmacology. 1992; 29(4): 335-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=1311219&dopt=Abstract
•
Isolated leptomeningeal carcinomatosis (carcinomatous meningitis) after taxaneinduced major remission in patients with advanced breast cancer. Author(s): Kosmas C, Malamos NA, Tsavaris NB, Stamataki M, Gregoriou A, Rokana S, Vartholomeou M, Antonopoulos MJ. Source: Oncology. 2002; 63(1): 6-15. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12187065&dopt=Abstract
•
Isolation of parainfluenza virus type 3 from cerebrospinal fluid associated with aseptic meningitis. Author(s): Craver RD, Gohd RS, Sundin DR, Hierholzer JC. Source: American Journal of Clinical Pathology. 1993 June; 99(6): 705-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8391749&dopt=Abstract
•
Long-term impairments of brain and auditory functions of children recovered from purulent meningitis. Author(s): Jiang ZD, Liu XY, Wu YY, Zheng MS, Liu HC. Source: Developmental Medicine and Child Neurology. 1990 June; 32(6): 473-80. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2365140&dopt=Abstract
•
Meningitis from canine Pasteurella multocida following mastoidectomy. Author(s): Dammeijer PF, McCombe AW. Source: The Journal of Laryngology and Otology. 1991 July; 105(7): 571-2. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=1875142&dopt=Abstract
•
Meningitis with Burkitt like B-cell lymphoma in HIV infection. Author(s): Bomfim da Paz R, Kolmel HW.
Alternative Medicine 235
Source: Journal of Neuro-Oncology. 1992 May; 13(1): 73-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=1613539&dopt=Abstract •
Neuroretinitis, aseptic meningitis, and lymphadenitis associated with Bartonella (Rochalimaea) henselae infection in immunocompetent patients and patients infected with human immunodeficiency virus type 1. Author(s): Wong MT, Dolan MJ, Lattuada CP Jr, Regnery RL, Garcia ML, Mokulis EC, LaBarre RA, Ascher DP, Delmar JA, Kelly JW, et al. Source: Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America. 1995 August; 21(2): 352-60. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8562744&dopt=Abstract
•
Observations with a variant of lymphocytic choriomeningitis virus in mouse tumors. Author(s): Eiselein J, Biggs MW. Source: Cancer Research. 1970 July; 30(7): 1953-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=4989547&dopt=Abstract
•
Pasteurella multocida meningitis following orbital exenteration. Author(s): Dolman PJ, Ezzat S, Rootman J, Bowie WR. Source: American Journal of Ophthalmology. 1988 June 15; 105(6): 698-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3377053&dopt=Abstract
•
Pasteurella multocida meningitis in infancy - (a lick may be as bad as a bite). Author(s): Wade T, Booy R, Teare EL, Kroll S. Source: European Journal of Pediatrics. 1999 November; 158(11): 875-8. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10541939&dopt=Abstract
•
Pasteurella multocida meningitis in infancy. An avoidable infection. Author(s): Clapp DW, Kleiman MB, Reynolds JK, Allen SD. Source: Am J Dis Child. 1986 May; 140(5): 444-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3962937&dopt=Abstract
•
Pathologic quiz case: progressive diffuse weakness after chemotherapy for large cell lymphoma in a middle-aged woman. Lymphomatous meningitis with neurolymphomatosis. Author(s): Carey MJ, Smith AG, Townsend JJ. Source: Archives of Pathology & Laboratory Medicine. 2000 April; 124(4): 645-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10747335&dopt=Abstract
•
Prevention of hearing loss in experimental pneumococcal meningitis administration of dexamethasone and ketorolac. Author(s): Rappaport JM, Bhatt SM, Burkard RF, Merchant SN, Nadol JB Jr.
by
236 Meningitis
Source: The Journal of Infectious Diseases. 1999 January; 179(1): 264-8. Erratum In: J Infect Dis 1999 March; 179(3): 753. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9841852&dopt=Abstract •
Primary pseudomonas meningitis in an adult, splenectomized, multitransfused thalassaemia major patient. Author(s): Ghosh K, Daar S, Hiwase D, Nursat N. Source: Haematologia. 2000; 30(1): 69-72. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10841329&dopt=Abstract
•
Regional cerebral blood flow during hyperventilation in patients with acute bacterial meningitis. Author(s): Moller K, Hogh P, Larsen FS, Strauss GI, Skinhoj P, Sperling BK, Knudsen GM. Source: Clinical Physiology (Oxford, England). 2000 September; 20(5): 399-410. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10971552&dopt=Abstract
•
Transitional cell carcinomatous meningitis after M-VAC (methotrexate, vinblastine, doxorubicin, and cisplatin) chemotherapy. Author(s): Bishop JR Jr, Moul JW, Maldonado L, McLeod DG. Source: Urology. 1990 October; 36(4): 373-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2219624&dopt=Abstract
•
Treatment of carcinomatous meningitis from transitional cell carcinoma of the bladder. Author(s): Raghavan D, Chye RW. Source: British Journal of Urology. 1991 April; 67(4): 438-40. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2032089&dopt=Abstract
•
Treatment of malignant meningitis in retinoblastoma. Author(s): Stannard CE, Sealy R, Sevel D, Brinton FA. Source: The British Journal of Ophthalmology. 1975 July; 59(7): 362-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=1242674&dopt=Abstract
•
Update on bacterial meningitis. Author(s): Kaplan SL, Fishman MA. Source: Journal of Child Neurology. 1988 April; 3(2): 82-93. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3286749&dopt=Abstract
Alternative Medicine 237
Additional Web Resources A number of additional Web sites offer encyclopedic information covering CAM and related topics. The following is a representative sample: •
Alternative Medicine Foundation, Inc.: http://www.herbmed.org/
•
AOL: http://search.aol.com/cat.adp?id=169&layer=&from=subcats
•
Chinese Medicine: http://www.newcenturynutrition.com/
•
drkoop.com: http://www.drkoop.com/InteractiveMedicine/IndexC.html
•
Family Village: http://www.familyvillage.wisc.edu/med_altn.htm
•
Google: http://directory.google.com/Top/Health/Alternative/
•
Healthnotes: http://www.healthnotes.com/
•
MedWebPlus: http://medwebplus.com/subject/Alternative_and_Complementary_Medicine
•
Open Directory Project: http://dmoz.org/Health/Alternative/
•
HealthGate: http://www.tnp.com/
•
WebMDHealth: http://my.webmd.com/drugs_and_herbs
•
WholeHealthMD.com: http://www.wholehealthmd.com/reflib/0,1529,00.html
•
Yahoo.com: http://dir.yahoo.com/Health/Alternative_Medicine/
The following is a specific Web list relating to meningitis; please note that any particular subject below may indicate either a therapeutic use, or a contraindication (potential danger), and does not reflect an official recommendation: •
General Overview AIDS and HIV Source: Integrative Medicine Communications; www.drkoop.com Epilepsy Source: Integrative Medicine Communications; www.drkoop.com Histoplasmosis Source: Integrative Medicine Communications; www.drkoop.com Lyme Disease Source: Integrative Medicine Communications; www.drkoop.com Meningitis Source: Integrative Medicine Communications; www.drkoop.com Seizure Disorders Source: Integrative Medicine Communications; www.drkoop.com
238 Meningitis
Tuberculosis Source: Integrative Medicine Communications; www.drkoop.com •
Alternative Therapy Osteopathy Source: WholeHealthMD.com, LLC. www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/substances_view/0,1525,724,00.html
•
Chinese Medicine Angong Niuhuang San Alternative names: (An Gong Niu Huang San) Source: Pharmacopoeia Commission of the Ministry of Health, People's Republic of China Hyperlink: http://www.newcenturynutrition.com/cgilocal/patent_herbs_db/db.cgi?db=default&Chinese=Angong%20Niuhuang%20San &mh=10&sb=---&view_records=View+Records Nambaniangan Alternative names: Baphicacanthus Root; Rhizoma et Radix Baphicacanthis Cusae Source: Chinese Materia Medica
•
Herbs and Supplements Aloe Alternative names: Aloe vera, Aloe barbadensis, Aloe ferox , Aloe Vera Source: Integrative Medicine Communications; www.drkoop.com Aloe Vera Source: Integrative Medicine Communications; www.drkoop.com Fluconazole Source: Healthnotes, Inc. www.healthnotes.com
General References A good place to find general background information on CAM is the National Library of Medicine. It has prepared within the MEDLINEplus system an information topic page dedicated to complementary and alternative medicine. To access this page, go to the MEDLINEplus site at http://www.nlm.nih.gov/medlineplus/alternativemedicine.html. This Web site provides a general overview of various topics and can lead to a number of general sources.
239
CHAPTER 4. DISSERTATIONS ON MENINGITIS Overview In this chapter, we will give you a bibliography on recent dissertations relating to meningitis. We will also provide you with information on how to use the Internet to stay current on dissertations. IMPORTANT NOTE: When following the search strategy described below, you may discover non-medical dissertations that use the generic term “meningitis” (or a synonym) in their titles. To accurately reflect the results that you might find while conducting research on meningitis, we have not necessarily excluded nonmedical dissertations in this bibliography.
Dissertations on Meningitis ProQuest Digital Dissertations, the largest archive of academic dissertations available, is located at the following Web address: http://wwwlib.umi.com/dissertations. From this archive, we have compiled the following list covering dissertations devoted to meningitis. You will see that the information provided includes the dissertation’s title, its author, and the institution with which the author is associated. The following covers recent dissertations found when using this search procedure: •
A Comparative Study of Children Who Have Recovered from Aseptic Meningitis and Their Unaffected Siblings. by Rosen, Linda Merle, Phd from University of Pittsburgh, 1978, 158 pages http://wwwlib.umi.com/dissertations/fullcit/7817276
•
Meningitis in South African Adults: an Evaluation of Prognostic Indicators, Impact of Hiv-infection, and Diagnostic Dilemmas by Schutte, Clara-maria; Md from University of Pretoria (south Africa), 2002 http://wwwlib.umi.com/dissertations/fullcit/f304497
•
Sequelae of H. Influenzae Meningitis in Children by Topp, Sylvia, Phd from Boston College, 1980, 129 pages http://wwwlib.umi.com/dissertations/fullcit/8017619
240 Meningitis
Keeping Current Ask the medical librarian at your library if it has full and unlimited access to the ProQuest Digital Dissertations database. From the library, you should be able to do more complete searches via http://wwwlib.umi.com/dissertations.
241
CHAPTER 5. CLINICAL TRIALS AND MENINGITIS Overview In this chapter, we will show you how to keep informed of the latest clinical trials concerning meningitis.
Recent Trials on Meningitis The following is a list of recent trials dedicated to meningitis.8 Further information on a trial is available at the Web site indicated. •
DepoCyt Therapy in Patients with Neoplastic Meningitis from Lymphoma or a Solid Tumor Condition(s): Meningeal Neoplasms Study Status: This study is currently recruiting patients. Sponsor(s): SkyePharma Purpose - Excerpt: The purpose of this study is to find out how well an experimental drug called DepoCyt works for neoplastic meningitis (cancer that has spread to the tissues around the brain and spinal cord). DepoCyt is a new slow-release form of the cancer drug called ara-C (cytarabine). Cytarabine has been used for many years to treat cancer. Phase(s): Phase IV Study Type: Interventional Contact(s): see Web site below Web Site: http://clinicaltrials.gov/ct/show/NCT00029523
•
Gemcitabine in Treating Neoplastic Meningitis in Patients With Leukemia, Lymphoma, or Solid Tumors Condition(s): leptomeningeal metastases Study Status: This study is currently recruiting patients.
8
These are listed at www.ClinicalTrials.gov.
242 Meningitis
Sponsor(s): National Cancer Institute (NCI) Purpose - Excerpt: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of gemcitabine in treating neoplastic meningitis in patients who have leukemia, lymphoma, or solid tumors. Phase(s): Phase I Study Type: Interventional Contact(s): see Web site below Web Site: http://clinicaltrials.gov/ct/show/NCT00052806 •
Intrathecal Gemcitabine in Treating Patients With Cancer and Neoplastic Meningitis Condition(s): leptomeningeal metastases Study Status: This study is currently recruiting patients. Sponsor(s): Baylor College of Medicine Purpose - Excerpt: RATIONALE: Giving gemcitabine intrathecally may be an effective treatment for neoplastic meningitis. PURPOSE: Phase I trial to study the effectiveness of intrathecal gemcitabine in treating patients who have cancer and neoplastic meningitis. Phase(s): Phase I Study Type: Interventional Contact(s): see Web site below Web Site: http://clinicaltrials.gov/ct/show/NCT00039143
•
Safety and Antifungal Activity of Recombinant Interferon-gamma 1b (rIFN-gamma 1b) Given with Standard Therapy in Patients with Cryptococcal Meningitis Condition(s): Meningitis, Cryptococcal; HIV Infections Study Status: This study is no longer recruiting patients. Sponsor(s): InterMune Pharmaceuticals Purpose - Excerpt: The purpose of this study is to examine the antifungal activity of recombinant interferon-gamma 1b (rIFN-gamma 1b) given with standard antifungal therapy. Phase(s): Phase II Study Type: Interventional Contact(s): see Web site below Web Site: http://clinicaltrials.gov/ct/show/NCT00012467
•
A Comparison of Fluconazole and Amphotericin B in the Treatment of Cryptococcal Meningitis Condition(s): Meningitis, Cryptococcal; HIV Infections Study Status: This study is completed. Sponsor(s): Pfizer
Clinical Trials 243
Purpose - Excerpt: To compare the safety and effectiveness of fluconazole and amphotericin B, alone or in combination with flucytosine, as treatment for acute cryptococcal meningitis. Study Type: Interventional Contact(s): see Web site below Web Site: http://clinicaltrials.gov/ct/show/NCT00002305 •
A Multicenter Comparison of Fluconazole (UK-49,858) and Amphotericin B as Treatment for Acute Cryptococcal Meningitis Condition(s): Meningitis, Cryptococcal; HIV Infections Study Status: This study is completed. Sponsor(s): Pfizer Purpose - Excerpt: To compare the safety and effectiveness of fluconazole and amphotericin B, alone or in combination with flucytosine, as treatment for acute cryptococcal meningitis. Study Type: Interventional Contact(s): see Web site below Web Site: http://clinicaltrials.gov/ct/show/NCT00002068
•
A Pilot Study of Fluconazole Plus Flucytosine for the Treatment of AIDS Patients With Acute Cryptococcal Meningitis. Condition(s): Meningitis, Cryptococcal; HIV Infections Study Status: This study is completed. Sponsor(s): Pfizer Purpose - Excerpt: To evaluate and estimate the safety and efficacy of the combination of fluconazole and flucytosine as treatment for acute cryptococcal meningitis in patients with AIDS. Fluconazole and flucytosine have different mechanisms of action. Since fluconazole has not been associated with hematologic suppression and does not produce renal impairment that can result in higher serum flucytosine levels, this combination may be better tolerated than is amphotericin B plus flucytosine. Study Type: Interventional Contact(s): see Web site below Web Site: http://clinicaltrials.gov/ct/show/NCT00002113
•
A Randomized Double Blind Protocol Comparing Amphotericin B With Flucytosine to Amphotericin B Alone Followed by a Comparison of Fluconazole and Itraconazole in the Treatment of Acute Cryptococcal Meningitis Condition(s): Meningitis, Cryptococcal; HIV Infections Study Status: This study is completed. Sponsor(s): National Institute of Allergy and Infectious Diseases (NIAID) Purpose - Excerpt: To evaluate the effectiveness and safety of amphotericin B plus flucytosine (5-fluorocytosine) compared to amphotericin B alone for a first episode of acute cryptococcal meningitis in AIDS patients, and to compare the effectiveness and
244 Meningitis
safety of fluconazole versus itraconazole. At least 10 percent of patients with a low CD4 count and HIV infection will develop meningitis due to Cryptococcus neoformans. More effective treatments than the standard therapy need to be explored. Study Type: Interventional Contact(s): see Web site below Web Site: http://clinicaltrials.gov/ct/show/NCT00000639 •
A Study of Fluconazole in the Treatment of Cryptococcal Meningitis in Patients Who Have Not Had Success with Amphotericin B Condition(s): Meningitis, Cryptococcal; HIV Infections Study Status: This study is completed. Sponsor(s): Pfizer Purpose - Excerpt: To evaluate the safety and effectiveness of fluconazole as treatment for acute cryptococcal meningitis in patients who have had an unsatisfactory response to or have experienced unacceptable toxicity with amphotericin B. Study Type: Interventional Contact(s): see Web site below Web Site: http://clinicaltrials.gov/ct/show/NCT00002306
•
A Study of Fluconazole in the Treatment of Cryptococcal Meningitis in Patients with AIDS Condition(s): Meningitis, Cryptococcal; HIV Infections Study Status: This study is completed. Sponsor(s): Pfizer Purpose - Excerpt: To compare the safety and effectiveness of fluconazole with that of placebo as maintenance treatment for preventing the relapse of cryptococcal meningitis in patients with AIDS. Study Type: Interventional Contact(s): see Web site below Web Site: http://clinicaltrials.gov/ct/show/NCT00002294
•
An Open, Non-Comparative Study of Intravenous and Oral Fluconazole in the Treatment of Acute Cryptococcal Meningitis Condition(s): Meningitis, Cryptococcal; HIV Infections Study Status: This study is completed. Sponsor(s): Pfizer Purpose - Excerpt: To evaluate the safety and effectiveness of fluconazole as an intravenous dose as initial treatment for acute cryptococcal meningitis followed by oral therapy in AIDS and non-AIDS patients. Lack of satisfactory response will allow increase of dose. Both newly diagnosed and relapsed patients are eligible. Study Type: Interventional Contact(s): see Web site below
Clinical Trials 245
Web Site: http://clinicaltrials.gov/ct/show/NCT00002077 •
Comparison of Fluconazole and Amphotericin B in the Treatment of Brain Infections in Patients with AIDS Condition(s): Meningitis, Cryptococcal; HIV Infections Study Status: This study is completed. Sponsor(s): Pfizer; National Institute of Allergy and Infectious Diseases (NIAID) Purpose - Excerpt: To compare the safety and effectiveness of a new drug, fluconazole, with that of the usual therapy, amphotericin B, in the prevention of a relapse of cryptococcal meningitis (CM) in patients with AIDS who have been successfully treated for acute CM in the last 6 months. Cryptococcal meningitis is a life-threatening infectious complication of AIDS. Because relapse after treatment occurs in over 50 percent of cases, chronic maintenance therapy with intravenous (IV) amphotericin B is usually given. However, amphotericin B is not always effective, has toxic effects, and must be given by the intravenous route. Fluconazole is an antifungal agent that can be given orally and has been shown to be effective against cryptococcal infections in animals and against acute CM in a few AIDS patients. Also, the side effects experienced by over 2000 patients or volunteers given fluconazole have seldom been severe enough to require withdrawal of the drug. Phase(s): Phase III Study Type: Interventional Contact(s): see Web site below Web Site: http://clinicaltrials.gov/ct/show/NCT00001017
•
Dexamethasone in Cryptococcal Meningitis Condition(s): Meningitis, Cryptococcal; HIV Infections Study Status: This study is completed. Sponsor(s): National Institute of Allergy and Infectious Diseases (NIAID) Purpose - Excerpt: To evaluate the effect of corticosteroids on reducing elevated intracranial pressure in cryptococcal meningitis. To evaluate the safety of corticosteroids in patients with cryptococcal meningitis and intracranial hypertension. In AIDS patients with cryptococcal meningitis, a correlation has been found between early death and elevated intracranial pressure. Since dexamethasone has been found to reduce intracranial pressure resulting from other forms of meningitis, it may be of benefit in AIDS patients with cryptococcal meningitis. Phase(s): Phase II Study Type: Interventional Contact(s): see Web site below Web Site: http://clinicaltrials.gov/ct/show/NCT00000776
•
Multicenter Comparison of Fluconazole (UK-49,858) and Amphotericin B as Maintenance Treatment for the Prevention of Relapse of Cryptococcal Meningitis in Patients With Acquired Immunodeficiency Syndrome Condition(s): Meningitis, Cryptococcal; HIV Infections
246 Meningitis
Study Status: This study is completed. Sponsor(s): Pfizer Purpose - Excerpt: To compare the safety and effectiveness of fluconazole and amphotericin B as maintenance treatment for preventing the relapse of cryptococcal meningitis in patients with AIDS. Study Type: Interventional Contact(s): see Web site below Web Site: http://clinicaltrials.gov/ct/show/NCT00002074 •
Multi-center Comparison of Fluconazole (UK-49,858) and Amphotericin B as Treatment for Acute Cryptococcal Meningitis Condition(s): Meningitis, Cryptococcal; HIV Infections Study Status: This study is completed. Sponsor(s): National Institute of Allergy and Infectious Diseases (NIAID) Purpose - Excerpt: To compare the safety and effectiveness of fluconazole (FCZ) and amphotericin B (AMB), alone or in combination with flucytosine (FLC), as treatment for acute cryptococcal meningitis in patients who have not been treated previously or who have relapsed after a previous successful treatment. Cryptococcal meningitis is an important cause of disease and death among patients with AIDS. Usually AMB is given either alone or with FLC to patients with this infection, but these treatments are not always effective and both have toxic effects. Animal studies and preliminary studies in humans show that FCZ is active in cryptococcal meningitis and suggest that it may be less toxic than either AMB or FLC. Study Type: Interventional Contact(s): see Web site below Web Site: http://clinicaltrials.gov/ct/show/NCT00000708
•
Multicenter Comparison of Fluconazole (UK-49,858) and Amphotericin B as Treatment for Acute Cryptococcal Meningitis Condition(s): Meningitis, Cryptococcal; HIV Infections Study Status: This study is completed. Sponsor(s): Pfizer Purpose - Excerpt: To compare the safety and effectiveness of fluconazole and amphotericin B, alone or in combination with flucytosine, as treatment for acute cryptococcal meningitis. Study Type: Interventional Contact(s): see Web site below Web Site: http://clinicaltrials.gov/ct/show/NCT00002075
•
Open, Non-comparative Study of Fluconazole in Patients With Coccidioidal Meningitis Condition(s): Meningitis; HIV Infections Study Status: This study is completed.
Clinical Trials 247
Sponsor(s): Pfizer Purpose - Excerpt: The study is intended to examine the efficacy of fluconazole for the treatment of coccidioidal meningitis in patients with new onset of infection, relapse of previous infection, or failed previous therapy. Drug efficacy, safety and tolerance will be examined. Study Type: Interventional Contact(s): see Web site below Web Site: http://clinicaltrials.gov/ct/show/NCT00002010 •
Open, Non-Comparative Study of Intravenous and Oral Fluconazole in the Treatment of Acute Cryptococcal Meningitis Condition(s): Meningitis, Cryptococcal; HIV Infections Study Status: This study is completed. Sponsor(s): Pfizer Purpose - Excerpt: To evaluate the safety and effectiveness of fluconazole as an intravenous dose as initial treatment for acute cryptococcal meningitis followed by oral therapy in AIDS and non-AIDS patients. Both newly diagnosed and relapsed patients are eligible. The effectiveness of maintenance fluconazole therapy in sustaining a clinical cure in AIDS patients will also be evaluated. Study Type: Interventional Contact(s): see Web site below Web Site: http://clinicaltrials.gov/ct/show/NCT00002040
•
Pilot Study of Oral Fluconazole in the Treatment of Acute Cryptococcal Meningitis Condition(s): Meningitis, Cryptococcal; HIV Infections Study Status: This study is completed. Sponsor(s): Pfizer Purpose - Excerpt: To evaluate the safety and effectiveness of fluconazole as treatment for acute cryptococcal meningitis in AIDS patients. Both newly diagnosed and relapsed patients are eligible. Study Type: Interventional Contact(s): see Web site below Web Site: http://clinicaltrials.gov/ct/show/NCT00002076
•
Safety and Efficacy of Amphotericin B Lipid Complex in the Treatment of Cryptococcal Meningitis in Patients With the Acquired Immunodeficiency Syndrome Condition(s): Meningitis, Cryptococcal; HIV Infections Study Status: This study is completed. Sponsor(s): Liposome Purpose - Excerpt: To evaluate the safety, tolerance and efficacy of three different dosage regimens of Amphotericin B Lipid Complex (ABLC) compared to Fungizone (Amphotericin B) in patients with AIDS and cryptococcal meningitis. Study Type: Interventional
248 Meningitis
Contact(s): see Web site below Web Site: http://clinicaltrials.gov/ct/show/NCT00002019 •
SCH 39304 as Therapy for Acute Cryptococcal Meningitis in HIV-Infected Patients Followed by Maintenance Therapy Condition(s): Meningitis, Cryptococcal; HIV Infections Study Status: This study is completed. Sponsor(s): National Institute of Allergy and Infectious Diseases (NIAID); ScheringPlough Purpose - Excerpt: To assess the safety and effectiveness of SCH 39304 as primary treatment of acute cryptococcal meningitis in HIV-infected patients. Safety and effectiveness of maintenance therapy following successful treatment of acute disease are also evaluated. Cryptococcal meningitis is a significant cause of illness and death in HIV-infected patients. Intravenous amphotericin B is effective for acute disease but relapse occurs in the majority of patients. Maintenance therapy is recommended but must be balanced against the multiple toxicities of the drugs used and the problems associated with the weekly administration of intravenous therapy. Treatments that are equally or more effective and less toxic than traditional methods are needed, especially oral therapy. SCH 39304 is an orally active antifungal drug that in animal studies is active against a wide range of systemic fungal infections including infections due to Cryptococcus. Features of SCH 39304 suggest that it might be of value in the treatment of cryptococcal meningitis. Phase(s): Phase I Study Type: Interventional Contact(s): see Web site below Web Site: http://clinicaltrials.gov/ct/show/NCT00000677
•
The Safety and Effectiveness of RMP-7 Plus Amphotericin B in Patients with HIV and Cryptococcal Meningitis Condition(s): Meningitis, Cryptococcal; HIV Infections Study Status: This study is completed. Sponsor(s): Alkermes Purpose - Excerpt: To evaluate the safety of escalating doses of RMP-7 administered in persons with HIV infection and cryptococcal meningitis and to determine the MTD of the drug. To evaluate the pharmacokinetics, including cerebrospinal fluid (CSF) penetration, of amphotericin B when administered with RMP-7. Phase(s): Phase I Study Type: Interventional Contact(s): see Web site below Web Site: http://clinicaltrials.gov/ct/show/NCT00002316
Clinical Trials 249
Keeping Current on Clinical Trials The U.S. National Institutes of Health, through the National Library of Medicine, has developed ClinicalTrials.gov to provide current information about clinical research across the broadest number of diseases and conditions. The site was launched in February 2000 and currently contains approximately 5,700 clinical studies in over 59,000 locations worldwide, with most studies being conducted in the United States. ClinicalTrials.gov receives about 2 million hits per month and hosts approximately 5,400 visitors daily. To access this database, simply go to the Web site at http://www.clinicaltrials.gov/ and search by “meningitis” (or synonyms). While ClinicalTrials.gov is the most comprehensive listing of NIH-supported clinical trials available, not all trials are in the database. The database is updated regularly, so clinical trials are continually being added. The following is a list of specialty databases affiliated with the National Institutes of Health that offer additional information on trials: •
For clinical studies at the Warren Grant Magnuson Clinical Center located in Bethesda, Maryland, visit their Web site: http://clinicalstudies.info.nih.gov/
•
For clinical studies conducted at the Bayview Campus in Baltimore, Maryland, visit their Web site: http://www.jhbmc.jhu.edu/studies/index.html
•
For cancer trials, visit the National Cancer Institute: http://cancertrials.nci.nih.gov/
•
For eye-related trials, visit and search the Web page of the National Eye Institute: http://www.nei.nih.gov/neitrials/index.htm
•
For heart, lung and blood trials, visit the Web page of the National Heart, Lung and Blood Institute: http://www.nhlbi.nih.gov/studies/index.htm
•
For trials on aging, visit and search the Web site of the National Institute on Aging: http://www.grc.nia.nih.gov/studies/index.htm
•
For rare diseases, visit and search the Web site sponsored by the Office of Rare Diseases: http://ord.aspensys.com/asp/resources/rsch_trials.asp
•
For alcoholism, visit the National Institute on Alcohol Abuse and Alcoholism: http://www.niaaa.nih.gov/intramural/Web_dicbr_hp/particip.htm
•
For trials on infectious, immune, and allergic diseases, visit the site of the National Institute of Allergy and Infectious Diseases: http://www.niaid.nih.gov/clintrials/
•
For trials on arthritis, musculoskeletal and skin diseases, visit newly revised site of the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health: http://www.niams.nih.gov/hi/studies/index.htm
•
For hearing-related trials, visit the National Institute on Deafness and Other Communication Disorders: http://www.nidcd.nih.gov/health/clinical/index.htm
•
For trials on diseases of the digestive system and kidneys, and diabetes, visit the National Institute of Diabetes and Digestive and Kidney Diseases: http://www.niddk.nih.gov/patient/patient.htm
•
For drug abuse trials, visit and search the Web site sponsored by the National Institute on Drug Abuse: http://www.nida.nih.gov/CTN/Index.htm
250 Meningitis
•
For trials on mental disorders, visit and search the Web site of the National Institute of Mental Health: http://www.nimh.nih.gov/studies/index.cfm
•
For trials on neurological disorders and stroke, visit and search the Web site sponsored by the National Institute of Neurological Disorders and Stroke of the NIH: http://www.ninds.nih.gov/funding/funding_opportunities.htm#Clinical_Trials
251
CHAPTER 6. PATENTS ON MENINGITIS Overview Patents can be physical innovations (e.g. chemicals, pharmaceuticals, medical equipment) or processes (e.g. treatments or diagnostic procedures). The United States Patent and Trademark Office defines a patent as a grant of a property right to the inventor, issued by the Patent and Trademark Office.9 Patents, therefore, are intellectual property. For the United States, the term of a new patent is 20 years from the date when the patent application was filed. If the inventor wishes to receive economic benefits, it is likely that the invention will become commercially available within 20 years of the initial filing. It is important to understand, therefore, that an inventor’s patent does not indicate that a product or service is or will be commercially available. The patent implies only that the inventor has “the right to exclude others from making, using, offering for sale, or selling” the invention in the United States. While this relates to U.S. patents, similar rules govern foreign patents. In this chapter, we show you how to locate information on patents and their inventors. If you find a patent that is particularly interesting to you, contact the inventor or the assignee for further information. IMPORTANT NOTE: When following the search strategy described below, you may discover non-medical patents that use the generic term “meningitis” (or a synonym) in their titles. To accurately reflect the results that you might find while conducting research on meningitis, we have not necessarily excluded nonmedical patents in this bibliography.
Patents on Meningitis By performing a patent search focusing on meningitis, you can obtain information such as the title of the invention, the names of the inventor(s), the assignee(s) or the company that owns or controls the patent, a short abstract that summarizes the patent, and a few excerpts from the description of the patent. The abstract of a patent tends to be more technical in nature, while the description is often written for the public. Full patent descriptions contain much more information than is presented here (e.g. claims, references, figures, diagrams, etc.). We will tell you how to obtain this information later in the chapter. The following is an 9Adapted
from the United States Patent and Trademark Office: http://www.uspto.gov/web/offices/pac/doc/general/whatis.htm.
252 Meningitis
example of the type of information that you can expect to obtain from a patent search on meningitis: •
Antibodies which bind meningitis related homologous antigenic sequences Inventor(s): Van Alstyne; Diane (Vancouver, CA), Sharma; Lawrence R. (Vancouver, CA) Assignee(s): Insight Biotech Inc. (St. Michael, BB) Patent Number: 5,510,264 Date filed: September 28, 1993 Abstract: Monoclonal antibodies capable of binding to a Meningitis Related Homologous Antigenic Sequence (MRHAS) are provided. The MRHAS is found in meningitis-causing organisms and chemokines involved in cell chemotaxis. The monoclonal antibodies are useful for detection and diagnosis of meningitis. Excerpt(s): This invention relates to the application of immunological techniques that provide novel materials useful in the diagnosis, treatment and vaccination against meningitis caused by either bacterial or viral agents. These techniques include the production and application of novel monoclonal antibodies, peptides, and mixtures and combinations thereof that are useful for detecting meningitis infections. The techniques also include eliciting antibodies specific to meningitis causing agents. These immunological techniques may also be applied to the treatment of such disease. The term meningitis is a general one, referring to the inflammatory response to infection of the meninges and the cerebrospinal fluid (CSF). See Roos, "Chapter 16", in Scheld, et al. eds., 1991, Infections of the Central Nervous System:335-403 which is incorporated herein in its entirety by reference. The fact that the inflammatory response occurs in the proximity of the brain and in the space limited by a rigid cranium, makes these infections serious and life threatening. Most patients exhibit nonspecific clinical signs and symptoms such as fever, irritability, altered mental status usually accompanied by vomiting and loss of appetite. In children one year of age and older, photophobia and headache are common complaints. Specific clinical signs indicative of meningitis are neck rigidity and pain on neck flexion. Brudzinski's sign (neck flexion producing knee and hip flexion) and Kernig's sign (difficulty and pain in raising extended leg) are other useful clinical signs. Web site: http://www.delphion.com/details?pn=US05510264__
•
Combined meningitis vaccine Inventor(s): Costantino; Paolo (Colle Val D'Elsa, IT), D'Ascenzi; Sandro (Colle Val D'Elsa, IT), Norelli; Francesco (Siena, IT), Giannozzi; Aldo (Siena, IT), Ceccarini; Costante (Castelnuovo Berardenga, IT) Assignee(s): Chiron S.p.A. (Siena, IT) Patent Number: 6,251,401 Date filed: May 1, 1997 Abstract: A combined vaccine for bacterial meningitis comprises Hib and MenC oligosaccharide conjugates.
Patents 253
Excerpt(s): The present invention relates to a combined vaccine for the treatment of bacterial meningitis. In particular, the combined vaccine effectively protects against infection by Haemophilus influenzae type B (Hib) and Neisseria meningitidis (meningococcus) serotypes B and C (MenB, MenC). Bacterial meningitis caused by infection with Hib, MenB and/or MenC represents a worldwide problem. Infection by these organisms can result in permanent disability and death among young children. Recently, however, a conjugate Hib vaccine has become generally available and has resulted in the effective control of Hib infections. Similar vaccines are shortly to become available for MenC infection and also for MenB infection (see Costantino et al., 1992 Vaccine, 10,691-698). The Hib and meningococcal vaccines are based on conjugates between oligosaccharides derived from the bacterial surface, which define epitopes specific for the bacterium in question, conjugated to carrier proteins, such as non-toxic mutants of diphtheria toxin, for example CRM197. Web site: http://www.delphion.com/details?pn=US06251401__ •
Method for differential diagnosis of meningitis with a limulus lysate test Inventor(s): Khan; Waheed N. (Potomac, MD) Assignee(s): Research Foundation of Children's Hospital (Washington, DC) Patent Number: 4,067,776 Date filed: November 25, 1975 Abstract: A method for rapid bedside diagnostic differentiation between aseptic meningitis and Gram-negative bacterial meningitis is carried out in a positive control vessel, a negative control vessel and a test vessel, wherein each vessel contains an equal amount of lyophilized limulus lysate and the positive control vessel also contains an amount of lyophilized Gram-negative bacterial endotoxin. Excerpt(s): As is known in the art, meningitis may be broadly characterized as aseptic meningitis or bacterial meningitis. Aseptic meningitis may refer to two different but related forms of meningitis. Firstly, it may be referring to an acute febrile illness with meningeal irritation and cerebro-spinal fluid (CSF) pleocytosis, but with normal glucose contents and on culture of the CSF no bacterial isolation is obtained. The second form of aseptic meningitis can be characterized by CSF pleocytosis, normal glucose and the absence of organism involvement. This can include not only viral but other infections as well as non-infectious causes. When viral infections of the central nervous system are invovled, these infections may take three different forms. In the first form, there may be no symptoms and only fever and malaise, but the CSF may be abnormal with a lymphocytic pleocytosis. In a second form, the symptoms may be confined to meningeal manifestations, such as fever, headache, vomiting, stiff neck and back and the like. In the third form, referred to as encephalitis, the meningeal symptoms, noted above, may be accompanied by cerebral disorders including alterations of consciousness, personality changes and the like. Bacterial meningitis may be caused by one or more of several known bacteria. Among the generally accepted bacteria are the Gram-negative bacteria Neisseria meningitidis, Haemophilus influenzae, Escherichia coli, Salmonella enteridis (or group B), Proteus species (indole positive and negative) and Pseudomonas arugeniosa, and the Gram-positive bacteria, Diplococcus pneumoniae, Strepococcus pyogenes, and Straphylococcus aureus. In bacterial meningitis, clinical indications show brain and meninges involvement. Some of the clinical signs can include fever, headache, stiff neck and vomiting. Thus, from a clinical observation, it is difficult to tell whether aseptic meningitis or bacterial meningitis is involved, since the clinical symptoms of the
254 Meningitis
different forms of meningitis can be, at least, overlapping in their manifestations. However, the proper treatment for the forms of meningitis vary significantly, and a rapid and positive diagnosis of the form of meningitis is extremely important in the treatment of meningitis. If the meningitis is diagnosed as bacterial meningitis, the more usual therapy involves administration of antibiotics, of specific types, and such administration should be given as promptly as possible once the diagnosis has been established. The prompt commencement of the thereapy is fundamental to the more successful treatment of bacterial meningitis. Web site: http://www.delphion.com/details?pn=US04067776__ •
Method of discriminating bacterial from aseptic meningitis Inventor(s): Stahel; Phillip (Birmingham, AL), Barnum; Scott R. (Sterrett, AL) Assignee(s): UAB Research Foundation (Birmingham, AL) Patent Number: 5,778,895 Date filed: January 29, 1997 Abstract: The present invention provides a method for the differential diagnosis of bacterial meningitis in an individual in need of such diagnosis, comprising the steps of: measuring the levels of complement C3 and complement factor B in the cerebrospinal fluid of the individual; and determining whether that individual has bacterial menigitis based on the levels of complement C3 and complement factor B in the cerebrospinal fluid of that individual. Also provided is a method for the differential diagnosis of bacterial menigitis in an individual in need of such diagnosis, comprising the steps of: measuring the levels of complement factor B in a sample from the individual; and determining whether that individual has bacterial menigitis based on the levels of complement factor B in the sample from that individual. Excerpt(s): The present invention relates generally to the fields of medicine, neuroimmunology and protein chemistry. More specifically, the present invention relates to a method of discriminating bacterial from aseptic meningitis. Bacterial meningitis occurs in about 25,000 cases per year in the United States with an overall mortality rate of from 10-35%. About 30% of individuals with acute bacterial meningitis experience seizures and about 10-30% of those who survive a case of bacterial meningitis exhibit long-term neurological sequelae. Bacterial meningitis remains a major cause of morbidity and mortality, with a high incidence of residual neurological impairment (reviewed in Quagliarello & Scheld 1992). Early diagnosis and immediate onset of adequate antimicrobial treatment are essential for the survival of patients with bacterial meningitis (Lieu et al. 1992). However, establishing the diagnosis of bacterial meningitis represents a difficult task in most cases, since clinical signs of acute meningitis are non-specific, and laboratory examinations of cerebrospinal fluid (CSF) often do not accurately differentiate between bacterial and aseptic meningitis (Lindquist et al. 1988, Rodewald et al. 1991). Accurate differentiation between bacterial and aseptic (viral) meningitis is difficult as both are inflammatory diseases that elicit similar host defense responses and clinical symptoms. Differential diagnosis can be made on positive identification of the bacteria from the cerebrospinal fluid of the affected individual. Unfortunately, it may take several days to grow and identify the bacteria and twentyfive percent of the time culture results are negative or equivocal even though the patients have bacterial meningitis. Similar or greater error rates affect nearly every laboratory parameter used for diagnostic purposes.
Patents 255
Web site: http://www.delphion.com/details?pn=US05778895__ •
Method of treating bacterial meningitis with anti-tumor necrosis factor antibody Inventor(s): Hector; Richard F. (Dublin, CA), Collins; Michael S. (Madison, CT) Assignee(s): Bayer Corporation (Berkeley, CA) Patent Number: 5,616,321 Date filed: March 23, 1995 Abstract: Bacterial meningitis infection in a mammal is treated by intravenous infusion of a therapeutically effective amount of a monoclonal antibody which binds to tumor necrosis factor alpha and an antibiotic. Treatment can be initiated up to five hours after bacterial challenge and the antibiotic is preferably selected from cephalosporins and aminoglycosides. Excerpt(s): This application is concerned generally with a treatment of infection and specifically with the use of monoclonal antibodies that bind to TNF to treat bacterial meningitis. Bacterial meningitis remains one of the more difficult management problems in clinical medicine. Evidence suggests that bacterial meningitis represents infection in a site with a reduced potential for host resistance. With essentially no antibodies or complement present in the spinal fluid, polymorphonucleocytes are essentially unable to contribute to the clearing of the intruding bacteria in the early steps of disease. Morbidity and mortality from bacterial meningitis remains high; a death rate of 30% for pneumococcal meningitis has not changed over the past 40 years despite new antibiotics and improved understanding of therapy practices. Bacterial meningitis is described in detail in Cecil, Textbook of Medicine, 19th addition at pages 1655-161, the details of which are incorporated into this application. The role of tumor necrosis factor (TNF) in bacterial meningitis is described in an article by Arditi et al. in the Journal of Infectious Diseases, 162:p. 139-145(1990). See also related articles by Arditi et al., in the Journal of Infectious Diseases, vol. 160, no. 6, pp. 1005-1011, December 1989 and an article by Mustafa et al., the Journal of Infectious Diseases, vol. 160, no. 5, pp. 818-825, November 1989. Web site: http://www.delphion.com/details?pn=US05616321__
•
PCR assay for bacterial and viral meningitis Inventor(s): Glustein; Joseph Z. (Pittsburgh, PA), Ehrlich; Garth D. (Pittsburgh, PA), Zhang; Yingze (Pittsburgh, PA) Assignee(s): University of Pittsburgh (Pittsburgh, PA) Patent Number: 6,258,570 Date filed: April 17, 1998 Abstract: A multiplex assay is provided for the simultaneous detection and discrimination of pathogens that cause bacterial and viral meningitis. Excerpt(s): The present invention relates generally to methods for clinically distinguishing between bacterial and viral meningitis. In particular, the present invention relates to a PCR-based multiplex assay for the rapid detection and discrimination of pathogens causing bacterial and viral meningitis. Bacterial meningitis is a neurologically devastating and often life threatening illness. Rapid and accurate
256 Meningitis
diagnosis is therefore of utmost importance in providing timely and optimal care. In contrast, viral meningitis, which often presents with the same clinical signs and symptoms as bacterial meningitis, is a self-limiting illness that does not require antimicrobial treatment and hospitalization. See, Cherry, J. D., Textbook of Pediatric Infectious Diseases, 3rd ed. Feigin, R. D., et al. (Eds.) W.B. Saunders Co., Philadelphia, pp. 439-445 (1992), the disclosure of which is incorporated herein by reference. Currently, physicians in the emergency room setting are repeatedly faced with the diagnostic dilemma of how to clinically distinguish between bacterial and viral meningitis. This feat is virtually impossible with any degree of certainty. Therefore, a patient is often hospitalized and treated with intravenous antibiotics until the results of bacterial cultures from the cerebrospinal fluid ("CSF") are determined. This process generally takes between 48 to 72 hours to complete. The waiting period can therefore result in a tremendous increase in health care costs and the provision of suboptimal care, particularly since greater than 90% of meningitis cases are of a viral etiology. Web site: http://www.delphion.com/details?pn=US06258570__ •
Peptides representing epitopic sites for bacterial and viral meningitis causing agents and their CNS carrier and uses thereof Inventor(s): Sharma; Lawrence R. (Vancouver, CA), Alstyne; Diane V. (Vancouver, CA) Assignee(s): Insight Biotek, Inc. (St. Michaels, BB) Patent Number: 5,556,757 Date filed: June 7, 1995 Abstract: Peptides comprising a Meningitis Related Homologous Antigenic Sequence (MRHAS) are provided. The MRHAS is found in meningitis-causing organisms and chemokines involved in cell chemotaxis. The peptides are useful as antigens and vaccines for detection, diagnosis and treatment of meningitis. Excerpt(s): This invention relates to the application of immunological techniques that provide novel materials useful in the diagnosis, treatment and vaccination against meningitis caused by either bacterial or viral agents. These techniques include the production and application of novel monoclonal antibodies, peptides, and mixtures and combinations thereof that are useful for detecting meningitis infections. The techniques also include eliciting antibodies specific to meningitis causing agents. These immunological techniques may also be applied to the treatment of such disease. The term meningitis is a general one, referring to the inflammatory response to infection of the meninges and the cerebrospinal fluid (CSF). See Roos, "Chapter 16", in Scheld, et al. eds., 1991, Infections of the Central Nervous System:335-403 which is incorporated herein in its entirety by reference. The fact that the inflammatory response occurs in the proximity of the brain and in the space limited by a rigid cranium, makes these infections serious and life threatening. Most patients exhibit nonspecific clinical signs and symptoms such as fever, irritability, altered mental status usually accompanied by vomiting and loss of appetite. In children one year of age and older, photophobia and headache are common complaints. Specific clinical signs indicative of meningitis are neck rigidity and pain on neck flexicn. Brudzinski's sign (neck flexion producing knee and hip flexicn) and Kernig's sign (difficulty and pain in raising extended leg) are other useful clinical signs. Web site: http://www.delphion.com/details?pn=US05556757__
Patents 257
Patent Applications on Meningitis As of December 2000, U.S. patent applications are open to public viewing.10 Applications are patent requests which have yet to be granted. (The process to achieve a patent can take several years.) The following patent applications have been filed since December 2000 relating to meningitis: •
Novel meningitis conjugate vaccine Inventor(s): D'Ambra, Anello J. (Mount Pocono, PA), Arnold, Frank J. (Newfoundland, PA), Maleckar, James R. (Nazareth, PA), McMaster, Ronald P. (Stroudsburg, PA) Correspondence: Aventis Pasteur, Inc. Route 611, Discovery Drive; Swiftwater; PA; 18370; US Patent Application Number: 20030035806 Date filed: May 9, 2002 Abstract: The present invention relates to immunogenic protein-polysaccharide conjugates comprising pneumococcal surface protein (PspA) obtained from Streptococcus pneumoniae conjugated to a capsular polysaccharide from N. meningitidis, and compositions comprising the same. Also provided are methods of manufacture of such immunogenic combinations as well as methods of use of such immunogenic combinations in the prevention and treatment of bacterial meningitis, particularly pneumococcal and meningococcal meningitis. Excerpt(s): The present invention relates to the fields of immunology, vaccines and the prevention of bacterial infections by immunization, more specifically to polysaccharideprotein conjugates useful as vaccines, vaccine compositions comprising two or more polysaccharide-protein conjugates and methods of vaccination using the same. Neisseria meningitidis (N. meningitidis) is a leading cause of bacterial meningitis and sepsis throughout the world. Pathogenic meningococci are enveloped by a polysaccharide capsule that is attached to the outer membrane surface of the organism. N. meningitidis is classified by the immunological specificity of the capsular polysaccharide. Thirteen different serogroups of meningococci have been identified, of which five (A, B, C, W135, and Y) cause the majority of meningococcal disease. Serogroup A is responsible for most epidemic disease, which is rare in the industrialized world but occurs periodically in developing countries. Serogroups B, C, and Y cause the majority of endemic disease and localized outbreaks. Although more rare, serogroup W135 outbreaks have increased worldwide in recent years. [Samuelsson S., Eurosurveillance Weekly, 2000:17:1-5.] There are approximately 2,600 cases of bacterial meningitis per year in the United States and on average 330,000 cases in developing countries, with case fatality rates ranging between 10 and 20%. Current meningococcal vaccines elicit an immune response against the capsular polysaccharide. The antibodies thus generated are capable of complementmediated bacteriolysis of the serogroup specific meningococci. Meningococcal polysaccharide vaccines have been shown to be efficacious in older children and adults (Artenstein, M. S., et al. New Engl. J. Med. 282: 417-420, 1970 and Peltola, H., et al. New Engl. J. Med. 297: 686-691, 1977, but the efficacy is limited in infants and young children Reingold, A. L., et al. Lancet 2: 114-118, 1985). Subsequent doses of polysaccharide in younger populations elicited weak or no booster responses (Goldschneider, I., et al. J. Inf. Dis. 128: 769-776, 1973 and Gold, R., et al. J. Inf. Dis. 136: S31-S35, 1977). Also, the protection elicited by the meningococcal polysaccharide vaccines is not long-lasting
10
This has been a common practice outside the United States prior to December 2000.
258 Meningitis
having been estimated to be between 3 to 5 years (Brandt, B., et al. J. Inf. Dis. 131: S69S72, 1975, and Kyhty, H., et al. J. Inf. Dis. 142: 861-868, 1980, and Ceesay, S. J., et al. J. Inf. Dis. 167: 1212-1216, 1993). Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html
Keeping Current In order to stay informed about patents and patent applications dealing with meningitis, you can access the U.S. Patent Office archive via the Internet at the following Web address: http://www.uspto.gov/patft/index.html. You will see two broad options: (1) Issued Patent, and (2) Published Applications. To see a list of issued patents, perform the following steps: Under “Issued Patents,” click “Quick Search.” Then, type “meningitis” (or synonyms) into the “Term 1” box. After clicking on the search button, scroll down to see the various patents which have been granted to date on meningitis. You can also use this procedure to view pending patent applications concerning meningitis. Simply go back to http://www.uspto.gov/patft/index.html. Select “Quick Search” under “Published Applications.” Then proceed with the steps listed above.
259
CHAPTER 7. BOOKS ON MENINGITIS Overview This chapter provides bibliographic book references relating to meningitis. In addition to online booksellers such as www.amazon.com and www.bn.com, excellent sources for book titles on meningitis include the Combined Health Information Database and the National Library of Medicine. Your local medical library also may have these titles available for loan.
Book Summaries: Federal Agencies The Combined Health Information Database collects various book abstracts from a variety of healthcare institutions and federal agencies. To access these summaries, go directly to the following hyperlink: http://chid.nih.gov/detail/detail.html. You will need to use the “Detailed Search” option. To find book summaries, use the drop boxes at the bottom of the search page where “You may refine your search by.” Select the dates and language you prefer. For the format option, select “Monograph/Book.” Now type “meningitis” (or synonyms) into the “For these words:” box. You should check back periodically with this database which is updated every three months. The following is a typical result when searching for books on meningitis: •
AIDS Clinical Review Contact: Marcel Dekker, Incorporated, 270 Madison Ave, New York, NY, 10016, (800) 228-1160. Summary: This monograph presents 14 papers, all written within 12 months of publication, focusing on specific areas in which significant new advances have occurred in the epidemiology, diagnosis, therapy, and prevention of HIV infection and HIVassociated complications. Chapter One discusses the clinical significance of the biological phenotype of HIV. Counseling and medical evaluation of HTLV-I and HTLVII infected persons is explored in Chapter Two. Chapter Three through Eight emphasize developments in epidemiology, diagnosis, treatment and prevention of opportunistic infections resulting from HIV disease, such as: bacillary angiomatosis, syphilis, tuberculosis, pneumocystis carinii pneumonia, cryptococcal meningitis, and hepatitis B and C. Chapter Nine summarizes the diagnosis and management of AIDS-related lymphoma; Chapter Ten surveys treatment of HIV disease presently available; Chapter
260 Meningitis
Eleven describes the clinical uses of hematopoietic growth hormones in HIV-related illness; and the final three chapters report on vaccines, risk of HIV infection in health care workers, patient rights and physician responsibility. •
Directory of Chicago HIV/AIDS Clinical Trials. Translated title Contact: AIDS Foundation of Chicago, 411 S Wells Ste 300, Chicago, IL, 60607-3924, (312) 922-2322, http://www.aidschicago.org. Test Positive Aware Network, 5537 N Broadway, Chicago, IL, 60640, (773) 989-9400, http://www.tpan.com. African American AIDS Network, 1307 S Wabash Ave 2nd Fl, Chicago, IL, 60605, (773) 371-0032. Summary: This directory provides access to clinical trials related to Acquired immunodeficiency syndrome (AIDS) in the Chicago area. It explains what clinical trials are and the Food and Drug Administration (FDA) approval process, and answers questions about drug studies. The entries include information on anemia, anorexia, cytomegalovirus (CMV) retinitis, meningitis, herpes simplex, histoplasmosis, Human immunodeficiency virus (HIV) infection, Kaposi's sarcoma, lymphoma, mycobacterial prophylaxis, Pneumocystis carinii pneumonia (PCP), and toxoplasma, and studies on women and children.
•
The Edge of Discovery Contact: US Department of Health and Human Services, Public Health Service, National Institutes of Health, National Institute of Allergy and Infectious Diseases, 31 Center Dr MSC 2520, Bethesda, MD, 20892-2520, (301) 496-5717, http://www.niaid.nih.gov. Summary: This monograph presents information about intramural and extramural programs conducted by the National Institute of Allergy and Infectious Diseases (NIAID). It presents highlights of research projects in immunology; allergy and asthma; Acquired immunodeficiency syndrome (AIDS); Human immunodeficiency virus (HIV), including treatment programs and epidemiology; and other Sexually transmitted diseases (STD's). Development of new vaccines for pertussis, meningitis, and hepatitis B is described, as is antiviral drug research and international collaborations in malaria and other parasite research.
•
First Responder Refresher Training Program: National Standard Curriculum Contact: National Association of State Emergency Medical, Services Directors, 111 Park Pl, Falls Church, VA, 22046-4513, (703) 538-1799, http://www.nasemsd.org. Summary: Designed to assure the continuing competency of the individual first responder, this teaching guide establishes the minimum set of objectives which must be met to maintain acceptable knowledge and skill levels. The course is divided into four separate modules addressing trauma management and triage; patient management and operations; cardiovascular and respiratory assessment; and medical emergencies, including the appropriate prehospital management of communicable diseases, such as Acquired immunodeficiency syndrome (AIDS), Hepatitis B, and meningitis. Safety precautions to prevent the transmission of Human immunodeficiency virus (HIV) are consistent with the universal blood and body fluid precautions observed among health care providers. Course scope, performance objectives, and instructional strategies are each delineated, with recommendations for training materials, student appraisal, and instructor recruitment.
Books 261
•
HIV Infection in Developing Countries: Emerging Clinical Pictures in Africa Source: The Global Impact of AIDS. Proceedings of the First International Conference on the Global Impact of AIDS; London, United Kingdom, March 8-10, 1988. Contact: Alan R. Liss, Incorporated, 41 E 11th St, New York, NY, 10003, (212) 353-2957. Summary: This book chapter describes a presentation from the First International Conference on the Global Impact of AIDS held in London on March 8-10, 1988. It discusses the clinical manifestations associated with Human immunodeficiency virus (HIV) infection in Africa. It examines the interrelation between prevalent endemic infectious diseases and Acquired immunodeficiency syndrome (AIDS), particularly Sexually transmitted diseases (STD's), tuberculosis, and tuberculosis meningitis. It also describes symptoms such as generalized weakness syndrome, cough, dementia, and dermatological manifestations.
•
When I Die, Will I Get Better? Source: New York, NY: Peter Bedrick Books. 1993. 33 p. Contact: Available from Peter Bedrick Books, 2112 Broadway, New York, NY 10023. (212) 496-0751. $11.95. ISBN 0-87226-375-4. Summary: This storybook was created by a boy whose younger brother died of meningitis at the age of 2 1/2 years. The book describes Joeri Breebaart's own experiences with his brother's death (i.e., how his brother got ill, how he died, and the funeral) using a family of rabbits to play the roles of his brother, his parents, and himself. When young Fred Rabbit becomes sick and dies, the death has an effect on all the animals in the forest. The storybook is intended to help children come to an understanding of death and express their feelings about it.
•
All by myself Source: Boulder, CO: Light On Books and Videotapes. 1991. ca. 60 pp. Contact: Available from Light On Books and Videotapes, Suite 358, P.O. Box 8005, Boulder, CO 80306. Telephone: (303) 444-3340. $12.00; price includes postage and handling. Summary: This book contains two versions of the story of Micah, the author's son, who developed meningitis at the age of three weeks. The infection left him with cerebral palsy. The first version is appropriate for young children through third grade, and the second, more in-depth version is for adults. Both address the joys and trials one experiences living with children who have special needs.
Book Summaries: Online Booksellers Commercial Internet-based booksellers, such as Amazon.com and Barnes&Noble.com, offer summaries which have been supplied by each title’s publisher. Some summaries also include customer reviews. Your local bookseller may have access to in-house and commercial databases that index all published books (e.g. Books in Print). IMPORTANT NOTE: Online booksellers typically produce search results for medical and non-medical books. When searching for “meningitis” at online booksellers’ Web sites, you may discover non-medical books that use the generic term “meningitis” (or a synonym) in their titles. The
262 Meningitis
following is indicative of the results you might find when searching for “meningitis” (sorted alphabetically by title; follow the hyperlink to view more details at Amazon.com): •
A Dr Spot Casebook: George Has Meningitis by Leigh Jenny; ISBN: 1902463919; http://www.amazon.com/exec/obidos/ASIN/1902463919/icongroupinterna
•
Bacterial Meningitis by J. D. Williams (Editor), J. Burnie (Editor); ISBN: 0127551557; http://www.amazon.com/exec/obidos/ASIN/0127551557/icongroupinterna
•
Bacterial Meningitis by Allan R. Tunkel; ISBN: 0781711029; http://www.amazon.com/exec/obidos/ASIN/0781711029/icongroupinterna
•
Bacterial Meningitis (Antibiotics and Chemotherapy, Vol 45) by H. Schonfeld, et al (1992); ISBN: 3805554842; http://www.amazon.com/exec/obidos/ASIN/3805554842/icongroupinterna
•
Bacterial Meningitis (Contemporary Issues in Infectious Disease Vol 3) by Merle A. Sande, et al; ISBN: 0443083266; http://www.amazon.com/exec/obidos/ASIN/0443083266/icongroupinterna
•
Brain abscess and meningitis; Subarachnoid hemorrhage : timing problems; ISBN: 0387105395; http://www.amazon.com/exec/obidos/ASIN/0387105395/icongroupinterna
•
Cerebrospinal Meningitis Control: Report (1976); ISBN: 9241205881; http://www.amazon.com/exec/obidos/ASIN/9241205881/icongroupinterna
•
Cerebrospinal Meningitis Epidemics : A Scientific American article [DOWNLOAD: PDF] by Patrick S. Moore (Author), Claire V. Broome (Author); ISBN: B00006BNNC; http://www.amazon.com/exec/obidos/ASIN/B00006BNNC/icongroupinterna
•
Cerebrospinal Meningitis in West Africa and Sudan in the Twentieth Century by K. David Patterson, Gerald W. Hartwig; ISBN: 091845655X; http://www.amazon.com/exec/obidos/ASIN/091845655X/icongroupinterna
•
Die menschliche Herpes-simplex-Encephalitis und -Meningitis : e. klin.neuropatholog. Unters by Friedrich-Wilhelm Spaar; ISBN: 3437104306; http://www.amazon.com/exec/obidos/ASIN/3437104306/icongroupinterna
•
Emerging Strategies in the Fight Against Meningitis by Carlos Ferreiros (Editor), et al; ISBN: 1898486344; http://www.amazon.com/exec/obidos/ASIN/1898486344/icongroupinterna
•
Meningitis by Yuriy Tarnawsky; ISBN: 0914590480; http://www.amazon.com/exec/obidos/ASIN/0914590480/icongroupinterna
•
Meningitis (Diseases and People) by Edward Willett (1999); ISBN: 0766011879; http://www.amazon.com/exec/obidos/ASIN/0766011879/icongroupinterna
•
Meningitis : a work of fiction by IUrii Tarnavs§kyi; ISBN: 0914590499; http://www.amazon.com/exec/obidos/ASIN/0914590499/icongroupinterna
•
MENINGITIS C AUDIO TAPE by HPE; ISBN: 0752119613; http://www.amazon.com/exec/obidos/ASIN/0752119613/icongroupinterna
•
MENINGITIS C LEAFLET BRAILLE by HPE; ISBN: 0752119605; http://www.amazon.com/exec/obidos/ASIN/0752119605/icongroupinterna
•
Meningitis Im Kindesalter by H. Isenberg (1993); ISBN: 3798509409; http://www.amazon.com/exec/obidos/ASIN/3798509409/icongroupinterna
Books 263
•
Meningitis: 100 Maxims (100 Maxims in Neurology, 4) by Karen L. Roos (1996); ISBN: 034060879X; http://www.amazon.com/exec/obidos/ASIN/034060879X/icongroupinterna
•
Meningitis: a Guide for Families by J.S. Kroll; ISBN: 190133600X; http://www.amazon.com/exec/obidos/ASIN/190133600X/icongroupinterna
•
Neonatal Meningitis by Pamela A. Davies (Author), P. T. Rudd (Author) (1995); ISBN: 0901260967; http://www.amazon.com/exec/obidos/ASIN/0901260967/icongroupinterna
•
Neonatal Sepsis and Meningitis by Alistair Philip; ISBN: 0816122539; http://www.amazon.com/exec/obidos/ASIN/0816122539/icongroupinterna
•
Stephen--Learning about Meningitis by Jenny Wilson (2000); ISBN: 1857925726; http://www.amazon.com/exec/obidos/ASIN/1857925726/icongroupinterna
•
The Official Patient's Sourcebook on Meningitis: A Revised and Updated Directory for the Internet Age by Icon Health Publications (2002); ISBN: 0597833303; http://www.amazon.com/exec/obidos/ASIN/0597833303/icongroupinterna
•
Tuberculous Meningitis by Malcolm L. Parsons; ISBN: 0192611666; http://www.amazon.com/exec/obidos/ASIN/0192611666/icongroupinterna
•
Tuberculous Meningitis: Tuberculomas and Spinal Tuberculosis: A Handbook for Clinicians (Oxford Medical Publications) by Malcolm Parsons; ISBN: 0192617214; http://www.amazon.com/exec/obidos/ASIN/0192617214/icongroupinterna
The National Library of Medicine Book Index The National Library of Medicine at the National Institutes of Health has a massive database of books published on healthcare and biomedicine. Go to the following Internet site, http://locatorplus.gov/, and then select “Search LOCATORplus.” Once you are in the search area, simply type “meningitis” (or synonyms) into the search box, and select “books only.” From there, results can be sorted by publication date, author, or relevance. The following was recently catalogued by the National Library of Medicine:11 •
An Annotated bibliography of the sequelae of acute bacterial meningitis, 1945-1968 [by] Sarah H. Sell [et al.]. Author: Sell, Sarah Hamilton Wood,; Year: 1970; Nashville, Dept. of Psychiatry, Vanderbilt Univ., 1969
•
Animal experimentation in relation to epidemic cerebrospinal meningitis Author: Dunn, Charles Hunter,; Year: 1954; Chicago: American Medical Association., 1911
•
CRDA special report on the 1989 meningitis epidemic. Author: Christian Relief; Development Association (Ethiopia); Year: 1971; Addis Ababa: Christian Relief; Development Association, Ethiopia, [1989?]
11
In addition to LOCATORPlus, in collaboration with authors and publishers, the National Center for Biotechnology Information (NCBI) is currently adapting biomedical books for the Web. The books may be accessed in two ways: (1) by searching directly using any search term or phrase (in the same way as the bibliographic database PubMed), or (2) by following the links to PubMed abstracts. Each PubMed abstract has a "Books" button that displays a facsimile of the abstract in which some phrases are hypertext links. These phrases are also found in the books available at NCBI. Click on hyperlinked results in the list of books in which the phrase is found. Currently, the majority of the links are between the books and PubMed. In the future, more links will be created between the books and other types of information, such as gene and protein sequences and macromolecular structures. See http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=Books.
264 Meningitis
•
Factors contributing to incidences of meningitis in Chavuma District in the past one year Author: Likando, C. M.; Year: 1969; Kabwe, Zambia: Pan African Institute for Development, East and Southern Africa, [1997]
•
Gastroenteritis, encephalitis, meningitis, & kala-azar: an epidemiological review Author: Bista, Mahendra Bahadur.; Year: 1971; Kathmandu, Napal: Epidemiology Division, Ministry of Health, [1993]
•
Infective meningitis Author: Furth, Ralph van.; Year: 1942; The Netherlands: Boerhaave Committee for Postgraduate Medical Education, Leiden University, [1989?]; ISBN: 9067671835
•
Management of bacterial meningitis and septicaemia in children: role of antibiotics, immunoglobulins and corticosteroids Author: Iwarson, Sten.; Year: 1952; Stockholm, Sweden: Distributed by Almqvist; Wiksell International, [1990]
•
Meningitis [by] George Gee Jackson [and] Lowell W. Lapham. Author: Jackson, George Gee,; Year: 1958; Chicago, Year Book Publishers, 1958
•
Present-day antibiotic treatment of bacterial meningitis Author: Modaï, J. (Jacques); Year: 1942; Basel, Switzerland: Editiones Roche, c1990; ISBN: 3907946235
•
Report of a committee of the Massachusetts Medical Society on spotted fever or cerebro-spinal meningitis in the state of Massachusetts, May, 1866. Author: Daniels, Worth B., donor.; Year: 1950; Boston: David Clapp; Son., 1867
•
Social and medical prognosis of child with acute nontuberculous purulent meningitis Author: Sillanpää, Matti.; Year: 1964; Stockholm: Almqvist; Wiksell, 1977
•
The treatment of meningococcic meningitis with sulfanilamide: preliminary report Author: Schwentker, Francis F.; Year: 1955; Chicago, Ill.: American Medical Association, c1937
•
Workshop on Problems of Bacterial Meningitis: February 4, 1984, Wiesbaden Author: Klein, Jerome O.,; Year: 1957; München: MMV Medizin Verlag, c1984
Chapters on Meningitis In order to find chapters that specifically relate to meningitis, an excellent source of abstracts is the Combined Health Information Database. You will need to limit your search to book chapters and meningitis using the “Detailed Search” option. Go to the following hyperlink: http://chid.nih.gov/detail/detail.html. To find book chapters, use the drop boxes at the bottom of the search page where “You may refine your search by.” Select the dates and language you prefer, and the format option “Book Chapter.” Type “meningitis” (or synonyms) into the “For these words:” box. The following is a typical result when searching for book chapters on meningitis: •
Dementia Source: in Cassel, C.K., et al., eds. Geriatric Medicine. 2nd ed. New York, NY: SpringerVerlag. 1990. p. 428-448. ISBN: 0387178864. Contact: This publication may be available from your local medical library. Call for information. Summary: This chapter defines and summarizes the causes, evaluation, and treatment of dementia. Behavioral syndromes of elderly individuals that must be distinguished from dementia are briefly described prior to the discussion of the dementing disorders.
Books 265
Specific information is provided about delirium; amnestic syndromes; organic delusional, mood, anxiety, and personality syndromes; organic hallucinosis; aphasic syndromes; ageassociated memory impairment; and the various dementias and their characteristics. In the discussion of dementias, attention is given to primary dementias, including Alzheimer's disease, dementia with extrapyramidal disorders, Pick's disease, Parkinson's disease, Huntington's diseases, and other extrapyramidal disorders; secondary dementias, including vascular dementia syndromes, drug-induced dementia, and dementias induced by alcohol and nondrug toxins; infectious causes of dementia, including AIDS, Jakob-Creutzfeldt disease, Gerstmann-Straussler syndrome, general paresis, chronic meningitis, and non-infectious systemic illnesses, including neoplasms; traumatic dementias; hydrocephalus; and depression. Finally, attention is focused on the history and varied applications of neuropsychiatric assessments and to the various treatments. 76 references. •
Chapter 21-D: Vasculitides: Vasculitis of the Central nervous System Source: in Klippel, J.H., et al., eds. Primer on the Rheumatic Diseases. 12th ed. Atlanta, GA: Arthritis Foundation. 2001. p. 405-409. Contact: Available from Arthritis Foundation. P.O. Box 1616, Alpharetta, GA 300091616. (800) 207-8633. Fax (credit card orders only) (770) 442-9742. Website: www.arthritis.org. PRICE: $69.95 plus shipping and handling. ISBN: 0912423293. Summary: This chapter provides health professionals with information on vasculitis of the central nervous system (CNS). CNS vasculitis can be divided into primary and secondary forms. The primary form is known as primary angiitis of the CNS (PACNS). Using the criteria for PACNS established by Calabrese and Malek, a diverse group of disorders can be defined, including granulomatous angiitis of the CNS (GACNS) and benign angiopathy of the CNS (BACNS). GACNS is a slowly progressive disorder characterized by a prodrome of 6 or more months. The most common clinical features are chronic headache, neurologic defects, alternations in higher cortical function, cerebrospinal fluid (CSF) abnormalities consistent with chronic meningitis, and inflammatory spinal cord lesions. When GACNS is suspected, biopsy of CNS tissues is the diagnostic mode of choice. Normal lumbar puncture and normal magnetic imaging results virtually rule out the possibility of GACNS. BACNS tends to occur in young women. Clinical features include acute onset of a severe headache or focal neurologic deficit, relatively normal CSF analyses, and highly abnormal angiograms. The diagnosis of BACNS is usually based on both clinical and radiographic findings and requires further analysis to differentiate it from more progressive forms of PACNS. No controlled trials of any therapy for PACNS or BACNS have been conducted, but reports suggest that if patients are diagnosed and treated promptly, most can achieve remission. GACNS is treated with high dose prednisone and cyclophosphamide. For people who are diagnosed with BACNS, a short course of high dose corticosteroids for a period of 2 to 3 months with taper is prescribed. For patients who do not fall into the GACNS or BACNS categories, an empirically derived therapy based on the severity of disease manifestations and the rate of illness progression is justified. The secondary forms of CNS vasculitis include those caused by infections, drugs, neoplasms, systemic vasculitides, and connective tissue diseases. Various infectious agents, including bacteria, fungi, mycobacteria, viruses, spirochetes, and other atypical agents are capable of causing a vascular inflammatory disease within the CNS. The most commonly implicated drugs with CNS vasculitis are cocaine, amphetamines, ephedrine, phenylpropanolamine, and other sympathomimetric agents. Vasculitis of the CNS has been associated with various neoplasms, particularly with lymphoproliferative diseases.
266 Meningitis
Vasculitis of the CNS is found in patients with various connective tissue diseases and vasculitic syndromes, particularly systemic lupus erythematosus and Sjogren's syndrome. 1 figure, 1 table, and 13 references. •
Complications of Cochlear Implant Surgery Source: in Waltzman, S.B. and Cohen, N.L., eds. Cochlear Implants. New York, NY: Thieme. 2000. p. 171-184. Contact: Available from Thieme. 333 Seventh Avenue, New York, NY 10001. (800) 7823488. Fax (212) 947-0108. E-mail:
[email protected]. PRICE: $89.00 plus shipping and handling. ISBN: 0865778825. Summary: This chapter on complications of cochlear implant surgery is from a book that incorporates original chapters on relevant topics with related papers. The papers were presented at the Fifth International Cochlear Implant Conference held in New York, in May, 1997. The book provides professionals involved in the field of cochlear implants with a comprehensive reference text. All aspects of implantation are covered including the effects of electrical stimulation, processing capabilities, preoperative criteria, medical, surgical and radiological issues, results and postoperative programming, rehabilitation, and education. In this chapter, the author outlines complications related to cochlear implantation and provides suggestions for prevention of these complications. Surgical and medical complications discussed include scalp flap, otitis media (ear infection) and meningitis (brain infection), facial nerve paralysis, tinnitus (ringing in the ears), vertigo, and device migration. Device related complications covered include device failure and facial nerve stimulation. Accompanying the chapter are five articles covering: surgical complications and equipment failures of the University of Navarra cochlear implant program; insertional trauma with different types of electrodes in Combi 40 cochlear implantation; reimplantation of Ineraid cochlear implants; the practical and ethical considerations of facial nerve monitoring during cochlear implant surgery; and nonauditory stimulation in cochlear implant patients. 1 figure. 5 tables. 36 references.
•
Medical and Surgical Treatment of Cochlear Hearing Loss Source: in Valente, M. Hosford-Dunn, H. Roeser, R.J., eds. Audiology: Treatment. New York, NY: Thieme. 2000. p. 377-396. Contact: Available from Thieme. 333 Seventh Avenue, New York, NY 10001. (800) 7823488. Fax (212) 947-0108. E-mail:
[email protected]. PRICE: $69.00 plus shipping and handling. ISBN: 0865778590. Summary: This chapter on the medical and surgical management of cochlear hearing loss is from a textbook that provides a comprehensive overview of the numerous treatment options available to help patients relieve the clinical symptoms seen in an audiology practice. Cochlear hearing loss may be caused by a wide variety of medical problems; it is the responsibility of the practitioner to identify the cause of hearing loss and to evaluate the other potential associated medical ramifications to treat the patient as a whole. Topics covered include metabolic disorders, including Meniere's disease, diabetes mellitus, renal disease, hypothyroidism, and cochlear otosclerosis; immunologic disorders, including autoimmune inner ear disease, Cogan's syndrome, polyarteritis nodosa, Vogt Koyanagi Harada syndrome, Wegener's granulomatosis, sarcoidosis, and postapedectomy granuloma; ototoxicity, including that from aminoglycoside antibiotics, erythromycin, vancomycin, other antibiotics, loop diuretics, antineoplastic (chemotherapy) agents, antiinflammatory agents, and antimalarials;
Books 267
trauma, including temporal bone fractures, noise trauma, and barotrauma (from barometric pressure changes); infections, including cytomegalovirus, toxoplasmosis, congenital rubella, mumps, measles, Varicella Zoster virus, HIV, other viruses and Mycoplasma, meningitis, labyrinthitis, fungal infections, and syphilis; malignancy; presbycusis; sudden idiopathic sensorineural hearing loss; and hereditary or development causes. The authors stress that complete audiological assessments are crucial in the initial evaluation and subsequent therapeutic monitoring of sensorineural hearing losses. The chapter includes an outline of the topic covered, a list of references, a summary outline of the related preferred practice guidelines, and various 'pearls and pitfalls' offering practical advice to the reader. 11 figures. 1 table. 67 references. •
Otosclerosis Source: in Canalis, R.F. and Lambert, P.R., eds. Ear: Comprehensive Otology. Philadelphia, PA: Lippincott Williams and Wilkins. 2000. p. 467-487. Contact: Available from Lippincott Williams and Wilkins. P.O. Box 1600, Hagerstown, MD 21741. (800) 638-3030. Fax (301) 223-2300. Website: www.lww.com. PRICE: $179.00 plus shipping and handling. ISBN: 078171558X. Summary: Otosclerosis is a bone disease limited to the temporal bone and primarily affecting the otic capsule. The growth of spongy bone usually results in stapes fixation but may also involve the cochlea and other parts of the labyrinth. This chapter on the clinical features of otosclerosis is from a textbook that offers complete coverage of the field of clinical otology (study of the ear). The book is oriented to serve both the otolaryngology resident as a practical learning tool and the practicing otolaryngologist as an updated reference source of clinical and basic information. Topics include definition; historical perspective; epidemiology; pathogenesis; pathology; history and physical findings; audiometry, including tuning fork tests, standard audiometry, the Carhart notch, and acoustic impedance; radiographic studies; differential diagnosis; medical management; surgical management, including candidate selection and preoperative management; surgical techniques, including stapedioplasty, stapedectomy, stapedotomy, laser stapedectomy, bilateral stapedectomy, closure, and postoperative care; intraoperative problems and complications, including intraoperative vertigo(dizziness), tympanic membrane (eardrum) perforation, obliterative otosclerosis, cerebrospinal fluid otorrhea (fluid from the ear), dehiscence of the facial nerve, floating footplate, and subluxation of the incus; postoperative complications, including vertigo, tinnitus (ringing or other sounds in the ears), cochlear hearing loss, facial paralysis, otitis media (middle ear infection), taste disturbance and oral dryness, perilymph fistula, incus necrosis, middle ear fibrosis, granuloma, postoperative labyrinthitis, meningitis, and recurrence; the evaluation of the results of stapes surgery; results of primary stapes surgery; stapedectomy (removal of the stapes of the middle ear and insertion of a graft and prosthesis) in children; revision stapedectomy; fenestration (surgical opening) and postfenestration stapedectomy; nonotosclerotic lesions of the stapes, including Paget's disease, osteogenesis imperfecta, tympanosclerosis, and degenerative arthritis; and other causes of ossicular fixation, including lateral ossicular fixation and incus annulus fusion. 31 figures. 112 references.
•
Possible Causes Source: in Haybach, P.J. Meniere's Disease: What You Need to Know. Portland, OR: Vestibular Disorders Association. 1998. p. 53-60.
268 Meningitis
Contact: Available from Vestibular Disorders Association. P.O. Box 4467, Portland, OR 97208-4467. (800) 837-8428. E-mail:
[email protected]. Website: www.vestibular.org. PRICE: $24.95 plus shipping and handling. ISBN: 0963261118. Summary: The cause of Meniere's disease is unknown, however many theories have been proposed to explain the symptoms of Meniere's or the factors that may aggravate those symptoms. This chapter is from a book that provides information for people who have or suspect they have Meniere's disease want to know more about its diagnosis and treatment, as well as strategies for coping with its effects. Written in nontechnical language, this chapter discusses the possible causes of Meniere's disease. Listed in alphabetical order, they include: abnormal circulation, adrenal-pituitary insufficiency, allergy, autoimmune disease, autonomic nervous system malfunction, bacterial infection, blockage of endolymph, estrogen insufficiency, head injury, heredity, hormonal imbalance, malformed or small endolymphatic sac, malfunction in the use of foods by the body (high cholesterol, triglycerides, or lipids), meningitis, menstrual or premenstrual problems, noise pollution (noise trauma or acoustic trauma), otosclerosis, stress, and viral infection. The author discusses the most widely accepted theories of the causes of Meniere's disease and then briefly considers specific conditions that are known or thought to sometimes cause symptoms like those of Meniere's disease. 24 references. •
Acquired Hearing Loss Due to Other Infections and Causes Source: in Pappas, D.G. Diagnosis and Treatment of Hearing Impairment in Children. 2nd ed. San Diego, CA: Singular Publishing Group, Inc. 1998. p. 115-168. Contact: Available from Singular Publishing Group, Inc. 401 West 'A' Street, Suite 325, San Diego, CA 92101-7904. (800) 521-8545. Fax (800) 774-8398. E-mail:
[email protected]. Website: www.singpub.com. PRICE: $55.00 plus shipping and handling. ISBN: 1565938658. Summary: This chapter on acquired hearing loss due to other infections (non viral) and causes is from a text that discusses the prevention, diagnosis, and treatment of hearing impairment in children. A follow up to the chapter on viral infections, this chapter focuses on serous otitis media (otitis media with effusion, or OME), the incidence of OME, complications from chronic otitis media, preexisting sensorineural hearing loss (SNHL) and negative middle ear pressure, organism (i.e., bacteria) and drug related factors, the pathogenesis of OME, the benefits of ventilation tubes, the surgical management of chronic otitis media (with ventilation tube placement), complications with ventilation tubes, when to remove a ventilation tube, protection from water when tubes are in place, the technique of closure of posttympanotomy perforation (when a tympanotomy tube perforates the eardrum), congenital cholesteatoma, bacterial meningitis (including routes of infections, diagnosis, treatment, pathophysiology, and vestibular involvement), complications of hearing loss associated with meningitis, perilymph fistula in children with preexisting SNHL, autoimmune inner ear disease, and SNHL in children with autoimmune inner ear disease. In each case, the authors focus on the diagnostic tests and treatment options for children with that particular condition. 11 figures. 7 tables. 133 references.
•
Acquired Hearing Impairment Source: in Mencher, G.T. Gerber, S.E. McCombe, A. Audiology and Auditory Dysfunction. Needham Heights, MA: Allyn and Bacon. 1997. p. 143-165.
Books 269
Contact: Available from Allyn and Bacon. 160 Gould Street, Needham Heights, MA 02194-2310. (800) 278-3525; Fax (617) 455-7024; E-mail:
[email protected]; http://www.abacon.com. PRICE: $46.95 plus shipping and handling. ISBN: 0205161014. Summary: This chapter on acquired hearing impairment is from an audiology textbook on auditory dysfunction. The author notes that, from a clinical perspective, the auditory behavior of an acquired loss is not very different from that of a congenital loss, and the audiological treatment thus may be similar. The overt results of systemic disturbances, diseases, and hereditary degenerative disorders, all acquired, are often quite similar and difficult to tell apart, and therefore lend themselves to combined study. On the other hand, ototoxicity, noise trauma, and presbycusis (hearing loss due to aging) each has its own special effect on hearing and thus are discussed in separate chapters. This chapter covers tinnitus and recruitment; acquired disease, including cytomegalovirus, mumps, AIDS, herpes, meningitis, and syphilis; sudden onset and degenerative disorders; trauma; and hearing loss associated with systemic disease, including thyroid disease, diabetes mellitus, kidney disease, multiple sclerosis, connective tissue disease, and Meniere's disease. Hearing impairment after viral or bacterial disease is usually unchanging, that is, the hearing loss should not get worse. Metabolic disorders often display fluctuating hearing losses. Except for Meniere's disease, there is little that can be done surgically specifically for acquired sensory hearing impairments. They are not subject to surgical intervention, nor are they usually amenable to medical otologic treatment. Of course, the underlying disease is a medical problem that needs to be treated, and that treatment may have a beneficial effect on the hearing impairment. 6 figures. 1 table. •
Special Considerations for Children with Fluctuating-Progressive Hearing Loss Source: in Bess, F.H. Gravel, J.S. Tharpe, A.M., eds. Amplification for Children with Auditory Deficits. Nashville, TN: Bill Wilkerson Center Press. 1996. p. 339-365. Contact: Available from Bill Wilkerson Center Press. 1114 19th Avenue South, Nashville, TN 37212-2197. (615) 936-5023. Fax (615) 936-5013. PRICE: $55.00 plus shipping and handling. ISBN: 096314393X. Summary: This chapter, from a textbook on amplification for children with auditory deficits, discusses special considerations for children with fluctuating or progressive hearing loss. One consideration, particularly for younger children, is that audiologists may assume that changes in audiometric results reflect attention or nonsensory factors, as opposed to true changes in hearing sensitivity. The author attempts to raise the reader's level of suspicion for fluctuating or progressive hearing loss in children by reviewing several causes and patterns of such changes. The causes discussed include genetic hearing loss without associated abnormalities, including autosomal dominant progressive SNHL, x-linked progressive hearing loss, and otosclerosis; genetic hearing loss with associated abnormalities, including Albers-Schonberg